isoniazid has been researched along with HIV Coinfection in 690 studies
Hydra: A genus of freshwater polyps in the family Hydridae, order Hydroida, class HYDROZOA. They are of special interest because of their complex organization and because their adult organization corresponds roughly to the gastrula of higher animals.
hydrazide : Compounds derived from oxoacids RkE(=O)l(OH)m (l =/= 0) by replacing -OH by -NRNR2 (R groups are commonly H). (IUPAC).
| Excerpt | Relevance | Reference |
|---|---|---|
| "In people with HIV-associated DS-PTB with CD4+ counts ≥100 cells/μL on efavirenz-based ART, the 4-month daily rifapentine-moxifloxacin regimen was noninferior to the 6-month control regimen and was safe." | 9.69 | Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349). ( Bryant, K; Chaisson, RE; Dawson, R; Dooley, KE; Dorman, SE; Johnson, JL; Kurbatova, E; Lalloo, UG; Mohapi, L; Muzanyi, G; Nahid, P; Pettit, AC; Phillips, PPJ; Podany, AT; Samaneka, W; Sanne, I; Savic, RM; Scott, N; Sizemore, E; Swindells, S; Vernon, A; Waja, Z, 2023) |
| "Our findings suggest that twice-daily dolutegravir might be unnecessary in people with HIV-associated tuberculosis." | 9.69 | Standard-dose versus double-dose dolutegravir in HIV-associated tuberculosis in South Africa (RADIANT-TB): a phase 2, non-comparative, randomised controlled trial. ( Griesel, R; Hill, AM; Keene, CM; Maartens, G; Meintjes, G; Omar, Z; Simmons, B; Wiesner, L; Zhao, Y, 2023) |
| " Of 749 infants, 694 (93%) received Bacille Calmette-Guérin (BCG) vaccination, 675 (90%) were born to mothers who had completed isoniazid treatment, 20 (3%) were exposed to tuberculosis, seven (1%) became HIV positive, and one (<1%) developed probable tuberculosis." | 9.69 | Timing of maternal isoniazid preventive therapy on tuberculosis infection among infants exposed to HIV in low-income and middle-income settings: a secondary analysis of the TB APPRISE trial. ( Aaron, L; Bradford, S; Chakhtoura, N; Chanaiwa, V; Chipato, T; Costello, D; Golner, A; Gupta, A; Jean-Phillippe, P; Kabugho, E; Kulkarni, V; Masheto, G; Montepiedra, G; Mutambanengwe, M; Raesi, M; Shayo, A; Singh, P; Sterling, TR; Stranix-Chibanda, L; Theron, G; Vhembo, T; Weinberg, A, 2023) |
| "Alcohol use is common among people with HIV and is a risk factor for tuberculosis disease and non-adherence to isoniazid preventive therapy (IPT)." | 9.69 | Financial incentives for reduced alcohol use and increased isoniazid adherence during tuberculosis preventive therapy among people with HIV in Uganda: an open-label, factorial randomised controlled trial. ( Adong, J; Beesiga, B; Bryant, K; Chamie, G; Emenyonu, NI; Fatch, R; Gandhi, M; Hahn, JA; Havlir, DV; Kamya, MR; Kekibiina, A; Lodi, S; Marson, K; McDonell, MG; Muyindike, WR; Thirumurthy, H, 2023) |
| " Rifapentine clearance is higher among women with HIV, but all women achieved exposures of rifapentine and isoniazid associated with successful tuberculosis prevention." | 9.51 | Pharmacokinetics and Safety of 3 Months of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention in Pregnant Women. ( Bradford, S; Britto, P; Chakhtoura, N; Chalermchockcharoentkit, A; Chipato, T; Dooley, KE; Gupta, A; Jayachandran, P; Kamthunzi, P; Langat, D; Mathad, JS; Montepiedra, G; Norman, J; Patil, S; Popson, S; Rouzier, V; Savic, R; Townley, E; Wiesner, L; Zhang, N, 2022) |
| "In AIDS Clinical Trials Group study A5338, concomitant rifampicin, isoniazid, and efavirenz was associated with more rapid plasma medroxyprogesterone acetate (MPA) clearance compared to historical controls without tuberculosis or HIV therapy." | 9.51 | Pharmacogenetics of interaction between depot medroxyprogesterone acetate and efavirenz, rifampicin, and isoniazid during treatment of HIV and tuberculosis. ( Angira, F; Badal-Faesen, S; Baker, P; Cohn, SE; Denti, P; Francis, J; Haas, DW; Kendall, MA; Mawlana, S; McIlleron, H; Mngqibisa, R; Omoz-Oarhe, A; Robinson, JA; Samaneka, WP, 2022) |
| "Scaling up shorter regimens for tuberculosis (TB) prevention such as once weekly isoniazid-rifapentine (3HP) taken for 3 months is a key priority for achieving targets set forth in the World Health Organization's (WHO) END TB Strategy." | 9.41 | Completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV: Interim analysis of a hybrid type 3 effectiveness-implementation randomized trial. ( Akello, L; Belknap, R; Berger, CA; Bishop, O; Cattamanchi, A; Dowdy, DW; Handley, MA; Kadota, JL; Kamya, MR; Katahoire, A; Katamba, A; Kiwanuka, N; Musinguzi, A; Nabunje, J; Nahid, P; Nakitende, A; Patel, D; Phillips, PPJ; Sammann, A; Semitala, FC; Welishe, F, 2021) |
| "The aim of this study was to systematically assess the efficacy, safety, and tolerability of isoniazid preventive therapy (IPT) for tuberculosis (TB) in people with HIV (PWH)." | 9.41 | Efficacy, safety, and tolerability of isoniazid preventive therapy for tuberculosis in people living with HIV. ( Gudi, SK; Jagi, JL; Thomas, C; Undela, K, 2023) |
| "International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) P1078, a randomized noninferiority study designed to compare the safety of starting isoniazid preventive therapy (IPT) in women living with human immunodeficiency virus (HIV) either during pregnancy or after delivery, showed that IPT during pregnancy increased the risk of composite adverse pregnancy outcomes, but not individual outcomes." | 9.41 | Individual and Composite Adverse Pregnancy Outcomes in a Randomized Trial on Isoniazid Preventative Therapy Among Women Living With Human Immunodeficiency Virus. ( Aaron, L; Chakhtoura, N; Chipato, T; Gupta, A; Jean-Philippe, P; Lespinasse, D; Loftis, AJ; Masheto, G; McCarthy, K; Montepiedra, G; Nematadzira, T; Ngocho, J; Nyati, M; Onyango-Makumbi, C; Patil, S; Theron, G; Tongprasert, F; Weinberg, A; Zimmer, B, 2021) |
| "Short-course preventive therapy with 12 doses of once-weekly rifapentine (900 mg) plus isoniazid (900 mg) could greatly improve tuberculosis control, especially in areas with high co-endemicity with HIV." | 9.34 | Once-weekly rifapentine and isoniazid for tuberculosis prevention in patients with HIV taking dolutegravir-based antiretroviral therapy: a phase 1/2 trial. ( Beattie, T; Chaisson, RE; Churchyard, GJ; Dooley, KE; Edward, VA; Fyvie, MJ; Gupte, A; Likoti, M; Marzinke, MA; Savic, R; Sebe, M; Shibambo, I; Wolf, L; Zhang, N, 2020) |
| "We conducted a randomized, open-label, phase 3 noninferiority trial comparing the efficacy and safety of a 1-month regimen of daily rifapentine plus isoniazid (1-month group) with 9 months of isoniazid alone (9-month group) in HIV-infected patients who were living in areas of high tuberculosis prevalence or who had evidence of latent tuberculosis infection." | 9.30 | One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis. ( Andersen, J; Banda, P; Benson, CA; Chaisson, RE; da Silva Escada, RO; Fletcher, CV; Gupta, A; Hakim, J; Jean Juste, MA; Kanyama, C; Lama, JR; Langat, D; Leon-Cruz, J; Masheto, G; Mawlana, S; Mohapi, L; Moran, L; Mwelase, N; Nuermberger, E; Omoz-Oarhe, A; Ramchandani, R; Severe, P; Supparatpinyo, K; Swindells, S; Valencia, J, 2019) |
| "Hepatotoxicity associated with isoniazid preventive therapy (IPT) and antiretroviral therapy (ART) has not been well studied in severely immunosuppressed people with HIV." | 9.27 | Hepatotoxicity During Isoniazid Preventive Therapy and Antiretroviral Therapy in People Living With HIV With Severe Immunosuppression: A Secondary Analysis of a Multi-Country Open-Label Randomized Controlled Clinical Trial. ( Bisson, GP; Gupta, A; Hosseinipour, MC; Hughes, MD; Kidonge, KK; Kumwenda, J; Lavenberg, JA; Miyahara, S; Ngongondo, M; Nyirenda, M; Sun, X; Torres, TS, 2018) |
| "We conducted a systematic review examining the cost effectiveness of a 3-month course of isoniazid and rifapentine, known as 3HP, given by directly observed treatment, compared to 9 months of isoniazid that is directly observed or self-administered, for latent tuberculosis infection." | 9.22 | Cost-effectiveness of 3-months isoniazid and rifapentine compared to 9-months isoniazid for latent tuberculosis infection: a systematic review. ( Brethour, K; Chaisson, RE; D'Silva, O; Lai, WA; Zwerling, AA, 2022) |
| "We did a multicountry open-label randomised clinical trial comparing empirical tuberculosis therapy with isoniazid preventive therapy in HIV-positive outpatients initiating antiretroviral therapy with CD4 cell counts of less than 50 cells per μL." | 9.22 | Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label randomised controlled trial. ( Alave, J; Badal-Faesen, S; Bao, J; Bisson, GP; Gupta, A; Hakim, J; Henostroza, G; Hogg, E; Hosseinipour, MC; Jones, L; Kirui, FK; Kumarasamy, N; Kumwenda, J; Lagat, D; Lama, JR; Leger, PD; Mave, V; Miyahara, S; Mohapi, L; Moses, A; Mugyenyi, P; Naidoo, K; Nyirenda, M; Pillay, S; Riviere, C; Sun, X; Veloso, VG; Zolopa, A, 2016) |
| "Thirty-six months of isoniazid preventive therapy (36IPT) was superior to 6 months of IPT (6IPT) in preventing tuberculosis (TB) among HIV-infected adults in Botswana." | 9.20 | Tuberculosis incidence after 36 months' isoniazid prophylaxis in HIV-infected adults in Botswana: a posttrial observational analysis. ( Agizew, TB; Mosimaneotsile, B; Motsamai, OI; Nyirenda, S; Rose, CE; Samandari, T; Shang, N; Shepherd, J; Sibanda, T; Tedla, Z, 2015) |
| "A recent major cluster randomized trial of screening, active disease treatment, and mass isoniazid preventive therapy for 9 months during 2006-2011 among South African gold miners showed reduced individual-level tuberculosis incidence but no detectable population-level impact." | 9.20 | Tuberculosis control in South African gold mines: mathematical modeling of a trial of community-wide isoniazid preventive therapy. ( Churchyard, GJ; Corbett, EL; Cox, AP; Fielding, KL; Grant, AD; Hayes, RJ; Lewis, JJ; Sumner, T; Vynnycky, E; White, RG, 2015) |
| "In Botswana, a 36-month course of isoniazid treatment of latent tuberculosis (TB) infection [isoniazid preventive therapy (IPT)] was superior to 6-month IPT in reducing TB and death in persons living with HIV (PLHIV), having positive tuberculin skin tests (TSTs) but not in those with negative TST." | 9.20 | Implementation and Operational Research: Cost-Effectiveness of Antiretroviral Therapy and Isoniazid Prophylaxis to Reduce Tuberculosis and Death in People Living With HIV in Botswana. ( Abimbola, T; Marston, B; Samandari, T; Sangrujee, N; Smith, T, 2015) |
| "We investigated the population pharmacokinetics and pharmacogenetics of efavirenz in 307 patients coinfected with human immunodeficiency virus and tuberculosis and included in the Cambodian Early vs Late Initiation of Antiretrovirals trial (CAMELIA) in Cambodia." | 9.19 | Dependence of efavirenz- and rifampicin-isoniazid-based antituberculosis treatment drug-drug interaction on CYP2B6 and NAT2 genetic polymorphisms: ANRS 12154 study in Cambodia. ( Bertrand, J; Blanc, FX; Borand, L; Chea, P; Chou, M; Mentré, F; Nay, KH; Taburet, AM; Verstuyft, C, 2014) |
| "This is a substudy of the Agence Nationale de Recherches sur le Sida et les Hépatites Virales (ANRS) Comparison of Nevirapine and Efavirenz for the Treatment of HIV-TB Co-infected Patients (ANRS 12146-CARINEMO) trial, which assessed the pharmacokinetics of rifampin or isoniazid with or without the coadministration of nonnucleoside reverse transcriptase inhibitor-based HIV antiretroviral therapy in HIV-tuberculosis-coinfected patients in Mozambique." | 9.19 | Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatment. ( Amin, A; Barau, C; Barrail-Tran, A; Baudin, E; Bhatt, NB; Bonnet, M; Furlan, V; Grinsztejn, B; Meggi, B; Silva, C; Taburet, AM, 2014) |
| "Sixteen patients with TB-HIV co-infection received rifabutin 300 mg QD in combination with tuberculosis chemotherapy (initially pyrazinamide, isoniazid and ethambutol then only isoniazid), and were then randomized to receive isoniazid and LPV/r based ART with rifabutin 150 mg tiw or rifabutin 150 mg daily." | 9.19 | Randomized pharmacokinetic evaluation of different rifabutin doses in African HIV- infected tuberculosis patients on lopinavir/ritonavir-based antiretroviral therapy. ( Connolly, C; Harries, A; Kellerman, T; Lienhardt, C; McIlleron, H; Naiker, S; Pym, A; Reddy, T; Wiesner, L, 2014) |
| "While 6- to 12-month courses of isoniazid for tuberculosis prevention are considered safe in pregnant women, the effects of longer-term isoniazid prophylaxis or isoniazid in combination with antiretroviral therapy (ART) are not established in human-immunodeficiency-virus-(HIV-) infected women who experience pregnancy during the course of therapy." | 9.17 | Pregnancy outcomes in HIV-infected women receiving long-term isoniazid prophylaxis for tuberculosis and antiretroviral therapy. ( Mathebula, U; Mathoma, A; Moathlodi, R; Mosimaneotsile, B; Samandari, T; Taylor, AW; Theebetsile, I, 2013) |
| " Clinic staff were trained in tuberculosis screening, use of tuberculin skin tests, and use of isoniazid preventive therapy." | 9.17 | Effect of improved tuberculosis screening and isoniazid preventive therapy on incidence of tuberculosis and death in patients with HIV in clinics in Rio de Janeiro, Brazil: a stepped wedge, cluster-randomised trial. ( Cavalcante, SC; Chaisson, RE; Cohn, S; Durovni, B; Efron, A; Golub, JE; King, BS; Moulton, LH; Pacheco, AG; Saraceni, V, 2013) |
| "In accordance with WHO guidelines, people with HIV infection in Botswana receive daily isoniazid preventive therapy against tuberculosis without obtaining a tuberculin skin test, but duration of prophylaxis is restricted to 6 months." | 9.15 | 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial. ( Agizew, TB; Bozeman, L; Castro, KG; Davis, MK; Kilmarx, PH; Moeti, TL; Moffat, HJ; Mosimaneotsile, B; Motsamai, OI; Nyirenda, S; Samandari, T; Shang, N; Sibanda, T; Talbot, EA; Tedla, Z; Wells, CD, 2011) |
| "Primary isoniazid prophylaxis did not improve tuberculosis-disease-free survival among HIV-infected children or tuberculosis-infection-free survival among HIV-uninfected children immunized with BCG vaccine." | 9.15 | Primary isoniazid prophylaxis against tuberculosis in HIV-exposed children. ( Bobat, R; Cotton, MF; Jean-Philippe, P; Kim, S; Madhi, SA; McSherry, G; Mitchell, C; Nachman, S; Violari, A, 2011) |
| " The aim of the study was to document the pharmacokinetics of the first-line anti-TB agents in children <2 years of age comparing previous and revised WHO dosages of isoniazid (INH; 5 versus 10 mg/kg/day), rifampin (RMP; 10 versus 15 mg/kg/day), and pyrazinamide (PZA; 25 versus 35 mg/kg/day) and to investigate the effects of clinical covariates, including HIV coinfection, nutritional status, age, gender, and type of tuberculosis (TB), and the effect of NAT2 acetylator status." | 9.15 | Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations. ( Donald, PR; Hesseling, AC; Magdorf, K; Roll, S; Rosenkranz, B; Schaaf, HS; Seddon, JA; Seifart, HI; Thee, S; Werely, CJ, 2011) |
| "The World Health Organization recommends isoniazid preventive therapy (IPT) for preventing tuberculosis in HIV-infected adults, although few countries have instituted this policy." | 9.14 | Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort. ( Chaisson, RE; Golub, JE; Gray, GE; Martinson, NA; McIntyre, JA; Mohapi, L; Moshabela, M; Pronyk, P; Struthers, H; Thsabangu, N, 2009) |
| "To describe reasons for exclusion from isoniazid tuberculosis preventive therapy (IPT) and outcomes of persons living with HIV (PLWH) during 6 months of IPT." | 9.14 | Isoniazid tuberculosis preventive therapy in HIV-infected adults accessing antiretroviral therapy: a Botswana Experience, 2004-2006. ( Agizew, TB; Chengeta, B; Kilmarx, PH; Mathoma, A; Mosimaneotsile, B; Motsamai, OI; Nyirenda, S; Samandari, T; Tedla, Z; Wells, CD, 2010) |
| "Isoniazid preventive therapy prevents active tuberculosis in people with HIV, but previous studies have found no evidence of benefit in people with HIV who had a negative tuberculin skin test, and a non-significant effect on mortality." | 9.12 | Isoniazid preventive therapy plus antiretroviral therapy for the prevention of tuberculosis: a systematic review and meta-analysis of individual participant data. ( Anglaret, X; Badje, A; Barnabas, RV; Boulle, A; Eholie, S; Ford, N; Gabillard, D; Golub, JE; Maartens, G; Rangaka, MX; Ross, JM; Shapiro, AE; Thomas, KK; Walker, AS; Wilkinson, RJ; Williams, BG, 2021) |
| "Pellagra is a clinical syndrome caused by a deficiency of niacin (nicotinic acid) and/or its precursor tryptophan." | 9.12 | Pellagra a review exploring causes and mechanisms, including isoniazid-induced pellagra. ( Dawe, RS; Mponda, K; Prabhu, D, 2021) |
| "To characterize the bidirectional interaction between twice-daily nelfinavir and twice-weekly rifabutin and isoniazid in patients with tuberculosis and human immunodeficiency virus (HIV) infection." | 9.12 | Clinical evaluation of the nelfinavir-rifabutin interaction in patients with tuberculosis and human immunodeficiency virus infection. ( Becker, MI; Benator, DA; Burman, WJ; Engle, M; Hsyu, PH; Jones, BE; Khan, AE; Peloquin, CA; Sandman, L; Silva-Trigo, C; Vernon, AA; Weiner, MH; Zhao, ZA, 2007) |
| "We evaluated the effects of human immunodeficiency virus (HIV) disease on pharmacokinetics of antituberculosis medications by measuring concentrations of isoniazid and rifampin in blood and of pyrazinamide and ethambutol in urine." | 9.11 | Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease. ( Bhagavathy, S; Gurumurthy, P; Hemanth Kumar, AK; Mahilmaran, A; Padmapriyadarsini, C; Paramesh, P; Rajasekaran, S; Ramachandran, G; Ravichandran, N; Sekar, L; Swaminathan, S; Venkatesan, P, 2004) |
| "Lower plasma concentrations of rifabutin and, perhaps, isoniazid were associated with ARR failure or relapse in patients with tuberculosis and HIV infection treated with twice-weekly therapy." | 9.11 | Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. ( Benator, D; Burman, W; Hodge, T; Jones, B; Khan, A; Peloquin, CA; Silva-Trigo, C; Vernon, A; Weiner, M; Zhao, Z, 2005) |
| "To compare a 2-month regimen of daily rifampin and pyrazinamide with a 12-month regimen of daily isoniazid in preventing tuberculosis in persons with human immunodeficiency virus (HIV) infection." | 9.09 | Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health O ( Barry, MA; Chaisson, RE; Coberly, J; de Lourdes Garcia, M; Gordin, F; Hafner, R; Klukowicz, AJ; Matts, JP; Miller, C; O'Brien, RJ; Schechter, M; Valdespino, JL, 2000) |
| "Patients older than 18 years who were diagnosed with a first episode of tuberculosis at the national HIV testing centre in Haiti, and who successfully completed a 6-month rifampicin-containing regimen for active pulmonary tuberculosis, were randomly assigned 1 year of post-treatment isoniazid prophylaxis or placebo." | 9.09 | Effect of post-treatment isoniazid on prevention of recurrent tuberculosis in HIV-1-infected individuals: a randomised trial. ( Desvarieux, M; Fitzgerald, DW; Johnson, WD; Joseph, P; Pape, JW; Severe, P, 2000) |
| "A prospective comparative study was conducted to determine the effect of isoniazid prophylaxis on the incidence of active tuberculosis among Thai HIV-infected patients for 1 year." | 9.08 | Effect of isoniazid prophylaxis on incidence of active tuberculosis among Thai HIV-infected individuals. ( Saenghirunvattana, S, 1996) |
| " Thus, scaling up the isoniazid preventive therapy program and its strict compliance is necessary to avert HIV fueled tuberculosis." | 9.01 | The protective effect of isoniazid preventive therapy on tuberculosis incidence among HIV positive patients receiving ART in Ethiopian settings: a meta-analysis. ( Endalamaw, A; Eshetie, S; Geremew, D; Negash, M; Tessema, B, 2019) |
| "Isoniazid is recommended for prevention of tuberculosis (TB) in HIV-infected adults, but its efficacy in children living with HIV (CLHIV) is not known." | 8.98 | Isoniazid for the Prevention of Tuberculosis in HIV-Infected Children: A Systematic Review and Meta-Analysis. ( Charan, J; Emmanuel, P; Goyal, JP; Kumar, A; Patel, A; Reljic, T, 2018) |
| "This systematic review was carried out to determine the effectiveness of continuous isoniazid (given for at least 36 months) for the treatment of latent tuberculosis infection (LTBI) in people living with HIV (PLHIV)." | 8.93 | Continuous isoniazid for the treatment of latent tuberculosis infection in people living with HIV. ( Den Boon, S; Ford, N; Getahun, H; Matteelli, A, 2016) |
| "To systematically identify from qualitative data in the published literature the main barriers to adherence to isoniazid preventive therapy (IPT) for tuberculosis (TB) among people living with HIV/AIDS (PLWHA)." | 8.90 | Factors associated with adherence to treatment with isoniazid for the prevention of tuberculosis amongst people living with HIV/AIDS: a systematic review of qualitative data. ( Booth, A; Makanjuola, T; Taddese, HB, 2014) |
| " Upon combining data from all eight studies, isoniazid prophylaxis was found to be efficacious in preventing development of tuberculosis, with a pooled RR of 0." | 8.90 | Efficacy of isoniazid prophylactic therapy in prevention of tuberculosis in children: a meta-analysis. ( Abuogi, L; Ayieko, J; Bukusi, EA; Reingold, A; Simchowitz, B; Smith, AH, 2014) |
| "To compare the incidence of severe hepatitis in HIV-infected patients receiving rifampicin plus pyrazinamide (RZ) for antituberculosis prophylaxis with that of patients receiving a conventional isoniazid-based regime for 6 to 12 months (6-12H)." | 8.86 | [Use of rifampicin plus pyrazinamide for antituberculosis prophylaxis does not increase the risk of severe hepatotoxicity in HIV patients: meta-analysis of randomized controlled clinical trials]. ( Camacho, A; Castón, JJ; Gallo, M; García-Lázaro, M; Kindelán, JM; Natera, C; Pérez-Camacho, I; Rivero, A; Torre-Cisneros, J, 2010) |
| " isoniazid (INH) for the prevention of tuberculosis (TB) among persons with or without human immunodeficiency virus (HIV) infection." | 8.83 | Rifampicin plus pyrazinamide versus isoniazid for treating latent tuberculosis infection: a meta-analysis. ( Gao, XF; Li, YP; Liu, GJ; Sun, X; Wang, L; Wen, J; Xie, Y, 2006) |
| "Isoniazid pharmacokinetics are not yet well-described during once weekly, high-dose administrations with rifapentine (3HP) for latent tuberculosis infection (LTBI)." | 8.31 | High Isoniazid Exposures When Administered with Rifapentine Once Weekly for Latent Tuberculosis in Individuals with Human Immunodeficiency Virus. ( Chaisson, RE; Chihota, V; Churchyard, GJ; Dooley, KE; Jarrett, RT; Marzinke, MA; Shotwell, MS; van der Heijden, Y, 2023) |
| "Isoniazid (INH) preventive therapy is recommended to prevent tuberculosis (TB) disease for persons with HIV (PWH), except for those with regular and heavy alcohol consumption, due to hepatotoxicity concerns." | 8.31 | Safety and tolerability of isoniazid preventive therapy for tuberculosis for persons with HIV with and without alcohol use. ( Adong, J; Cheng, DM; Emenyonu, NI; Fatch, R; Hahn, JA; Jacobson, KR; Linas, BP; Muyindike, WR; Ngabirano, C; Terrault, NA; Tumwegamire, A, 2023) |
| "Cisgender women receiving efavirenz- or dolutegravir-based HIV therapy, or on isoniazid-rifampin for tuberculosis, were followed after a single oral dose of levonorgestrel." | 8.31 | Pharmacogenetic interactions of efavirenz or rifampin and isoniazid with levonorgestrel emergency contraception during treatment of HIV or tuberculosis. ( Agyemang, N; Badal-Faesen, S; Baker, P; Barr, E; Belaunzaran-Zamudio, PF; Cohn, SE; Gadama, L; Gatechompol, S; Godfrey, C; Haas, DW; Jalil, EM; Kayama, C; Mawlana, S; Mngqibisa, R; Olefsky, M; Pham, M; Podany, AT; Scarsi, KK; Smeaton, LM; Supparatpinyo, K; Van Schalkwyk, M; Woolley, E, 2023) |
| "Pellagra is caused by niacin (vitamin B3) deficiency and patients with pellagra present with a characteristic rash." | 8.12 | Isoniazid-associated pellagra during mass scale-up of tuberculosis preventive therapy: a case-control study. ( Auld, AF; Buono, N; Chilikutali, L; Chisuwo, L; Chiwaula, MJ; da Silva, R; Girma, B; Gunde, LJ; Gutreuter, S; Jahn, A; Kalua, T; Kaunda, E; Kim, EJ; Kumwenda, T; Maida, A; Maphosa, T; Marshall, RE; Mbewe, K; Mekonnen, TF; Melgar, M; Mhango, V; Moffitt, A; Mponda, K; Mtoto, F; Muula, AS; Mwamale, S; Mwenyeheri, G; Nabity, SA; Nagoli, E; Ngongonda, D; Nyirenda, R; Odo, M; Oeltmann, JE; Sharma, AJ; Sunguti, J; Surie, D; Williams, AM; Woelk, G; Zimba, SB, 2022) |
| "Although antiretroviral therapy (ART) can avert tuberculosis (TB) incidence among human immunodeficiency virus (HIV) infected patients, the concomitant use of ART with isoniazid (INH) has a paramount effect." | 8.12 | Tuberculosis and isoniazid prophylaxis among adult HIV positive patients on ART in Northwest Ethiopia. ( Adem, M; Bayleyegn, B; Geremew, D; Geremew, H; Tamir, M; Tegene, B, 2022) |
| "Isoniazid preventive therapy (IPT) is effective in treating tuberculosis (TB) infection and hence limiting progression to active disease." | 8.12 | Incidence of tuberculosis among PLHIV on antiretroviral therapy who initiated isoniazid preventive therapy: A multi-center retrospective cohort study. ( Alinga, SB; Biraro, IA; Etukoit, MB; Kagimu, D; Kakumba, K; Kateeba Tusiime, A; Kato, D; Kazibwe, A; Kirenga, B; Mafabi, CG; Miya, Y; Mugenyi, L; Nkabala, R; Ochwo, M; Odoi, C; Oluka, AI; Opito, R; Oryokot, B; Ouma, S; Tayebwakushaba, E; Tusiimire, W, 2022) |
| "To examine the association between isoniazid preventive therapy (IPT) or nontuberculous mycobacteria (NTM) sputum culture positivity and tuberculosis (TB) transcriptional signatures in people with HIV." | 8.12 | Isoniazid preventive therapy and tuberculosis transcriptional signatures in people with HIV. ( Barnabas, RV; Cangelosi, GA; Gersh, JK; Hatherill, M; Hawn, TR; Horne, DJ; Joudeh, LL; Kinuthia, J; Matemo, D; Mendelsohn, SC; Scriba, TJ; Valinetz, ED; Wald, A, 2022) |
| "Tuberculosis (TB) is major public health concern and Isoniazid Preventive Therapy (IPT) helps to prevent TB development among patients living with human immune deficiency virus (PLWHIV)." | 8.12 | Prevalence and associated factors of tuberculosis among isoniazid users and non-users of HIV patients in Dessie, Ethiopia. ( Damtew, Y; Endawkie, A; Mebratu, W; Mohammed, S; Wedajo, S, 2022) |
| "We aimed to assess the coverage of tuberculosis screening and isoniazid preventive therapy (IPT) among people living with human immunodeficiency virus (PLHIV) at Gambella Hospital, southwest Ethiopia." | 8.02 | Tuberculosis screening coverage and isoniazid preventive therapy among people living with HIV at Gambella Hospital, southwest Ethiopia: a retrospective study design. ( Aboma, M; Dida, N, 2021) |
| "Short-course preventive therapy with 1-month course of daily administration of isoniazid (300-mg) plus rifapentine (600-mg) (1HP) and 3-month course of weekly administration of isoniazid (900-mg) plus rifapentine (900-mg) (3HP) has higher completion rates than 9-month course of daily isoniazid (9H) for individuals with latent tuberculosis infection (LTBI)." | 8.02 | Short-course daily isoniazid and rifapentine for latent tuberculosis infection in people living with HIV who received coformulated bictegravir/emtricitabine/tenofovir alafenamide. ( Cheng, CN; Chuang, YC; Hung, CC; Kuo, CH; Lin, KY; Lin, SW; Lin, YJ; Lin, YT; Liou, BH; Liu, WC; Sun, HY, 2021) |
| "Rifampin appears to be safe and as effective as isoniazid across many populations with health conditions, including HIV." | 8.02 | Safety and Efficacy of Rifampin or Isoniazid Among People With Mycobacterium tuberculosis Infection and Living With Human Immunodeficiency Virus or Other Health Conditions: Post Hoc Analysis of 2 Randomized Trials. ( Al-Jahdali, H; Bah, B; Belo, M; Campbell, JR; Cook, VJ; Long, R; Menzies, D; Schwartzman, K; Trajman, A, 2021) |
| "Isoniazid preventive therapy (IPT) against tuberculosis (TB) is a life-saving intervention for people living with HIV (PLHIV)." | 8.02 | Early-phase scale-up of isoniazid preventive therapy for people living with HIV in two districts in Malawi (2017). ( Auld, AF; Gunde, LJ; Jahn, A; Kirking, HL; Maida, A; Nabity, SA; Nyirenda, RK; Odo, M; Oeltmann, JE; Shiraishi, RW; Surie, D, 2021) |
| "Depot medroxyprogesterone acetate is an injectable hormonal contraceptive, widely used by women of childbearing potential living with HIV and/or tuberculosis." | 8.02 | A Semimechanistic Pharmacokinetic Model for Depot Medroxyprogesterone Acetate and Drug-Drug Interactions With Antiretroviral and Antituberculosis Treatment. ( Cohn, SE; Denti, P; Dooley, KE; Firnhaber, C; Francis, J; Godfrey, C; Kendall, MA; McIlleron, H; Mngqibisa, R; Wu, X, 2021) |
| "Niacin or tryptophan deficiency causes pellagra." | 8.02 | A peculiarly characterised case of isoniazid-induced pellagra- 2 Ds and a C: a case report. ( Kabengele, C; M'hango, H; Malumani, M; Mweemba, D, 2021) |
| "Antiretroviral therapy (ART) and isoniazid preventive therapy (IPT) are known to have a tuberculosis (TB) protective effect at the individual level among people living with HIV (PLHIV)." | 7.96 | Trend analysis of tuberculosis case notifications with scale-up of antiretroviral therapy and roll-out of isoniazid preventive therapy in Zimbabwe, 2000-2018. ( Choto, RC; Harries, AD; Mabaya, S; Mbito, C; Mutasa-Apollo, T; Sandy, C; Takarinda, KC; Timire, C, 2020) |
| "A multicentre, prospective pilot study was initiated among adults living with HIV on isoniazid 300 mg with pyridoxine 50 mg after ruling out active tuberculosis (TB)." | 7.96 | Effectiveness of isoniazid preventive therapy on incidence of tuberculosis among HIV-infected adults in programme setting. ( Agarwal, U; Bhavani, PK; Chitra, A; Maheshmanisha, J; Mothi, SN; Nandagopal, K; Padmapriyadarsini, C; Poornagangadevi, N; Reddy, D; Rewari, BB; Sekar, L; Selvaraj, M; Swaminathan, S; Tamizhselvan, M; Vennila, S, 2020) |
| "The World Health Organization recommends isoniazid preventive therapy (IPT) for people living with HIV (PLHIV) to prevent tuberculosis (TB), including pregnant women." | 7.91 | Brief Report: High Programmatic Isoniazid Preventive Therapy (IPT) Use in Pregnancy Among HIV-Infected Women. ( Copeland, A; Cranmer, LM; John-Stewart, G; Kinuthia, J; LaCourse, SM; Maleche-Obimbo, E; Matemo, D; Richardson, BA; Wagner, AD, 2019) |
| "Gynecomastia is known to occur in some men taking an efavirenz-based antiretroviral therapy (ART) regimen." | 7.91 | Gynecomastia in HIV-positive adult men receiving efavirenz-based antiretroviral therapy at Newlands clinic, Harare, Zimbabwe. ( Chimbetete, C; Shamu, T; Shawarira-Bote, S, 2019) |
| "Isoniazid resistant tuberculosis is the most prevalent type of resistance in Swaziland and over two-thirds of the isoniazid resistant tuberculosis patients are tuberculosis and human immunodeficiency virus co-infected." | 7.91 | Factors associated with isoniazid resistant tuberculosis among human immunodeficiency virus positive patients in Swaziland: a case-control study. ( Chien, LY; Dlamini, NC; Ji, DD, 2019) |
| " The research method applied was comparative analysis of the results of own study and studies by other researchers, concerning the effectiveness of tuberculosis prophylaxis in patients with HIV/AIDS when treated with isoniazid." | 7.91 | Comparative analysis of the effectiveness of tuberculosis prophylaxis in patients with HIV/AIDS treated with isoniazid. ( Głowacka, M; Jarosz, MJ; Juszkiewicz, K; Włoszczak-Szubzda, A, 2019) |
| "Lopinavir-ritonavir forms the backbone of current first-line antiretroviral regimens in young HIV-infected children." | 7.88 | Pharmacokinetics and Drug-Drug Interactions of Lopinavir-Ritonavir Administered with First- and Second-Line Antituberculosis Drugs in HIV-Infected Children Treated for Multidrug-Resistant Tuberculosis. ( de Kock, M; Denti, P; Garcia-Prats, AJ; Hesseling, AC; McIlleron, H; Norman, J; Schaaf, HS; Tikiso, T; van der Laan, LE; Wiesner, L; Winckler, J, 2018) |
| "A short-course regimen of 3 months of weekly rifapentine and isoniazid (3HP) has recently been recommended by the World Health Organization as an alternative to at least 6 months of daily isoniazid (isoniazid preventive therapy [IPT]) for prevention of tuberculosis (TB)." | 7.88 | Cost-effectiveness of Preventive Therapy for Tuberculosis With Isoniazid and Rifapentine Versus Isoniazid Alone in High-Burden Settings. ( Churchyard, GJ; Dowdy, DW; Johnson, KT; Sohn, H, 2018) |
| "We model the epidemiological impact of providing isoniazid preventive therapy (IPT) to South African adolescents, among whom HIV prevalence is low, latent tuberculosis (TB) prevalence is high, and school-based programs may enable population-level coverage." | 7.88 | Modeling the implementation of population-level isoniazid preventive therapy for tuberculosis control in a high HIV-prevalence setting. ( Bendavid, E; Feldman, MW; Rhines, AS, 2018) |
| "To describe outcomes associated with the implementation of isoniazid preventive therapy (IPT) in a cohort of tuberculosis (TB) treatment-experienced human immunodeficiency virus (HIV) infected patients on antiretroviral therapy (ART)." | 7.85 | Implementing isoniazid preventive therapy in a tuberculosis treatment-experienced cohort on ART. ( Gengiah, S; Gengiah, TN; Maharaj, B; Naidoo, A; Naidoo, K; Yende-Zuma, N, 2017) |
| "One of the reasons why Isoniazid preventive therapy (IPT) for Tuberculosis (TB) is not widely used in low income countries is concerns on cost of excluding active TB." | 7.85 | Cost-Effectiveness of isoniazid preventive therapy among HIV-infected patients clinicaly screened for latent tuberculosis infection in Dar es Salaam, Tanzania: A prospective Cohort study. ( Aboud, S; Bakari, M; Chitama, D; Moshiro, C; Mugusi, F; Shayo, GA, 2017) |
| "Rifampin (RIF) mono-resistant tuberculosis (RMR-TB) is a rare disease." | 7.85 | Treatment outcomes of rifampin-sparing treatment in patients with pulmonary tuberculosis with rifampin-mono-resistance or rifampin adverse events: A retrospective cohort analysis. ( Jo, KW; Kim, WS; Lee, SD; Park, S; Shim, TS, 2017) |
| "Tuberculosis (TB) screening affords clinicians the opportunity to diagnose or exclude TB disease and initiate isoniazid preventive therapy (IPT) for people living with HIV (PLHIV)." | 7.85 | Programmatic Evaluation of an Algorithm for Intensified Tuberculosis Case Finding and Isoniazid Preventive Therapy for People Living With HIV in Thailand and Vietnam. ( Cowger, TL; Danyuttapolchai, J; Duong, BD; Khanh, VT; Kittimunkong, S; Monkongdee, P; Nateniyom, S; Ngoc, DV; Nhan, DT; Nhung, NV; Pevzner, ES; Thai, LH; Thinh, T; Thoa, CK; Whitehead, S; Yen, NTB, 2017) |
| "To compare the pharmacokinetics of rifampicin (RMP), isoniazid (INH) and pyrazinamide (PZA) between HIV-infected and HIV-uninfected children with tuberculosis (TB) and correlate it with TB treatment outcome." | 7.83 | Low Serum Concentrations of Rifampicin and Pyrazinamide Associated with Poor Treatment Outcomes in Children with Tuberculosis Related to HIV Status. ( Agarwal, D; Banurekha, VV; Bhavani, PK; Gangadevi, NP; Kalpana, S; Kannan, T; Kumar, AK; Kumar, SR; Mathevan, G; Ramachandran, G; Ravichandran, N; Sanjeeva, GN; Sudha, V; Swaminathan, S; Venkatesh, S, 2016) |
| "In HIV-uninfected individuals, isoniazid preventive therapy (IPT) has been associated with long-term protection against tuberculosis (TB)." | 7.83 | Post-treatment effect of isoniazid preventive therapy on tuberculosis incidence in HIV-infected individuals on antiretroviral therapy. ( Boulle, A; Houben, RM; Maartens, G; Rangaka, MX; Sumner, T; White, RG; Wilkinson, RJ, 2016) |
| "World Health Organization advocates for integration of HIV-tuberculosis (TB) services and recommends intensive case finding (ICF), isoniazid preventive therapy (IPT), and infection control ("Three I's") for TB prevention and control among persons living with HIV." | 7.83 | Implementation of Tuberculosis Intensive Case Finding, Isoniazid Preventive Therapy, and Infection Control ("Three I's") and HIV-Tuberculosis Service Integration in Lower Income Countries. ( Avit-Edi, D; Ballif, M; Blevins, M; Castelnuovo, B; Charles, MK; Cortes, CP; Dung, NT; Durier, N; Dusingize, JC; Fenner, L; Lindegren, ML; Nakigozi, G; Sterling, TR; Wester, CW, 2016) |
| "Extending the duration of isoniazid preventive therapy (IPT) among people living with HIV (PLHIV) may improve its effectiveness at both individual and population levels, but could also increase selective pressure in favor of isoniazid-resistant tuberculosis (TB) strains." | 7.83 | Benefits of continuous isoniazid preventive therapy may outweigh resistance risks in a declining tuberculosis/HIV coepidemic. ( Cohen, T; Crawford, FW; Kunkel, A; Shepherd, J, 2016) |
| "The duration of protection against tuberculosis provided by isoniazid preventive therapy is not known for human immunodeficiency virus (HIV)-infected individuals living in settings of medium tuberculosis incidence." | 7.81 | Long-term protection from isoniazid preventive therapy for tuberculosis in HIV-infected patients in a medium-burden tuberculosis setting: the TB/HIV in Rio (THRio) study. ( Cavalcante, SC; Chaisson, RE; Cohn, S; Durovni, B; Golub, JE; Moulton, LH; Pacheco, AG; Saraceni, V, 2015) |
| "Data on feasibility and completion rates of isoniazid preventive therapy (IPT) in HIV-infected patient in Asia are limited." | 7.81 | Implementation of isoniazid preventive therapy in an HIV clinic in Cambodia: high rates of discontinuation when combined with antiretroviral therapy. ( Chim, B; Choun, K; Lorent, N; Lynen, L; Thai, S; van Griensven, J, 2015) |
| " We report a case of clopidogrel non-responsiveness in a patient with HIV, latent tuberculosis and cardiovascular disease with a history of myocardial infarction." | 7.80 | A patient with HIV and tuberculosis with diminished clopidogrel response. ( Metzger, NL; Momary, KM, 2014) |
| "The Lesotho Ministry of Health issued guidelines on active case finding (ACF) for tuberculosis (TB) and isoniazid preventive therapy (IPT) in April 2011." | 7.80 | Preventing tuberculosis among HIV-infected pregnant women in Lesotho: the case for rolling out active case finding and isoniazid preventive therapy. ( Ahimbisibwe, A; Barnes, GL; Chaisson, RE; Gounder, CR; Guay, L; Isavwa, A; Kassaye, S; Maama-Maime, LB; Machekano, R; Mokone, M; Ntene-Sealiete, K; Oyebanji, O; Sahu, M; Tiam, A, 2014) |
| " The main barriers as reported by 144 HCWs working in hospitals without IPT programme, were: (1) unclear direction of national policy (60%), (2) fear of emerging Isoniazid resistant tuberculosis (52%), and (3) fear of poor adherence (30%)." | 7.79 | Barriers to and motivations for the implementation of a treatment programme for latent tuberculosis infection using isoniazid for people living with HIV, in upper northern Thailand. ( Kaewkungwal, J; Lawpoolsri, S; Moolphate, S; Pungrassami, P; Sanguanwongse, N; Yamada, N, 2013) |
| "The World Health Organization (WHO) recommends active tuberculosis (TB) case finding among people living with human immunodeficiency virus (HIV) in resource-limited settings using a symptom-based algorithm; those without active TB disease should be offered isoniazid preventive therapy (IPT)." | 7.79 | Improving tuberculosis screening and isoniazid preventive therapy in an HIV clinic in Addis Ababa, Ethiopia. ( Blumberg, HM; Kempker, R; Ofotokun, I; Stenehjem, E; Temesgen, O; Tenna, A; Zaeh, S, 2013) |
| "Comprehensive information on the effects of cytochrome P450 2B6 (CYP2B6) polymorphisms, clinical factors, and drug-drug interactions on efavirenz concentrations in HIV/tuberculosis-coinfected (HIV/TB) patients is unavailable." | 7.79 | Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients. ( Lueangniyomkul, A; Mankatitham, W; Manosuthi, S; Manosuthi, W; Nilkamhang, S; Sukasem, C; Sungkanuparph, S; Thongyen, S, 2013) |
| "To describe the characteristics and outcomes of incident tuberculosis (TB) cases in human immunodeficiency virus (HIV) infected adults exposed to isoniazid preventive therapy (IPT) with access to antiretroviral and anti-tuberculosis treatment." | 7.79 | Anti-tuberculosis treatment outcomes in HIV-infected adults exposed to isoniazid preventive therapy in Botswana. ( Agizew, T; Johnson, JL; Marape, M; Miranda, AG; Nyirenda, S; Reuter, H; Samandari, T; Sibanda, T; Tedla, Z, 2013) |
| "Limited data exist about the clinical characteristics of Mycobacterium tuberculosis (TB) isolates with resistance to isoniazid (IZN)." | 7.77 | Comparison of isoniazid monoresistant tuberculosis with drug-susceptible tuberculosis and multidrug-resistant tuberculosis. ( Fox, L; Haim, I; Kramer, MR; Metvachuk, A; Priess, R; Shitrit, D, 2011) |
| "Quantifying isoniazid resistant (INH-R) tuberculosis (TB) is important because isoniazid resistance reduces the probability of treatment success, may facilitate the spread of multidrug resistance, and may reduce the effectiveness of isoniazid preventive therapy (IPT)." | 7.77 | Quantifying the burden and trends of isoniazid resistant tuberculosis, 1994-2009. ( Cohen, T; Jenkins, HE; Zignol, M, 2011) |
| "Active tuberculosis (TB) must be excluded before initiating isoniazid preventive therapy (IPT) in persons infected with human immunodeficiency virus (HIV), but currently used screening strategies have poor sensitivity and specificity and high patient attrition rates." | 7.76 | Microscopic observation drug susceptibility assay for tuberculosis screening before isoniazid preventive therapy in HIV-infected persons. ( Benites, C; Brady, MF; Chavez, G; Coronel, J; Friedland, JS; Gilman, RH; Moore, DA; Navincopa, M; Pinedo, Y; Reddy, KP; Rojas, C; Sánchez, E; Solari, L; Ticona, E; Valencia, J, 2010) |
| "Despite World Health Organization recommendations, concerns about promoting resistance have impeded implementation of isoniazid preventive therapy (IPT) for tuberculosis (TB)." | 7.76 | Tuberculosis outcomes and drug susceptibility in individuals exposed to isoniazid preventive therapy in a high HIV prevalence setting. ( Chihota, VN; Churchyard, GJ; Fielding, KL; Grant, AD; Lewis, JJ; Russell, EC; van Halsema, CL, 2010) |
| "Antiretroviral therapy and isoniazid preventive therapy (IPT) are both effective interventions to prevent HIV-associated tuberculosis, but work via different mechanisms." | 7.76 | Antiretrovirals and isoniazid preventive therapy in the prevention of HIV-associated tuberculosis in settings with limited health-care resources. ( Churchyard, GJ; De Cock, KM; Kranzer, K; Lawn, SD; Lewis, JJ; Wood, R, 2010) |
| "The absorption of rifampin, isoniazid, and D-xylose in patients with human immunodeficiency virus (HIV) infection and diarrhea, in patients with HIV infection and tuberculosis (TB), in patients with pulmonary TB alone, and in healthy subjects was studied." | 7.72 | Malabsorption of rifampin and isoniazid in HIV-infected patients with and without tuberculosis. ( Gurumurthy, P; Hemanth Kumar, AK; Krishnarajasekhar, OR; Kumar, S; Padmapriyadarsini, C; Paramesh, P; Rajasekaran, S; Ramachandran, G; Sekar, L; Swaminathan, S; Venkatesan, P, 2004) |
| "In 2000, results of a multinational trial demonstrated that a 2-month course of rifampin and pyrazinamide (RZ) was as effective as isoniazid (INH) in reducing tuberculosis in human immunodeficiency virus (HIV)-infected individuals with latent tuberculosis infection (LTBI)." | 7.72 | Hepatotoxicity of rifampin and pyrazinamide in the treatment of latent tuberculosis infection in HIV-infected persons: is it different than in HIV-uninfected persons? ( Chaisson, RE; Cohn, DL; Gordin, FM; Matts, JP; O'Brien, RJ, 2004) |
| "Treatment of latent Mycobacterium tuberculosis infection with isoniazid can cause hepatotoxicity, but the risk of isoniazid-associated hepatotoxicity among persons coinfected with hepatitis C virus (HCV) is unknown." | 7.71 | Isoniazid preventive therapy, hepatitis C virus infection, and hepatotoxicity among injection drug users infected with Mycobacterium tuberculosis. ( Astemborski, J; Bonds, M; Graham, NM; Madison, A; Sadaphal, P; Sheely, L; Sterling, TR; Thomas, DL; Vlahov, D, 2001) |
| "To determine the acceptability, compliance and side effects of isoniazid (INH) prophylaxis against tuberculosis among HIV infected police officers (PO) in Dar es Salaam." | 7.70 | Isoniazid prophylaxis for tuberculosis prevention among HIV infected police officers in Dar es Salaam. ( Aris, EA; Bakari, M; Biberfeld, G; Chale, S; Josiah, R; Magao, P; Mhalu, F; Moshi, A; Mugusi, F; Pallangyo, K; Pallangyo, N; Sandström, E, 2000) |
| "To compare the strategy of TB vaccination with that of tuberculin skin-testing in conjunction with isoniazid (INH) in preventing tuberculosis in HIV-infected persons." | 7.70 | Tuberculosis vaccination versus isoniazid preventive therapy: a decision analysis to determine the preferred strategy of tuberculosis prevention in HIV-infected adults in the developing world. ( Brehm, WT; Chaisson, RE; Moore, RD; Sterling, TR, 1999) |
| "Cumulative 24-month Mycobacterium tuberculosis infection incidence (measured primarily by tuberculin skin test [TST]) was high among human immunodeficiency virus exposed but uninfected infants (8." | 7.11 | Cumulative Mycobacterium tuberculosis Infection Incidence (Measured Primarily by Tuberculin Skin Test) Among Infants With Human Immunodeficiency Virus Exposure: Observational Follow-up of an Isoniazid Prophylaxis Trial. ( Carimo, N; Cranmer, LM; Escudero, JN; Hawn, TR; John-Stewart, G; Kinuthia, J; LaCourse, SM; Maleche-Obimbo, E; Matemo, D; Mecha, J; Richardson, BA; Warr, AJ, 2022) |
| "Pregnancy is accompanied by immune suppression." | 7.01 | Effects of Pregnancy and Isoniazid Preventive Therapy on Mycobacterium tuberculosis Interferon Gamma Response Assays in Women With HIV. ( Aaron, L; Bradford, S; Browning, R; Costello, D; Denti, P; Gausi, K; Gupta, A; Haas, DW; Kabugho, E; LaCourse, SM; Masheto, G; Mathad, JS; McCarthy, K; Mmbaga, B; Montepiedra, G; Naik, S; Pahwa, S; Pierre, MF; Sterling, TR; Theron, G; Vhembo, T; Weinberg, A; Zimmer, B, 2021) |
| "Participants receiving daily rifapentine and isoniazid with efavirenz had pharmacokinetic evaluations at baseline and weeks 2 and 4 of concomitant therapy." | 6.80 | Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention. ( Andersen, JW; Bao, Y; Benson, CA; Chaisson, RE; Fletcher, CV; Gupta, A; Kim, P; Mohapi, L; Mwelase, T; Podany, AT; Supparatpinyo, K; Swindells, S, 2015) |
| " It is evident that guidelines established for the prevention and treatment of this problem differ between industrialised and developing countries, and that further research is needed to define the optimum dosing of pyridoxine supplementation in populations where there is a significant burden of TB and HIV." | 6.47 | Polyneuropathy, anti-tuberculosis treatment and the role of pyridoxine in the HIV/AIDS era: a systematic review. ( Benatar, M; Harrison, TB; Heckmann, JM; van der Watt, JJ, 2011) |
| " We provide suggested dolutegravir dosing considerations with concomitant rifapentine use, not currently addressed in recommended guidelines." | 5.91 | Alternative dolutegravir dosing strategies with concurrent rifapentine utilized for latent tuberculosis treatment. ( Pecora Fulco, P; Taylor, A; Winthrop, E, 2023) |
| " The findings of the present study indicate the need to periodically assess adherence and persistence to IPT in the child TB contacts as high intermittent missed dosing rates can undermine the effectiveness of IPT in preventing incident disease." | 5.72 | Adherence to Isoniazid Preventive Therapy among children living with tuberculosis patients in Delhi, India: An exploratory prospective study. ( Basu, S; Chandra, S; Chopra, KK; Khanna, A; Sharma, N; Sharma, P, 2022) |
| " Simulations were performed to assess INH exposure and optimal dosing regimens, using 2 targets: Cmax at 3-6 mg/L and area under the curve (AUC) ≥ 10." | 5.72 | Influence of NAT2 Genotype and Maturation on Isoniazid Exposure in Low-Birth-Weight and Preterm Infants With or Without Human Immunodeficiency Virus (HIV) Exposure. ( Bekker, A; Béranger, A; Browning, R; Cababasay, M; Capparelli, EV; Cotton, MF; Mirochnick, M; Moye, J; Savic, RM; Solans, BP; Violari, A; Wang, J; Wiesner, L, 2022) |
| " Nonlinear mixed-effects models were developed to describe the pharmacokinetic data." | 5.72 | Effects of Enzyme Induction and Polymorphism on the Pharmacokinetics of Isoniazid and Rifampin in Tuberculosis/HIV Patients. ( Äbelö, A; Ashton, M; Bienvenu, E; Birgersson, S; Sundell, J, 2022) |
| "In people with HIV-associated DS-PTB with CD4+ counts ≥100 cells/μL on efavirenz-based ART, the 4-month daily rifapentine-moxifloxacin regimen was noninferior to the 6-month control regimen and was safe." | 5.69 | Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349). ( Bryant, K; Chaisson, RE; Dawson, R; Dooley, KE; Dorman, SE; Johnson, JL; Kurbatova, E; Lalloo, UG; Mohapi, L; Muzanyi, G; Nahid, P; Pettit, AC; Phillips, PPJ; Podany, AT; Samaneka, W; Sanne, I; Savic, RM; Scott, N; Sizemore, E; Swindells, S; Vernon, A; Waja, Z, 2023) |
| "Our findings suggest that twice-daily dolutegravir might be unnecessary in people with HIV-associated tuberculosis." | 5.69 | Standard-dose versus double-dose dolutegravir in HIV-associated tuberculosis in South Africa (RADIANT-TB): a phase 2, non-comparative, randomised controlled trial. ( Griesel, R; Hill, AM; Keene, CM; Maartens, G; Meintjes, G; Omar, Z; Simmons, B; Wiesner, L; Zhao, Y, 2023) |
| " Of 749 infants, 694 (93%) received Bacille Calmette-Guérin (BCG) vaccination, 675 (90%) were born to mothers who had completed isoniazid treatment, 20 (3%) were exposed to tuberculosis, seven (1%) became HIV positive, and one (<1%) developed probable tuberculosis." | 5.69 | Timing of maternal isoniazid preventive therapy on tuberculosis infection among infants exposed to HIV in low-income and middle-income settings: a secondary analysis of the TB APPRISE trial. ( Aaron, L; Bradford, S; Chakhtoura, N; Chanaiwa, V; Chipato, T; Costello, D; Golner, A; Gupta, A; Jean-Phillippe, P; Kabugho, E; Kulkarni, V; Masheto, G; Montepiedra, G; Mutambanengwe, M; Raesi, M; Shayo, A; Singh, P; Sterling, TR; Stranix-Chibanda, L; Theron, G; Vhembo, T; Weinberg, A, 2023) |
| "Alcohol use is common among people with HIV and is a risk factor for tuberculosis disease and non-adherence to isoniazid preventive therapy (IPT)." | 5.69 | Financial incentives for reduced alcohol use and increased isoniazid adherence during tuberculosis preventive therapy among people with HIV in Uganda: an open-label, factorial randomised controlled trial. ( Adong, J; Beesiga, B; Bryant, K; Chamie, G; Emenyonu, NI; Fatch, R; Gandhi, M; Hahn, JA; Havlir, DV; Kamya, MR; Kekibiina, A; Lodi, S; Marson, K; McDonell, MG; Muyindike, WR; Thirumurthy, H, 2023) |
| " Both sex and CD4 cell count affected the bioavailability of isoniazid." | 5.56 | Model-Based Assessment of Variability in Isoniazid Pharmacokinetics and Metabolism in Patients Co-Infected With Tuberculosis and HIV: Implications for a Novel Dosing Strategy. ( Äbelö, A; Ashton, M; Bienvenu, E; Birgersson, S; Janzén, D; Sundell, J, 2020) |
| "We report pregnancy outcomes among South African women with HIV enrolled in a randomized trial of 4 TPT regimens (two 3-month regimens, rifapentine/isoniazid [3HP] or rifampin/isoniazid [3HR], isoniazid for 6 months, or isoniazid continuously)." | 5.51 | Pregnancy in Women With HIV in a Tuberculosis Preventive Therapy Trial. ( Barnes, GL; Chaisson, RE; Gupta, A; Martinson, NA; Moulton, LH; Msandiwa, R; Singh, P, 2022) |
| " Rifapentine clearance is higher among women with HIV, but all women achieved exposures of rifapentine and isoniazid associated with successful tuberculosis prevention." | 5.51 | Pharmacokinetics and Safety of 3 Months of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention in Pregnant Women. ( Bradford, S; Britto, P; Chakhtoura, N; Chalermchockcharoentkit, A; Chipato, T; Dooley, KE; Gupta, A; Jayachandran, P; Kamthunzi, P; Langat, D; Mathad, JS; Montepiedra, G; Norman, J; Patil, S; Popson, S; Rouzier, V; Savic, R; Townley, E; Wiesner, L; Zhang, N, 2022) |
| "In AIDS Clinical Trials Group study A5338, concomitant rifampicin, isoniazid, and efavirenz was associated with more rapid plasma medroxyprogesterone acetate (MPA) clearance compared to historical controls without tuberculosis or HIV therapy." | 5.51 | Pharmacogenetics of interaction between depot medroxyprogesterone acetate and efavirenz, rifampicin, and isoniazid during treatment of HIV and tuberculosis. ( Angira, F; Badal-Faesen, S; Baker, P; Cohn, SE; Denti, P; Francis, J; Haas, DW; Kendall, MA; Mawlana, S; McIlleron, H; Mngqibisa, R; Omoz-Oarhe, A; Robinson, JA; Samaneka, WP, 2022) |
| "We identified significant gaps in the treatment for M." | 5.43 | Isoniazid therapy for Mycobacterium tuberculosis infection in HIV clinics, Los Angeles, California. ( Bolan, R; Chang, AH; Dubé, MP; Ghosh, JK; Kerndt, PR; Shin, SS; Yang, OO, 2016) |
| " One hundred patients with pulmonary tuberculosis (65% coinfected with HIV-1) were intensively sampled to determine rifampin, isoniazid, and pyrazinamide plasma concentrations after 7 to 8 weeks of a daily quadruple-therapy regimen dosed according to World Health Organization (WHO) weight bands." | 5.43 | HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients. ( Chirehwa, M; Denti, P; McIlleron, H; Meintjes, G; Rockwood, N; Wiesner, L; Wilkinson, RJ, 2016) |
| "Scaling up shorter regimens for tuberculosis (TB) prevention such as once weekly isoniazid-rifapentine (3HP) taken for 3 months is a key priority for achieving targets set forth in the World Health Organization's (WHO) END TB Strategy." | 5.41 | Completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV: Interim analysis of a hybrid type 3 effectiveness-implementation randomized trial. ( Akello, L; Belknap, R; Berger, CA; Bishop, O; Cattamanchi, A; Dowdy, DW; Handley, MA; Kadota, JL; Kamya, MR; Katahoire, A; Katamba, A; Kiwanuka, N; Musinguzi, A; Nabunje, J; Nahid, P; Nakitende, A; Patel, D; Phillips, PPJ; Sammann, A; Semitala, FC; Welishe, F, 2021) |
| "The aim of this study was to systematically assess the efficacy, safety, and tolerability of isoniazid preventive therapy (IPT) for tuberculosis (TB) in people with HIV (PWH)." | 5.41 | Efficacy, safety, and tolerability of isoniazid preventive therapy for tuberculosis in people living with HIV. ( Gudi, SK; Jagi, JL; Thomas, C; Undela, K, 2023) |
| " We included studies in children aged <18 years being treated for drug-susceptible tuberculosis with rifampicin (RIF), pyrazinamide, isoniazid, and ethambutol." | 5.41 | Effectiveness and Pharmacokinetic Exposures of First-Line Drugs Used to Treat Drug-Susceptible Tuberculosis in Children: A Systematic Review and Meta-Analysis. ( Béranger, A; Gegia, M; Linh, NN; Mirzayev, F; Mohamed, A; Nahid, P; Radtke, K; Savic, RM; Schumacher, SG; Solans, BP, 2023) |
| "International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) P1078, a randomized noninferiority study designed to compare the safety of starting isoniazid preventive therapy (IPT) in women living with human immunodeficiency virus (HIV) either during pregnancy or after delivery, showed that IPT during pregnancy increased the risk of composite adverse pregnancy outcomes, but not individual outcomes." | 5.41 | Individual and Composite Adverse Pregnancy Outcomes in a Randomized Trial on Isoniazid Preventative Therapy Among Women Living With Human Immunodeficiency Virus. ( Aaron, L; Chakhtoura, N; Chipato, T; Gupta, A; Jean-Philippe, P; Lespinasse, D; Loftis, AJ; Masheto, G; McCarthy, K; Montepiedra, G; Nematadzira, T; Ngocho, J; Nyati, M; Onyango-Makumbi, C; Patil, S; Theron, G; Tongprasert, F; Weinberg, A; Zimmer, B, 2021) |
| "Short-course preventive therapy with 12 doses of once-weekly rifapentine (900 mg) plus isoniazid (900 mg) could greatly improve tuberculosis control, especially in areas with high co-endemicity with HIV." | 5.34 | Once-weekly rifapentine and isoniazid for tuberculosis prevention in patients with HIV taking dolutegravir-based antiretroviral therapy: a phase 1/2 trial. ( Beattie, T; Chaisson, RE; Churchyard, GJ; Dooley, KE; Edward, VA; Fyvie, MJ; Gupte, A; Likoti, M; Marzinke, MA; Savic, R; Sebe, M; Shibambo, I; Wolf, L; Zhang, N, 2020) |
| " Its use in combination with rifapentine (RPT), an antituberculosis (TB) antibiotic, may reduce the exposure of DOR compromising viral suppression in those living with HIV-1 co-infected with TB." | 5.34 | Twice-Daily Doravirine Overcomes the Interaction Effect from Once-Weekly Rifapentine and Isoniazid in Healthy Volunteers. ( Kraft, WK; Lam, E; Schaefer, J; Zhan, T; Zheng, R, 2020) |
| " We provide inferential tools for SCQE and its first application, examining whether isoniazid preventive therapy (IPT) reduced tuberculosis (TB) incidence among 26 715 HIV patients in Tanzania." | 5.34 | Inference without randomization or ignorability: A stability-controlled quasi-experiment on the prevention of tuberculosis. ( Hazlett, C; Maokola, W; Wulf, DA, 2020) |
| "Tuberculosis is a common complication and leading cause of death in HIV infection." | 5.34 | The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. ( Cavalcante, SC; Chaisson, RE; Durovni, B; Efron, A; Golub, JE; King, BS; Moore, RD; Moulton, LH; Pacheco, AG; Saraceni, V, 2007) |
| "Treatment with isoniazid was beneficial in HIV-infected, tuberculin-positive IDUs." | 5.32 | Effectiveness of isoniazid treatment for latent tuberculosis infection among human immunodeficiency virus (HIV)-infected and HIV-uninfected injection drug users in methadone programs. ( Amofa, J; Driver, CR; Fujiwara, PI; Gourevitch, MN; Highley, E; Kaye, K; Munsiff, SS; Rubino, MA; Scholten, JN; Seewald, R; Trim, C, 2003) |
| "In this multicenter, double-blind, placebo-controlled, noninferiority trial, we randomly assigned pregnant women with HIV infection to receive isoniazid preventive therapy for 28 weeks, initiated either during pregnancy (immediate group) or at week 12 after delivery (deferred group)." | 5.30 | Isoniazid Preventive Therapy in HIV-Infected Pregnant and Postpartum Women. ( Aaron, L; Aurpibul, L; Bhosale, R; Bradford, S; Chakhtoura, N; Chipato, T; Costello, D; Gupta, A; Hesseling, A; Jean-Philippe, P; Masheto, GR; Mave, V; McCarthy, K; Mmbaga, BT; Montepiedra, G; Onyango-Makumbi, C; Rouzier, V; Shin, K; Sterling, TR; Stranix-Chibanda, L; Theron, G; Vhembo, T; Violari, A; Weinberg, A; Zimmer, B, 2019) |
| "We conducted a randomized, open-label, phase 3 noninferiority trial comparing the efficacy and safety of a 1-month regimen of daily rifapentine plus isoniazid (1-month group) with 9 months of isoniazid alone (9-month group) in HIV-infected patients who were living in areas of high tuberculosis prevalence or who had evidence of latent tuberculosis infection." | 5.30 | One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis. ( Andersen, J; Banda, P; Benson, CA; Chaisson, RE; da Silva Escada, RO; Fletcher, CV; Gupta, A; Hakim, J; Jean Juste, MA; Kanyama, C; Lama, JR; Langat, D; Leon-Cruz, J; Masheto, G; Mawlana, S; Mohapi, L; Moran, L; Mwelase, N; Nuermberger, E; Omoz-Oarhe, A; Ramchandani, R; Severe, P; Supparatpinyo, K; Swindells, S; Valencia, J, 2019) |
| "Hepatotoxicity associated with isoniazid preventive therapy (IPT) and antiretroviral therapy (ART) has not been well studied in severely immunosuppressed people with HIV." | 5.27 | Hepatotoxicity During Isoniazid Preventive Therapy and Antiretroviral Therapy in People Living With HIV With Severe Immunosuppression: A Secondary Analysis of a Multi-Country Open-Label Randomized Controlled Clinical Trial. ( Bisson, GP; Gupta, A; Hosseinipour, MC; Hughes, MD; Kidonge, KK; Kumwenda, J; Lavenberg, JA; Miyahara, S; Ngongondo, M; Nyirenda, M; Sun, X; Torres, TS, 2018) |
| "Once-weekly isoniazid and rifapentine for 3 months is a treatment option in persons with human immunodeficiency virus and latent tuberculosis infection." | 5.27 | Cytokine-Mediated Systemic Adverse Drug Reactions in a Drug-Drug Interaction Study of Dolutegravir With Once-Weekly Isoniazid and Rifapentine. ( Alfaro, RM; Brooks, KM; De, P; Dobos, KM; George, JM; Hadigan, C; Kellogg, A; Kovacs, JA; Kumar, P; McLaughlin, M; McManus, M; Mehaffy, C; Pau, AK; Rupert, A, 2018) |
| "To reduce the risk of tuberculosis (TB) among individuals with human immunodeficiency virus (HIV) infection, the World Health Organization recommends at least 6 months of isoniazid preventive therapy (IPT)." | 5.27 | Predictors of isoniazid preventive therapy completion among adults newly diagnosed with HIV in rural Malawi. ( Barnes, GL; Chaisson, RE; Corbett, EL; Dowdy, DW; Khundi, M; Little, KM; Makombe, S; Ngwira, LG; Nkhoma, A, 2018) |
| "We conducted a systematic review examining the cost effectiveness of a 3-month course of isoniazid and rifapentine, known as 3HP, given by directly observed treatment, compared to 9 months of isoniazid that is directly observed or self-administered, for latent tuberculosis infection." | 5.22 | Cost-effectiveness of 3-months isoniazid and rifapentine compared to 9-months isoniazid for latent tuberculosis infection: a systematic review. ( Brethour, K; Chaisson, RE; D'Silva, O; Lai, WA; Zwerling, AA, 2022) |
| "We did a multicountry open-label randomised clinical trial comparing empirical tuberculosis therapy with isoniazid preventive therapy in HIV-positive outpatients initiating antiretroviral therapy with CD4 cell counts of less than 50 cells per μL." | 5.22 | Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label randomised controlled trial. ( Alave, J; Badal-Faesen, S; Bao, J; Bisson, GP; Gupta, A; Hakim, J; Henostroza, G; Hogg, E; Hosseinipour, MC; Jones, L; Kirui, FK; Kumarasamy, N; Kumwenda, J; Lagat, D; Lama, JR; Leger, PD; Mave, V; Miyahara, S; Mohapi, L; Moses, A; Mugyenyi, P; Naidoo, K; Nyirenda, M; Pillay, S; Riviere, C; Sun, X; Veloso, VG; Zolopa, A, 2016) |
| "The objective of this report was to study the pharmacokinetics of rifampin (RMP), isoniazid (INH), and pyrazinamide (PZA) in HIV-infected children with tuberculosis (TB) treated with a thrice-weekly anti-TB regimen in the government program in India." | 5.20 | Pharmacokinetics of first-line antituberculosis drugs in HIV-infected children with tuberculosis treated with intermittent regimens in India. ( Banurekha, VV; Bhavani, PK; Dayal, R; Gangadevi, NP; Kannan, T; Kumar, AK; Kumar, SR; Mathevan, G; Ramachandran, G; Ravichandran, N; Sanjeeva, GN; Sekar, L; Swaminathan, S, 2015) |
| "Thirty-six months of isoniazid preventive therapy (36IPT) was superior to 6 months of IPT (6IPT) in preventing tuberculosis (TB) among HIV-infected adults in Botswana." | 5.20 | Tuberculosis incidence after 36 months' isoniazid prophylaxis in HIV-infected adults in Botswana: a posttrial observational analysis. ( Agizew, TB; Mosimaneotsile, B; Motsamai, OI; Nyirenda, S; Rose, CE; Samandari, T; Shang, N; Shepherd, J; Sibanda, T; Tedla, Z, 2015) |
| "A recent major cluster randomized trial of screening, active disease treatment, and mass isoniazid preventive therapy for 9 months during 2006-2011 among South African gold miners showed reduced individual-level tuberculosis incidence but no detectable population-level impact." | 5.20 | Tuberculosis control in South African gold mines: mathematical modeling of a trial of community-wide isoniazid preventive therapy. ( Churchyard, GJ; Corbett, EL; Cox, AP; Fielding, KL; Grant, AD; Hayes, RJ; Lewis, JJ; Sumner, T; Vynnycky, E; White, RG, 2015) |
| "In Botswana, a 36-month course of isoniazid treatment of latent tuberculosis (TB) infection [isoniazid preventive therapy (IPT)] was superior to 6-month IPT in reducing TB and death in persons living with HIV (PLHIV), having positive tuberculin skin tests (TSTs) but not in those with negative TST." | 5.20 | Implementation and Operational Research: Cost-Effectiveness of Antiretroviral Therapy and Isoniazid Prophylaxis to Reduce Tuberculosis and Death in People Living With HIV in Botswana. ( Abimbola, T; Marston, B; Samandari, T; Sangrujee, N; Smith, T, 2015) |
| "We investigated the population pharmacokinetics and pharmacogenetics of efavirenz in 307 patients coinfected with human immunodeficiency virus and tuberculosis and included in the Cambodian Early vs Late Initiation of Antiretrovirals trial (CAMELIA) in Cambodia." | 5.19 | Dependence of efavirenz- and rifampicin-isoniazid-based antituberculosis treatment drug-drug interaction on CYP2B6 and NAT2 genetic polymorphisms: ANRS 12154 study in Cambodia. ( Bertrand, J; Blanc, FX; Borand, L; Chea, P; Chou, M; Mentré, F; Nay, KH; Taburet, AM; Verstuyft, C, 2014) |
| "This is a substudy of the Agence Nationale de Recherches sur le Sida et les Hépatites Virales (ANRS) Comparison of Nevirapine and Efavirenz for the Treatment of HIV-TB Co-infected Patients (ANRS 12146-CARINEMO) trial, which assessed the pharmacokinetics of rifampin or isoniazid with or without the coadministration of nonnucleoside reverse transcriptase inhibitor-based HIV antiretroviral therapy in HIV-tuberculosis-coinfected patients in Mozambique." | 5.19 | Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatment. ( Amin, A; Barau, C; Barrail-Tran, A; Baudin, E; Bhatt, NB; Bonnet, M; Furlan, V; Grinsztejn, B; Meggi, B; Silva, C; Taburet, AM, 2014) |
| "To assess the performance of QuantiFERON-TB Gold In-Tube (QFT-GIT) test for active tuberculosis (TB) in HIV adults, and its variation over time in patients on antiretroviral therapy (ART) and/or isoniazide preventive therapy (IPT)." | 5.19 | Quantiferon-TB Gold: performance for ruling out active tuberculosis in HIV-infected adults with high CD4 count in Côte d'Ivoire, West Africa. ( Anglaret, X; Badje, A; Danel, C; Deschamps, N; Eholie, S; Gabillard, D; Herrmann, JL; Inwoley, A; Kabran, M; Lecarrou, J; Moh, R; Ntakpe, JB; Ouattara, E; Perronne, C, 2014) |
| "Sixteen patients with TB-HIV co-infection received rifabutin 300 mg QD in combination with tuberculosis chemotherapy (initially pyrazinamide, isoniazid and ethambutol then only isoniazid), and were then randomized to receive isoniazid and LPV/r based ART with rifabutin 150 mg tiw or rifabutin 150 mg daily." | 5.19 | Randomized pharmacokinetic evaluation of different rifabutin doses in African HIV- infected tuberculosis patients on lopinavir/ritonavir-based antiretroviral therapy. ( Connolly, C; Harries, A; Kellerman, T; Lienhardt, C; McIlleron, H; Naiker, S; Pym, A; Reddy, T; Wiesner, L, 2014) |
| "While 6- to 12-month courses of isoniazid for tuberculosis prevention are considered safe in pregnant women, the effects of longer-term isoniazid prophylaxis or isoniazid in combination with antiretroviral therapy (ART) are not established in human-immunodeficiency-virus-(HIV-) infected women who experience pregnancy during the course of therapy." | 5.17 | Pregnancy outcomes in HIV-infected women receiving long-term isoniazid prophylaxis for tuberculosis and antiretroviral therapy. ( Mathebula, U; Mathoma, A; Moathlodi, R; Mosimaneotsile, B; Samandari, T; Taylor, AW; Theebetsile, I, 2013) |
| " Clinic staff were trained in tuberculosis screening, use of tuberculin skin tests, and use of isoniazid preventive therapy." | 5.17 | Effect of improved tuberculosis screening and isoniazid preventive therapy on incidence of tuberculosis and death in patients with HIV in clinics in Rio de Janeiro, Brazil: a stepped wedge, cluster-randomised trial. ( Cavalcante, SC; Chaisson, RE; Cohn, S; Durovni, B; Efron, A; Golub, JE; King, BS; Moulton, LH; Pacheco, AG; Saraceni, V, 2013) |
| "The roles of the NAT2 genotype and enzyme maturation on isoniazid pharmacokinetics were investigated in South African infants with perinatal HIV exposure enrolled in a randomized, double-blind, controlled trial of isoniazid for prevention of tuberculosis disease and latent infection." | 5.16 | The pharmacogenetics of NAT2 enzyme maturation in perinatally HIV exposed infants receiving isoniazid. ( D'Argenio, DZ; Fletcher, CV; Kiser, JJ; Mitchell, CD; Seifart, HI; Werely, CJ; Zhu, R, 2012) |
| "In accordance with WHO guidelines, people with HIV infection in Botswana receive daily isoniazid preventive therapy against tuberculosis without obtaining a tuberculin skin test, but duration of prophylaxis is restricted to 6 months." | 5.15 | 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial. ( Agizew, TB; Bozeman, L; Castro, KG; Davis, MK; Kilmarx, PH; Moeti, TL; Moffat, HJ; Mosimaneotsile, B; Motsamai, OI; Nyirenda, S; Samandari, T; Shang, N; Sibanda, T; Talbot, EA; Tedla, Z; Wells, CD, 2011) |
| "Primary isoniazid prophylaxis did not improve tuberculosis-disease-free survival among HIV-infected children or tuberculosis-infection-free survival among HIV-uninfected children immunized with BCG vaccine." | 5.15 | Primary isoniazid prophylaxis against tuberculosis in HIV-exposed children. ( Bobat, R; Cotton, MF; Jean-Philippe, P; Kim, S; Madhi, SA; McSherry, G; Mitchell, C; Nachman, S; Violari, A, 2011) |
| " The aim of the study was to document the pharmacokinetics of the first-line anti-TB agents in children <2 years of age comparing previous and revised WHO dosages of isoniazid (INH; 5 versus 10 mg/kg/day), rifampin (RMP; 10 versus 15 mg/kg/day), and pyrazinamide (PZA; 25 versus 35 mg/kg/day) and to investigate the effects of clinical covariates, including HIV coinfection, nutritional status, age, gender, and type of tuberculosis (TB), and the effect of NAT2 acetylator status." | 5.15 | Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations. ( Donald, PR; Hesseling, AC; Magdorf, K; Roll, S; Rosenkranz, B; Schaaf, HS; Seddon, JA; Seifart, HI; Thee, S; Werely, CJ, 2011) |
| "The World Health Organization recommends isoniazid preventive therapy (IPT) for preventing tuberculosis in HIV-infected adults, although few countries have instituted this policy." | 5.14 | Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort. ( Chaisson, RE; Golub, JE; Gray, GE; Martinson, NA; McIntyre, JA; Mohapi, L; Moshabela, M; Pronyk, P; Struthers, H; Thsabangu, N, 2009) |
| "To describe reasons for exclusion from isoniazid tuberculosis preventive therapy (IPT) and outcomes of persons living with HIV (PLWH) during 6 months of IPT." | 5.14 | Isoniazid tuberculosis preventive therapy in HIV-infected adults accessing antiretroviral therapy: a Botswana Experience, 2004-2006. ( Agizew, TB; Chengeta, B; Kilmarx, PH; Mathoma, A; Mosimaneotsile, B; Motsamai, OI; Nyirenda, S; Samandari, T; Tedla, Z; Wells, CD, 2010) |
| "To compare the efficacy of an intermittent 6-month regimen (Reg6M: 2EHRZ(3)/4HR(3) [ethambutol, 1,200 mg; isoniazid, 600 mg; rifampicin, 450 or 600 mg depending on body weight <60 or > or =60 kg; and pyrazinamide, 1,500 mg for 2 mo; followed by 4 mo of isoniazid and rifampicin at the same doses]) versus a 9-month regimen (Reg9M: 2EHRZ(3)/7HR(3)) in HIV/tuberculosis (TB)." | 5.14 | Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: a randomized clinical trial. ( Chinnaiyan, P; Iliayas, S; Menon, PA; Narayanan, PR; Narendran, G; Padmapriyadarsini, C; Ramachandran, R; Sakthivel, R; Santhanakrishnan, R; Suhadev, M; Swaminathan, S; Venkatesan, P, 2010) |
| "South African guidelines recommend protease-inhibitor-based antiretroviral therapy (ART) with lopinavir-ritonavir for human immunodeficiency virus (HIV)-infected children <36 months of age." | 5.14 | Initial response to protease-inhibitor-based antiretroviral therapy among children less than 2 years of age in South Africa: effect of cotreatment for tuberculosis. ( Abrams, EJ; Coovadia, A; Ko, S; Kuhn, L; Meyers, T; Reitz, C; Sherman, G; Strehlau, R, 2010) |
| "Consenting employees were screened prior to IPT for active tuberculosis and increased risk of isoniazid toxicity using a questionnaire and chest radiograph." | 5.14 | Adverse events with isoniazid preventive therapy: experience from a large trial. ( Churchyard, GJ; Fielding, KL; Grant, AD; Luttig, MM; Mngadi, KT; van Halsema, CL, 2010) |
| "Isoniazid preventive therapy prevents active tuberculosis in people with HIV, but previous studies have found no evidence of benefit in people with HIV who had a negative tuberculin skin test, and a non-significant effect on mortality." | 5.12 | Isoniazid preventive therapy plus antiretroviral therapy for the prevention of tuberculosis: a systematic review and meta-analysis of individual participant data. ( Anglaret, X; Badje, A; Barnabas, RV; Boulle, A; Eholie, S; Ford, N; Gabillard, D; Golub, JE; Maartens, G; Rangaka, MX; Ross, JM; Shapiro, AE; Thomas, KK; Walker, AS; Wilkinson, RJ; Williams, BG, 2021) |
| "Pellagra is a clinical syndrome caused by a deficiency of niacin (nicotinic acid) and/or its precursor tryptophan." | 5.12 | Pellagra a review exploring causes and mechanisms, including isoniazid-induced pellagra. ( Dawe, RS; Mponda, K; Prabhu, D, 2021) |
| "To characterize the bidirectional interaction between twice-daily nelfinavir and twice-weekly rifabutin and isoniazid in patients with tuberculosis and human immunodeficiency virus (HIV) infection." | 5.12 | Clinical evaluation of the nelfinavir-rifabutin interaction in patients with tuberculosis and human immunodeficiency virus infection. ( Becker, MI; Benator, DA; Burman, WJ; Engle, M; Hsyu, PH; Jones, BE; Khan, AE; Peloquin, CA; Sandman, L; Silva-Trigo, C; Vernon, AA; Weiner, MH; Zhao, ZA, 2007) |
| "We evaluated the effects of human immunodeficiency virus (HIV) disease on pharmacokinetics of antituberculosis medications by measuring concentrations of isoniazid and rifampin in blood and of pyrazinamide and ethambutol in urine." | 5.11 | Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease. ( Bhagavathy, S; Gurumurthy, P; Hemanth Kumar, AK; Mahilmaran, A; Padmapriyadarsini, C; Paramesh, P; Rajasekaran, S; Ramachandran, G; Ravichandran, N; Sekar, L; Swaminathan, S; Venkatesan, P, 2004) |
| "Although isoniazid (INH) preventive therapy (IPT) can reduce the risk of active TB among HIV-infected individuals, preventive therapy is rarely used in developing countries." | 5.11 | INH preventive therapy among adult HIV-infected patients in Thailand. ( Hiransuthikul, N; Hiransuthikul, P; Nelson, KE; Paewplot, R; Vorayingyong, A, 2005) |
| "Lower plasma concentrations of rifabutin and, perhaps, isoniazid were associated with ARR failure or relapse in patients with tuberculosis and HIV infection treated with twice-weekly therapy." | 5.11 | Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. ( Benator, D; Burman, W; Hodge, T; Jones, B; Khan, A; Peloquin, CA; Silva-Trigo, C; Vernon, A; Weiner, M; Zhao, Z, 2005) |
| "To compare a 2-month regimen of daily rifampin and pyrazinamide with a 12-month regimen of daily isoniazid in preventing tuberculosis in persons with human immunodeficiency virus (HIV) infection." | 5.09 | Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health O ( Barry, MA; Chaisson, RE; Coberly, J; de Lourdes Garcia, M; Gordin, F; Hafner, R; Klukowicz, AJ; Matts, JP; Miller, C; O'Brien, RJ; Schechter, M; Valdespino, JL, 2000) |
| "Patients older than 18 years who were diagnosed with a first episode of tuberculosis at the national HIV testing centre in Haiti, and who successfully completed a 6-month rifampicin-containing regimen for active pulmonary tuberculosis, were randomly assigned 1 year of post-treatment isoniazid prophylaxis or placebo." | 5.09 | Effect of post-treatment isoniazid on prevention of recurrent tuberculosis in HIV-1-infected individuals: a randomised trial. ( Desvarieux, M; Fitzgerald, DW; Johnson, WD; Joseph, P; Pape, JW; Severe, P, 2000) |
| "A prospective comparative study was conducted to determine the effect of isoniazid prophylaxis on the incidence of active tuberculosis among Thai HIV-infected patients for 1 year." | 5.08 | Effect of isoniazid prophylaxis on incidence of active tuberculosis among Thai HIV-infected individuals. ( Saenghirunvattana, S, 1996) |
| " Thus, scaling up the isoniazid preventive therapy program and its strict compliance is necessary to avert HIV fueled tuberculosis." | 5.01 | The protective effect of isoniazid preventive therapy on tuberculosis incidence among HIV positive patients receiving ART in Ethiopian settings: a meta-analysis. ( Endalamaw, A; Eshetie, S; Geremew, D; Negash, M; Tessema, B, 2019) |
| "Isoniazid is recommended for prevention of tuberculosis (TB) in HIV-infected adults, but its efficacy in children living with HIV (CLHIV) is not known." | 4.98 | Isoniazid for the Prevention of Tuberculosis in HIV-Infected Children: A Systematic Review and Meta-Analysis. ( Charan, J; Emmanuel, P; Goyal, JP; Kumar, A; Patel, A; Reljic, T, 2018) |
| "Efavirenz (EFV) and rifampicin-isoniazid (RH) are cornerstone drugs in human immunodeficiency virus (HIV)-tuberculosis (TB) coinfection treatment but with complex drug interactions, efficacy and safety challenges." | 4.98 | Pharmacokinetics of efavirenz in patients on antituberculosis treatment in high human immunodeficiency virus and tuberculosis burden countries: A systematic review. ( Atwine, D; Bonnet, M; Taburet, AM, 2018) |
| "This systematic review was carried out to determine the effectiveness of continuous isoniazid (given for at least 36 months) for the treatment of latent tuberculosis infection (LTBI) in people living with HIV (PLHIV)." | 4.93 | Continuous isoniazid for the treatment of latent tuberculosis infection in people living with HIV. ( Den Boon, S; Ford, N; Getahun, H; Matteelli, A, 2016) |
| "To systematically identify from qualitative data in the published literature the main barriers to adherence to isoniazid preventive therapy (IPT) for tuberculosis (TB) among people living with HIV/AIDS (PLWHA)." | 4.90 | Factors associated with adherence to treatment with isoniazid for the prevention of tuberculosis amongst people living with HIV/AIDS: a systematic review of qualitative data. ( Booth, A; Makanjuola, T; Taddese, HB, 2014) |
| " Upon combining data from all eight studies, isoniazid prophylaxis was found to be efficacious in preventing development of tuberculosis, with a pooled RR of 0." | 4.90 | Efficacy of isoniazid prophylactic therapy in prevention of tuberculosis in children: a meta-analysis. ( Abuogi, L; Ayieko, J; Bukusi, EA; Reingold, A; Simchowitz, B; Smith, AH, 2014) |
| "Uptake of isoniazid preventive therapy (IPT) to prevent tuberculosis has been poor, particularly in the highest risk populations." | 4.90 | Interventions to improve delivery of isoniazid preventive therapy: an overview of systematic reviews. ( Adams, LV; Blunt, H; Odato, K; Steingart, KR; Talbot, EA, 2014) |
| "Isoniazid preventive therapy (IPT) prevents tuberculosis (TB) in immunocompetent children <5 years of age after exposure to an infectious TB source case." | 4.89 | Isoniazid preventive therapy in HIV-infected and -uninfected children (0 - 14 years). ( Boon, GP; Cotton, MF; Jeena, PM; Schaaf, HS, 2013) |
| " Key recent developments to address HIV-related TB among PWIDs include the use of simplified symptom-based algorithm to provide isoniazid-preventive therapy, molecular DNA detection methods for Mycobacterium tuberculosis and the immediate provision of antiretroviral therapy within the first 2 weeks of initiation of anti-TB treatment." | 4.88 | Tuberculosis and HIV in people who inject drugs: evidence for action for tuberculosis, HIV, prison and harm reduction services. ( Getahun, H; Gunneberg, C; Raviglione, M; Sculier, D; Verster, A, 2012) |
| "In this systematic review, we present information relating to the effectiveness and safety of the following interventions: adding pyrazinamide in chemotherapy regimens lasting up to 6 months, adding rifampicin to isoniazid regimens, benefits of different regimens, chemotherapy for <6 months, daily chemotherapy, direct observation treatment, intermittent chemotherapy for 6 months or longer, isoniazid, low-level laser therapy for pulmonary tuberculosis, regimens containing quinolones, rifampicin plus isoniazid, substituting rifampicin with ethambutol in the continuous phase, and support mechanisms for directly observed treatment." | 4.87 | Tuberculosis (HIV-negative people). ( Eisenhut, M; Ziganshina, LE, 2011) |
| "To compare the incidence of severe hepatitis in HIV-infected patients receiving rifampicin plus pyrazinamide (RZ) for antituberculosis prophylaxis with that of patients receiving a conventional isoniazid-based regime for 6 to 12 months (6-12H)." | 4.86 | [Use of rifampicin plus pyrazinamide for antituberculosis prophylaxis does not increase the risk of severe hepatotoxicity in HIV patients: meta-analysis of randomized controlled clinical trials]. ( Camacho, A; Castón, JJ; Gallo, M; García-Lázaro, M; Kindelán, JM; Natera, C; Pérez-Camacho, I; Rivero, A; Torre-Cisneros, J, 2010) |
| "In this systematic review we present information relating to the effectiveness and safety of the following interventions: adding pyrazinamide in chemotherapy regimens lasting up to 6 months; adding rifampicin to isoniazid regimens; benefits of different regimens; chemotherapy for less than 6 months; daily chemotherapy; direct observation treatment; intermittent chemotherapy for 6 months or longer; isoniazid; low-level laser therapy for pulmonary tuberculosis; regimens containing quinolones; rifampicin plus isoniazid; substituting rifampicin with ethambutol in the continuous phase; and support mechanisms for directly observed treatment." | 4.85 | Tuberculosis (HIV-negative people). ( Garner, P; Ziganshina, LE, 2009) |
| " isoniazid (INH) for the prevention of tuberculosis (TB) among persons with or without human immunodeficiency virus (HIV) infection." | 4.83 | Rifampicin plus pyrazinamide versus isoniazid for treating latent tuberculosis infection: a meta-analysis. ( Gao, XF; Li, YP; Liu, GJ; Sun, X; Wang, L; Wen, J; Xie, Y, 2006) |
| "Isoniazid pharmacokinetics are not yet well-described during once weekly, high-dose administrations with rifapentine (3HP) for latent tuberculosis infection (LTBI)." | 4.31 | High Isoniazid Exposures When Administered with Rifapentine Once Weekly for Latent Tuberculosis in Individuals with Human Immunodeficiency Virus. ( Chaisson, RE; Chihota, V; Churchyard, GJ; Dooley, KE; Jarrett, RT; Marzinke, MA; Shotwell, MS; van der Heijden, Y, 2023) |
| "Isoniazid (INH) preventive therapy is recommended to prevent tuberculosis (TB) disease for persons with HIV (PWH), except for those with regular and heavy alcohol consumption, due to hepatotoxicity concerns." | 4.31 | Safety and tolerability of isoniazid preventive therapy for tuberculosis for persons with HIV with and without alcohol use. ( Adong, J; Cheng, DM; Emenyonu, NI; Fatch, R; Hahn, JA; Jacobson, KR; Linas, BP; Muyindike, WR; Ngabirano, C; Terrault, NA; Tumwegamire, A, 2023) |
| "Cisgender women receiving efavirenz- or dolutegravir-based HIV therapy, or on isoniazid-rifampin for tuberculosis, were followed after a single oral dose of levonorgestrel." | 4.31 | Pharmacogenetic interactions of efavirenz or rifampin and isoniazid with levonorgestrel emergency contraception during treatment of HIV or tuberculosis. ( Agyemang, N; Badal-Faesen, S; Baker, P; Barr, E; Belaunzaran-Zamudio, PF; Cohn, SE; Gadama, L; Gatechompol, S; Godfrey, C; Haas, DW; Jalil, EM; Kayama, C; Mawlana, S; Mngqibisa, R; Olefsky, M; Pham, M; Podany, AT; Scarsi, KK; Smeaton, LM; Supparatpinyo, K; Van Schalkwyk, M; Woolley, E, 2023) |
| "We used nonlinear mixed-effects modeling to characterize the pharmacokinetics of rifampicin, isoniazid, and pyrazinamide, and investigated the association of human immunodeficiency virus (HIV), antiretroviral therapy (ART), drug formulation, age, and body size with their pharmacokinetics." | 4.31 | Evaluating pediatric tuberculosis dosing guidelines: A model-based individual data pooled analysis. ( Aarnoutse, R; Chabala, C; Cotton, MF; Denti, P; Galileya, LT; Gibb, D; Hesseling, A; Lee, J; McIlleron, H; Njahira Mukui, I; Rabie, H; Turkova, A; Wasmann, RE; Zar, H, 2023) |
| "Pellagra is caused by niacin (vitamin B3) deficiency and patients with pellagra present with a characteristic rash." | 4.12 | Isoniazid-associated pellagra during mass scale-up of tuberculosis preventive therapy: a case-control study. ( Auld, AF; Buono, N; Chilikutali, L; Chisuwo, L; Chiwaula, MJ; da Silva, R; Girma, B; Gunde, LJ; Gutreuter, S; Jahn, A; Kalua, T; Kaunda, E; Kim, EJ; Kumwenda, T; Maida, A; Maphosa, T; Marshall, RE; Mbewe, K; Mekonnen, TF; Melgar, M; Mhango, V; Moffitt, A; Mponda, K; Mtoto, F; Muula, AS; Mwamale, S; Mwenyeheri, G; Nabity, SA; Nagoli, E; Ngongonda, D; Nyirenda, R; Odo, M; Oeltmann, JE; Sharma, AJ; Sunguti, J; Surie, D; Williams, AM; Woelk, G; Zimba, SB, 2022) |
| "Although antiretroviral therapy (ART) can avert tuberculosis (TB) incidence among human immunodeficiency virus (HIV) infected patients, the concomitant use of ART with isoniazid (INH) has a paramount effect." | 4.12 | Tuberculosis and isoniazid prophylaxis among adult HIV positive patients on ART in Northwest Ethiopia. ( Adem, M; Bayleyegn, B; Geremew, D; Geremew, H; Tamir, M; Tegene, B, 2022) |
| "Isoniazid preventive therapy (IPT) is effective in treating tuberculosis (TB) infection and hence limiting progression to active disease." | 4.12 | Incidence of tuberculosis among PLHIV on antiretroviral therapy who initiated isoniazid preventive therapy: A multi-center retrospective cohort study. ( Alinga, SB; Biraro, IA; Etukoit, MB; Kagimu, D; Kakumba, K; Kateeba Tusiime, A; Kato, D; Kazibwe, A; Kirenga, B; Mafabi, CG; Miya, Y; Mugenyi, L; Nkabala, R; Ochwo, M; Odoi, C; Oluka, AI; Opito, R; Oryokot, B; Ouma, S; Tayebwakushaba, E; Tusiimire, W, 2022) |
| "To examine the association between isoniazid preventive therapy (IPT) or nontuberculous mycobacteria (NTM) sputum culture positivity and tuberculosis (TB) transcriptional signatures in people with HIV." | 4.12 | Isoniazid preventive therapy and tuberculosis transcriptional signatures in people with HIV. ( Barnabas, RV; Cangelosi, GA; Gersh, JK; Hatherill, M; Hawn, TR; Horne, DJ; Joudeh, LL; Kinuthia, J; Matemo, D; Mendelsohn, SC; Scriba, TJ; Valinetz, ED; Wald, A, 2022) |
| "To quantify the South African adult tuberculosis (TB) incidence and mortality attributable to HIV between 1990 and 2019 and to estimate the reduction in TB incidence due to directly observed therapy, antiretroviral therapy (ART), isoniazid preventive therapy, increased TB screening, and Xpert MTB/RIF." | 4.12 | The impact of HIV and tuberculosis interventions on South African adult tuberculosis trends, 1990-2019: a mathematical modeling analysis. ( Boulle, A; Johnson, LF; Kubjane, M; Osman, M, 2022) |
| "Isoniazid preventive therapy (IPT) can reduce the risk of tuberculosis (TB) in children living with HIV (CLHIV), but data on the outcomes of the IPT cascade in CLHIV are limited." | 4.12 | Drop-offs in the isoniazid preventive therapy cascade among children living with HIV in western Kenya, 2015-2019. ( John-Stewart, G; Kinuthia, J; LaCourse, SM; Matemo, D; Mecha, J; Oele, E; Onyango, DO; van der Sande, MAB; Yuen, CM, 2022) |
| "Tuberculosis (TB) is major public health concern and Isoniazid Preventive Therapy (IPT) helps to prevent TB development among patients living with human immune deficiency virus (PLWHIV)." | 4.12 | Prevalence and associated factors of tuberculosis among isoniazid users and non-users of HIV patients in Dessie, Ethiopia. ( Damtew, Y; Endawkie, A; Mebratu, W; Mohammed, S; Wedajo, S, 2022) |
| "Isoniazid preventive therapy (IPT) can prevent tuberculosis among people receiving antiretroviral therapy (ART)." | 4.12 | Re-evaluating the health impact and cost-effectiveness of tuberculosis preventive treatment for modern HIV cohorts on antiretroviral therapy: a modelling analysis using data from Tanzania. ( Chisonjela, F; Cohen, T; Kiravu, A; Lyatuu, G; Machumi, L; Menzies, NA; Minde, J; Sando, D; Sudfeld, CR; Zhu, J, 2022) |
| "We aimed to assess the coverage of tuberculosis screening and isoniazid preventive therapy (IPT) among people living with human immunodeficiency virus (PLHIV) at Gambella Hospital, southwest Ethiopia." | 4.02 | Tuberculosis screening coverage and isoniazid preventive therapy among people living with HIV at Gambella Hospital, southwest Ethiopia: a retrospective study design. ( Aboma, M; Dida, N, 2021) |
| "HIV-infected persons are at increased risk of developing tuberculosis and Isoniazid preventive therapy has been shown to reduce the occurrence of tuberculosis among this group of persons." | 4.02 | Effect of mobile-phone messaging on patient and health-worker knowledge and adherence to the isoniazid preventive therapy guideline in HIV clinics in Southeast, Nigeria. ( Agu, AP; Akamike, IC; Alo, C; Ogbonnaya, LU; Okedo-Alex, IN; Uneke, CJ, 2021) |
| "Short-course preventive therapy with 1-month course of daily administration of isoniazid (300-mg) plus rifapentine (600-mg) (1HP) and 3-month course of weekly administration of isoniazid (900-mg) plus rifapentine (900-mg) (3HP) has higher completion rates than 9-month course of daily isoniazid (9H) for individuals with latent tuberculosis infection (LTBI)." | 4.02 | Short-course daily isoniazid and rifapentine for latent tuberculosis infection in people living with HIV who received coformulated bictegravir/emtricitabine/tenofovir alafenamide. ( Cheng, CN; Chuang, YC; Hung, CC; Kuo, CH; Lin, KY; Lin, SW; Lin, YJ; Lin, YT; Liou, BH; Liu, WC; Sun, HY, 2021) |
| "Rifampin appears to be safe and as effective as isoniazid across many populations with health conditions, including HIV." | 4.02 | Safety and Efficacy of Rifampin or Isoniazid Among People With Mycobacterium tuberculosis Infection and Living With Human Immunodeficiency Virus or Other Health Conditions: Post Hoc Analysis of 2 Randomized Trials. ( Al-Jahdali, H; Bah, B; Belo, M; Campbell, JR; Cook, VJ; Long, R; Menzies, D; Schwartzman, K; Trajman, A, 2021) |
| "We assessed adherence in an infant tuberculosis prevention trial in Kenya with a urine isoniazid metabolite-detecting dipstick." | 4.02 | Urine Biomarker Assessment of Infant Adherence to Isoniazid Prophylaxis. ( Escudero, JN; John-Stewart, G; Kinuthia, J; LaCourse, SM; Leon, D; Lutz, B; Maleche-Obimbo, E; Matemo, D; Mecha, J; Panpradist, N; Richardson, BA, 2021) |
| "Isoniazid Preventive Therapy (IPT) is a proven public health tool to reduce Tuberculosis (TB) among people living with HIV." | 4.02 | Coverage of isoniazid preventive therapy among people living with HIV; A retrospective cohort study in Tanzania (2012-2016). ( Lawson, L; Mahande, M; Maokola, W; Msuya, S; Ngowi, B; Robert, M; Todd, J, 2021) |
| "Isoniazid preventive therapy (IPT) against tuberculosis (TB) is a life-saving intervention for people living with HIV (PLHIV)." | 4.02 | Early-phase scale-up of isoniazid preventive therapy for people living with HIV in two districts in Malawi (2017). ( Auld, AF; Gunde, LJ; Jahn, A; Kirking, HL; Maida, A; Nabity, SA; Nyirenda, RK; Odo, M; Oeltmann, JE; Shiraishi, RW; Surie, D, 2021) |
| "isoniazid preventive therapy for people living with HIV is an essential public health intervention in low-income countries with high tuberculosis and HIV burden." | 4.02 | Facility and patient barriers in the implementation of isoniazid preventive therapy for people living with HIV attending Care and Treatment Centers, Songea Municipality, Tanzania. ( Frumence, G; Komba, FF, 2021) |
| "Depot medroxyprogesterone acetate is an injectable hormonal contraceptive, widely used by women of childbearing potential living with HIV and/or tuberculosis." | 4.02 | A Semimechanistic Pharmacokinetic Model for Depot Medroxyprogesterone Acetate and Drug-Drug Interactions With Antiretroviral and Antituberculosis Treatment. ( Cohn, SE; Denti, P; Dooley, KE; Firnhaber, C; Francis, J; Godfrey, C; Kendall, MA; McIlleron, H; Mngqibisa, R; Wu, X, 2021) |
| "Secondary analysis of the stepped-wedge, cluster-randomized THRio trial for isoniazid preventive therapy (IPT) to prevent tuberculosis (TB)." | 4.02 | Brief Report: Yield of Repeat Tuberculin Skin Testing for People Living With HIV in Brazil. ( Cavalcante, SC; Chaisson, LH; Chaisson, RE; Cohn, S; Durovni, B; Golub, JE; Saraceni, V, 2021) |
| "Niacin or tryptophan deficiency causes pellagra." | 4.02 | A peculiarly characterised case of isoniazid-induced pellagra- 2 Ds and a C: a case report. ( Kabengele, C; M'hango, H; Malumani, M; Mweemba, D, 2021) |
| "Isoniazid preventive therapy (IPT) reduces the risk of active tuberculosis among people living with HIV, but implementation of IPT in South Africa and elsewhere remains slow." | 3.96 | Promoting Tuberculosis Preventive Therapy for People Living with HIV in South Africa: Interventions Hindered by Complicated Clinical Guidelines and Imbalanced Patient-Provider Dynamics. ( Golub, JE; Hanrahan, CF; Jarrett, BA; Martinson, NA; Motlhaoleng, K; Mpungose, N; Tilchin, C; Woznica, DM, 2020) |
| "Isoniazid preventive therapy (IPT) is widely used to protect against tuberculosis (TB) in people living with human immunodeficiency virus (HIV)." | 3.96 | Safety and Effectiveness of Isoniazid Preventive Therapy in Pregnant Women Living with Human Immunodeficiency Virus on Antiretroviral Therapy: An Observational Study Using Linked Population Data. ( Boulle, A; Cohen, K; Davies, MA; de Waal, R; Heekes, A; Jacob, N; Kalk, E; Maartens, G; Mehta, U; Myer, L, 2020) |
| "Antiretroviral therapy (ART) and isoniazid preventive therapy (IPT) are known to have a tuberculosis (TB) protective effect at the individual level among people living with HIV (PLHIV)." | 3.96 | Trend analysis of tuberculosis case notifications with scale-up of antiretroviral therapy and roll-out of isoniazid preventive therapy in Zimbabwe, 2000-2018. ( Choto, RC; Harries, AD; Mabaya, S; Mbito, C; Mutasa-Apollo, T; Sandy, C; Takarinda, KC; Timire, C, 2020) |
| "In accordance with international guidance for tuberculosis (TB) prevention, the Tanzanian Ministry of Health recommends isoniazid preventive therapy (IPT) for children aged 12 months and older who are living with HIV." | 3.96 | Successful implementation of isoniazid preventive therapy at a pediatric HIV clinic in Tanzania. ( Adams, LV; Ahluwalia, AK; Daffé, ZN; Hunter, OF; Kyesi, F; Munseri, P; von Reyn, CF, 2020) |
| "Isoniazid preventive therapy (IPT) taken by People Living with HIV (PLHIV) protects against active tuberculosis (TB)." | 3.96 | Outcomes of isoniazid preventive therapy among people living with HIV in Kenya: A retrospective study of routine health care data. ( Karanja, M; Kingwara, L; Kiplimo, R; Kirui, E; Maina, M; Masini, E; Ngari, F; Ngugi, C; Onyango, E; Owiti, P, 2020) |
| "A multicentre, prospective pilot study was initiated among adults living with HIV on isoniazid 300 mg with pyridoxine 50 mg after ruling out active tuberculosis (TB)." | 3.96 | Effectiveness of isoniazid preventive therapy on incidence of tuberculosis among HIV-infected adults in programme setting. ( Agarwal, U; Bhavani, PK; Chitra, A; Maheshmanisha, J; Mothi, SN; Nandagopal, K; Padmapriyadarsini, C; Poornagangadevi, N; Reddy, D; Rewari, BB; Sekar, L; Selvaraj, M; Swaminathan, S; Tamizhselvan, M; Vennila, S, 2020) |
| "The World Health Organization recommends isoniazid preventive therapy (IPT) for people living with HIV (PLHIV) to prevent tuberculosis (TB), including pregnant women." | 3.91 | Brief Report: High Programmatic Isoniazid Preventive Therapy (IPT) Use in Pregnancy Among HIV-Infected Women. ( Copeland, A; Cranmer, LM; John-Stewart, G; Kinuthia, J; LaCourse, SM; Maleche-Obimbo, E; Matemo, D; Richardson, BA; Wagner, AD, 2019) |
| "Gynecomastia is known to occur in some men taking an efavirenz-based antiretroviral therapy (ART) regimen." | 3.91 | Gynecomastia in HIV-positive adult men receiving efavirenz-based antiretroviral therapy at Newlands clinic, Harare, Zimbabwe. ( Chimbetete, C; Shamu, T; Shawarira-Bote, S, 2019) |
| "Isoniazid resistant tuberculosis is the most prevalent type of resistance in Swaziland and over two-thirds of the isoniazid resistant tuberculosis patients are tuberculosis and human immunodeficiency virus co-infected." | 3.91 | Factors associated with isoniazid resistant tuberculosis among human immunodeficiency virus positive patients in Swaziland: a case-control study. ( Chien, LY; Dlamini, NC; Ji, DD, 2019) |
| " The research method applied was comparative analysis of the results of own study and studies by other researchers, concerning the effectiveness of tuberculosis prophylaxis in patients with HIV/AIDS when treated with isoniazid." | 3.91 | Comparative analysis of the effectiveness of tuberculosis prophylaxis in patients with HIV/AIDS treated with isoniazid. ( Głowacka, M; Jarosz, MJ; Juszkiewicz, K; Włoszczak-Szubzda, A, 2019) |
| "Both isoniazid preventive therapy (IPT) and antiretroviral therapy (ART) reduce tuberculosis risk in individuals living with HIV." | 3.91 | Projected population-wide impact of antiretroviral therapy-linked isoniazid preventive therapy in a high-burden setting. ( Azman, AS; Boulle, A; Dowdy, DW; Kendall, EA; Maartens, G; Rangaka, MX; Wilkinson, RJ, 2019) |
| " The secondary objective was to determine the overall incidence of hepatitis in children on Anti tubercular treatment (ATT) and isoniazid prophylactic therapy (IPT)." | 3.91 | Revised Antituberculosis Drug Doses and Hepatotoxicity in HIV Negative Children. ( Indumathi, CK; Jain, S; Krishnamurthy, S; Sethuraman, A, 2019) |
| "Isoniazid preventive therapy (IPT) is a proven means to prevent tuberculosis (TB) disease among people living with HIV (PLHIV)." | 3.91 | Breakthrough tuberculosis disease among people with HIV - Should we be worried? A retrospective longitudinal study. ( Mamuye, AT; Teklu, AM; Yirdaw, KD; Zewdu, S, 2019) |
| "Isoniazid preventive therapy (IPT), for people living with HIV (PLHIV) is the proven and recommended intervention to avert tuberculosis (TB)." | 3.91 | Initiation and completion rates of isoniazid preventive therapy among people living with HIV in Far-Western Region of Nepal: a retrospective cohort study. ( Bhatta, U; Chinnakali, P; Dhungana, GP; Pandey, B; Thekkur, P; Zhang, WH, 2019) |
| "Lopinavir-ritonavir forms the backbone of current first-line antiretroviral regimens in young HIV-infected children." | 3.88 | Pharmacokinetics and Drug-Drug Interactions of Lopinavir-Ritonavir Administered with First- and Second-Line Antituberculosis Drugs in HIV-Infected Children Treated for Multidrug-Resistant Tuberculosis. ( de Kock, M; Denti, P; Garcia-Prats, AJ; Hesseling, AC; McIlleron, H; Norman, J; Schaaf, HS; Tikiso, T; van der Laan, LE; Wiesner, L; Winckler, J, 2018) |
| "Isoniazid preventive therapy (IPT) reduces mortality among people living with HIV (PLHIV) and is recommended for those without active tuberculosis (TB) symptoms." | 3.88 | Isoniazid Preventive Therapy for People With HIV Who Are Heavy Alcohol Drinkers in High TB-/HIV-Burden Countries: A Risk-Benefit Analysis. ( Ellner, JJ; Freiman, JM; Hahn, JA; Horsburgh, CR; Jacobson, KR; Linas, BP; Muyindike, WR, 2018) |
| "In this high-incidence setting, the use of targeted active case finding in combination with secondary isoniazid preventive therapy in previously treated individuals could accelerate decreases in tuberculosis morbidity and mortality." | 3.88 | Tuberculosis control interventions targeted to previously treated people in a high-incidence setting: a modelling study. ( Beyers, N; Bilinski, A; Cohen, T; Marx, FM; Menzies, NA; Salomon, JA; Yaesoubi, R, 2018) |
| "To compare daily exposure to tuberculosis (TB) patients between HIV-infected and non-HIV-infected health care workers (HCWs), and examine the uptake of antiretroviral therapy (ART) and isoniazid preventive therapy (IPT) among HIV-infected HCWs in Botswana." | 3.88 | High rates of exposure to tuberculosis patients among HIV-infected health care workers in Botswana. ( Ho-Foster, A; Kestler, M; Modongo, C; Phologolo, T; Shin, SS; Wang, Q; Zetola, NM, 2018) |
| "A short-course regimen of 3 months of weekly rifapentine and isoniazid (3HP) has recently been recommended by the World Health Organization as an alternative to at least 6 months of daily isoniazid (isoniazid preventive therapy [IPT]) for prevention of tuberculosis (TB)." | 3.88 | Cost-effectiveness of Preventive Therapy for Tuberculosis With Isoniazid and Rifapentine Versus Isoniazid Alone in High-Burden Settings. ( Churchyard, GJ; Dowdy, DW; Johnson, KT; Sohn, H, 2018) |
| "We model the epidemiological impact of providing isoniazid preventive therapy (IPT) to South African adolescents, among whom HIV prevalence is low, latent tuberculosis (TB) prevalence is high, and school-based programs may enable population-level coverage." | 3.88 | Modeling the implementation of population-level isoniazid preventive therapy for tuberculosis control in a high HIV-prevalence setting. ( Bendavid, E; Feldman, MW; Rhines, AS, 2018) |
| "Despite being globally recommended as an effective intervention in tuberculosis (TB) prevention among people living with HIV, isoniazid preventive therapy (IPT) implementation remains suboptimal, especially in sub-Saharan Africa." | 3.88 | Factors affecting the acceptability of isoniazid preventive therapy among healthcare providers in selected HIV clinics in Nairobi County, Kenya: a qualitative study. ( Atela, M; Eboreime, E; Ibisomi, L; Wambiya, EOA, 2018) |
| "Optimal testing strategies for diagnosing latent tuberculosis infection and the administration of isoniazid preventive therapy (IPT) remain uncertain among human immunodeficiency virus (HIV)-infected patients." | 3.85 | QuantiFERON-TB Gold In-Tube Test for Tuberculosis Prevention in HIV-Infected Patients. ( Apisarnthanarak, A; Khawcharoenporn, T; Phetsuksiri, B; Rudeeaneksin, J; Srisungngam, S, 2017) |
| "To describe outcomes associated with the implementation of isoniazid preventive therapy (IPT) in a cohort of tuberculosis (TB) treatment-experienced human immunodeficiency virus (HIV) infected patients on antiretroviral therapy (ART)." | 3.85 | Implementing isoniazid preventive therapy in a tuberculosis treatment-experienced cohort on ART. ( Gengiah, S; Gengiah, TN; Maharaj, B; Naidoo, A; Naidoo, K; Yende-Zuma, N, 2017) |
| "One of the reasons why Isoniazid preventive therapy (IPT) for Tuberculosis (TB) is not widely used in low income countries is concerns on cost of excluding active TB." | 3.85 | Cost-Effectiveness of isoniazid preventive therapy among HIV-infected patients clinicaly screened for latent tuberculosis infection in Dar es Salaam, Tanzania: A prospective Cohort study. ( Aboud, S; Bakari, M; Chitama, D; Moshiro, C; Mugusi, F; Shayo, GA, 2017) |
| "Rifampin (RIF) mono-resistant tuberculosis (RMR-TB) is a rare disease." | 3.85 | Treatment outcomes of rifampin-sparing treatment in patients with pulmonary tuberculosis with rifampin-mono-resistance or rifampin adverse events: A retrospective cohort analysis. ( Jo, KW; Kim, WS; Lee, SD; Park, S; Shim, TS, 2017) |
| "Treatment of people living with HIV (PLHIV) with latent tuberculosis (TB) infection using isoniazid preventive therapy (IPT) can reduce the risk of TB disease, however, the scale-up of IPT among PLHIV in Thailand and worldwide has been slow." | 3.85 | Implementing an isoniazid preventive therapy program for people living with HIV in Thailand. ( Danyuttapolchai, J; Kanphukiew, A; Kittimunkong, S; Klinbuayaem, V; Maipanich, N; Maokamnerd, Y; Martin, M; Monkongdee, P; Nateniyom, S; Painujit, S; Pevzner, E; Whitehead, S, 2017) |
| "Tuberculosis (TB) screening affords clinicians the opportunity to diagnose or exclude TB disease and initiate isoniazid preventive therapy (IPT) for people living with HIV (PLHIV)." | 3.85 | Programmatic Evaluation of an Algorithm for Intensified Tuberculosis Case Finding and Isoniazid Preventive Therapy for People Living With HIV in Thailand and Vietnam. ( Cowger, TL; Danyuttapolchai, J; Duong, BD; Khanh, VT; Kittimunkong, S; Monkongdee, P; Nateniyom, S; Ngoc, DV; Nhan, DT; Nhung, NV; Pevzner, ES; Thai, LH; Thinh, T; Thoa, CK; Whitehead, S; Yen, NTB, 2017) |
| " In 2014, we evaluated patient acceptability toward IVR as part of the ENRICH Study, aimed to enhance adherence to isoniazid preventive therapy for tuberculosis prevention among HIV-positive adults in Ethiopia." | 3.85 | A Qualitative Evaluation of the Acceptability of an Interactive Voice Response System to Enhance Adherence to Isoniazid Preventive Therapy Among People Living with HIV in Ethiopia. ( Daftary, A; Gadisa, T; Hirsch-Moverman, Y; Howard, AA; Kassie, GM; Melaku, Z; Saito, S, 2017) |
| "The prevalence of tuberculosis among HIV positive patients in Xinjiang was higher than in China taken as a whole, and HIV was diagnosed late, with underuse of isoniazid preventive therapy." | 3.85 | High prevalence and low cure rate of tuberculosis among patients with HIV in Xinjiang, China. ( Andersson, R; Maimaiti, R; Mijiti, P; Musa, M; Pan, K; Wubili, M; Zhang, Y, 2017) |
| "Intensified tuberculosis (TB) case finding and isoniazid preventive therapy (IPT) are strongly recommended for children who are HIV infected." | 3.83 | Implementation and Operational Research: Implementation of the WHO 2011 Recommendations for Isoniazid Preventive Therapy (IPT) in Children Living With HIV/AIDS: A Ugandan Experience. ( Alowo, A; Bilardi, D; Costenaro, P; Cotton, MF; Fregonese, F; Giaquinto, C; Kizito, S; Lundin, R; Massavon, W; Mazza, A; Morelli, E; Nabachwa, SM; Namisi, CP; Nannyonga Musoke, M; Penazzato, M, 2016) |
| "To compare the pharmacokinetics of rifampicin (RMP), isoniazid (INH) and pyrazinamide (PZA) between HIV-infected and HIV-uninfected children with tuberculosis (TB) and correlate it with TB treatment outcome." | 3.83 | Low Serum Concentrations of Rifampicin and Pyrazinamide Associated with Poor Treatment Outcomes in Children with Tuberculosis Related to HIV Status. ( Agarwal, D; Banurekha, VV; Bhavani, PK; Gangadevi, NP; Kalpana, S; Kannan, T; Kumar, AK; Kumar, SR; Mathevan, G; Ramachandran, G; Ravichandran, N; Sanjeeva, GN; Sudha, V; Swaminathan, S; Venkatesh, S, 2016) |
| "In HIV-uninfected individuals, isoniazid preventive therapy (IPT) has been associated with long-term protection against tuberculosis (TB)." | 3.83 | Post-treatment effect of isoniazid preventive therapy on tuberculosis incidence in HIV-infected individuals on antiretroviral therapy. ( Boulle, A; Houben, RM; Maartens, G; Rangaka, MX; Sumner, T; White, RG; Wilkinson, RJ, 2016) |
| "World Health Organization advocates for integration of HIV-tuberculosis (TB) services and recommends intensive case finding (ICF), isoniazid preventive therapy (IPT), and infection control ("Three I's") for TB prevention and control among persons living with HIV." | 3.83 | Implementation of Tuberculosis Intensive Case Finding, Isoniazid Preventive Therapy, and Infection Control ("Three I's") and HIV-Tuberculosis Service Integration in Lower Income Countries. ( Avit-Edi, D; Ballif, M; Blevins, M; Castelnuovo, B; Charles, MK; Cortes, CP; Dung, NT; Durier, N; Dusingize, JC; Fenner, L; Lindegren, ML; Nakigozi, G; Sterling, TR; Wester, CW, 2016) |
| "Isoniazid preventive therapy is a key public health intervention for the prevention of tuberculosis disease among people living with HIV." | 3.83 | Barriers in the implementation of isoniazid preventive therapy for people living with HIV in Northern Ethiopia: a mixed quantitative and qualitative study. ( Klinkenberg, E; Legesse, B; Tedla, K; Teklay, G; Teklu, T, 2016) |
| " However, the models projected that, in the South Africa national tuberculosis programme scenario, a combination of continuous isoniazid preventive therapy for individuals on antiretroviral therapy, expanded facility-based screening for symptoms of tuberculosis at health centres, and improved tuberculosis care could achieve a 55% reduction in incidence (range 31-62%) and a 72% reduction in mortality (range 64-82%) compared with 2015 levels." | 3.83 | Feasibility of achieving the 2025 WHO global tuberculosis targets in South Africa, China, and India: a combined analysis of 11 mathematical models. ( Arinaminpathy, N; Azman, AS; Bacaër, N; Bendavid, E; Boccia, D; Chadha, VK; Chang, ST; Charalambous, S; Chin, DP; Churchyard, G; Cohen, T; Daniels, C; Denholm, JT; Dewan, P; Ditiu, L; Dowdy, DW; Eaton, JW; Eckhoff, PA; Feldman, MW; Goldhaber-Fiebert, JD; Gomez, GB; Grant, AD; Handel, A; Hippner, P; Hosseini, M; Houben, RMGJ; Huynh, GH; Kimerling, ME; Lalli, M; Lin, HH; Mametja, LD; Mandal, S; McBryde, ES; Menzies, NA; Pandey, S; Pillay, Y; Pretorius, C; Rade, K; Rhines, AS; Sahu, S; Salomon, JA; Suen, SC; Sumner, T; Trauer, JM; Vassall, A; Wagner, BG; Wang, L; Whalen, CC; White, RG; Wu, CY, 2016) |
| "Although isoniazid preventive therapy (IPT) is effective in the prevention of tuberculosis (TB) in people living with the human immunodeficiency virus (PLHIV), patient adherence to this strategy is suboptimal." | 3.83 | Predictors of adherence to isoniazid preventive therapy in people living with HIV in Ethiopia. ( Ayele, HT; Bonten, MJ; van Mourik, MS, 2016) |
| "Extending the duration of isoniazid preventive therapy (IPT) among people living with HIV (PLHIV) may improve its effectiveness at both individual and population levels, but could also increase selective pressure in favor of isoniazid-resistant tuberculosis (TB) strains." | 3.83 | Benefits of continuous isoniazid preventive therapy may outweigh resistance risks in a declining tuberculosis/HIV coepidemic. ( Cohen, T; Crawford, FW; Kunkel, A; Shepherd, J, 2016) |
| "The duration of protection against tuberculosis provided by isoniazid preventive therapy is not known for human immunodeficiency virus (HIV)-infected individuals living in settings of medium tuberculosis incidence." | 3.81 | Long-term protection from isoniazid preventive therapy for tuberculosis in HIV-infected patients in a medium-burden tuberculosis setting: the TB/HIV in Rio (THRio) study. ( Cavalcante, SC; Chaisson, RE; Cohn, S; Durovni, B; Golub, JE; Moulton, LH; Pacheco, AG; Saraceni, V, 2015) |
| "The World Health Organization recommends for tuberculosis retreatment a regimen of isoniazid (H), rifampicin (R), ethambutol (E), pyrazinamide (Z), and streptomycin (S) for 2 months, followed by H, R, E, and Z for 1 month and H, R, and E for 5 months." | 3.81 | High mortality associated with retreatment of tuberculosis in a clinic in Kampala, Uganda: a retrospective study. ( Acuña-Villaorduña, C; Ayakaka, I; Dryden-Peterson, S; Fennelly, KP; Hosford, J; Jones-López, EC; Nakubulwa, S; Okwera, A; Reilly, N; Worodria, W, 2015) |
| "Data on feasibility and completion rates of isoniazid preventive therapy (IPT) in HIV-infected patient in Asia are limited." | 3.81 | Implementation of isoniazid preventive therapy in an HIV clinic in Cambodia: high rates of discontinuation when combined with antiretroviral therapy. ( Chim, B; Choun, K; Lorent, N; Lynen, L; Thai, S; van Griensven, J, 2015) |
| "Symptom-based tuberculosis screening identifies less than one-third of eligible HIV-infected patients as candidates for isoniazid preventive therapy (IPT)." | 3.80 | Point-of-care C-reactive protein testing to facilitate implementation of isoniazid preventive therapy for people living with HIV. ( Bangsberg, DR; Byakwaga, H; Cattamanchi, A; Davis, JL; Huang, L; Hunt, PW; Martin, JN; Muzoora, C; Nahid, P; Scibetta, C; Semitala, FC; Yoon, C, 2014) |
| " We report a case of clopidogrel non-responsiveness in a patient with HIV, latent tuberculosis and cardiovascular disease with a history of myocardial infarction." | 3.80 | A patient with HIV and tuberculosis with diminished clopidogrel response. ( Metzger, NL; Momary, KM, 2014) |
| "Isoniazid preventive therapy (IPT) with antiretroviral therapy (ART) reduces incident tuberculosis among patients infected with the human immunodeficiency virus." | 3.80 | Isoniazid preventive therapy use among patients on antiretroviral therapy: a missed opportunity. ( Charalambous, S; Chihota, VN; Churchyard, GJ; Kufa, T, 2014) |
| " TB-exposed newborns requiring isoniazid preventive therapy (IPT) or anti-tuberculosis treatment were followed to 6 months of age." | 3.80 | Determinants of tuberculosis treatment completion among newborns in a high-burden setting. ( Bekker, A; Du Preez, K; Hesseling, AC; Schaaf, HS; Slogrove, AL, 2014) |
| "The Lesotho Ministry of Health issued guidelines on active case finding (ACF) for tuberculosis (TB) and isoniazid preventive therapy (IPT) in April 2011." | 3.80 | Preventing tuberculosis among HIV-infected pregnant women in Lesotho: the case for rolling out active case finding and isoniazid preventive therapy. ( Ahimbisibwe, A; Barnes, GL; Chaisson, RE; Gounder, CR; Guay, L; Isavwa, A; Kassaye, S; Maama-Maime, LB; Machekano, R; Mokone, M; Ntene-Sealiete, K; Oyebanji, O; Sahu, M; Tiam, A, 2014) |
| "To evaluate the cost-effectiveness of the Three I's for HIV/TB (human immunodeficiency virus/tuberculosis): antiretroviral therapy (ART), intensified TB case finding (ICF), isoniazid preventive treatment (IPT), and TB infection control (IC)." | 3.80 | Cost-effectiveness of the Three I's for HIV/TB and ART to prevent TB among people living with HIV. ( Abimbola, T; Bennett, R; Date, A; Granich, R; Gupta, S; Sangrujee, N; Suthar, AB, 2014) |
| " The main barriers as reported by 144 HCWs working in hospitals without IPT programme, were: (1) unclear direction of national policy (60%), (2) fear of emerging Isoniazid resistant tuberculosis (52%), and (3) fear of poor adherence (30%)." | 3.79 | Barriers to and motivations for the implementation of a treatment programme for latent tuberculosis infection using isoniazid for people living with HIV, in upper northern Thailand. ( Kaewkungwal, J; Lawpoolsri, S; Moolphate, S; Pungrassami, P; Sanguanwongse, N; Yamada, N, 2013) |
| "The World Health Organization (WHO) recommends active tuberculosis (TB) case finding among people living with human immunodeficiency virus (HIV) in resource-limited settings using a symptom-based algorithm; those without active TB disease should be offered isoniazid preventive therapy (IPT)." | 3.79 | Improving tuberculosis screening and isoniazid preventive therapy in an HIV clinic in Addis Ababa, Ethiopia. ( Blumberg, HM; Kempker, R; Ofotokun, I; Stenehjem, E; Temesgen, O; Tenna, A; Zaeh, S, 2013) |
| "Comprehensive information on the effects of cytochrome P450 2B6 (CYP2B6) polymorphisms, clinical factors, and drug-drug interactions on efavirenz concentrations in HIV/tuberculosis-coinfected (HIV/TB) patients is unavailable." | 3.79 | Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients. ( Lueangniyomkul, A; Mankatitham, W; Manosuthi, S; Manosuthi, W; Nilkamhang, S; Sukasem, C; Sungkanuparph, S; Thongyen, S, 2013) |
| "To describe the characteristics and outcomes of incident tuberculosis (TB) cases in human immunodeficiency virus (HIV) infected adults exposed to isoniazid preventive therapy (IPT) with access to antiretroviral and anti-tuberculosis treatment." | 3.79 | Anti-tuberculosis treatment outcomes in HIV-infected adults exposed to isoniazid preventive therapy in Botswana. ( Agizew, T; Johnson, JL; Marape, M; Miranda, AG; Nyirenda, S; Reuter, H; Samandari, T; Sibanda, T; Tedla, Z, 2013) |
| "Clinical algorithms for evaluating HIV-infected individuals for tuberculosis (TB) prior to isoniazid preventive therapy (IPT) perform poorly, and interferon-γ release assays (IGRAs) have moderate accuracy for active TB." | 3.78 | Interferon release does not add discriminatory value to smear-negative HIV-tuberculosis algorithms. ( Boulle, A; Fielding, K; Gideon, HP; Glynn, JR; Goliath, R; Maartens, G; Mathee, S; Mwansa-Kambafwile, J; Pai, M; Rangaka, MX; Titus, R; Wilkinson, KA; Wilkinson, RJ, 2012) |
| "Regimens for isoniazid-based preventive therapy (IPT) for tuberculosis (TB) in HIV-infected individuals have not been widely adopted given concerns regarding efficacy, adherence and drug resistance." | 3.78 | The cost-effectiveness of tuberculosis preventive therapy for HIV-infected individuals in southern India: a trial-based analysis. ( Freedberg, KA; Kumarasamy, N; Losina, E; Mayer, KH; Pho, MT; Ponnuraja, C; Scott, CA; Swaminathan, S; Uhler, LM; Walensky, RP, 2012) |
| "Limited data exist about the clinical characteristics of Mycobacterium tuberculosis (TB) isolates with resistance to isoniazid (IZN)." | 3.77 | Comparison of isoniazid monoresistant tuberculosis with drug-susceptible tuberculosis and multidrug-resistant tuberculosis. ( Fox, L; Haim, I; Kramer, MR; Metvachuk, A; Priess, R; Shitrit, D, 2011) |
| "Quantifying isoniazid resistant (INH-R) tuberculosis (TB) is important because isoniazid resistance reduces the probability of treatment success, may facilitate the spread of multidrug resistance, and may reduce the effectiveness of isoniazid preventive therapy (IPT)." | 3.77 | Quantifying the burden and trends of isoniazid resistant tuberculosis, 1994-2009. ( Cohen, T; Jenkins, HE; Zignol, M, 2011) |
| "Isoniazid preventive therapy (IPT) prevents tuberculosis (TB) in people living with HIV (human immunodeficiency virus, PLWH)." | 3.76 | Tuberculosis in asymptomatic HIV-infected adults with abnormal chest radiographs screened for tuberculosis prevention. ( Agizew, TB; Arwady, MA; Kilmarx, PH; Mosimaneotsile, B; Motsamai, O; Nyirenda, S; Samandari, T; Tedla, Z; Wells, CD; Yoon, JC, 2010) |
| "Chest radiography is used to screen for tuberculosis (TB) in asymptomatic persons living with the human immunodeficiency virus (PLWH) seeking isoniazid preventive therapy (IPT)." | 3.76 | Association of chest radiographic abnormalities with tuberculosis disease in asymptomatic HIV-infected adults. ( Agizew, T; Bachhuber, MA; Makwaruzi, VZ; Mboya, JJ; Nyirenda, S; Parker, JE; Samandari, T; Tallaksen, RJ; Tedla, Z, 2010) |
| "Active tuberculosis (TB) must be excluded before initiating isoniazid preventive therapy (IPT) in persons infected with human immunodeficiency virus (HIV), but currently used screening strategies have poor sensitivity and specificity and high patient attrition rates." | 3.76 | Microscopic observation drug susceptibility assay for tuberculosis screening before isoniazid preventive therapy in HIV-infected persons. ( Benites, C; Brady, MF; Chavez, G; Coronel, J; Friedland, JS; Gilman, RH; Moore, DA; Navincopa, M; Pinedo, Y; Reddy, KP; Rojas, C; Sánchez, E; Solari, L; Ticona, E; Valencia, J, 2010) |
| "Despite World Health Organization recommendations, concerns about promoting resistance have impeded implementation of isoniazid preventive therapy (IPT) for tuberculosis (TB)." | 3.76 | Tuberculosis outcomes and drug susceptibility in individuals exposed to isoniazid preventive therapy in a high HIV prevalence setting. ( Chihota, VN; Churchyard, GJ; Fielding, KL; Grant, AD; Lewis, JJ; Russell, EC; van Halsema, CL, 2010) |
| "Antiretroviral therapy and isoniazid preventive therapy (IPT) are both effective interventions to prevent HIV-associated tuberculosis, but work via different mechanisms." | 3.76 | Antiretrovirals and isoniazid preventive therapy in the prevention of HIV-associated tuberculosis in settings with limited health-care resources. ( Churchyard, GJ; De Cock, KM; Kranzer, K; Lawn, SD; Lewis, JJ; Wood, R, 2010) |
| "Despite good evidence that isoniazid preventive therapy (IPT) reduces incidence of tuberculosis among people with HIV infection, implementation of IPT is low." | 3.76 | Barriers to implementation of isoniazid preventive therapy in HIV clinics: a qualitative study. ( Chandler, C; Charalambous, S; Churchyard, GJ; Dwadwa, T; Grant, AD; Hamilton, R; Lester, R, 2010) |
| "To describe the association between isoniazid preventive therapy (IPT) and mortality among individuals starting antiretroviral therapy (ART) in a workplace programme in South Africa where tuberculosis (TB) incidence is very high." | 3.76 | Association of isoniazid preventive therapy with lower early mortality in individuals on antiretroviral therapy in a workplace programme. ( Charalambous, S; Churchyard, GJ; Dowdeswell, R; Fielding, KL; Grant, AD; Hoffmann, CJ; Innes, C; Pienaar, J, 2010) |
| "Isoniazid preventive therapy (IPT) is recognised as an important component of collaborative tuberculosis (TB) and human immunodeficiency virus (HIV) activities to reduce the burden of TB in people living with HIV (PLHIV)." | 3.75 | Isoniazid preventive therapy for people living with HIV: public health challenges and implementation issues. ( Aït-Khaled, N; Alarcon, E; Bissell, K; Boillot, F; Caminero, JA; Chiang, CY; Clevenbergh, P; Dlodlo, R; Enarson, DA; Enarson, P; Ferroussier, O; Fujiwara, PI; Harries, AD; Heldal, E; Hinderaker, SG; Kim, SJ; Lienhardt, C; Rieder, HL; Rusen, ID; Trébucq, A; Van Deun, A; Wilson, N, 2009) |
| "A meta-analysis of isoniazid preventive therapy (IPT) in human immunodeficiency virus-positive individuals failed to show a mortality benefit even though tuberculosis is a leading cause of death in this group." | 3.75 | Mortality benefit of isoniazid preventive therapy in HIV-positive persons: a simulation study. ( Bachhuber, MA; Gross, R, 2009) |
| "Isoniazid preventive therapy (IPT) has been shown to reduce the risk of active tuberculosis in tuberculin skin test (TST) positive human immunodeficiency virus (HIV) infected individuals." | 3.73 | Physician adherence to isoniazid preventive therapy guidelines for HIV-infected patients in Thailand. ( Hiransuthikul, N; Hiransuthikul, P; Jirawisit, M; Kasak, S; Nelson, KE; Paewplot, R, 2005) |
| "To determine the efficacy of secondary preventive therapy against tuberculosis (TB) among gold miners working in South Africa." | 3.72 | Efficacy of secondary isoniazid preventive therapy among HIV-infected Southern Africans: time to change policy? ( Chaisson, RE; Charalambous, S; Churchyard, GJ; Corbett, EL; Day, JH; De Cock, KM; Fielding, K; Grant, AD; Hayes, RJ; Samb, B, 2003) |
| "The absorption of rifampin, isoniazid, and D-xylose in patients with human immunodeficiency virus (HIV) infection and diarrhea, in patients with HIV infection and tuberculosis (TB), in patients with pulmonary TB alone, and in healthy subjects was studied." | 3.72 | Malabsorption of rifampin and isoniazid in HIV-infected patients with and without tuberculosis. ( Gurumurthy, P; Hemanth Kumar, AK; Krishnarajasekhar, OR; Kumar, S; Padmapriyadarsini, C; Paramesh, P; Rajasekaran, S; Ramachandran, G; Sekar, L; Swaminathan, S; Venkatesan, P, 2004) |
| "In 2000, results of a multinational trial demonstrated that a 2-month course of rifampin and pyrazinamide (RZ) was as effective as isoniazid (INH) in reducing tuberculosis in human immunodeficiency virus (HIV)-infected individuals with latent tuberculosis infection (LTBI)." | 3.72 | Hepatotoxicity of rifampin and pyrazinamide in the treatment of latent tuberculosis infection in HIV-infected persons: is it different than in HIV-uninfected persons? ( Chaisson, RE; Cohn, DL; Gordin, FM; Matts, JP; O'Brien, RJ, 2004) |
| "To evaluate tuberculosis (TB) prevention in HIV clinics based on the prevalence and incidence of TB and the efficacy of preventive therapy with isoniazid (INH)." | 3.71 | TB prevention in HIV clinics in New York City. ( Frieden, TR; Sackoff, JE; Torian, LV, 2001) |
| "Treatment of latent Mycobacterium tuberculosis infection with isoniazid can cause hepatotoxicity, but the risk of isoniazid-associated hepatotoxicity among persons coinfected with hepatitis C virus (HCV) is unknown." | 3.71 | Isoniazid preventive therapy, hepatitis C virus infection, and hepatotoxicity among injection drug users infected with Mycobacterium tuberculosis. ( Astemborski, J; Bonds, M; Graham, NM; Madison, A; Sadaphal, P; Sheely, L; Sterling, TR; Thomas, DL; Vlahov, D, 2001) |
| "To determine the acceptability, compliance and side effects of isoniazid (INH) prophylaxis against tuberculosis among HIV infected police officers (PO) in Dar es Salaam." | 3.70 | Isoniazid prophylaxis for tuberculosis prevention among HIV infected police officers in Dar es Salaam. ( Aris, EA; Bakari, M; Biberfeld, G; Chale, S; Josiah, R; Magao, P; Mhalu, F; Moshi, A; Mugusi, F; Pallangyo, K; Pallangyo, N; Sandström, E, 2000) |
| "To compare the strategy of TB vaccination with that of tuberculin skin-testing in conjunction with isoniazid (INH) in preventing tuberculosis in HIV-infected persons." | 3.70 | Tuberculosis vaccination versus isoniazid preventive therapy: a decision analysis to determine the preferred strategy of tuberculosis prevention in HIV-infected adults in the developing world. ( Brehm, WT; Chaisson, RE; Moore, RD; Sterling, TR, 1999) |
| "This study was designed to provide a preliminary assessment of the occurrence of tuberculosis exposure, infection and disease within a national sample of infants and children with human immunodeficiency virus (HIV) exposure or infection, and to determine the prevalence of Mycobacterium tuberculosis isolates resistant both to isoniazid and rifampin in these patients or their adult source contacts." | 3.69 | Tuberculosis in human immunodeficiency virus-exposed or -infected United States children. ( Gutman, LT; Moye, J; Tian, C; Zimmer, B, 1994) |
| " The objectives of this research were thus to describe the use and the results of TST among patients with HIV infection in Switzerland and to measure the usefulness of isoniazid preventive chemotherapy and the incidence of tuberculosis (TB) relative to TST and CD4 cell count at the time of TST." | 3.69 | [HIV infection, tuberculosis and tuberculin test in Switzerland. The Swiss HIV Cohort Study]. ( Bassetti, S; Hirschel, BJ; Ledergerber, B; Malvy, D; Rieder, H; Sudre, P, 1996) |
| " Peak drug exposure to isoniazid was lower in patients with diarrhea." | 3.69 | Reduced plasma concentrations of antituberculosis drugs in patients with HIV infection. ( Cameron, DW; Gallicano, K; Garber, G; Oliveras, L; Rachlis, A; Sahai, J; Seguin, I; Swick, L; Tailor, S; Walker, S, 1997) |
| "Isoniazid prophylaxis in HIV-positive injecting drug users has been shown to significantly reduce the incidence of tuberculosis (TB)." | 3.69 | Isoniazid TB prophylaxis effective in drug users with HIV. ( , 1996) |
| " The risk for active tuberculosis to develop in patients not receiving isoniazid chemoprophylaxis was similar in patients with a positive PPD test result (10." | 3.68 | Risk for developing tuberculosis among anergic patients infected with HIV. ( Alberdi, JC; Baraia-Etxaburu, J; Bouza, E; Cosín, J; López-Gay, D; Miralles, P; Moreno, S; Parras, F; Pérez-Tascón, M; Vicente, T, 1993) |
| " Overall, 33 percent of these patients had isolates resistant to one or more antituberculosis drugs, 26 percent had isolates resistant to at least isoniazid, and 19 percent had isolates resistant to both isoniazid and rifampin." | 3.68 | The emergence of drug-resistant tuberculosis in New York City. ( Cauthen, GM; Dooley, SW; Frieden, TR; Kilburn, JO; Pablos-Mendez, A; Sterling, T, 1993) |
| " tuberculosis, reactivation of the disease may be prevented by chemoprophylaxis with isoniazid or rifampicin." | 3.68 | [Indications for chemoprophylaxis of tuberculosis. Arguments for]. ( Nicod, LP, 1993) |
| "Cumulative 24-month Mycobacterium tuberculosis infection incidence (measured primarily by tuberculin skin test [TST]) was high among human immunodeficiency virus exposed but uninfected infants (8." | 3.11 | Cumulative Mycobacterium tuberculosis Infection Incidence (Measured Primarily by Tuberculin Skin Test) Among Infants With Human Immunodeficiency Virus Exposure: Observational Follow-up of an Isoniazid Prophylaxis Trial. ( Carimo, N; Cranmer, LM; Escudero, JN; Hawn, TR; John-Stewart, G; Kinuthia, J; LaCourse, SM; Maleche-Obimbo, E; Matemo, D; Mecha, J; Richardson, BA; Warr, AJ, 2022) |
| " Data on IPT-related adverse events (AE) from sub-Saharan Africa are scarce." | 3.11 | Isoniazid preventive therapy-related adverse events among Malawian adults on antiretroviral therapy: A cohort study. ( Buchwald, A; Divala, T; Laufer, MK; Laurens, MB; Mallewa, J; Mategula, D; Milanzi, E; Mungwira, R; Mwapasa, V; Nampota, N; Tsirizani-Galileya, L; Van Oosterhout, JJ, 2022) |
| "Pregnancy is accompanied by immune suppression." | 3.01 | Effects of Pregnancy and Isoniazid Preventive Therapy on Mycobacterium tuberculosis Interferon Gamma Response Assays in Women With HIV. ( Aaron, L; Bradford, S; Browning, R; Costello, D; Denti, P; Gausi, K; Gupta, A; Haas, DW; Kabugho, E; LaCourse, SM; Masheto, G; Mathad, JS; McCarthy, K; Mmbaga, B; Montepiedra, G; Naik, S; Pahwa, S; Pierre, MF; Sterling, TR; Theron, G; Vhembo, T; Weinberg, A; Zimmer, B, 2021) |
| " We investigated pregnancy-induced and pharmacogenetic-associated pharmacokinetic changes and drug-drug interactions between isoniazid and efavirenz in pregnant women." | 3.01 | Pharmacokinetics and Drug-Drug Interactions of Isoniazid and Efavirenz in Pregnant Women Living With HIV in High TB Incidence Settings: Importance of Genotyping. ( Aaron, L; Aurpibul, L; Bhosale, R; Bradford, S; Browning, R; Chakhtoura, N; Chanaiwa, V; Chipato, T; Costello, D; Denti, P; Gausi, K; Gupta, A; Haas, DW; Hesseling, A; Jean-Philippe, P; Kabugho, E; Masheto, GR; McCarthy, K; Mhembere, T; Mmbaga, BT; Montepiedra, G; Mutambanengwe, M; Nevrekhar, N; Norman, J; Nyati, M; Onyango-Makumbi, C; Rouzier, V; Shin, K; Sterling, TR; Stranix-Chibanda, L; Theron, G; Tongprasert, F; Vhembo, T; Violari, A; Wallis, CL; Weinberg, A; Wiesner, L; Zimmer, B, 2021) |
| " Participants provided sparse pharmacokinetic (PK) sampling at baseline and weeks 2 and 4 for trough nevirapine determination." | 3.01 | Nevirapine pharmacokinetics in HIV-infected persons receiving rifapentine and isoniazid for TB prevention. ( Benson, CA; Chaisson, RE; Fletcher, CV; Gupta, A; Hakim, J; Kanyama, C; Langat, D; Leon-Cruz, J; Mwelase, N; Omoz-Oarhe, A; Podany, AT; Supparatpinyo, K; Swindells, S, 2021) |
| "To describe the pharmacokinetics of isoniazid and acetyl-isoniazid in TB/HIV-coinfected patients, and assess the effects of efavirenz co-administration and a 50% increase in the dose of rifampicin on the pharmacokinetic parameters of isoniazid and acetyl-isoniazid." | 2.90 | Effect of efavirenz-based antiretroviral therapy and high-dose rifampicin on the pharmacokinetics of isoniazid and acetyl-isoniazid. ( Affolabi, D; Bah-Sow, O; Chirehwa, MT; Denti, P; McIlleron, H; Merle, C; Wiesner, L, 2019) |
| "We enrolled HIV-infected Ugandans with pulmonary tuberculosis." | 2.87 | Delayed Sputum Culture Conversion in Tuberculosis-Human Immunodeficiency Virus-Coinfected Patients With Low Isoniazid and Rifampicin Concentrations. ( Buzibye, A; Byakika-Kibwika, P; Castelnuovo, B; Corti, N; de Kock, M; Denti, P; Eberhard, N; Fehr, JS; Gutteck, U; Henning, L; Jetter, A; Joloba, M; Kambugu, A; Kamya, MR; Lamorde, M; Ledergerber, B; Manabe, YC; Matovu, J; Muller, D; Musaazi, J; Sekaggya-Wiltshire, C; von Braun, A, 2018) |
| " Nonlinear mixed-effects modeling found that influential covariates for the pharmacokinetics were weight, sex, and a 30% increased bioavailability among heterozygous carriers of SLCO1B1 rs1104581 (previously associated with low rifampin concentrations)." | 2.82 | Effect of SLCO1B1 Polymorphisms on Rifabutin Pharmacokinetics in African HIV-Infected Patients with Tuberculosis. ( Egan, D; Hennig, S; Kellerman, T; McIlleron, H; Naiker, S; Owen, A; Pym, A; Reddy, T; Wiesner, L, 2016) |
| "There are limited pharmacokinetic data for use of the first-line antituberculosis drugs during infancy (<12 months of age), when drug disposition may differ." | 2.82 | Pharmacokinetics of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol in Infants Dosed According to Revised WHO-Recommended Treatment Guidelines. ( Bekker, A; Donald, PR; Draper, HR; Hesseling, AC; McIlleron, HM; Murray, S; Schaaf, HS; van der Laan, L; Wiesner, L, 2016) |
| " The pharmacokinetic parameters of rifampin, isoniazid, ethambutol, and pyrazinamide were determined for each patient." | 2.80 | Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis. ( Chigutsa, E; Gumbo, T; McIlleron, H; Pasipanodya, JG; Sirgel, FA; Smith, PJ; van Helden, PD; Visser, ME, 2015) |
| "Participants receiving daily rifapentine and isoniazid with efavirenz had pharmacokinetic evaluations at baseline and weeks 2 and 4 of concomitant therapy." | 2.80 | Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention. ( Andersen, JW; Bao, Y; Benson, CA; Chaisson, RE; Fletcher, CV; Gupta, A; Kim, P; Mohapi, L; Mwelase, T; Podany, AT; Supparatpinyo, K; Swindells, S, 2015) |
| " A total of 47 Malawian adults underwent rich pharmacokinetic sampling at 0, 0." | 2.80 | Pharmacokinetics of Antituberculosis Drugs in HIV-Positive and HIV-Negative Adults in Malawi. ( Davies, G; Dimba, A; Dzinjalamala, FK; Molyneux, EM; Molyneux, ME; van Oosterhout, JJ; Ward, S; Waterhouse, D; Zijlstra, EE, 2015) |
| " We studied the effect of INH on LPV concentrations by administering INH for 7 days and performing intensive pharmacokinetic sampling in 16 human immunodeficiency virus infected patients established on LPV/r-based ART." | 2.80 | The pharmacokinetics of lopinavir/ritonavir when given with isoniazid in South African HIV-infected individuals. ( Decloedt, EH; Maartens, G; McIlleron, H; van der Walt, JS; Wiesner, L, 2015) |
| " INH was associated with a 24% increase in median NVP area under the plasma concentration-time curve for the 12 h dosing interval, which was not statistically significant (P = 0." | 2.78 | The pharmacokinetics of nevirapine when given with isoniazid in South African HIV-infected individuals. ( Decloedt, EH; Denti, P; Maartens, G; McIlleron, H; Mwansa-Kambafwile, J; Rangaka, M; Smith, P; van der Walt, JS; Wiesner, L; Wilkinson, RJ, 2013) |
| " Adverse events were mostly mild and no serious adverse events or drug discontinuations were reported." | 2.78 | Efavirenz, tenofovir and emtricitabine combined with first-line tuberculosis treatment in tuberculosis-HIV-coinfected Tanzanian patients: a pharmacokinetic and safety study. ( Aarnoutse, RE; Boeree, MJ; Burger, DM; Fillekes, Q; Kibiki, GS; Kisanga, ER; Kisonga, RM; Mleoh, L; Mtabho, CM; Ndaro, A; Semvua, HH; van den Boogaard, J; van der Ven, A, 2013) |
| " INH pharmacokinetic parameters were characterized using a population pharmacokinetic approach." | 2.77 | Isoniazid pharmacokinetics, pharmacodynamics, and dosing in South African infants. ( Bobat, R; Carey, VJ; Cotton, MF; DʼArgenio, DZ; Fletcher, CV; Kiser, JJ; Madhi, SA; McSherry, GD; Seifart, HI; Werely, CJ; Zhu, R, 2012) |
| "We investigated adherence to study medication in a two centre, randomized trial comparing daily to three times a week dosing of isoniazid." | 2.74 | Adherence to isoniazid prophylaxis among HIV-infected children: a randomized controlled trial comparing two dosing schedules. ( Cotton, MF; Golub, JE; le Roux, DM; le Roux, SM; Workman, L; Zar, HJ, 2009) |
| "Tuberculosis was associated with an increased mortality (adjusted rate ratio 1." | 2.70 | Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults. ( Fuchs, D; Godfrey-Faussett, P; Hosp, M; Lisse, I; Mwinga, A; Quigley, MA, 2001) |
| " Inter-individual pharmacokinetic variability and the effect of age, nutritional status, Human immunodeficiency virus (HIV) infection, acetylator genotype may need to be accounted for in striving for the dosages best suited for an individual." | 2.61 | Pharmacokinetics of First-Line Anti-Tubercular Drugs. ( Kabra, SK; Lodha, R; Mukherjee, A, 2019) |
| "The preventive treatment of latent tuberculosis infection (LTBI) is of great importance for the elimination and control of tuberculosis (TB) worldwide, but existing screening methods for LTBI are still limited in predicting the onset of TB." | 2.53 | Updates on the risk factors for latent tuberculosis reactivation and their managements. ( Ai, JW; Liu, QH; Ruan, QL; Zhang, WH, 2016) |
| "HIV is the top and tuberculosis is the second leading cause of death from infectious disease worldwide, with an estimated 8." | 2.50 | Tuberculosis and HIV co-infection in children. ( Chiappini, E; de Martino, M; Galli, L; Thorne, C; Turkova, A; Venturini, E, 2014) |
| "This review will introduce pharmacokinetic parameters for key anti-TB drugs, as well as the indications and limitations of measuring these parameters in clinical practice." | 2.50 | Understanding pharmacokinetics to improve tuberculosis treatment outcome. ( Heysell, SK; Reynolds, J, 2014) |
| "The treatment of latent tuberculosis infection (LTBI) has been established as valid for patients at high risk for developing active tuberculosis." | 2.50 | Treatment guidelines for latent tuberculosis infection. ( , 2014) |
| "Drug-resistant tuberculous meningitis is associated with a high mortality." | 2.49 | Drug-resistant tuberculous meningitis. ( Agrawal, A; Garg, R; Garg, RK; Jain, A; Malhotra, HS, 2013) |
| " It is evident that guidelines established for the prevention and treatment of this problem differ between industrialised and developing countries, and that further research is needed to define the optimum dosing of pyridoxine supplementation in populations where there is a significant burden of TB and HIV." | 2.47 | Polyneuropathy, anti-tuberculosis treatment and the role of pyridoxine in the HIV/AIDS era: a systematic review. ( Benatar, M; Harrison, TB; Heckmann, JM; van der Watt, JJ, 2011) |
| "Treatment of latent tuberculosis infection reduces the risk of active TB in HIV positive individuals especially in those with a positive tuberculin skin test." | 2.46 | Treatment of latent tuberculosis infection in HIV infected persons. ( Adetifa, I; Akolo, C; Shepperd, S; Volmink, J, 2010) |
| "Treatment was rifampin, isoniazide, and pyrazinamide or ethambutol." | 2.46 | Tuberculous orchiepididymitis during 1978-2003 period: review of 34 cases and role of 16S rRNA amplification. ( Baquero, F; Buitrago, LA; Burgos Revilla, J; Gómez García, I; Gómez Mampaso, E; Gómez Rodríguez, A; Molina, MR; Sampietro Crespo, A, 2010) |
| "Tuberculosis is the commonest opportunistic infection in HIV-infected patients in developing countries including India." | 2.41 | Tuberculosis with human immunodeficiency virus infection. ( Cherian, T; Verghese, VP, 2000) |
| "Isoniazid (INH) has been the mainstay of preventive therapy for 40 years, but its use is limited by concerns about toxicity and poor adherence." | 2.41 | New developments in the treatment of latent tuberculosis. ( Chaisson, RE, 2000) |
| "Pneumocystis pneumonia is decreased in frequency by any one of several prophylactic agents, the best established being pentamidine administered as an inhaled aerosol." | 2.38 | Prevention of lung infections associated with human immunodeficiency virus infection. ( Hopewell, PC, 1989) |
| " We provide suggested dolutegravir dosing considerations with concomitant rifapentine use, not currently addressed in recommended guidelines." | 1.91 | Alternative dolutegravir dosing strategies with concurrent rifapentine utilized for latent tuberculosis treatment. ( Pecora Fulco, P; Taylor, A; Winthrop, E, 2023) |
| "Darunavir exposures were significantly decreased with HP coadministration." | 1.91 | Pharmacokinetics, Safety, and Tolerability of Once-Daily Darunavir With Cobicistat and Weekly Isoniazid/Rifapentine. ( Adeojo, L; Brooks, KM; Bunn, HT; George, JM; Kovacs, JA; Kumar, P; Pau, AK; Peloquin, CA; Swaim, D, 2023) |
| " The findings of the present study indicate the need to periodically assess adherence and persistence to IPT in the child TB contacts as high intermittent missed dosing rates can undermine the effectiveness of IPT in preventing incident disease." | 1.72 | Adherence to Isoniazid Preventive Therapy among children living with tuberculosis patients in Delhi, India: An exploratory prospective study. ( Basu, S; Chandra, S; Chopra, KK; Khanna, A; Sharma, N; Sharma, P, 2022) |
| " Simulations were performed to assess INH exposure and optimal dosing regimens, using 2 targets: Cmax at 3-6 mg/L and area under the curve (AUC) ≥ 10." | 1.72 | Influence of NAT2 Genotype and Maturation on Isoniazid Exposure in Low-Birth-Weight and Preterm Infants With or Without Human Immunodeficiency Virus (HIV) Exposure. ( Bekker, A; Béranger, A; Browning, R; Cababasay, M; Capparelli, EV; Cotton, MF; Mirochnick, M; Moye, J; Savic, RM; Solans, BP; Violari, A; Wang, J; Wiesner, L, 2022) |
| "Isoniazid prophylaxis treatment period is long and can cause liver damage." | 1.72 | Effectiveness and safety of available preventive tuberculosis treatment regimens for children and adolescents: protocol for a systematic review and network meta-analysis. ( Acosta-Reyes, J; Benjumea-Bedoya, D; Estupiñán-Bohorquez, AF; Florez, ID; Hoyos Mendez, Y; Sabella-Jiménez, V, 2022) |
| " Nonlinear mixed-effects models were developed to describe the pharmacokinetic data." | 1.72 | Effects of Enzyme Induction and Polymorphism on the Pharmacokinetics of Isoniazid and Rifampin in Tuberculosis/HIV Patients. ( Äbelö, A; Ashton, M; Bienvenu, E; Birgersson, S; Sundell, J, 2022) |
| "Tuberculosis has remained a leading cause of death among people living with HIV (PLHIV) globally." | 1.72 | Assessment of contextual factors shaping delivery and uptake of isoniazid preventive therapy among people living with HIV in Dar es salaam, Tanzania. ( Jacobs, C; Maritim, P; Mdoe, P; Nyarubamba, RF; Silumbwe, A; Zulu, JM, 2022) |
| "Tuberculosis was the predominant comorbidity (15." | 1.62 | Low prevalence of isoniazid preventive therapy uptake among HIV-infected patients attending tertiary health facility in Lagos, Southwest Nigeria. ( Adejumo, IA; Badru, WA; Busari, AA; Olanrewaju, OA; Olayemi, SO; Oreagba, IA; Oshikoya, KA; Usman, SO, 2021) |
| "BACKGROUND Antituberculosis drug-induced hepatotoxicity (ADIH) is a possible adverse event of antitubercular treatment." | 1.62 | Unusual Recurrence of Antituberculosis Drug-Induced Hepatotoxicity in Children: A Case Series. ( Aliyannissa, A; Febrianti, SA; Nataprawira, HM, 2021) |
| " Both sex and CD4 cell count affected the bioavailability of isoniazid." | 1.56 | Model-Based Assessment of Variability in Isoniazid Pharmacokinetics and Metabolism in Patients Co-Infected With Tuberculosis and HIV: Implications for a Novel Dosing Strategy. ( Äbelö, A; Ashton, M; Bienvenu, E; Birgersson, S; Janzén, D; Sundell, J, 2020) |
| "Active tuberculosis was diagnosed in three of the 196 TST-positive patients who adhered to PTI (1." | 1.56 | Access and adherence to isoniazid preventive therapy and occurrence of active TB in a cohort of people living with HIV: a retrospective cohort study in Sao Paulo, Brazil. ( Avelino-Silva, VI; Freitas, AC; Gutierrez, EB; Picone, CM, 2020) |
| " The prospective cohort were HIV patients without TB disease initiated on a dosage of Isoniazid 300 mg/day for adults and 150 mg/day for children for a period of 6 months." | 1.56 | A prospective cohort study of outcomes for isoniazid prevention therapy: a nested study from a national QI collaborative in Uganda. ( Calnan, J; Kadama, H; Karungi Karamagi Nkolo, E; Katureebe, C; Kiragga, D; Lawino, A; Muhire, M; Musinguzi, J; Nabwire, J; Namuwenge, P; Sensalire, S; Seyoum, D, 2020) |
| "Isoniazid resistance was observed in 40% (23/58 tested) and rifampin resistance in 19." | 1.51 | High mortality during tuberculosis retreatment at a Ghanaian tertiary center: a retrospective cohort study. ( Bamfo, TD; Bouton, TC; Carter, J; Forson, A; Jacobson, K; Jenkins, H; Kudzawu, S; Kwara, A; Zigah, F, 2019) |
| " Genetic polymorphisms and pharmacokinetic (PK) parameters of EFV400 without (PK1) and with INH/RIF following 4 (PK2) and 12 (PK3) weeks of coadministration were evaluated." | 1.51 | Pharmacokinetics of Efavirenz 400 mg Once Daily Coadministered With Isoniazid and Rifampicin in Human Immunodeficiency Virus-Infected Individuals. ( Boffito, M; Cerrone, M; Day-Weber, I; Fedele, S; Hill, A; McClure, M; Neary, M; Owen, A; Wang, X; Weaver, C, 2019) |
| "Patients were mainly in advanced acquired immunodeficiency syndrome (AIDS) stage." | 1.51 | Drug resistance and pathogenic spectrum of patients coinfected with nontuberculous mycobacteria and human-immunodeficiency virus in Chengdu, China. ( Li, QF; Li, YJ; Liao, Y; Luo, J; Wang, DM; Wu, GH; Xu, YH; Zhong, J; Zhu, M, 2019) |
| " Isoniazid, rifampin, and pyrazinamide concentration-time profiles and treatment outcome were obtained from 161 Indian children with drug-sensitive tuberculosis undergoing thrice-weekly dosing as per previous Indian pediatric guidelines." | 1.48 | Suboptimal Antituberculosis Drug Concentrations and Outcomes in Small and HIV-Coinfected Children in India: Recommendations for Dose Modifications. ( Bhavani, PK; Dooley, KE; Gangadevi, NP; Guiastrennec, B; Gupta, A; Karlsson, MO; Kumar, AKH; Ramachandran, G; Savic, RM; Swaminathan, S, 2018) |
| "Tuberculosis, pneumonia, and severe bacterial infections are the main causes of hospital admission in HIV-infected children." | 1.48 | Priorities for Decreasing Morbidity and Mortality in Children With Advanced HIV Disease. ( Archary, M; Ford, N; Frigati, L; Penazzato, M; Rabie, H, 2018) |
| " EFV is well known to cause neuropsychiatric side-effects on initiation, and a recent adult case series described late-onset neurotoxicity in the form of subacute ataxia and encephalopathy in patients treated with EFV for a median of 2 years, in association with toxic plasma levels of the drug." | 1.48 | A proposed management algorithm for late-onset efavirenz neurotoxicity. ( Asukile, MT; Chetty, S; Cross, HM; Hussey, HS; Lee Pan, EB; Tucker, LM, 2018) |
| "People with HIV infection with latent tuberculosis (TB) infection (LTBI) are at a 10-fold greater risk of developing active disease." | 1.48 | New and Noteworthy in Tuberculosis Diagnostics and Treatment. ( Swindells, S, 2018) |
| "WHO information note indicates that isoniazid preventive therapy (IPT) is generally safe with little risk of hepatotoxicity." | 1.48 | Serious hepatotoxicity following use of isoniazid preventive therapy in HIV patients in Eritrea. ( Berhane, A; Debesai, M; Russom, M; Tekeste, T; Teklesenbet, T; Zeregabr, M, 2018) |
| " Pyrazinamide pharmacokinetic (PK) data from 61 HIV/TB-coinfected patients in South Africa were used in the analysis." | 1.46 | Pharmacokinetics of Pyrazinamide and Optimal Dosing Regimens for Drug-Sensitive and -Resistant Tuberculosis. ( Chirehwa, MT; Denti, P; McIlleron, H; Mthiyane, T; Onyebujoh, P; Rustomjee, R; Smith, P, 2017) |
| "Treatment with standardized antituberculosis regimens dosed daily throughout, high uptake of antiretroviral therapy, and low prevalence of isoniazid monoresistance were associated with a low frequency of ADR." | 1.46 | Low Frequency of Acquired Isoniazid and Rifampicin Resistance in Rifampicin-Susceptible Pulmonary Tuberculosis in a Setting of High HIV-1 Infection and Tuberculosis Coprevalence. ( Meintjes, G; Rockwood, N; Sirgel, F; Streicher, E; Warren, R; Wilkinson, RJ, 2017) |
| "If isoniazid Cmax was <4." | 1.46 | Concentration-Dependent Antagonism and Culture Conversion in Pulmonary Tuberculosis. ( Denti, P; Gumbo, T; Lesosky, M; McIlleron, H; Meintjes, G; Pasipanodya, JG; Rockwood, N; Sirgel, F; Wilkinson, RJ, 2017) |
| "Rifampin is a key sterilizing drug in the treatment of tuberculosis (TB)." | 1.43 | Model-Based Evaluation of Higher Doses of Rifampin Using a Semimechanistic Model Incorporating Autoinduction and Saturation of Hepatic Extraction. ( Chirehwa, MT; Denti, P; McIlleron, H; Mthiyane, T; Onyebujoh, P; Rustomjee, R; Smith, P, 2016) |
| "HIV-infected adults with substance abuse (tobacco smoking, khat chewing and alcohol) should be prioritised for TB screening." | 1.43 | Determinants for tuberculosis in HIV-infected adults in Northwest Ethiopia: a multicentre case-control study. ( Alemu, YM; Awoke, W; Wilder-Smith, A, 2016) |
| "We identified significant gaps in the treatment for M." | 1.43 | Isoniazid therapy for Mycobacterium tuberculosis infection in HIV clinics, Los Angeles, California. ( Bolan, R; Chang, AH; Dubé, MP; Ghosh, JK; Kerndt, PR; Shin, SS; Yang, OO, 2016) |
| " One hundred patients with pulmonary tuberculosis (65% coinfected with HIV-1) were intensively sampled to determine rifampin, isoniazid, and pyrazinamide plasma concentrations after 7 to 8 weeks of a daily quadruple-therapy regimen dosed according to World Health Organization (WHO) weight bands." | 1.43 | HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients. ( Chirehwa, M; Denti, P; McIlleron, H; Meintjes, G; Rockwood, N; Wiesner, L; Wilkinson, RJ, 2016) |
| "Recurrent tuberculosis is a major health burden and may be due to relapse with the original strain or reinfection with a new strain." | 1.42 | Recurrence due to relapse or reinfection with Mycobacterium tuberculosis: a whole-genome sequencing approach in a large, population-based cohort with a high HIV infection prevalence and active follow-up. ( Banda, L; Chiwaya, A; Clark, TG; Coll, F; Crampin, AC; Glynn, JR; Guerra-Assunção, JA; Harris, D; Houben, RM; Khan, P; Mallard, K; McNerney, R; Mzembe, T; Parkhill, J; Pereira, RP, 2015) |
| "Isoniazid levels were analyzed at 2 and 6 h after drug intake using liquid chromatography mass spectrometric methods." | 1.40 | Effects of dosage, comorbidities, and food on isoniazid pharmacokinetics in Peruvian tuberculosis patients. ( Ardrey, A; Davies, G; Jave, O; López-Romero, SL; Moore, DA; Requena-Méndez, A; Ward, SA; Waterhouse, D, 2014) |
| "To evaluate IPT feasibility, treatment completion and adverse events (AE) and their determinants under field conditions." | 1.39 | Isoniazid preventive treatment: predictors of adverse events and treatment completion. ( Besozzi, G; Casali, L; Codecasa, LR; Delmastro, M; Ferrara, G; Ferrarese, M; Murgia, N; Raviglione, MC; Repossi, AC, 2013) |
| "Active tuberculosis is common among human immunodeficiency virus (HIV)-infected persons living in tuberculosis-endemic areas, but the hazard of subsequent tuberculosis disease has not been quantified in a single prospective cohort." | 1.39 | Recurrent tuberculosis risk among HIV-infected adults in Tanzania with prior active tuberculosis. ( Arbeit, RD; Bakari, M; Horsburgh, CR; Lahey, T; Mackenzie, T; Maro, I; Matee, M; Mtei, L; Pallangyo, K; von Reyn, CF, 2013) |
| " Rifampicin concentrations during the dosing interval were determined by HPLC at three different timepoints: (i) after 2 weeks of TB therapy and before starting HIV therapy (T0); (ii) after 4 weeks of combined therapy (T1); and (iii) after 10 weeks of combined therapy (T2)." | 1.38 | Systemic exposure to rifampicin in patients with tuberculosis and advanced HIV disease during highly active antiretroviral therapy in Burkina Faso. ( Bonkoungou, V; Carvalho, AC; Comelli, M; Cusato, M; Dembélé, SM; Kouanda, S; Matteelli, A; Nacanabo, R; Regazzi, M; Saleri, N; Villani, P, 2012) |
| "The frequency of late recurrences following treatment completion has not been well-studied." | 1.37 | When tuberculosis comes back: who develops recurrent tuberculosis in california? ( Deriemer, K; Flood, JM; Pascopella, L; Watt, JP, 2011) |
| "Tuberculosis is a major cause of mortality among patients with HIV and poses a risk throughout the course of HIV disease, even after successful initiation of antiretroviral therapy (ART)." | 1.35 | Opportunities and challenges for HIV care in overlapping HIV and TB epidemics. ( Getahun, H; Havlir, DV; Nunn, P; Sanne, I, 2008) |
| "When active tuberculosis is identified, combination therapy with isoniazid, rifampin, pyrazinamide, and ethambutol should be promptly initiated for a two-month "intensive phase," and in most cases, followed by isoniazid and a rifamycin product for a four- to seven-month "continuation phase." | 1.35 | Update on the treatment of tuberculosis. ( Inge, LD; Wilson, JW, 2008) |
| "Liver diseases are common in patients with HIV due to viral hepatitis B and C co-infections, opportunistic infections or malignancies, antiretroviral drugs and drugs for opportunistic infections." | 1.35 | The spectrum of liver diseases in HIV infected individuals at an HIV treatment clinic in Kampala, Uganda. ( Colebunders, R; Feld, J; Kambugu, A; Katabira, E; Katwere, M; Ocama, P; Opio, KC; Piloya, T; Ronald, A; Thomas, D, 2008) |
| " The median number of dosage adjustments to attain normal concentrations was 1 (range 0-4 adjustments)." | 1.35 | Therapeutic drug monitoring of antimycobacterial drugs in patients with both tuberculosis and advanced human immunodeficiency virus infection. ( Engemann, JJ; Fortenberry, ER; Hamilton, CD; Holland, DP; Peloquin, CA; Stout, JE; Weintrob, AC, 2009) |
| "Tuberculosis is a common complication and leading cause of death in HIV infection." | 1.34 | The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. ( Cavalcante, SC; Chaisson, RE; Durovni, B; Efron, A; Golub, JE; King, BS; Moore, RD; Moulton, LH; Pacheco, AG; Saraceni, V, 2007) |
| " Pyridoxine is preventative in low dosage and curative in high dosage." | 1.33 | [Isoniazid induced neuropathy: consider prevention]. ( De Broucker, T; Martinez-Almoyna, L; Steichen, O, 2006) |
| "Treatment with isoniazid was beneficial in HIV-infected, tuberculin-positive IDUs." | 1.32 | Effectiveness of isoniazid treatment for latent tuberculosis infection among human immunodeficiency virus (HIV)-infected and HIV-uninfected injection drug users in methadone programs. ( Amofa, J; Driver, CR; Fujiwara, PI; Gourevitch, MN; Highley, E; Kaye, K; Munsiff, SS; Rubino, MA; Scholten, JN; Seewald, R; Trim, C, 2003) |
| " Severe adverse reactions included rash (two), toxic hepatitis (six), Immune Reconstitution Syndrome (seven), and four deaths." | 1.32 | Efficacy and safety of Efavirenz in HIV patients on Rifampin for tuberculosis. ( Alves, CR; Badaro, R; Brites, C; Netto, EM; Oliveira, AS; Pedral-Sampaio, DB, 2004) |
| "Isoniazid (INH) treatment for latent TB infection (LTBI) reduces the riskfor developing active TB by 41%-92% (1)." | 1.31 | Missed opportunities for prevention of tuberculosis among persons with HIV infection--selected locations, United States, 1996-1997. ( , 2000) |
| "The prevalence of smear-positive pulmonary tuberculosis was 568 per 100,000 inmates, which was eight times higher than that in the general population." | 1.31 | Tuberculosis in Thai prisons: magnitude, transmission and drug susceptibility. ( Palittapongarnpim, P; Phongdara, A; Silapapojakul, K; Sretrirutchai, S; Vuddhakul, V, 2002) |
| "Treatment with isoniazid and a fluoroquinolone antibiotic was also independently associated with longer survival." | 1.29 | A multi-institutional outbreak of highly drug-resistant tuberculosis: epidemiology and clinical outcomes. ( Alland, D; Brudney, K; Crawford, JT; Frieden, TR; Fujiwara, PI; Hewlett, D; Kreisworth, BN; Maw, KL; Nivin, B; Sharp, V; Sherman, LF, 1996) |
| "The decision was analyzed for an intravenous drug abuser who may have been anergic, while tuberculin test status, race, and gender were varied." | 1.28 | Isoniazid as preventive therapy in HIV-infected intravenous drug abusers. A decision analysis. ( Jordan, TJ; Lewit, EM; Montgomery, RL; Reichman, LB, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.14) | 18.7374 |
| 1990's | 74 (10.72) | 18.2507 |
| 2000's | 102 (14.78) | 29.6817 |
| 2010's | 357 (51.74) | 24.3611 |
| 2020's | 156 (22.61) | 2.80 |
| Authors | Studies |
|---|---|
| Banerjee, D | 1 |
| Yogeeswari, P | 1 |
| Bhat, P | 1 |
| Thomas, A | 1 |
| Srividya, M | 1 |
| Sriram, D | 1 |
| Gengiah, S | 4 |
| Barker, PM | 3 |
| Yende-Zuma, N | 4 |
| Mbatha, M | 1 |
| Naidoo, S | 1 |
| Taylor, M | 3 |
| Loveday, M | 3 |
| Mhlongo, M | 1 |
| Jackson, C | 1 |
| Nunn, AJ | 3 |
| Padayatchi, N | 3 |
| Karim, SSA | 1 |
| Naidoo, K | 5 |
| Oxlade, O | 4 |
| Rochon, H | 1 |
| Campbell, JR | 3 |
| Menzies, D | 6 |
| Yanes-Lane, M | 1 |
| Ortiz-Brizuela, E | 1 |
| Benedetti, A | 2 |
| Churchyard, G | 6 |
| Busari, AA | 1 |
| Oshikoya, KA | 1 |
| Adejumo, IA | 1 |
| Olanrewaju, OA | 1 |
| Usman, SO | 1 |
| Badru, WA | 1 |
| Oreagba, IA | 1 |
| Olayemi, SO | 1 |
| Connolly, C | 3 |
| Aboma, M | 1 |
| Dida, N | 1 |
| Saavedra, B | 2 |
| Mambuque, E | 2 |
| Gomes, N | 1 |
| Nguenha, D | 3 |
| Mabunda, R | 1 |
| Faife, L | 1 |
| Langa, R | 1 |
| Munguambe, S | 2 |
| Manjate, F | 1 |
| Cossa, A | 1 |
| Scott, L | 2 |
| García-Basteiro, AL | 3 |
| Mlobeli, R | 1 |
| Tshabalala, MF | 1 |
| Narh-Bana, SA | 1 |
| Chirwa, TF | 1 |
| Chirwa, ED | 1 |
| Bonsu, F | 1 |
| Ibisomi, L | 2 |
| Kawonga, M | 1 |
| Akamike, IC | 5 |
| Okedo-Alex, IN | 5 |
| Alo, C | 2 |
| Agu, AP | 2 |
| Uneke, CJ | 4 |
| Ogbonnaya, LU | 5 |
| Nardotto, GHB | 1 |
| Bollela, VR | 1 |
| Rocha, A | 1 |
| Della Pasqua, O | 1 |
| Lanchote, VL | 1 |
| Nanyonga, SM | 1 |
| Kitutu, FE | 1 |
| Kalyango, J | 1 |
| Frank, M | 2 |
| Kiguba, R | 1 |
| Sumner, T | 4 |
| Mendelsohn, SC | 2 |
| Scriba, TJ | 2 |
| Hatherill, M | 2 |
| White, RG | 5 |
| Liou, BH | 1 |
| Cheng, CN | 1 |
| Lin, YT | 1 |
| Lin, YJ | 1 |
| Chuang, YC | 1 |
| Lin, KY | 1 |
| Liu, WC | 1 |
| Lin, SW | 1 |
| Kuo, CH | 1 |
| Sun, HY | 1 |
| Hung, CC | 1 |
| van Rensburg, R | 1 |
| Nightingale, S | 1 |
| Brey, N | 1 |
| Albertyn, CH | 1 |
| Kellermann, TA | 1 |
| Taljaard, JJ | 1 |
| Esterhuizen, TM | 1 |
| Sinxadi, PZ | 1 |
| Decloedt, EH | 3 |
| Semitala, FC | 4 |
| Kadota, JL | 1 |
| Musinguzi, A | 1 |
| Nabunje, J | 1 |
| Welishe, F | 1 |
| Nakitende, A | 1 |
| Akello, L | 1 |
| Bishop, O | 1 |
| Patel, D | 1 |
| Sammann, A | 1 |
| Nahid, P | 4 |
| Belknap, R | 1 |
| Kamya, MR | 9 |
| Handley, MA | 1 |
| Phillips, PPJ | 4 |
| Katahoire, A | 1 |
| Berger, CA | 1 |
| Kiwanuka, N | 1 |
| Katamba, A | 2 |
| Dowdy, DW | 12 |
| Cattamanchi, A | 3 |
| Sharma, N | 1 |
| Basu, S | 1 |
| Khanna, A | 1 |
| Sharma, P | 1 |
| Chopra, KK | 1 |
| Chandra, S | 1 |
| Béranger, A | 2 |
| Bekker, A | 3 |
| Solans, BP | 2 |
| Cotton, MF | 19 |
| Mirochnick, M | 1 |
| Violari, A | 9 |
| Wang, J | 1 |
| Cababasay, M | 1 |
| Wiesner, L | 14 |
| Browning, R | 3 |
| Moye, J | 2 |
| Capparelli, EV | 1 |
| Savic, RM | 4 |
| Crabtree-Ramirez, B | 1 |
| Jenkins, CA | 1 |
| Shepherd, BE | 3 |
| Jayathilake, K | 1 |
| Veloso, VG | 2 |
| Carriquiry, G | 1 |
| Gotuzzo, E | 1 |
| Cortes, CP | 2 |
| Padgett, D | 1 |
| McGowan, C | 1 |
| Sierra-Madero, J | 1 |
| Koenig, S | 1 |
| Pape, JW | 7 |
| Sterling, TR | 15 |
| Benoit Vásquez, GI | 1 |
| Morrobel, AL | 1 |
| Benjumea-Bedoya, D | 2 |
| Del Corral-Londoño, H | 1 |
| Nabity, SA | 2 |
| Mponda, K | 2 |
| Gutreuter, S | 1 |
| Surie, D | 2 |
| Zimba, SB | 1 |
| Chisuwo, L | 1 |
| Moffitt, A | 1 |
| Williams, AM | 1 |
| Sharma, AJ | 1 |
| Marshall, RE | 1 |
| Chiwaula, MJ | 1 |
| da Silva, R | 1 |
| Kumwenda, T | 1 |
| Chilikutali, L | 1 |
| Mwamale, S | 1 |
| Nagoli, E | 1 |
| Mwenyeheri, G | 1 |
| Ngongonda, D | 1 |
| Kaunda, E | 1 |
| Mtoto, F | 1 |
| Mhango, V | 1 |
| Mbewe, K | 1 |
| Melgar, M | 1 |
| Odo, M | 3 |
| Jahn, A | 3 |
| Buono, N | 1 |
| Maida, A | 2 |
| Girma, B | 2 |
| Kalua, T | 3 |
| Nyirenda, R | 1 |
| Sunguti, J | 1 |
| Woelk, G | 1 |
| Gunde, LJ | 2 |
| Mekonnen, TF | 1 |
| Maphosa, T | 2 |
| Kim, EJ | 1 |
| Auld, AF | 2 |
| Muula, AS | 1 |
| Oeltmann, JE | 3 |
| Geremew, D | 2 |
| Geremew, H | 1 |
| Tamir, M | 1 |
| Adem, M | 1 |
| Tegene, B | 1 |
| Bayleyegn, B | 1 |
| Warr, AJ | 4 |
| Anterasian, C | 1 |
| Shah, JA | 1 |
| De Rosa, SC | 1 |
| Nguyen, FK | 1 |
| Maleche-Obimbo, E | 6 |
| Cranmer, LM | 8 |
| Matemo, D | 8 |
| Mecha, J | 5 |
| Kinuthia, J | 9 |
| LaCourse, SM | 12 |
| John-Stewart, GC | 3 |
| Hawn, TR | 5 |
| Kazibwe, A | 1 |
| Oryokot, B | 1 |
| Mugenyi, L | 1 |
| Kagimu, D | 1 |
| Oluka, AI | 1 |
| Kato, D | 1 |
| Ouma, S | 1 |
| Tayebwakushaba, E | 1 |
| Odoi, C | 1 |
| Kakumba, K | 1 |
| Opito, R | 1 |
| Mafabi, CG | 1 |
| Ochwo, M | 1 |
| Nkabala, R | 1 |
| Tusiimire, W | 1 |
| Kateeba Tusiime, A | 1 |
| Alinga, SB | 1 |
| Miya, Y | 1 |
| Etukoit, MB | 1 |
| Biraro, IA | 1 |
| Kirenga, B | 1 |
| Anderson, G | 1 |
| Vinnard, C | 2 |
| Escudero, JN | 4 |
| Richardson, BA | 5 |
| Carimo, N | 1 |
| John-Stewart, G | 6 |
| Anderson, K | 1 |
| Pietersen, E | 1 |
| Bian, A | 1 |
| Dheda, K | 2 |
| Warren, R | 2 |
| van der Heijden, YF | 2 |
| Valinetz, ED | 1 |
| Gersh, JK | 1 |
| Joudeh, LL | 1 |
| Wald, A | 1 |
| Cangelosi, GA | 1 |
| Barnabas, RV | 3 |
| Horne, DJ | 1 |
| Porter, M | 1 |
| Choshi, P | 1 |
| Pedretti, S | 1 |
| Chimbetete, T | 1 |
| Smith, R | 1 |
| Meintjes, G | 8 |
| Phillips, E | 1 |
| Lehloenya, R | 1 |
| Peter, J | 1 |
| Ntinginya, NE | 1 |
| Te Brake, L | 1 |
| Sabi, I | 1 |
| Chamba, N | 1 |
| Kilonzo, K | 1 |
| Laizer, S | 1 |
| Andia-Biraro, I | 1 |
| Kibirige, D | 1 |
| Kyazze, AP | 1 |
| Ninsiima, S | 1 |
| Critchley, JA | 1 |
| Romeo, R | 1 |
| van de Maat, J | 1 |
| Olomi, W | 1 |
| Mrema, L | 1 |
| Magombola, D | 1 |
| Mwayula, IH | 1 |
| Sharples, K | 1 |
| Hill, PC | 1 |
| van Crevel, R | 1 |
| Kubjane, M | 1 |
| Osman, M | 1 |
| Boulle, A | 10 |
| Johnson, LF | 1 |
| Onyango, D | 2 |
| Kakande, E | 1 |
| Christian, C | 1 |
| Balzer, LB | 1 |
| Owaraganise, A | 3 |
| Nugent, JR | 1 |
| DiIeso, W | 1 |
| Rast, D | 1 |
| Kabami, J | 1 |
| Johnson Peretz, J | 1 |
| Camlin, CS | 2 |
| Shade, SB | 1 |
| Geng, EH | 1 |
| Kwarisiima, D | 3 |
| Havlir, DV | 6 |
| Chamie, G | 5 |
| Onyango, DO | 1 |
| van der Sande, MAB | 1 |
| Yuen, CM | 2 |
| Oele, E | 1 |
| Mebratu, W | 1 |
| Wedajo, S | 1 |
| Mohammed, S | 1 |
| Endawkie, A | 1 |
| Damtew, Y | 1 |
| Pham, MM | 1 |
| Podany, AT | 6 |
| Mwelase, N | 4 |
| Supparatpinyo, K | 6 |
| Mohapi, L | 7 |
| Gupta, A | 18 |
| Samaneka, W | 2 |
| Omoz-Oarhe, A | 4 |
| Langat, D | 4 |
| Benson, CA | 6 |
| Chaisson, RE | 43 |
| Swindells, S | 9 |
| Fletcher, CV | 7 |
| Singh, P | 2 |
| Moulton, LH | 10 |
| Barnes, GL | 4 |
| Msandiwa, R | 4 |
| Martinson, NA | 8 |
| Makova, NC | 1 |
| Muchekeza, M | 1 |
| Chirenda, J | 1 |
| Chadambuka, A | 1 |
| Govha, E | 1 |
| Juru, TP | 1 |
| Gombe, NT | 1 |
| Tshimanga, M | 1 |
| Pettit, AC | 1 |
| Kurbatova, E | 1 |
| Vernon, A | 5 |
| Dawson, R | 1 |
| Dooley, KE | 8 |
| Sanne, I | 3 |
| Waja, Z | 3 |
| Johnson, JL | 6 |
| Muzanyi, G | 1 |
| Lalloo, UG | 1 |
| Bryant, K | 2 |
| Sizemore, E | 1 |
| Scott, N | 1 |
| Dorman, SE | 1 |
| Muyindike, WR | 6 |
| Fatch, R | 4 |
| Cheng, DM | 3 |
| Emenyonu, NI | 4 |
| Forman, L | 1 |
| Ngabirano, C | 2 |
| Adong, J | 3 |
| Linas, B | 1 |
| Jacobson, KR | 4 |
| Hahn, JA | 5 |
| Sabella-Jiménez, V | 1 |
| Hoyos Mendez, Y | 1 |
| Estupiñán-Bohorquez, AF | 1 |
| Acosta-Reyes, J | 1 |
| Florez, ID | 1 |
| Sundell, J | 2 |
| Bienvenu, E | 2 |
| Birgersson, S | 2 |
| Äbelö, A | 2 |
| Ashton, M | 2 |
| Tsirizani-Galileya, L | 1 |
| Milanzi, E | 1 |
| Mungwira, R | 1 |
| Divala, T | 1 |
| Mallewa, J | 2 |
| Mategula, D | 1 |
| Nampota, N | 1 |
| Mwapasa, V | 1 |
| Buchwald, A | 1 |
| Laurens, MB | 1 |
| Laufer, MK | 1 |
| Van Oosterhout, JJ | 3 |
| Winardi, W | 1 |
| Yudistira Nalapraya, W | 1 |
| Sarifuddin, S | 1 |
| Anwar, S | 1 |
| Yufika, A | 1 |
| Wibowo, A | 1 |
| Fadhil, I | 1 |
| Wahyuni Ms, H | 1 |
| Arliny, Y | 1 |
| Behtri Yanifitri, D | 1 |
| Zulfikar, T | 1 |
| Harapan, H | 1 |
| Vojnov, L | 1 |
| Venter, WDF | 1 |
| Zhu, J | 1 |
| Lyatuu, G | 1 |
| Sudfeld, CR | 1 |
| Kiravu, A | 1 |
| Sando, D | 1 |
| Machumi, L | 1 |
| Minde, J | 1 |
| Chisonjela, F | 1 |
| Cohen, T | 8 |
| Menzies, NA | 4 |
| Moh, DR | 1 |
| Badjé, A | 7 |
| Kassi, AN | 1 |
| Ntakpé, JB | 4 |
| Kouame, GM | 4 |
| Ouassa, T | 4 |
| Danel, C | 6 |
| Domoua, SK | 3 |
| Anglaret, X | 8 |
| Eholié, SP | 3 |
| Madubueze, UC | 3 |
| Agbo, UN | 3 |
| Okeke, IM | 3 |
| Jagi, JL | 3 |
| Thomas, C | 3 |
| Gudi, SK | 3 |
| Undela, K | 3 |
| Nyarubamba, RF | 3 |
| Silumbwe, A | 3 |
| Jacobs, C | 3 |
| Maritim, P | 3 |
| Mdoe, P | 3 |
| Zulu, JM | 3 |
| Lai, WA | 2 |
| Brethour, K | 2 |
| D'Silva, O | 2 |
| Zwerling, AA | 2 |
| Radtke, K | 1 |
| Mohamed, A | 1 |
| Mirzayev, F | 1 |
| Gegia, M | 1 |
| Linh, NN | 1 |
| Schumacher, SG | 1 |
| Assefa, DG | 1 |
| Zeleke, ED | 1 |
| Bekele, D | 1 |
| Ejigu, DA | 1 |
| Molla, W | 1 |
| Woldesenbet, TT | 1 |
| Aynalem, A | 1 |
| Abebe, M | 2 |
| Mebratu, A | 1 |
| Manyazewal, T | 1 |
| Jarrett, RT | 1 |
| van der Heijden, Y | 1 |
| Shotwell, MS | 1 |
| Chihota, V | 2 |
| Marzinke, MA | 2 |
| Churchyard, GJ | 20 |
| Mandima, P | 1 |
| Baltrusaitis, K | 1 |
| Montepiedra, G | 9 |
| Aaron, L | 6 |
| Mathad, J | 1 |
| Onyango-Makumbi, C | 4 |
| Nyati, M | 3 |
| Ngocho, J | 2 |
| Chareka, G | 1 |
| Ponatshego, P | 1 |
| Masheto, G | 5 |
| McCarthy, K | 5 |
| Jean-Philippe, P | 7 |
| Stranix-Chibanda, L | 4 |
| Montoya I de Manuel-Rimbau, A | 1 |
| Ehrlich, J | 1 |
| Matsena, T | 1 |
| Chiconela, H | 1 |
| Casellas, A | 1 |
| López-Varela, E | 1 |
| Acacio, S | 1 |
| Chaisson, LH | 3 |
| Nangobi, F | 1 |
| Steinmetz, S | 1 |
| Marquez, C | 3 |
| Armstrong, DT | 1 |
| Opira, B | 1 |
| Yoon, C | 2 |
| Ying, C | 1 |
| He, C | 1 |
| Xu, K | 1 |
| Li, Y | 1 |
| Zhang, Y | 3 |
| Wu, W | 1 |
| Adepoju, VA | 1 |
| Adelekan, A | 1 |
| Adepoju, OE | 1 |
| Onyezue, OI | 1 |
| Imoyera, W | 1 |
| Nkeiruka, A | 1 |
| Olofinbiyi, AB | 1 |
| Motlhaoleng, K | 2 |
| Moropeng, L | 1 |
| Abraham, P | 1 |
| Moloantoa, T | 1 |
| Griesel, R | 1 |
| Zhao, Y | 2 |
| Simmons, B | 1 |
| Omar, Z | 1 |
| Keene, CM | 1 |
| Hill, AM | 1 |
| Maartens, G | 13 |
| Tumwegamire, A | 1 |
| Terrault, NA | 1 |
| Linas, BP | 2 |
| Agyemang, N | 1 |
| Scarsi, KK | 1 |
| Baker, P | 3 |
| Smeaton, LM | 1 |
| Olefsky, M | 1 |
| Woolley, E | 1 |
| Barr, E | 1 |
| Pham, M | 1 |
| Mawlana, S | 3 |
| Gatechompol, S | 1 |
| Jalil, EM | 1 |
| Gadama, L | 1 |
| Badal-Faesen, S | 3 |
| Van Schalkwyk, M | 1 |
| Kayama, C | 1 |
| Belaunzaran-Zamudio, PF | 1 |
| Godfrey, C | 2 |
| Cohn, SE | 3 |
| Mngqibisa, R | 3 |
| Haas, DW | 6 |
| Tanoglu, A | 1 |
| Erdem, H | 1 |
| Friedland, JS | 2 |
| Ankaralı, H | 1 |
| Garcia-Goez, JF | 1 |
| Albayrak, A | 1 |
| El-Kholy, A | 1 |
| Ceviker, SA | 1 |
| Amer, F | 1 |
| Erol, S | 1 |
| Darazam, IA | 1 |
| Rabiei, MM | 1 |
| Sarwar, MZ | 1 |
| Zeb, M | 1 |
| Nawaz, H | 1 |
| Ceylan, MR | 1 |
| Cernat, R | 1 |
| Tasbakan, M | 1 |
| Ayoade, F | 1 |
| Ruch, Y | 1 |
| Tigen, ET | 1 |
| Angioni, G | 1 |
| Rajani, DP | 1 |
| Akhtar, N | 1 |
| Surme, S | 1 |
| Sengoz, G | 1 |
| Karlıdag, GE | 1 |
| Marino, A | 1 |
| Ripon, RK | 1 |
| Çağ, Y | 1 |
| Aydın, Ö | 1 |
| Akkoyunlu, Y | 1 |
| Seyman, D | 1 |
| Angamuthu, K | 1 |
| Cascio, A | 1 |
| Popescu, CP | 1 |
| Sirmatel, F | 1 |
| Eren, E | 1 |
| Dar, RE | 1 |
| Munu, FU | 1 |
| Tanoglu, EG | 1 |
| Echeverry, E | 1 |
| Velez, JD | 1 |
| Artuk, C | 1 |
| Balin, SO | 1 |
| Pandya, N | 1 |
| Erdem, A | 1 |
| Demiray, EKD | 1 |
| Aypak, A | 1 |
| Mapingure, MP | 1 |
| Zech, JM | 1 |
| Hirsch-Moverman, Y | 3 |
| Msukwa, M | 1 |
| Howard, AA | 3 |
| Makoni, T | 1 |
| Gwanzura, C | 1 |
| Apollo, T | 1 |
| Sandy, C | 4 |
| Musuka, GN | 1 |
| Rabkin, M | 1 |
| Amanya, I | 1 |
| Muhoozi, M | 1 |
| Aruhomukama, D | 1 |
| Ssebagereka, A | 1 |
| Mugambe, R | 1 |
| Chipato, T | 5 |
| Chanaiwa, V | 2 |
| Vhembo, T | 4 |
| Mutambanengwe, M | 2 |
| Raesi, M | 1 |
| Bradford, S | 5 |
| Golner, A | 1 |
| Costello, D | 4 |
| Kulkarni, V | 1 |
| Shayo, A | 1 |
| Kabugho, E | 3 |
| Jean-Phillippe, P | 1 |
| Chakhtoura, N | 5 |
| Theron, G | 6 |
| Weinberg, A | 5 |
| Taylor, A | 1 |
| Winthrop, E | 1 |
| Pecora Fulco, P | 1 |
| Wondmeneh, TG | 1 |
| Mekonnen, AT | 1 |
| Sekayi, W | 1 |
| Namyalo, E | 1 |
| Namayanja, J | 1 |
| Kungu, JM | 1 |
| Brooks, KM | 2 |
| Pau, AK | 2 |
| Swaim, D | 1 |
| Bunn, HT | 1 |
| Adeojo, L | 1 |
| Peloquin, CA | 7 |
| Kumar, P | 2 |
| Kovacs, JA | 2 |
| George, JM | 2 |
| Kekibiina, A | 1 |
| Beesiga, B | 1 |
| Marson, K | 2 |
| Lodi, S | 2 |
| Thirumurthy, H | 2 |
| McDonell, MG | 2 |
| Gandhi, M | 2 |
| Galileya, LT | 1 |
| Wasmann, RE | 1 |
| Chabala, C | 1 |
| Rabie, H | 3 |
| Lee, J | 1 |
| Njahira Mukui, I | 1 |
| Hesseling, A | 3 |
| Zar, H | 3 |
| Aarnoutse, R | 1 |
| Turkova, A | 2 |
| Gibb, D | 1 |
| McIlleron, H | 19 |
| Denti, P | 16 |
| Quincer, EM | 1 |
| Lyland, A | 1 |
| Figueroa, J | 1 |
| Yang, H | 1 |
| Antwi, S | 1 |
| Maranchick, N | 1 |
| Dompreh, A | 1 |
| Amissah, AK | 1 |
| Sly-Moore, E | 1 |
| Martyn-Dickens, C | 1 |
| Opoku, T | 1 |
| Enimil, A | 1 |
| Bosomtwe, D | 1 |
| Ojewale, O | 1 |
| Sarfo, AD | 1 |
| Appiah, AF | 1 |
| Kusi-Amponsah, I | 1 |
| Dong, SK | 1 |
| Osei Kuffour, B | 1 |
| Morgan, R | 1 |
| Alshaer, MH | 1 |
| Kwara, A | 2 |
| Gupta, N | 1 |
| Mittal, A | 1 |
| Nischal, N | 1 |
| Wagner, AD | 1 |
| Copeland, A | 1 |
| Shawarira-Bote, S | 1 |
| Shamu, T | 1 |
| Chimbetete, C | 1 |
| Dlamini, NC | 1 |
| Ji, DD | 1 |
| Chien, LY | 1 |
| Tsegaye, AT | 2 |
| Alemu, W | 1 |
| Ayele, TA | 1 |
| Bouton, TC | 1 |
| Forson, A | 1 |
| Kudzawu, S | 1 |
| Zigah, F | 1 |
| Jenkins, H | 1 |
| Bamfo, TD | 1 |
| Carter, J | 1 |
| Jacobson, K | 1 |
| Mukherjee, TI | 1 |
| Saito, S | 2 |
| Gadisa, T | 2 |
| Melaku, Z | 2 |
| Jarrett, BA | 1 |
| Woznica, DM | 1 |
| Tilchin, C | 1 |
| Mpungose, N | 1 |
| Golub, JE | 16 |
| Hanrahan, CF | 5 |
| Baraki, AG | 1 |
| Gezie, LD | 1 |
| Zeleke, EG | 1 |
| Awoke, T | 1 |
| Juszkiewicz, K | 1 |
| Jarosz, MJ | 1 |
| Włoszczak-Szubzda, A | 1 |
| Głowacka, M | 1 |
| Kendall, EA | 2 |
| Durovni, B | 12 |
| Cavalacante, S | 1 |
| Masonoke, K | 1 |
| Saraceni, V | 10 |
| Lebina, L | 2 |
| Efron, A | 4 |
| Cohn, S | 10 |
| Chon, S | 1 |
| Masheto, GR | 2 |
| Mmbaga, BT | 2 |
| Aurpibul, L | 2 |
| Bhosale, R | 2 |
| Mave, V | 2 |
| Rouzier, V | 3 |
| Shin, K | 2 |
| Zimmer, B | 5 |
| Nyathi, S | 1 |
| Dlodlo, RA | 4 |
| Satyanarayana, S | 5 |
| Takarinda, KC | 4 |
| Tweya, H | 1 |
| Hove, S | 1 |
| Matambo, R | 1 |
| Mandewo, W | 1 |
| Nyathi, K | 1 |
| Sibanda, E | 2 |
| Harries, AD | 14 |
| Salazar-Austin, N | 1 |
| Lala, S | 1 |
| Hoffmann, CJ | 4 |
| Martinson, N | 6 |
| Seabrook, D | 1 |
| Cavalcante, SC | 8 |
| Kagujje, M | 1 |
| Mubiana, ML | 1 |
| Mwamba, E | 1 |
| Muyoyeta, M | 1 |
| Adeniyi, OV | 1 |
| Selanto-Chairman, N | 1 |
| Owolabi, EO | 1 |
| Ajayi, AI | 1 |
| Kayembe, DK | 1 |
| Ter Goon, D | 1 |
| Gordana, A | 1 |
| Lambert, J | 1 |
| Kumar, AMV | 5 |
| Timire, C | 3 |
| Kalk, E | 1 |
| Heekes, A | 1 |
| Mehta, U | 1 |
| de Waal, R | 1 |
| Jacob, N | 1 |
| Cohen, K | 1 |
| Myer, L | 3 |
| Davies, MA | 2 |
| Schutz, C | 1 |
| Chirehwa, M | 2 |
| Barr, D | 1 |
| Ward, A | 1 |
| Janssen, S | 2 |
| Burton, R | 1 |
| Wilkinson, RJ | 14 |
| Shey, M | 1 |
| Reddy, MM | 1 |
| Thekkur, P | 3 |
| Ramya, N | 1 |
| Kamath, PBT | 1 |
| Shastri, SG | 1 |
| Kumar, RBN | 1 |
| Chinnakali, P | 2 |
| Nirgude, AS | 1 |
| Rangaraju, C | 1 |
| Somashekar, N | 1 |
| Harshana, A | 1 |
| Sunder, S | 1 |
| Panwar, P | 1 |
| Maurya, SC | 1 |
| Nag, RK | 1 |
| Srivastava, SK | 1 |
| Chowdhary, S | 1 |
| Janzén, D | 1 |
| Picone, CM | 2 |
| Freitas, AC | 1 |
| Gutierrez, EB | 2 |
| Avelino-Silva, VI | 1 |
| Boffa, JM | 1 |
| Fisher, DA | 1 |
| Mayan, MJ | 1 |
| Sauve, RS | 1 |
| Williamson, TS | 1 |
| Ogunsola, OO | 1 |
| Ajayi, O | 1 |
| Ojo, O | 1 |
| Adeyeye, O | 1 |
| Akinro, Y | 1 |
| Oke, O | 1 |
| Adurogbola, AA | 1 |
| Olajide, O | 1 |
| Tiendrebeogo, T | 1 |
| Becquet, R | 1 |
| Mushtaq, A | 1 |
| Mayanja-Kizza, H | 2 |
| Savic, R | 2 |
| Gupte, A | 1 |
| Zhang, N | 2 |
| Edward, VA | 1 |
| Wolf, L | 1 |
| Sebe, M | 2 |
| Likoti, M | 1 |
| Fyvie, MJ | 1 |
| Shibambo, I | 1 |
| Beattie, T | 1 |
| Mutasa-Apollo, T | 1 |
| Choto, RC | 1 |
| Mabaya, S | 1 |
| Mbito, C | 1 |
| Robert, M | 3 |
| Todd, J | 3 |
| Ngowi, BJ | 2 |
| Msuya, SE | 2 |
| Ramadhani, A | 3 |
| Sambu, V | 1 |
| Jerry, I | 1 |
| Mujuni, MR | 1 |
| Mahande, MJ | 3 |
| Ngocho, JS | 1 |
| Maokola, W | 3 |
| Hughes, M | 1 |
| Stout, JE | 3 |
| Turner, NA | 1 |
| Belknap, RW | 1 |
| Horsburgh, CR | 6 |
| Kim, HY | 3 |
| Bridges, JFP | 2 |
| Lam, E | 1 |
| Schaefer, J | 1 |
| Zheng, R | 1 |
| Zhan, T | 1 |
| Kraft, WK | 1 |
| Sensalire, S | 1 |
| Karungi Karamagi Nkolo, E | 1 |
| Nabwire, J | 1 |
| Lawino, A | 1 |
| Kiragga, D | 1 |
| Muhire, M | 1 |
| Kadama, H | 1 |
| Katureebe, C | 1 |
| Namuwenge, P | 1 |
| Musinguzi, J | 1 |
| Calnan, J | 1 |
| Seyoum, D | 1 |
| Grande, SW | 1 |
| Adams, LV | 5 |
| Maseko, TSB | 1 |
| Talbot, EA | 7 |
| deGijsel, D | 1 |
| Mikal, J | 1 |
| Simelane, ZZ | 1 |
| Achili, A | 1 |
| Mkhontfo, M | 1 |
| Haumba, SM | 1 |
| Xiao, K | 1 |
| Zhong, L | 1 |
| Mmbaga, B | 1 |
| Naik, S | 1 |
| Pahwa, S | 1 |
| Mathad, JS | 2 |
| Pierre, MF | 1 |
| Gausi, K | 2 |
| David, A | 1 |
| Govender, L | 1 |
| Furrer, J | 1 |
| Rakgokong, M | 1 |
| Eisenberg, G | 1 |
| Marlowe, E | 1 |
| Stevens, W | 1 |
| Al-Jahdali, H | 1 |
| Bah, B | 1 |
| Belo, M | 1 |
| Cook, VJ | 1 |
| Long, R | 1 |
| Schwartzman, K | 2 |
| Trajman, A | 1 |
| E Ahiarakwem, II | 1 |
| Ekejindu, IM | 1 |
| Akujobi, CN | 1 |
| Aghanya, IN | 1 |
| Welekidan, LN | 1 |
| Skjerve, E | 1 |
| Dejene, TA | 1 |
| Gebremichael, MW | 1 |
| Brynildsrud, O | 1 |
| Agdestein, A | 1 |
| Tessema, GT | 1 |
| Tønjum, T | 1 |
| Yimer, SA | 1 |
| Bao, Y | 2 |
| Hazlett, C | 1 |
| Wulf, DA | 1 |
| Manyame-Murwira, B | 1 |
| Payera, B | 1 |
| Mutunzi, H | 1 |
| Simbi, R | 1 |
| Siziba, N | 1 |
| Banana, C | 1 |
| Muleya, N | 1 |
| Makombe, E | 1 |
| Jongwe, PL | 1 |
| Bhebhe, R | 1 |
| Mangwanya, D | 1 |
| Dzangare, J | 1 |
| Mudzengerere, FH | 1 |
| Wekiya, E | 1 |
| Norman, J | 3 |
| Wallis, CL | 1 |
| Nevrekhar, N | 1 |
| Mhembere, T | 1 |
| Tongprasert, F | 2 |
| Ignatius, EH | 1 |
| Loftis, AJ | 2 |
| Nematadzira, T | 1 |
| Patil, S | 2 |
| Lespinasse, D | 1 |
| Hunter, OF | 1 |
| Kyesi, F | 1 |
| Ahluwalia, AK | 1 |
| Daffé, ZN | 1 |
| Munseri, P | 1 |
| von Reyn, CF | 6 |
| Leon, D | 1 |
| Panpradist, N | 1 |
| Lutz, B | 1 |
| Ferguson, O | 1 |
| Jo, Y | 1 |
| Pennington, J | 1 |
| Johnson, K | 1 |
| Dowdy, D | 2 |
| Mandalakas, AM | 4 |
| Hesseling, AC | 14 |
| Kay, A | 1 |
| Du Preez, K | 4 |
| Martinez, L | 1 |
| Ronge, L | 1 |
| DiNardo, A | 1 |
| Lange, C | 2 |
| Kirchner, HL | 1 |
| Hsieh, YL | 1 |
| Yaesoubi, R | 2 |
| Salomon, JA | 3 |
| Gunde, L | 1 |
| Eaton, JW | 2 |
| Auld, A | 1 |
| Kiyiika, CN | 1 |
| Chiwandira, B | 1 |
| Mpunga, JU | 1 |
| Mbendra, K | 1 |
| Corbett, L | 1 |
| Hosseinipour, MC | 4 |
| Kunkel, A | 2 |
| Kuaban, C | 1 |
| Toukam, LDI | 1 |
| Sander, M | 1 |
| Leon-Cruz, J | 2 |
| Hakim, J | 4 |
| Kanyama, C | 2 |
| Roscoe, C | 1 |
| Lockhart, C | 1 |
| de Klerk, M | 1 |
| Baughman, A | 1 |
| Agolory, S | 1 |
| Gawanab, M | 1 |
| Menzies, H | 1 |
| Jonas, A | 1 |
| Salomo, N | 1 |
| Taffa, N | 1 |
| Lowrance, D | 1 |
| Robsky, K | 1 |
| Tollefson, D | 1 |
| Pevzner, E | 2 |
| Hamunime, N | 1 |
| Mavhunga, F | 1 |
| Mungunda, H | 1 |
| Karanja, M | 2 |
| Kingwara, L | 1 |
| Owiti, P | 2 |
| Kirui, E | 1 |
| Ngari, F | 1 |
| Kiplimo, R | 1 |
| Maina, M | 1 |
| Masini, E | 3 |
| Onyango, E | 2 |
| Ngugi, C | 1 |
| Ngowi, B | 1 |
| Lawson, L | 1 |
| Mahande, M | 1 |
| Msuya, S | 1 |
| Kay, AW | 2 |
| Thivalapill, N | 1 |
| Skinner, D | 1 |
| Dube, GS | 2 |
| Dlamini, N | 1 |
| Mzileni, B | 1 |
| Fuentes, P | 1 |
| Ustero, P | 1 |
| Nabisere, R | 1 |
| Arinaitwe, A | 1 |
| Muyise, R | 1 |
| Asienzo, J | 1 |
| Anguzu, G | 1 |
| Owarwo, N | 1 |
| Lwanga, I | 1 |
| Lamorde, M | 5 |
| Sekaggya-Wiltshire, C | 5 |
| Laker, E | 1 |
| Ross, JM | 1 |
| Rangaka, MX | 7 |
| Walker, AS | 4 |
| Shapiro, AE | 2 |
| Thomas, KK | 1 |
| Eholie, S | 4 |
| Gabillard, D | 6 |
| Ford, N | 4 |
| Williams, BG | 3 |
| Buck, WC | 1 |
| Nguyen, H | 1 |
| Siapka, M | 1 |
| Basu, L | 1 |
| Greenberg Cowan, J | 1 |
| De Deus, MI | 1 |
| Gleason, M | 1 |
| Ferreira, F | 1 |
| Xavier, C | 1 |
| Jose, B | 1 |
| Muthemba, C | 1 |
| Simione, B | 1 |
| Kerndt, P | 1 |
| Prabhu, D | 1 |
| Dawe, RS | 1 |
| Lim, RK | 1 |
| Atuhumuza, E | 1 |
| Sabiti, L | 1 |
| Namakula-Katende, J | 1 |
| Amisi, JA | 1 |
| Carter, EJ | 2 |
| Szkwarko, D | 1 |
| Hoffmann, J | 1 |
| Chedid, C | 1 |
| Ocheretina, O | 2 |
| Masetti, C | 1 |
| Joseph, P | 3 |
| Mabou, MM | 2 |
| Mathon, JE | 1 |
| Francois, EM | 1 |
| Gebelin, J | 1 |
| Babin, FX | 1 |
| Raskine, L | 1 |
| Shiraishi, RW | 1 |
| Kirking, HL | 1 |
| Nyirenda, RK | 1 |
| Zegarra-Chapoñan, R | 1 |
| Bonadonna, LV | 1 |
| Martina-Chávez, MB | 1 |
| Zeladita-Huaman, J | 1 |
| Weyenga, H | 1 |
| Katana, AK | 1 |
| Ng Ang A, LW | 1 |
| Sirengo, M | 1 |
| Ondondo, RO | 1 |
| Wambugu, C | 1 |
| Waruingi, RN | 1 |
| Muthee, RW | 1 |
| Ngugi, EW | 1 |
| Shah, NS | 2 |
| Pathmanathan, I | 1 |
| Maloney, S | 1 |
| De Cock, KM | 5 |
| Takamiya, M | 1 |
| Takarinda, K | 1 |
| Balachandra, S | 1 |
| Godfrey, M | 1 |
| Radin, E | 1 |
| Hakim, A | 1 |
| Pearson, ML | 1 |
| Choto, R | 1 |
| Rogers, JH | 1 |
| Komba, FF | 1 |
| Frumence, G | 1 |
| Mao, L | 1 |
| Kim, S | 7 |
| Liu, C | 1 |
| Ning, B | 1 |
| Bao, D | 1 |
| Fan, J | 1 |
| Lyon, CJ | 1 |
| Sun, Z | 1 |
| Nachman, S | 7 |
| Mitchell, CD | 3 |
| Hu, TY | 1 |
| Belay, M | 1 |
| Tulu, B | 1 |
| Younis, S | 1 |
| Jolliffe, DA | 1 |
| Tayachew, D | 1 |
| Manwandu, H | 1 |
| Abozen, T | 1 |
| Tirfie, EA | 1 |
| Tegegn, M | 1 |
| Zewude, A | 1 |
| Forrest, S | 1 |
| Mayito, J | 1 |
| Huggett, JF | 1 |
| Jones, GM | 1 |
| O'Sullivan, DM | 1 |
| Martineau, HM | 1 |
| Noursadeghi, M | 1 |
| Chandran, A | 1 |
| Harris, KA | 1 |
| Nikolayevskyy, V | 1 |
| Demaret, J | 1 |
| Berg, S | 1 |
| Vordermeier, M | 1 |
| Balcha, TT | 1 |
| Aseffa, A | 1 |
| Ameni, G | 2 |
| Reece, ST | 1 |
| Martineau, AR | 1 |
| Mollan, KR | 1 |
| Eron, JJ | 1 |
| Krajewski, TJ | 1 |
| Painter, W | 1 |
| Duke, ER | 1 |
| Morse, CG | 1 |
| Goecker, EA | 1 |
| Premkumar, L | 1 |
| Wolfe, CR | 1 |
| Szewczyk, LJ | 1 |
| Alabanza, PL | 1 |
| Degli-Angeli, EJ | 1 |
| Brown, AJ | 1 |
| Dragavon, JA | 1 |
| Won, JJ | 1 |
| Keys, J | 1 |
| Hudgens, MG | 1 |
| Fang, L | 1 |
| Wohl, DA | 1 |
| Cohen, MS | 1 |
| Baric, RS | 1 |
| Coombs, RW | 1 |
| Sheahan, TP | 1 |
| Fischer, WA | 1 |
| Li, B | 1 |
| Wang, X | 2 |
| Hong, S | 1 |
| Wang, Q | 2 |
| Li, L | 1 |
| Eltayeb, O | 1 |
| Dong, C | 1 |
| Shuang, S | 1 |
| Padmapriyadarsini, C | 6 |
| Sekar, L | 4 |
| Reddy, D | 2 |
| Chitra, A | 1 |
| Poornagangadevi, N | 1 |
| Selvaraj, M | 1 |
| Bhavani, PK | 4 |
| Mothi, SN | 1 |
| Nandagopal, K | 1 |
| Vennila, S | 1 |
| Tamizhselvan, M | 1 |
| Maheshmanisha, J | 1 |
| Agarwal, U | 1 |
| Rewari, BB | 1 |
| Swaminathan, S | 14 |
| Francis, J | 2 |
| Kendall, MA | 2 |
| Wu, X | 1 |
| Firnhaber, C | 2 |
| Peetluk, LS | 1 |
| Rebeiro, PF | 1 |
| Ridolfi, FM | 1 |
| Andrade, BB | 1 |
| Cordeiro-Santos, M | 1 |
| Kritski, A | 1 |
| Calvacante, S | 1 |
| Figueiredo, MC | 1 |
| Liu, D | 1 |
| Rolla, VC | 1 |
| Maokola, WM | 1 |
| Nataprawira, HM | 1 |
| Aliyannissa, A | 1 |
| Febrianti, SA | 1 |
| Sandoval, M | 1 |
| Mtetwa, G | 1 |
| Mkhabela, M | 1 |
| Ndlovu, B | 1 |
| Devezin, T | 1 |
| Sikhondze, W | 1 |
| Vambe, D | 1 |
| Sibanda, J | 1 |
| Stevens, RH | 1 |
| Lukhele, B | 1 |
| Britto, P | 1 |
| Jayachandran, P | 1 |
| Townley, E | 1 |
| Popson, S | 1 |
| Chalermchockcharoentkit, A | 1 |
| Kamthunzi, P | 1 |
| Robinson, JA | 1 |
| Angira, F | 1 |
| Samaneka, WP | 1 |
| Kabengele, C | 1 |
| M'hango, H | 1 |
| Mweemba, D | 1 |
| Malumani, M | 1 |
| Berhanu, RH | 1 |
| Cárdenas, V | 1 |
| Mngadi, K | 1 |
| Brumskine, W | 1 |
| Yimer, G | 1 |
| Wang, SH | 1 |
| Masilela, L | 1 |
| Waggie, Z | 1 |
| van den Hof, S | 1 |
| Charalambous, S | 11 |
| Cobelens, F | 2 |
| Grant, AD | 17 |
| Fielding, KL | 13 |
| Khawcharoenporn, T | 2 |
| Phetsuksiri, B | 1 |
| Rudeeaneksin, J | 1 |
| Srisungngam, S | 1 |
| Apisarnthanarak, A | 2 |
| Ssengooba, W | 1 |
| Lukoye, D | 1 |
| Meehan, CJ | 1 |
| Kateete, DP | 1 |
| Joloba, ML | 2 |
| de Jong, BC | 1 |
| Cobelens, FG | 2 |
| van Leth, F | 1 |
| Maharaj, B | 1 |
| Gengiah, TN | 1 |
| Naidoo, A | 1 |
| Mashabela, F | 1 |
| Hoffmann, JD | 1 |
| Shembe, S | 1 |
| Velaphi, S | 1 |
| Lala, SG | 1 |
| Karim, F | 1 |
| Mufamadi, G | 1 |
| Zako, L | 1 |
| Chinappa, T | 1 |
| Maruri, F | 1 |
| Moosa, MS | 1 |
| Pym, AS | 1 |
| Castro, C | 1 |
| Ricardo, A | 1 |
| Zabaleta, A | 1 |
| Llerena, C | 1 |
| Puerto, G | 1 |
| Omonge, E | 1 |
| Otieno, F | 1 |
| Kubo, M | 1 |
| Shiruli, B | 1 |
| Chirehwa, MT | 3 |
| Rustomjee, R | 4 |
| Mthiyane, T | 3 |
| Onyebujoh, P | 2 |
| Smith, P | 5 |
| Musiime, V | 1 |
| Szubert, AJ | 1 |
| Siika, A | 1 |
| Agutu, C | 1 |
| Walker, S | 2 |
| Pett, SL | 1 |
| Bwakura-Dangarembizi, M | 1 |
| Lugemwa, A | 2 |
| Kaunda, S | 1 |
| Karoney, M | 1 |
| Musoro, G | 3 |
| Kabahenda, S | 1 |
| Nathoo, K | 1 |
| Maitland, K | 1 |
| Griffiths, A | 1 |
| Thomason, MJ | 2 |
| Kityo, C | 1 |
| Mugyenyi, P | 3 |
| Prendergast, AJ | 1 |
| Gibb, DM | 1 |
| Shayo, GA | 2 |
| Chitama, D | 1 |
| Moshiro, C | 2 |
| Aboud, S | 4 |
| Bakari, M | 7 |
| Mugusi, F | 4 |
| Baghaei, P | 1 |
| Tabarsi, P | 1 |
| Moniri, A | 1 |
| Marjani, M | 1 |
| Farnia, P | 1 |
| Jabbehdari, S | 1 |
| Velayati, AA | 1 |
| Bonnet, M | 7 |
| Kyakwera, C | 1 |
| Kyomugasho, N | 1 |
| Atwine, D | 2 |
| Mugabe, F | 1 |
| Nansumba, M | 2 |
| Ii, YB | 1 |
| Mwanga-Amumpaire, J | 1 |
| Kiwanuka, J | 1 |
| Deya, RW | 1 |
| Graham, SM | 3 |
| Masese, LN | 1 |
| Jaoko, W | 1 |
| Mandaliya, KN | 1 |
| Overbaugh, J | 1 |
| McClelland, RS | 1 |
| Zunza, M | 1 |
| Gray, DM | 3 |
| Young, T | 1 |
| Cotton, M | 3 |
| Zar, HJ | 11 |
| Mueller, Y | 2 |
| Mpala, Q | 2 |
| Kerschberger, B | 1 |
| Rusch, B | 1 |
| Mchunu, G | 2 |
| Mazibuko, S | 1 |
| Tram, KH | 2 |
| Mwangwa, F | 2 |
| Atukunda, M | 2 |
| Ayieko, J | 3 |
| Plenty, A | 1 |
| Kwariisima, D | 1 |
| Clark, TD | 2 |
| Petersen, ML | 2 |
| Charlebois, ED | 2 |
| Mahlalela, N | 1 |
| Pasipamire, M | 1 |
| Ginindza, S | 1 |
| Calnan, M | 1 |
| Haumba, S | 1 |
| Castelnuovo, B | 5 |
| von Braun, A | 5 |
| Musaazi, J | 2 |
| Muller, D | 5 |
| Buzibye, A | 3 |
| Gutteck, U | 4 |
| Henning, L | 3 |
| Ledergerber, B | 4 |
| Corti, N | 4 |
| Fehr, J | 4 |
| Kambugu, A | 5 |
| Rockwood, N | 3 |
| Sirgel, F | 2 |
| Streicher, E | 1 |
| Park, S | 1 |
| Jo, KW | 1 |
| Lee, SD | 1 |
| Kim, WS | 1 |
| Shim, TS | 1 |
| Danyuttapolchai, J | 2 |
| Kittimunkong, S | 2 |
| Nateniyom, S | 2 |
| Painujit, S | 1 |
| Klinbuayaem, V | 1 |
| Maipanich, N | 1 |
| Maokamnerd, Y | 1 |
| Whitehead, S | 2 |
| Kanphukiew, A | 1 |
| Monkongdee, P | 2 |
| Martin, M | 1 |
| Cowger, TL | 1 |
| Thai, LH | 1 |
| Duong, BD | 1 |
| Nhung, NV | 1 |
| Nhan, DT | 1 |
| Thoa, CK | 1 |
| Khanh, VT | 1 |
| Yen, NTB | 1 |
| Ngoc, DV | 1 |
| Thinh, T | 1 |
| Pevzner, ES | 1 |
| Moh, R | 5 |
| Guéhi, C | 3 |
| Kabran, M | 3 |
| Carrou, JL | 1 |
| Ouattara, E | 5 |
| Messou, E | 3 |
| Anzian, A | 2 |
| Minga, A | 2 |
| Gnokoro, J | 2 |
| Gouesse, P | 2 |
| Emieme, A | 2 |
| Toni, TD | 2 |
| Rabe, C | 2 |
| Sidibé, B | 2 |
| Nzunetu, G | 2 |
| Dohoun, L | 2 |
| Yao, A | 2 |
| Kamagate, S | 2 |
| Amon, S | 2 |
| Kouame, AB | 2 |
| Koua, A | 2 |
| Kouamé, E | 2 |
| Daligou, M | 2 |
| Hawerlander, D | 2 |
| Ackoundzé, S | 2 |
| Koule, S | 2 |
| Séri, J | 2 |
| Ani, A | 2 |
| Dembélé, F | 2 |
| Koné, F | 2 |
| Oyebi, M | 2 |
| Mbakop, N | 2 |
| Makaila, O | 2 |
| Babatunde, C | 2 |
| Babatunde, N | 1 |
| Bleoué, G | 2 |
| Tchoutedjem, M | 2 |
| Kouadio, AC | 2 |
| Sena, G | 2 |
| Yededji, SY | 2 |
| Karcher, S | 2 |
| Rouzioux, C | 2 |
| Kouame, A | 3 |
| Assi, R | 2 |
| Bakayoko, A | 2 |
| Deschamps, N | 4 |
| Aka, K | 2 |
| N'Dri-Yoman, T | 2 |
| Salamon, R | 2 |
| Journot, V | 2 |
| Ahibo, H | 2 |
| Menan, H | 2 |
| Inwoley, A | 3 |
| van der Laan, LE | 1 |
| Garcia-Prats, AJ | 3 |
| Schaaf, HS | 16 |
| Tikiso, T | 1 |
| de Kock, M | 2 |
| Winckler, J | 1 |
| Wondale, B | 1 |
| Medihn, G | 1 |
| Teklu, T | 2 |
| Mersha, W | 1 |
| Tamirat, M | 1 |
| Freiman, JM | 1 |
| Ellner, JJ | 5 |
| Guiastrennec, B | 1 |
| Ramachandran, G | 6 |
| Karlsson, MO | 1 |
| Kumar, AKH | 1 |
| Gangadevi, NP | 3 |
| Kumbakumba, E | 1 |
| Orikiriza, P | 1 |
| Bastard, M | 1 |
| Mwanga, JA | 1 |
| Boum, Y | 1 |
| de Beaudrap, P | 1 |
| Charan, J | 1 |
| Goyal, JP | 1 |
| Reljic, T | 1 |
| Emmanuel, P | 1 |
| Patel, A | 1 |
| Kumar, A | 1 |
| Decroo, T | 1 |
| Van Deun, A | 2 |
| Lynen, L | 2 |
| N'takpé, JB | 2 |
| Le Carrou, J | 2 |
| Bohoussou, F | 1 |
| van Heerden, A | 1 |
| Schaafsma, TT | 1 |
| Hughes, JP | 1 |
| Baeten, JM | 1 |
| van Rooyen, H | 1 |
| Tumwesigye, E | 1 |
| Celum, CL | 1 |
| Ngongondo, M | 1 |
| Miyahara, S | 2 |
| Hughes, MD | 1 |
| Sun, X | 3 |
| Bisson, GP | 3 |
| Kumwenda, J | 2 |
| Lavenberg, JA | 1 |
| Torres, TS | 1 |
| Nyirenda, M | 2 |
| Kidonge, KK | 1 |
| Rupert, A | 1 |
| Mehaffy, C | 1 |
| De, P | 1 |
| Dobos, KM | 1 |
| Kellogg, A | 1 |
| McLaughlin, M | 1 |
| McManus, M | 1 |
| Alfaro, RM | 1 |
| Hadigan, C | 1 |
| Ahmed, A | 1 |
| Mekonnen, D | 1 |
| Shiferaw, AM | 1 |
| Belayneh, F | 1 |
| Yenit, MK | 1 |
| Draper, HR | 3 |
| McSherry, G | 5 |
| Krezinski, E | 1 |
| Coetzee, J | 2 |
| Mitchell, C | 5 |
| van der Linde, M | 2 |
| Adane, K | 1 |
| Spigt, M | 1 |
| Dinant, GJ | 1 |
| Thindwa, D | 1 |
| MacPherson, P | 1 |
| Choko, AT | 1 |
| Khundi, M | 2 |
| Sambakunsi, R | 1 |
| Ngwira, LG | 2 |
| Webb, EL | 1 |
| Corbett, EL | 7 |
| Marx, FM | 1 |
| Bilinski, A | 1 |
| Beyers, N | 3 |
| Page-Shipp, L | 2 |
| Lewis, JJ | 9 |
| Velen, K | 2 |
| Senoge, S | 1 |
| Zishiri, E | 1 |
| Popane, F | 3 |
| Chihota, VN | 6 |
| Clark, D | 1 |
| Gopalan, N | 2 |
| Santhanakrishnan, RK | 2 |
| Palaniappan, AN | 1 |
| Menon, PA | 3 |
| Lakshman, S | 1 |
| Chandrasekaran, P | 3 |
| Sivaramakrishnan, GN | 1 |
| Kannabiran, BP | 1 |
| Agiboth, HKK | 1 |
| Krishnamoorthy, V | 1 |
| Rathinam, S | 1 |
| Chockalingam, C | 1 |
| Manoharan, T | 1 |
| Ayyamperumal, M | 1 |
| Jayanthi, N | 1 |
| Satagopan, K | 1 |
| Narayanan, R | 1 |
| Krishnaraja, R | 1 |
| Sathiyavelu, S | 1 |
| Kesavamurthy, B | 1 |
| Suresh, C | 1 |
| Selvachitiram, M | 1 |
| Arasan, G | 1 |
| Susaimuthu, S | 1 |
| Rathinam, P | 1 |
| Angamuthu, P | 1 |
| Jayabal, L | 1 |
| Murali, L | 1 |
| Ramachandran, R | 3 |
| Tripathy, SP | 1 |
| Jetter, A | 1 |
| Byakika-Kibwika, P | 2 |
| Eberhard, N | 1 |
| Matovu, J | 1 |
| Joloba, M | 1 |
| Manabe, YC | 3 |
| Fehr, JS | 1 |
| Pasipanodya, JG | 3 |
| Gumbo, T | 4 |
| Frigati, L | 1 |
| Archary, M | 1 |
| Penazzato, M | 2 |
| Shin, SS | 2 |
| Modongo, C | 2 |
| Zetola, NM | 2 |
| Phologolo, T | 1 |
| Kestler, M | 1 |
| Ho-Foster, A | 1 |
| Little, KM | 1 |
| Nkhoma, A | 1 |
| Makombe, S | 1 |
| Golub, J | 1 |
| Johnson, KT | 1 |
| Sohn, H | 1 |
| Taburet, AM | 3 |
| Cross, HM | 1 |
| Chetty, S | 2 |
| Asukile, MT | 1 |
| Hussey, HS | 1 |
| Lee Pan, EB | 1 |
| Tucker, LM | 1 |
| Nagu, TJ | 2 |
| Matee, MI | 3 |
| Maeurer, MJ | 2 |
| Fawzi, WW | 2 |
| Mesfin, EA | 1 |
| Beyene, D | 1 |
| Tesfaye, A | 1 |
| Admasu, A | 1 |
| Addise, D | 1 |
| Amare, M | 1 |
| Dagne, B | 1 |
| Yaregal, Z | 1 |
| Tesfaye, E | 1 |
| Tessema, B | 2 |
| Weldegebreal, T | 1 |
| Ahmed, I | 1 |
| Muhiye, A | 1 |
| Belete, S | 1 |
| Bekele, A | 1 |
| Kaba, M | 1 |
| Russom, M | 1 |
| Debesai, M | 1 |
| Zeregabr, M | 1 |
| Berhane, A | 1 |
| Tekeste, T | 1 |
| Teklesenbet, T | 1 |
| Cerrone, M | 1 |
| Neary, M | 1 |
| Weaver, C | 1 |
| Fedele, S | 1 |
| Day-Weber, I | 1 |
| Owen, A | 2 |
| Hill, A | 1 |
| McClure, M | 1 |
| Boffito, M | 1 |
| du Plessis, L | 2 |
| O'Connell, N | 1 |
| Rhines, AS | 2 |
| Feldman, MW | 2 |
| Bendavid, E | 2 |
| Fox, T | 1 |
| Manning, K | 1 |
| Stewart, A | 1 |
| Tiffin, N | 1 |
| Khomo, N | 1 |
| Leslie, J | 1 |
| Mudaly, V | 1 |
| Kock, Y | 1 |
| Wasserman, S | 2 |
| Alffenaar, JC | 1 |
| Heysell, SK | 2 |
| Mpagama, SG | 1 |
| Lin, Y | 2 |
| Zachariah, R | 3 |
| Cohen, DB | 1 |
| Meghji, J | 1 |
| Squire, SB | 2 |
| Affolabi, D | 1 |
| Bah-Sow, O | 2 |
| Merle, C | 1 |
| Azman, AS | 2 |
| Sawry, S | 1 |
| Moultrie, H | 1 |
| Van Rie, A | 3 |
| Obregón, G | 1 |
| Zevallos, K | 1 |
| Alarcón, V | 1 |
| Puyén, ZM | 1 |
| Chávez Inagaki, O | 1 |
| Mendoza-Ticona, A | 1 |
| Alarcón-Arrascue, E | 1 |
| Heldal, E | 3 |
| Moore, DAJ | 1 |
| Indumathi, CK | 1 |
| Sethuraman, A | 1 |
| Jain, S | 1 |
| Krishnamurthy, S | 1 |
| Wambiya, EOA | 1 |
| Atela, M | 1 |
| Eboreime, E | 1 |
| Walsh, KF | 1 |
| Souroutzidis, A | 1 |
| Vilbrun, SC | 1 |
| Peeples, M | 1 |
| Joissaint, G | 1 |
| Delva, S | 1 |
| Widmann, P | 1 |
| Royal, G | 1 |
| Pry, J | 1 |
| Bang, H | 1 |
| Koenig, SP | 1 |
| Sabasaba, A | 1 |
| Mwambi, H | 1 |
| Somi, G | 1 |
| Yirdaw, KD | 2 |
| Teklu, AM | 3 |
| Mamuye, AT | 1 |
| Zewdu, S | 2 |
| Gezae, KE | 1 |
| Abebe, HT | 1 |
| Gebretsadik, LG | 1 |
| Calcagno, A | 1 |
| Cusato, J | 1 |
| Motta, I | 1 |
| Turyasingura, G | 1 |
| Di Perri, G | 1 |
| Schwoebel, V | 1 |
| Monedero-Recuero, I | 1 |
| Aung, TK | 3 |
| Chadha, S | 1 |
| Chiang, CY | 2 |
| Conradie, F | 1 |
| Dongo, JP | 1 |
| Jensen, P | 1 |
| Nyengele, JPK | 1 |
| Koura, KG | 1 |
| Mlilo, N | 1 |
| Nakanwagi-Mukwaya, A | 1 |
| Ncube, RT | 1 |
| Nyinoburyo, R | 1 |
| Oo, NL | 1 |
| Patel, LN | 1 |
| Piubello, A | 1 |
| Rusen, ID | 2 |
| Sanda, T | 1 |
| Syed, I | 1 |
| Thu, AS | 1 |
| Tonsing, J | 1 |
| Trébucq, A | 2 |
| Zamora, V | 1 |
| Zishiri, C | 1 |
| Hinderaker, SG | 2 |
| Aït-Khaled, N | 2 |
| Roggi, A | 1 |
| Caminero Luna, J | 1 |
| Fujiwara, PI | 4 |
| Meremikwu, M | 1 |
| Zumla, A | 5 |
| Ramchandani, R | 1 |
| Jean Juste, MA | 1 |
| Lama, JR | 2 |
| Valencia, J | 2 |
| da Silva Escada, RO | 1 |
| Banda, P | 1 |
| Severe, P | 3 |
| Moran, L | 1 |
| Andersen, J | 1 |
| Nuermberger, E | 1 |
| Kyaw, NTT | 1 |
| Kyaw, KWY | 1 |
| Magee, MJ | 1 |
| Min, AC | 2 |
| Moe, J | 2 |
| Aung, ZZ | 1 |
| Oo, MM | 2 |
| Soe, KT | 1 |
| Oo, HN | 2 |
| Aung, ST | 2 |
| Phyo, KH | 1 |
| Saw, S | 1 |
| Thuya, SS | 1 |
| Mon, YY | 1 |
| Naing, NN | 1 |
| Kyi, MS | 1 |
| Lai, J | 1 |
| Dememew, Z | 1 |
| Jerene, D | 3 |
| Abashawl, A | 1 |
| Feleke, B | 2 |
| Ruff, A | 2 |
| Mukherjee, A | 2 |
| Lodha, R | 2 |
| Kabra, SK | 2 |
| Alene, KA | 1 |
| Viney, K | 1 |
| McBryde, ES | 2 |
| Gray, DJ | 1 |
| Melku, M | 1 |
| Clements, ACA | 1 |
| Wang, DM | 1 |
| Liao, Y | 1 |
| Li, QF | 1 |
| Zhu, M | 1 |
| Wu, GH | 1 |
| Xu, YH | 1 |
| Zhong, J | 1 |
| Luo, J | 1 |
| Li, YJ | 1 |
| Saldanha, N | 1 |
| Runwal, K | 1 |
| Ghanekar, C | 1 |
| Gaikwad, S | 1 |
| Sane, S | 1 |
| Pujari, S | 1 |
| Endalamaw, A | 1 |
| Negash, M | 1 |
| Eshetie, S | 1 |
| Dhungana, GP | 1 |
| Bhatta, U | 1 |
| Pandey, B | 1 |
| Zhang, WH | 2 |
| Jain, V | 1 |
| Suárez, I | 1 |
| Maria Fünger, S | 1 |
| Jung, N | 1 |
| Lehmann, C | 1 |
| Reimer, RP | 1 |
| Mehrkens, D | 1 |
| Bunte, A | 1 |
| Plum, G | 1 |
| Jaspers, N | 1 |
| Schmidt, M | 1 |
| Fätkenheuer, G | 1 |
| Rybniker, J | 1 |
| Dye, C | 1 |
| Sharling, L | 1 |
| Marks, SM | 1 |
| Goodman, M | 1 |
| Chorba, T | 1 |
| Mase, S | 1 |
| Beshir, MT | 1 |
| Beyene, AH | 1 |
| Tlaye, KG | 1 |
| Demelew, TM | 1 |
| Mwansa-Kambafwile, J | 2 |
| van der Walt, JS | 2 |
| Rangaka, M | 1 |
| Eisenhut, M | 2 |
| Raviglione, M | 6 |
| Hafner, R | 3 |
| Chehab, JC | 2 |
| Vilakazi-Nhlapo, AK | 2 |
| Vranken, P | 2 |
| Peters, A | 2 |
| Klausner, JD | 3 |
| Taylor, AW | 1 |
| Mosimaneotsile, B | 6 |
| Mathebula, U | 1 |
| Mathoma, A | 2 |
| Moathlodi, R | 1 |
| Theebetsile, I | 1 |
| Samandari, T | 11 |
| Claassens, M | 1 |
| van Schalkwyk, C | 1 |
| den Haan, L | 1 |
| Floyd, S | 1 |
| Dunbar, R | 1 |
| van Helden, P | 2 |
| Godfrey-Faussett, P | 4 |
| Ayles, H | 1 |
| Borgdorff, M | 1 |
| Enarson, D | 2 |
| Codecasa, LR | 1 |
| Murgia, N | 1 |
| Ferrarese, M | 1 |
| Delmastro, M | 1 |
| Repossi, AC | 1 |
| Casali, L | 1 |
| Besozzi, G | 1 |
| Ferrara, G | 1 |
| Raviglione, MC | 2 |
| Kateruttanakul, P | 1 |
| Unsematham, S | 1 |
| Dierberg, KL | 1 |
| Garg, RK | 1 |
| Jain, A | 1 |
| Malhotra, HS | 1 |
| Agrawal, A | 1 |
| Garg, R | 1 |
| Smythe, W | 1 |
| Merle, CS | 1 |
| Gninafon, M | 1 |
| Lo, MB | 1 |
| Olliaro, PL | 1 |
| Lienhardt, C | 5 |
| Horton, J | 1 |
| Simonsson, US | 1 |
| Moolphate, S | 3 |
| Lawpoolsri, S | 1 |
| Pungrassami, P | 1 |
| Sanguanwongse, N | 1 |
| Yamada, N | 1 |
| Kaewkungwal, J | 2 |
| Wejse, C | 1 |
| Furtado, A | 1 |
| Camara, C | 1 |
| Lüneborg-Nielsen, M | 1 |
| Sodemann, M | 1 |
| Gerstoft, J | 1 |
| Katzenstein, TL | 1 |
| Sanchez-Padilla, E | 1 |
| Ardizzoni, E | 1 |
| Sauvageot, D | 1 |
| Ahoua, L | 1 |
| Martin, A | 1 |
| Varaine, F | 2 |
| Adatu-Engwau, F | 1 |
| Akeche, G | 1 |
| Salaniponi, F | 1 |
| Prach, LM | 1 |
| Pascopella, L | 2 |
| Barry, PM | 1 |
| Flood, J | 1 |
| Porco, TC | 1 |
| Hopewell, PC | 3 |
| Metcalfe, JZ | 1 |
| Pacheco, AG | 7 |
| King, BS | 3 |
| Bertrand, J | 1 |
| Verstuyft, C | 1 |
| Chou, M | 1 |
| Borand, L | 1 |
| Chea, P | 1 |
| Nay, KH | 1 |
| Blanc, FX | 1 |
| Mentré, F | 1 |
| Yang, CH | 1 |
| Chan, PC | 1 |
| Liao, ST | 1 |
| Cheng, SH | 1 |
| Wong, WW | 1 |
| Huang, LM | 1 |
| Hsueh, PR | 1 |
| Chiou, HY | 1 |
| Seddon, JA | 4 |
| Finlayson, H | 1 |
| Fielding, K | 5 |
| Cox, H | 1 |
| Hughes, J | 1 |
| Boon, GP | 1 |
| Jeena, PM | 1 |
| Zaeh, S | 1 |
| Kempker, R | 1 |
| Stenehjem, E | 1 |
| Blumberg, HM | 1 |
| Temesgen, O | 1 |
| Ofotokun, I | 1 |
| Tenna, A | 1 |
| Anuwatnonthakate, A | 1 |
| Whitehead, SJ | 1 |
| Varma, JK | 2 |
| Silachamroon, U | 1 |
| Kasetjaroen, Y | 1 |
| Limsomboon, P | 1 |
| Inyaphong, J | 1 |
| Suriyon, N | 1 |
| Kavinum, S | 1 |
| Chiengson, N | 1 |
| Tunteerapat, P | 1 |
| Davis, JL | 1 |
| Huang, L | 1 |
| Muzoora, C | 1 |
| Byakwaga, H | 1 |
| Scibetta, C | 1 |
| Bangsberg, DR | 2 |
| Hunt, PW | 1 |
| Martin, JN | 1 |
| Metzger, NL | 1 |
| Momary, KM | 1 |
| Denegetu, AW | 1 |
| Dolamo, BL | 1 |
| Makanjuola, T | 1 |
| Taddese, HB | 1 |
| Booth, A | 1 |
| Penfold, S | 1 |
| Simms, V | 1 |
| Downing, J | 1 |
| Powell, RA | 1 |
| Mwangi-Powell, F | 1 |
| Namisango, E | 1 |
| Moreland, S | 1 |
| Atieno, M | 1 |
| Gikaara, N | 1 |
| Kataike, J | 1 |
| Kwebiha, C | 1 |
| Munene, G | 1 |
| Banga, G | 1 |
| Higginson, IJ | 1 |
| Harding, R | 1 |
| Abuogi, L | 1 |
| Simchowitz, B | 1 |
| Bukusi, EA | 1 |
| Smith, AH | 1 |
| Reingold, A | 1 |
| Kurup, R | 1 |
| George, C | 1 |
| Venturini, E | 1 |
| Chiappini, E | 1 |
| Galli, L | 1 |
| de Martino, M | 1 |
| Thorne, C | 1 |
| Reynolds, J | 1 |
| Bhatt, NB | 1 |
| Barau, C | 1 |
| Amin, A | 1 |
| Baudin, E | 1 |
| Meggi, B | 1 |
| Silva, C | 1 |
| Furlan, V | 1 |
| Grinsztejn, B | 1 |
| Barrail-Tran, A | 1 |
| Kufa, T | 2 |
| Workman, LJ | 1 |
| Lombard, CJ | 4 |
| Jennings, T | 1 |
| Innes, S | 1 |
| Grobbelaar, CJ | 1 |
| Slogrove, AL | 1 |
| Soborg, C | 1 |
| Ruhwald, M | 1 |
| Andersen, PH | 1 |
| Ravn, P | 1 |
| Glynn, JR | 3 |
| van Cutsem, G | 2 |
| Wilkinson, KA | 3 |
| Goliath, R | 2 |
| Mathee, S | 2 |
| Goemaere, E | 2 |
| Odato, K | 1 |
| Blunt, H | 1 |
| Steingart, KR | 1 |
| Amlabu, V | 1 |
| Mulligan, C | 1 |
| Jele, N | 1 |
| Evans, A | 1 |
| Gray, D | 2 |
| Deery, CB | 1 |
| Selibas, K | 1 |
| Bassett, J | 1 |
| Mindachew, M | 1 |
| Deribew, A | 1 |
| Memiah, P | 1 |
| Biadgilign, S | 1 |
| Thakur, BK | 1 |
| Verma, S | 1 |
| Mishra, J | 1 |
| Naranbhai, V | 1 |
| Fletcher, H | 1 |
| McShane, H | 1 |
| Hill, AV | 1 |
| Madhi, SA | 5 |
| Gashu, Z | 1 |
| Edginton, ME | 1 |
| Kumar, AM | 1 |
| Letamo, Y | 1 |
| Weiss, B | 1 |
| Tiam, A | 1 |
| Machekano, R | 1 |
| Gounder, CR | 2 |
| Maama-Maime, LB | 1 |
| Ntene-Sealiete, K | 1 |
| Sahu, M | 1 |
| Isavwa, A | 1 |
| Oyebanji, O | 1 |
| Ahimbisibwe, A | 1 |
| Mokone, M | 1 |
| Guay, L | 1 |
| Kassaye, S | 1 |
| Al-Dwibe, H | 1 |
| Gashout, A | 1 |
| Morogum, AM | 1 |
| El-Zubi, S | 1 |
| Amro, A | 1 |
| Bhembe, NL | 1 |
| Nwodo, UU | 1 |
| Govender, S | 1 |
| Hayes, C | 1 |
| Ndip, RN | 1 |
| Okoh, AI | 1 |
| Green, E | 1 |
| McLeod, KE | 1 |
| Milovanovic, M | 1 |
| Gupta, S | 2 |
| Granich, R | 7 |
| Date, A | 4 |
| Lepere, P | 1 |
| Hersh, B | 1 |
| Gouws, E | 1 |
| Samb, B | 2 |
| Abimbola, T | 2 |
| Suthar, AB | 3 |
| Bennett, R | 2 |
| Sangrujee, N | 2 |
| Sacks, HS | 1 |
| Requena-Méndez, A | 1 |
| Davies, G | 2 |
| Waterhouse, D | 2 |
| Ardrey, A | 1 |
| Jave, O | 1 |
| López-Romero, SL | 1 |
| Ward, SA | 1 |
| Moore, DA | 2 |
| Traoré, FA | 1 |
| Sako, FB | 1 |
| Sylla, D | 1 |
| Bangoura, M | 1 |
| Kpamy, DO | 1 |
| Traoré, M | 1 |
| Doumbouya, M | 1 |
| Sangare, I | 1 |
| Supervía, A | 1 |
| Pallàs, O | 1 |
| Piccari, L | 1 |
| Herrera Fernández, S | 1 |
| Domínguez Álvarez, M | 1 |
| Cirera, I | 1 |
| del Baño, F | 1 |
| Chigutsa, E | 1 |
| Visser, ME | 2 |
| van Helden, PD | 2 |
| Smith, PJ | 2 |
| Sirgel, FA | 1 |
| Herrmann, JL | 1 |
| Lecarrou, J | 2 |
| Perronne, C | 2 |
| Guerra-Assunção, JA | 1 |
| Houben, RM | 2 |
| Crampin, AC | 1 |
| Mzembe, T | 1 |
| Mallard, K | 1 |
| Coll, F | 1 |
| Khan, P | 1 |
| Banda, L | 1 |
| Chiwaya, A | 1 |
| Pereira, RP | 1 |
| McNerney, R | 1 |
| Harris, D | 1 |
| Parkhill, J | 1 |
| Clark, TG | 1 |
| Tedla, Z | 8 |
| Nguyen, ML | 1 |
| Sibanda, T | 5 |
| Nyirenda, S | 8 |
| Agizew, TB | 5 |
| Girde, S | 1 |
| Rose, CE | 2 |
| Oshi, SN | 1 |
| Alobu, I | 1 |
| Ukwaja, KN | 1 |
| Oshi, DC | 1 |
| Naiker, S | 2 |
| Kellerman, T | 2 |
| Reddy, T | 2 |
| Harries, A | 1 |
| Pym, A | 4 |
| Kumar, AK | 2 |
| Kannan, T | 2 |
| Kumar, SR | 3 |
| Banurekha, VV | 2 |
| Ravichandran, N | 3 |
| Mathevan, G | 2 |
| Sanjeeva, GN | 2 |
| Dayal, R | 1 |
| Andrews, JR | 1 |
| Azadi, M | 1 |
| Bishai, DM | 1 |
| Cavalcante, S | 2 |
| Kiwuwa-Muyingo, S | 1 |
| Kikaire, B | 1 |
| Mambule, I | 1 |
| Musana, H | 2 |
| Gilks, CF | 1 |
| Levin, JB | 1 |
| Motsamai, OI | 3 |
| Shang, N | 2 |
| Shepherd, J | 2 |
| Honeyborne, I | 1 |
| Lipman, MC | 2 |
| Eckold, C | 1 |
| Evangelopoulos, D | 1 |
| Gillespie, SH | 1 |
| McHugh, TD | 1 |
| Modi, S | 2 |
| Briggs, MA | 1 |
| Emerson, C | 1 |
| Taylor, NK | 1 |
| Vynnycky, E | 1 |
| Cox, AP | 1 |
| Hayes, RJ | 4 |
| Knight, GM | 1 |
| Dodd, PJ | 1 |
| Green, EP | 1 |
| Catalani, C | 1 |
| Diero, L | 1 |
| Gardner, A | 1 |
| Ndwiga, C | 1 |
| Keny, A | 1 |
| Israelski, D | 1 |
| Biondich, P | 1 |
| Assebe, LF | 1 |
| Reda, HL | 1 |
| Wubeneh, AD | 1 |
| Lerebo, WT | 1 |
| Lambert, SM | 1 |
| Seung, KJ | 1 |
| Keshavjee, S | 1 |
| Rich, ML | 1 |
| Acuña-Villaorduña, C | 1 |
| Ayakaka, I | 1 |
| Dryden-Peterson, S | 1 |
| Nakubulwa, S | 1 |
| Worodria, W | 2 |
| Reilly, N | 1 |
| Hosford, J | 1 |
| Fennelly, KP | 1 |
| Okwera, A | 4 |
| Jones-López, EC | 1 |
| Shen, L | 1 |
| Escuyer, VE | 1 |
| Royal-Mardi, G | 1 |
| Collins, SE | 1 |
| Fitzgerald, DW | 3 |
| Andersen, JW | 1 |
| Mwelase, T | 1 |
| Kim, P | 1 |
| Strydom, K | 1 |
| Ismail, F | 1 |
| Matabane, MM | 1 |
| Onwuegbuna, O | 1 |
| Omar, SV | 1 |
| Ismail, N | 1 |
| Wilson, D | 2 |
| Goggin, K | 1 |
| Williams, K | 1 |
| Gerkovich, MM | 1 |
| Gqaleni, N | 1 |
| Syce, J | 1 |
| Bartman, P | 1 |
| Johnson, Q | 1 |
| Folk, WR | 1 |
| Abdool Karim, SS | 1 |
| Bouhoussou, F | 1 |
| Ahiboh, H | 1 |
| Konan, R | 1 |
| Ndri, Y | 1 |
| Ba-Gomis, O | 1 |
| Kanga, C | 1 |
| Babatounde, N | 1 |
| Mahassadi, A | 1 |
| Attia, A | 1 |
| Oussou, A | 1 |
| Mobio, M | 1 |
| Bamba, D | 1 |
| Koman, M | 1 |
| Horo, A | 1 |
| Chenal, H | 1 |
| Sassan-Morokro, M | 1 |
| Konate, S | 1 |
| Aoussi, E | 1 |
| Nchot, C | 1 |
| Chaix, ML | 1 |
| Sow, PS | 2 |
| Girard, PM | 1 |
| Bissagnene, E | 1 |
| Kadio, A | 1 |
| Ettiegne-Traore, V | 1 |
| Moh-Semdé, C | 1 |
| Massumbuko, JM | 1 |
| Chêne, G | 1 |
| Dosso, M | 1 |
| Dzinjalamala, FK | 1 |
| Dimba, A | 1 |
| Zijlstra, EE | 1 |
| Molyneux, ME | 1 |
| Molyneux, EM | 1 |
| Ward, S | 1 |
| Smith, T | 1 |
| Marston, B | 1 |
| Ayele, HT | 3 |
| van Mourik, MS | 2 |
| Bonten, MJ | 3 |
| Mugusi, FM | 1 |
| Sedgwick, P | 1 |
| Joekes, K | 1 |
| Arenas-Pinto, A | 1 |
| Thompson, J | 1 |
| Mweemba, A | 1 |
| Atwongyeire, D | 1 |
| Paton, NI | 1 |
| Edessa, D | 1 |
| Likisa, J | 1 |
| Yotebieng, M | 1 |
| Edmonds, A | 1 |
| Lelo, P | 1 |
| Wenzi, LK | 1 |
| Ndjibu, PT | 1 |
| Lusiama, J | 1 |
| Kabuayi, JP | 1 |
| Behets, F | 1 |
| Getahun, H | 9 |
| Matteelli, A | 3 |
| Abubakar, I | 1 |
| Aziz, MA | 1 |
| Baddeley, A | 1 |
| Barreira, D | 1 |
| Den Boon, S | 2 |
| Borroto Gutierrez, SM | 1 |
| Bruchfeld, J | 1 |
| Burhan, E | 1 |
| Cedillos, R | 1 |
| Chaisson, R | 1 |
| Chee, CB | 1 |
| Chesire, L | 1 |
| Corbett, E | 1 |
| Dara, M | 1 |
| Denholm, J | 1 |
| de Vries, G | 1 |
| Falzon, D | 2 |
| Gale-Rowe, M | 1 |
| Gilpin, C | 1 |
| Girardi, E | 3 |
| Go, UY | 1 |
| Govindasamy, D | 1 |
| D Grant, A | 1 |
| Grzemska, M | 1 |
| Harris, R | 1 |
| Ismayilov, A | 1 |
| Jaramillo, E | 1 |
| Kik, S | 1 |
| Kranzer, K | 4 |
| LoBue, P | 1 |
| Lönnroth, K | 1 |
| Marks, G | 1 |
| Migliori, GB | 2 |
| Mosca, D | 1 |
| Mukadi, YD | 1 |
| Mwinga, A | 3 |
| Nelson, L | 1 |
| Nishikiori, N | 1 |
| Oordt-Speets, A | 1 |
| Reis, A | 1 |
| Rotz, L | 1 |
| Sandgren, A | 1 |
| Sañé Schepisi, M | 1 |
| Schünemann, HJ | 1 |
| Sharma, SK | 2 |
| Sotgiu, G | 1 |
| Stagg, HR | 1 |
| Tayeb, T | 1 |
| Uplekar, M | 1 |
| van der Werf, MJ | 1 |
| Vandevelde, W | 1 |
| van Kessel, F | 1 |
| van't Hoog, A | 1 |
| Vezhnina, N | 1 |
| Voniatis, C | 1 |
| Vonk Noordegraaf-Schouten, M | 1 |
| Weil, D | 1 |
| Weyer, K | 1 |
| Yoshiyama, T | 1 |
| Zellweger, JP | 1 |
| van Griensven, J | 1 |
| Choun, K | 1 |
| Chim, B | 1 |
| Thai, S | 1 |
| Lorent, N | 1 |
| van der Watt, JJ | 2 |
| Benatar, MG | 1 |
| Harrison, TB | 2 |
| Carrara, H | 1 |
| Heckmann, JM | 2 |
| Hennig, S | 1 |
| Egan, D | 1 |
| Lawn, SD | 6 |
| David, S | 1 |
| Mateus, AR | 1 |
| Duarte, EL | 1 |
| Albuquerque, J | 1 |
| Portugal, C | 1 |
| Sancho, L | 1 |
| Lavinha, J | 1 |
| Gonçalves, G | 1 |
| Mourik, MS | 1 |
| Debray, TP | 1 |
| Barnett, B | 1 |
| Gokhale, RH | 1 |
| Krysiak, R | 1 |
| Kanyemba, C | 1 |
| Chikaonda, T | 1 |
| Bokosi, M | 1 |
| Mukuzunga, C | 1 |
| Saidi, F | 1 |
| Phiri, S | 2 |
| Hoffman, IF | 1 |
| Kapoor, S | 1 |
| Shah, M | 1 |
| Meloni, M | 1 |
| Weber, R | 1 |
| Costenaro, P | 1 |
| Massavon, W | 1 |
| Lundin, R | 1 |
| Nabachwa, SM | 1 |
| Fregonese, F | 1 |
| Morelli, E | 1 |
| Alowo, A | 1 |
| Nannyonga Musoke, M | 1 |
| Namisi, CP | 1 |
| Kizito, S | 1 |
| Bilardi, D | 1 |
| Mazza, A | 1 |
| Giaquinto, C | 1 |
| van der Laan, L | 1 |
| Murray, S | 1 |
| Donald, PR | 3 |
| McIlleron, HM | 1 |
| Sudha, V | 1 |
| Venkatesh, S | 1 |
| Kalpana, S | 1 |
| Agarwal, D | 1 |
| Ai, JW | 1 |
| Ruan, QL | 1 |
| Liu, QH | 1 |
| Aquino, DS | 1 |
| Moura, LC | 1 |
| Maruza, M | 1 |
| Silva, AP | 1 |
| Ximenes, RA | 1 |
| Lacerda, HR | 1 |
| Miranda Filho, Dde B | 1 |
| Albuquerque, Mde F | 1 |
| Huerga, H | 1 |
| Ferlazzo, G | 1 |
| Bevilacqua, P | 1 |
| Vasquez, B | 1 |
| Noël Mekiedje, C | 1 |
| Ouattara, A | 1 |
| Weyenga, HO | 1 |
| Koulé, SO | 1 |
| Ekouevi, D | 1 |
| Menan, GK | 1 |
| Calderón Hernáiz, R | 1 |
| Ruiz Giardín, JM | 1 |
| Cabello Clotet, N | 1 |
| Canora Lebrato, J | 1 |
| Moses, A | 1 |
| Riviere, C | 1 |
| Kirui, FK | 1 |
| Lagat, D | 1 |
| Henostroza, G | 1 |
| Leger, PD | 1 |
| Alave, J | 1 |
| Pillay, S | 1 |
| Kumarasamy, N | 3 |
| Bao, J | 1 |
| Hogg, E | 1 |
| Jones, L | 1 |
| Zolopa, A | 1 |
| Charles, MK | 1 |
| Lindegren, ML | 1 |
| Wester, CW | 1 |
| Blevins, M | 1 |
| Dung, NT | 1 |
| Dusingize, JC | 1 |
| Avit-Edi, D | 1 |
| Durier, N | 1 |
| Nakigozi, G | 1 |
| Ballif, M | 1 |
| Fenner, L | 2 |
| Alemu, YM | 1 |
| Awoke, W | 1 |
| Wilder-Smith, A | 1 |
| Velpandian, T | 1 |
| Singla, M | 1 |
| Kanhiya, K | 1 |
| Daftary, A | 1 |
| Kassie, GM | 1 |
| Scott, NA | 1 |
| Miro, JM | 1 |
| Calvet, G | 1 |
| La Rosa, A | 1 |
| Infante, R | 1 |
| Chen, MP | 1 |
| Benator, DA | 2 |
| Gordin, F | 2 |
| Villarino, ME | 1 |
| Chang, AH | 1 |
| Ghosh, JK | 1 |
| Dubé, MP | 1 |
| Bolan, R | 1 |
| Yang, OO | 1 |
| Kerndt, PR | 1 |
| Bélard, S | 1 |
| Remppis, J | 1 |
| Bootsma, S | 1 |
| Kombila, DU | 1 |
| Beyeme, JO | 1 |
| Rossatanga, EG | 1 |
| Kokou, C | 1 |
| Osbak, KK | 1 |
| Obiang Mba, RM | 1 |
| Kaba, HM | 1 |
| Traoré, AN | 1 |
| Ehrhardt, J | 1 |
| Bache, EB | 1 |
| Flamen, A | 1 |
| Rüsch-Gerdes, S | 1 |
| Adegnika, AA | 1 |
| Lell, B | 1 |
| Niemann, S | 1 |
| Kremsner, PG | 1 |
| Loembé, MM | 1 |
| Alabi, AS | 1 |
| Grobusch, MP | 1 |
| Maritz, ER | 1 |
| Liu, L | 1 |
| Bobat, R | 5 |
| Ogwu, A | 1 |
| Oloo, SA | 1 |
| Rautenbach, C | 1 |
| Teklay, G | 1 |
| Legesse, B | 1 |
| Tedla, K | 1 |
| Klinkenberg, E | 2 |
| Gupta-Wright, A | 1 |
| Wilson, DK | 1 |
| Flach, C | 1 |
| Reddy, KP | 2 |
| Walensky, RP | 4 |
| Peters, JA | 1 |
| Alufandika-Moyo, M | 1 |
| Houben, RMGJ | 1 |
| Huynh, GH | 1 |
| Arinaminpathy, N | 1 |
| Goldhaber-Fiebert, JD | 1 |
| Lin, HH | 1 |
| Wu, CY | 1 |
| Mandal, S | 1 |
| Pandey, S | 1 |
| Suen, SC | 1 |
| Bacaër, N | 2 |
| Handel, A | 1 |
| Whalen, CC | 6 |
| Chang, ST | 1 |
| Wagner, BG | 1 |
| Eckhoff, PA | 1 |
| Trauer, JM | 1 |
| Denholm, JT | 1 |
| Pretorius, C | 2 |
| Lalli, M | 1 |
| Boccia, D | 1 |
| Hosseini, M | 1 |
| Gomez, GB | 1 |
| Sahu, S | 1 |
| Daniels, C | 2 |
| Ditiu, L | 1 |
| Chin, DP | 1 |
| Wang, L | 2 |
| Chadha, VK | 1 |
| Rade, K | 1 |
| Dewan, P | 1 |
| Hippner, P | 1 |
| Pillay, Y | 1 |
| Mametja, LD | 1 |
| Kimerling, ME | 3 |
| Vassall, A | 1 |
| Walusimbi, S | 1 |
| Kwesiga, B | 1 |
| Rodrigues, R | 1 |
| Haile, M | 1 |
| de Costa, A | 1 |
| Bogg, L | 1 |
| Burger, A | 1 |
| Zimri, K | 1 |
| Crawford, FW | 1 |
| Ravimohan, S | 1 |
| Tamuhla, N | 1 |
| Ivaturi, V | 1 |
| Pasipanodya, J | 1 |
| Srivastava, S | 1 |
| Weissman, D | 2 |
| Okoli, EI | 1 |
| Roets, L | 1 |
| John, SF | 1 |
| Aniemeke, E | 1 |
| Ha, NP | 1 |
| Chong, CR | 1 |
| Gu, P | 1 |
| Zhou, J | 1 |
| Graviss, EA | 1 |
| Liu, JO | 1 |
| Olaleye, OA | 1 |
| Semu, M | 1 |
| Fenta, TG | 1 |
| Medhin, G | 1 |
| Assefa, D | 1 |
| Maimaiti, R | 1 |
| Pan, K | 1 |
| Mijiti, P | 1 |
| Wubili, M | 1 |
| Musa, M | 1 |
| Andersson, R | 1 |
| Scherrer, AU | 1 |
| Jacobson, KB | 1 |
| Niccolai, L | 1 |
| Mtungwa, N | 1 |
| Moll, AP | 2 |
| Shenoi, SV | 1 |
| Abebe, W | 1 |
| Taye, K | 1 |
| Suarez, PG | 2 |
| Feleke, Y | 1 |
| Hallström, I | 1 |
| Ruff, AJ | 1 |
| Zeldow, B | 2 |
| Mofenson, LM | 1 |
| Lesosky, M | 1 |
| Langat, A | 1 |
| Ronen, K | 1 |
| McGrath, CJ | 1 |
| LaCourse, S | 1 |
| Pintye, J | 1 |
| Odeny, B | 1 |
| Singa, B | 1 |
| Katana, A | 1 |
| Nganga, L | 1 |
| Aung, NM | 1 |
| Hanson, J | 1 |
| Kyi, TT | 1 |
| Htet, ZW | 1 |
| Cooper, DA | 1 |
| Boyd, MA | 1 |
| Kyi, MM | 1 |
| Saw, HA | 1 |
| Nunn, P | 3 |
| Munseri, PJ | 1 |
| Mtei, L | 4 |
| Fordham von Reyn, C | 1 |
| Inge, LD | 1 |
| Wilson, JW | 1 |
| Nunes, EA | 1 |
| De Capitani, EM | 1 |
| Coelho, E | 1 |
| Panunto, AC | 1 |
| Joaquim, OA | 1 |
| Ramos, Mde C | 1 |
| Breen, R | 1 |
| Perti, T | 1 |
| Cecchini, D | 1 |
| Ambrosioni, J | 1 |
| Brezzo, C | 1 |
| Corti, M | 1 |
| Rybko, A | 1 |
| Perez, M | 1 |
| Poggi, S | 1 |
| Ambroggi, M | 1 |
| Sar, B | 1 |
| Keo, C | 1 |
| Leng, C | 1 |
| Saman, M | 1 |
| Min, DC | 1 |
| Chan, S | 1 |
| Monchy, D | 1 |
| Sarthou, JL | 1 |
| Ocama, P | 1 |
| Katwere, M | 1 |
| Piloya, T | 1 |
| Feld, J | 1 |
| Opio, KC | 1 |
| Katabira, E | 1 |
| Thomas, D | 1 |
| Colebunders, R | 3 |
| Ronald, A | 1 |
| Holland, DP | 1 |
| Hamilton, CD | 1 |
| Weintrob, AC | 1 |
| Engemann, JJ | 1 |
| Fortenberry, ER | 1 |
| Chideya, S | 1 |
| Winston, CA | 1 |
| Bradford, WZ | 2 |
| Wells, CD | 5 |
| Reingold, AL | 3 |
| Kenyon, TA | 4 |
| Moeti, TL | 4 |
| Tappero, JW | 2 |
| Ziganshina, LE | 2 |
| Garner, P | 1 |
| Sutton, BS | 1 |
| Arias, MS | 1 |
| Chheng, P | 1 |
| Eang, MT | 1 |
| Pronyk, P | 1 |
| Thsabangu, N | 1 |
| Moshabela, M | 1 |
| Struthers, H | 1 |
| Gray, GE | 2 |
| McIntyre, JA | 2 |
| Asghar, RJ | 1 |
| Patlan, DE | 1 |
| Miner, MC | 1 |
| Rhodes, HD | 1 |
| Solages, A | 1 |
| Katz, DJ | 1 |
| Beall, DS | 1 |
| Ijaz, K | 1 |
| Singh-Minott, I | 1 |
| Pierre, RB | 1 |
| Olugbuyi, O | 1 |
| Dunkley-Thompson, J | 1 |
| Haughton, D | 1 |
| Christie, CD | 1 |
| Camacho, A | 1 |
| Pérez-Camacho, I | 1 |
| Rivero, A | 2 |
| Natera, C | 1 |
| García-Lázaro, M | 1 |
| Castón, JJ | 1 |
| Gallo, M | 1 |
| Kindelán, JM | 2 |
| Torre-Cisneros, J | 1 |
| Nuttall, J | 1 |
| Lombard, C | 2 |
| Workman, L | 2 |
| Apolles, P | 1 |
| Eley, B | 2 |
| Reid, A | 1 |
| Alarcon, E | 1 |
| Bissell, K | 1 |
| Boillot, F | 1 |
| Caminero, JA | 1 |
| Clevenbergh, P | 1 |
| Dlodlo, R | 1 |
| Enarson, DA | 1 |
| Enarson, P | 1 |
| Ferroussier, O | 1 |
| Kim, SJ | 1 |
| Rieder, HL | 4 |
| Wilson, N | 1 |
| Bachhuber, MA | 2 |
| Gross, R | 1 |
| Gomes, V | 1 |
| Suga, H | 1 |
| Atomiya, AN | 1 |
| le Roux, SM | 2 |
| le Roux, DM | 2 |
| Chengeta, B | 1 |
| Kilmarx, PH | 3 |
| Narendran, G | 1 |
| Venkatesan, P | 3 |
| Iliayas, S | 3 |
| Santhanakrishnan, R | 1 |
| Chinnaiyan, P | 2 |
| Suhadev, M | 1 |
| Sakthivel, R | 1 |
| Narayanan, PR | 2 |
| Arwady, MA | 1 |
| Yoon, JC | 1 |
| Motsamai, O | 2 |
| Akolo, C | 1 |
| Adetifa, I | 1 |
| Shepperd, S | 1 |
| Volmink, J | 2 |
| Agizew, T | 3 |
| Makwaruzi, VZ | 1 |
| Tallaksen, RJ | 1 |
| Parker, JE | 1 |
| Mboya, JJ | 1 |
| Cilliers, K | 1 |
| Labadarios, D | 1 |
| Willemse, M | 1 |
| Maritz, JS | 1 |
| Werely, CJ | 4 |
| Hussey, G | 2 |
| Mahan, CS | 1 |
| Walusimbi, M | 1 |
| Johnson, DF | 1 |
| Lancioni, C | 1 |
| Charlebois, E | 1 |
| Baseke, J | 1 |
| Chervenak, KA | 1 |
| Mugerwa, RD | 5 |
| Boom, WH | 1 |
| Minion, J | 1 |
| Pai, M | 3 |
| Brady, MF | 1 |
| Gilman, RH | 1 |
| Coronel, J | 1 |
| Navincopa, M | 1 |
| Ticona, E | 2 |
| Chavez, G | 1 |
| Sánchez, E | 1 |
| Rojas, C | 1 |
| Solari, L | 1 |
| Pinedo, Y | 1 |
| Benites, C | 1 |
| Reitz, C | 1 |
| Coovadia, A | 1 |
| Ko, S | 1 |
| Meyers, T | 1 |
| Strehlau, R | 1 |
| Sherman, G | 1 |
| Kuhn, L | 1 |
| Abrams, EJ | 1 |
| van Halsema, CL | 3 |
| Russell, EC | 1 |
| Gómez García, I | 1 |
| Gómez Mampaso, E | 1 |
| Burgos Revilla, J | 1 |
| Molina, MR | 1 |
| Sampietro Crespo, A | 1 |
| Buitrago, LA | 1 |
| Gómez Rodríguez, A | 1 |
| Baquero, F | 1 |
| Heymann, J | 1 |
| Royce, S | 1 |
| Peeler, C | 1 |
| Date, AA | 1 |
| Vitoria, M | 1 |
| Banda, M | 1 |
| Fox, MY | 1 |
| Gilks, C | 1 |
| Santos-Filho, ET | 1 |
| Chimzizi, R | 1 |
| Harrington, M | 1 |
| Maher, D | 1 |
| Centis, R | 1 |
| Mwaba, P | 3 |
| Bates, M | 1 |
| O'Grady, J | 1 |
| Hoelscher, M | 1 |
| Wood, R | 5 |
| Leung, CC | 1 |
| Yew, WW | 1 |
| Lahey, T | 3 |
| Arbeit, RD | 4 |
| Matee, M | 3 |
| Waddell, R | 2 |
| Vuola, JM | 1 |
| Pallangyo, K | 4 |
| Chevalier, B | 1 |
| Margery, J | 1 |
| Sane, M | 2 |
| Camara, P | 1 |
| Lefebvre, N | 1 |
| Gueye, M | 1 |
| Thiam, M | 1 |
| Perrier-Gros-Claude, JD | 1 |
| Simon, F | 1 |
| Fabre, M | 1 |
| Soler, C | 1 |
| Herve, V | 1 |
| Mbaye, PS | 2 |
| Debonne, JM | 1 |
| Eldred, LJ | 1 |
| Mngadi, KT | 2 |
| Luttig, MM | 2 |
| Hanifa, Y | 2 |
| Coetzee, L | 1 |
| Ntshele, S | 1 |
| Mdluli, J | 1 |
| Mngadi, N | 1 |
| Sefuthi, C | 1 |
| Clark, DA | 1 |
| Lester, R | 1 |
| Hamilton, R | 1 |
| Dwadwa, T | 1 |
| Chandler, C | 1 |
| Vellozo, V | 1 |
| Israel, G | 1 |
| Sculier, D | 2 |
| Gunneberg, C | 3 |
| Blanc, L | 1 |
| Innes, C | 1 |
| Dowdeswell, R | 1 |
| Pienaar, J | 1 |
| Cox, HS | 1 |
| McDermid, C | 1 |
| Azevedo, V | 1 |
| Muller, O | 1 |
| Coetzee, D | 2 |
| Simpson, J | 1 |
| Barnard, M | 1 |
| Coetzee, G | 1 |
| Bark, CM | 1 |
| Morrison, CS | 1 |
| Salata, RA | 1 |
| Byamugisha, JK | 1 |
| Katalemwa, NH | 1 |
| Mukasa, JB | 1 |
| Musoke, RN | 1 |
| Nankya-Mutyoba, J | 1 |
| Rwambuya, S | 1 |
| Walker, CJ | 1 |
| Wateba, MI | 1 |
| Diop, SA | 1 |
| Salou, M | 1 |
| Womitso, K | 1 |
| Nichols, S | 1 |
| Tidjani, O | 1 |
| Aberg, J | 1 |
| Powderly, W | 1 |
| Fox, L | 1 |
| Kramer, MR | 1 |
| Haim, I | 1 |
| Priess, R | 1 |
| Metvachuk, A | 1 |
| Shitrit, D | 1 |
| Bazira, J | 1 |
| Asiimwe, BB | 1 |
| Bwanga, F | 1 |
| Frigati, LJ | 1 |
| Benatar, M | 1 |
| Bozeman, L | 1 |
| Davis, MK | 1 |
| Moffat, HJ | 3 |
| Castro, KG | 1 |
| Dodd, LE | 1 |
| Mills, HL | 1 |
| Colijn, C | 1 |
| Zhu, R | 2 |
| Kiser, JJ | 2 |
| Seifart, HI | 4 |
| D'Argenio, DZ | 1 |
| Gideon, HP | 1 |
| Titus, R | 1 |
| Fortún, J | 3 |
| Martín-Dávila, P | 2 |
| Navas, E | 3 |
| López-Vélez, R | 1 |
| Pintado, V | 1 |
| Cobo, J | 2 |
| González, A | 1 |
| Bonilla, M | 1 |
| Aneiros, V | 1 |
| Gómez-Mampaso, E | 2 |
| Moreno, S | 5 |
| Hausler, H | 1 |
| Ram, M | 1 |
| Forster, M | 1 |
| Braitstein, P | 1 |
| Lewden, C | 1 |
| Schechter, M | 2 |
| Pascoe, M | 1 |
| Sprinz, E | 1 |
| Dickinson, D | 1 |
| Fox, MP | 1 |
| McIntyre, J | 1 |
| Khongphatthanayothin, M | 1 |
| Dabis, F | 1 |
| Brinkhof, MW | 1 |
| Egger, M | 1 |
| Jenkins, HE | 1 |
| Zignol, M | 1 |
| Tiwari, P | 1 |
| Soneja, M | 1 |
| Dutt, N | 1 |
| Thee, S | 1 |
| Rosenkranz, B | 1 |
| Roll, S | 1 |
| Magdorf, K | 1 |
| Kabali, C | 1 |
| Brooks, DR | 1 |
| Saleri, N | 1 |
| Dembélé, SM | 1 |
| Villani, P | 1 |
| Carvalho, AC | 1 |
| Cusato, M | 1 |
| Bonkoungou, V | 1 |
| Nacanabo, R | 1 |
| Kouanda, S | 1 |
| Comelli, M | 1 |
| Regazzi, M | 1 |
| Deriemer, K | 1 |
| Watt, JP | 1 |
| Flood, JM | 1 |
| Manosuthi, W | 2 |
| Sungkanuparph, S | 2 |
| Mundy, LM | 1 |
| Madhi, S | 1 |
| Victor, TC | 1 |
| Ndung'u, PW | 1 |
| Kariuki, S | 1 |
| Ng'ang'a, Z | 1 |
| Revathi, G | 1 |
| Maheswaran, H | 1 |
| Barton, P | 1 |
| Al-Darraji, HA | 1 |
| Kamarulzaman, A | 1 |
| Altice, FL | 1 |
| Vahedi, M | 1 |
| Rida, W | 1 |
| Onyebujoh, PC | 1 |
| Tho, DQ | 1 |
| Török, ME | 1 |
| Yen, NT | 1 |
| Bang, ND | 1 |
| Lan, NT | 2 |
| Kiet, VS | 1 |
| van Vinh Chau, N | 1 |
| Dung, NH | 1 |
| Day, J | 1 |
| Farrar, J | 1 |
| Wolbers, M | 1 |
| Caws, M | 2 |
| Egwaga, S | 1 |
| Evans, D | 1 |
| Takuva, S | 1 |
| Rassool, M | 1 |
| Maskew, M | 1 |
| Pho, MT | 2 |
| Losina, E | 2 |
| Ponnuraja, C | 1 |
| Uhler, LM | 1 |
| Scott, CA | 1 |
| Mayer, KH | 1 |
| Freedberg, KA | 2 |
| Boyles, TH | 1 |
| Abebe, G | 1 |
| Abdissa, K | 1 |
| Abdissa, A | 1 |
| Apers, L | 2 |
| Agonafir, M | 1 |
| de-Jong, BC | 1 |
| Marais, BJ | 2 |
| Jordaan, A | 1 |
| Victor, T | 2 |
| Vilakazi-Nhlapo, K | 1 |
| Mngomezulu, V | 1 |
| Wada, N | 1 |
| Ramsay, A | 1 |
| Garg, N | 1 |
| Towle, M | 1 |
| Sitienei, J | 1 |
| Smyth, C | 1 |
| Baggaley, R | 1 |
| Williams, B | 2 |
| van Gorkom, J | 2 |
| Granich, RM | 1 |
| Castell, S | 1 |
| Guglielmetti, L | 1 |
| Lattuada, E | 1 |
| Lanzafame, M | 1 |
| Vento, S | 1 |
| Bristow, CC | 1 |
| Larson, E | 1 |
| Wilson, M | 1 |
| Verster, A | 1 |
| Hirnschall, G | 1 |
| DʼArgenio, DZ | 1 |
| McSherry, GD | 1 |
| Carey, VJ | 1 |
| Hom, JK | 1 |
| Wang, B | 1 |
| Giddy, J | 1 |
| Mazibuko, M | 1 |
| Allen, J | 1 |
| Bassett, IV | 1 |
| Mackenzie, T | 1 |
| Maro, I | 1 |
| Semvua, HH | 1 |
| Mtabho, CM | 1 |
| Fillekes, Q | 1 |
| van den Boogaard, J | 1 |
| Kisonga, RM | 1 |
| Mleoh, L | 1 |
| Ndaro, A | 1 |
| Kisanga, ER | 1 |
| van der Ven, A | 1 |
| Aarnoutse, RE | 1 |
| Kibiki, GS | 1 |
| Boeree, MJ | 1 |
| Burger, DM | 1 |
| Gandhi, NR | 1 |
| Moodley, P | 1 |
| Ramathal, M | 1 |
| Elson, I | 1 |
| Kreiswirth, BN | 1 |
| Mathema, B | 1 |
| Shashkina, E | 1 |
| Rothenberg, R | 1 |
| Friedland, G | 1 |
| Sturm, AW | 1 |
| Kerkhoff, AD | 1 |
| Nakiyingi-Miiro, J | 1 |
| Loddenkemper, R | 1 |
| Diel, R | 1 |
| Beneri, CA | 1 |
| Pillay, E | 1 |
| Dittmer, S | 1 |
| Hawkins, E | 1 |
| Shaweno, D | 1 |
| Worku, A | 1 |
| Perumal, V | 1 |
| Navaneethapandian, PD | 1 |
| Elangovan, T | 1 |
| Wares, F | 1 |
| Paranji Ramaiyengar, N | 1 |
| Sukasem, C | 1 |
| Lueangniyomkul, A | 1 |
| Mankatitham, W | 1 |
| Thongyen, S | 1 |
| Nilkamhang, S | 1 |
| Manosuthi, S | 1 |
| van Kampen, S | 1 |
| Ochodo, E | 1 |
| Atun, R | 1 |
| Oni, T | 1 |
| Tsekela, R | 1 |
| Kwaza, B | 1 |
| Manjezi, L | 1 |
| Bangani, N | 1 |
| Marape, M | 1 |
| Miranda, AG | 1 |
| Reuter, H | 1 |
| Wanchu, A | 1 |
| Bhatnagar, A | 1 |
| Khullar, M | 1 |
| Sud, A | 1 |
| Bambery, P | 1 |
| Singh, S | 1 |
| Chan, KC | 1 |
| Tang, HW | 1 |
| Wong, K | 1 |
| Thwaites, GE | 1 |
| Chau, TT | 1 |
| Phu, NH | 1 |
| Chuong, LV | 1 |
| Sinh, DX | 1 |
| Drobniewski, F | 1 |
| White, NJ | 1 |
| Parry, CM | 1 |
| Farrar, JJ | 1 |
| Foreman, MG | 1 |
| Flenaugh, E | 1 |
| Stringer, HG | 1 |
| Hewan-Lowe, K | 1 |
| Moshi, A | 1 |
| Aris, EA | 1 |
| Chale, S | 1 |
| Josiah, R | 1 |
| Magao, P | 1 |
| Pallangyo, N | 1 |
| Sandström, E | 1 |
| Biberfeld, G | 1 |
| Mhalu, F | 1 |
| Chimzizi, RB | 1 |
| Nyirenda, TE | 1 |
| Salaniponi, FM | 1 |
| Day, JH | 2 |
| Spielmann, MP | 1 |
| Gomani, P | 1 |
| Bakali, E | 1 |
| Humblet, P | 1 |
| Chintu, C | 2 |
| Hone, NM | 1 |
| Moalosi, G | 1 |
| Lee, EJ | 1 |
| Scholten, JN | 1 |
| Driver, CR | 1 |
| Munsiff, SS | 1 |
| Kaye, K | 1 |
| Rubino, MA | 1 |
| Gourevitch, MN | 1 |
| Trim, C | 1 |
| Amofa, J | 1 |
| Seewald, R | 1 |
| Highley, E | 1 |
| Gurumurthy, P | 2 |
| Hemanth Kumar, AK | 3 |
| Rajasekaran, S | 2 |
| Kumar, S | 1 |
| Krishnarajasekhar, OR | 1 |
| Paramesh, P | 2 |
| Campos, PE | 1 |
| Sanchez, J | 1 |
| Zavala, D | 1 |
| Arevalo, J | 1 |
| Nolan, CM | 2 |
| Hooton, TM | 1 |
| Holmes, KK | 1 |
| Woldehanna, S | 1 |
| Wiid, I | 1 |
| Gie, RP | 2 |
| Warren, RM | 1 |
| Texeira-Swiegelaar, C | 1 |
| Gordin, FM | 2 |
| Cohn, DL | 1 |
| Matts, JP | 3 |
| O'Brien, RJ | 2 |
| Pedral-Sampaio, DB | 1 |
| Alves, CR | 1 |
| Netto, EM | 1 |
| Brites, C | 1 |
| Oliveira, AS | 1 |
| Badaro, R | 1 |
| Bhagavathy, S | 1 |
| Mahilmaran, A | 1 |
| Vanacore, P | 1 |
| Koehler, B | 1 |
| Carbonara, S | 1 |
| Zacchini, F | 1 |
| Bassetti, D | 1 |
| Antonucci, G | 1 |
| Ippolito, G | 1 |
| Hiransuthikul, N | 2 |
| Nelson, KE | 2 |
| Hiransuthikul, P | 2 |
| Vorayingyong, A | 1 |
| Paewplot, R | 2 |
| Ige, OM | 1 |
| Sogaolu, OM | 1 |
| Odaibo, GN | 1 |
| Olaleye, OD | 1 |
| Weiner, M | 1 |
| Benator, D | 1 |
| Burman, W | 1 |
| Khan, A | 1 |
| Jones, B | 1 |
| Silva-Trigo, C | 2 |
| Zhao, Z | 1 |
| Hodge, T | 1 |
| Valencia Ortega, ME | 1 |
| Agerton, TB | 1 |
| Hopewell, P | 1 |
| Lockman, S | 1 |
| Oyewo, A | 1 |
| Puthanakit, T | 1 |
| Oberdorfer, P | 1 |
| Punjaisee, S | 1 |
| Wannarit, P | 1 |
| Sirisanthana, T | 1 |
| Sirisanthana, V | 1 |
| Mermin, J | 2 |
| Bunnell, R | 2 |
| Lule, J | 1 |
| Opio, A | 1 |
| Gibbons, A | 1 |
| Dybul, M | 1 |
| Kaplan, J | 1 |
| Bachmann, MO | 1 |
| Jirawisit, M | 1 |
| Kasak, S | 1 |
| Quy, HT | 1 |
| Buu, TN | 1 |
| Lambregts, CS | 1 |
| Borgdorff, MW | 1 |
| Pitche, P | 1 |
| Mouzou, T | 1 |
| Padonou, C | 1 |
| Tchangai-Walla, K | 1 |
| Lipsitch, M | 1 |
| Murray, M | 1 |
| Szakacs, TA | 1 |
| Cameron, DW | 2 |
| Clark, M | 1 |
| Kocheleff, P | 1 |
| Muller, FJ | 1 |
| McCarthy, AE | 1 |
| Shrestha, RK | 1 |
| Mugisha, B | 1 |
| Hitimana-Lukanika, C | 1 |
| Odeke, R | 1 |
| Madra, P | 1 |
| Adatu, F | 1 |
| Blandford, JM | 1 |
| Steichen, O | 1 |
| Martinez-Almoyna, L | 1 |
| De Broucker, T | 1 |
| Gao, XF | 1 |
| Liu, GJ | 1 |
| Wen, J | 1 |
| Xie, Y | 1 |
| Li, YP | 1 |
| Strauss, S | 1 |
| Karpakis, J | 1 |
| Dieltiens, G | 1 |
| Molina, A | 1 |
| Hermida, JM | 1 |
| King, B | 1 |
| López-Cortés, L | 1 |
| Castillo, R | 1 |
| Verdejo, J | 1 |
| García, MA | 1 |
| Martínez-Marcos, FJ | 1 |
| Díez, F | 1 |
| Escribano, JC | 1 |
| Canueto, J | 1 |
| Lozano, F | 1 |
| Pasquau, J | 1 |
| Hernández, JJ | 1 |
| Márquez, M | 1 |
| Weiner, MH | 1 |
| Burman, WJ | 1 |
| Vernon, AA | 1 |
| Zhao, ZA | 1 |
| Khan, AE | 1 |
| Jones, BE | 2 |
| Sandman, L | 1 |
| Engle, M | 1 |
| Hsyu, PH | 1 |
| Becker, MI | 1 |
| Moore, RD | 2 |
| Sarala, K | 1 |
| Anitha, S | 1 |
| Tharani, CB | 1 |
| Kumaraswami, V | 1 |
| Schumann, A | 1 |
| Nyamathi, A | 1 |
| Stein, JA | 1 |
| Mohammed, A | 1 |
| Ehrlich, R | 1 |
| Cilliers, F | 1 |
| Sukumar, B | 1 |
| Triveni, C | 1 |
| Gomathy, P | 1 |
| Thomas, B | 1 |
| Mathew, M | 1 |
| Sarna, A | 1 |
| Luchters, SM | 1 |
| Geibel, S | 1 |
| Kaai, S | 1 |
| Munyao, P | 1 |
| Shikely, KS | 1 |
| Mandaliya, K | 1 |
| van Dam, J | 1 |
| Temmerman, M | 1 |
| Wasserman, E | 1 |
| Smit, J | 1 |
| Whitelaw, A | 1 |
| Ouifki, R | 1 |
| Yu, JK | 1 |
| Bong, CN | 1 |
| Chen, SC | 1 |
| Dzimadzi, R | 1 |
| Lu, DY | 1 |
| Makombe, SD | 1 |
| Schouten, EJ | 1 |
| Kamoto, K | 1 |
| Angarano, G | 1 |
| Carbonara, D | 1 |
| Costa, D | 1 |
| Pickwell, SM | 1 |
| Gutman, LT | 1 |
| Tian, C | 1 |
| Teira, R | 1 |
| Reeve, P | 1 |
| Wada, M | 1 |
| Yamamoto, S | 1 |
| Ogata, H | 1 |
| Sugita, N | 1 |
| Kino, T | 1 |
| Hayashi, A | 1 |
| Moreno Guillén, S | 1 |
| Sánchez Fuentes, D | 1 |
| Barragán Casas, JM | 1 |
| Garcinuño Jiménez, MA | 1 |
| Martín Casado, M | 1 |
| Martín Marcos, M | 1 |
| Nightingale, SL | 1 |
| Luo, C | 1 |
| Bhat, G | 1 |
| Diwan, V | 1 |
| DuPont, HL | 1 |
| Baraia-Etxaburu, J | 1 |
| Bouza, E | 1 |
| Parras, F | 1 |
| Pérez-Tascón, M | 1 |
| Miralles, P | 1 |
| Vicente, T | 1 |
| Alberdi, JC | 1 |
| Cosín, J | 1 |
| López-Gay, D | 1 |
| Jean, SS | 1 |
| Ho, JL | 1 |
| Hafner, A | 1 |
| Johnson, WD | 3 |
| Miller, B | 1 |
| Salpeter, SR | 1 |
| Kochi, A | 1 |
| Vareldzis, B | 1 |
| Styblo, K | 1 |
| Hinman, AR | 1 |
| Dooley, SW | 2 |
| Fischl, MA | 1 |
| Sepkowitz, KA | 1 |
| Goldberger, MJ | 1 |
| Shinnick, TM | 1 |
| Iseman, MD | 1 |
| Jacobs, WR | 1 |
| Dunphy, CA | 1 |
| Krueger, LE | 1 |
| Goldbaum, GM | 1 |
| Wood, RW | 1 |
| Frieden, TR | 3 |
| Sterling, T | 1 |
| Pablos-Mendez, A | 1 |
| Kilburn, JO | 1 |
| Cauthen, GM | 1 |
| Nicod, LP | 1 |
| Pugliese, G | 1 |
| Rubinstien, EM | 1 |
| Madden, GM | 1 |
| Lyons, RW | 1 |
| Sbarbaro, JA | 1 |
| Asch, S | 1 |
| Knowles, L | 1 |
| Rai, A | 1 |
| Pogoda, J | 1 |
| Barnes, PF | 1 |
| Saenghirunvattana, S | 1 |
| Ausina, V | 1 |
| Sherman, LF | 1 |
| Maw, KL | 1 |
| Crawford, JT | 1 |
| Nivin, B | 1 |
| Sharp, V | 1 |
| Hewlett, D | 1 |
| Brudney, K | 1 |
| Alland, D | 1 |
| Kreisworth, BN | 1 |
| Espinal, MA | 1 |
| Pérez, G | 2 |
| Camilo, E | 1 |
| Soto, S | 1 |
| Cruz, E | 1 |
| Matos, N | 1 |
| Gonzalez, G | 1 |
| Fisher, M | 1 |
| Tomlinson, DR | 1 |
| Coker, RJ | 1 |
| Schultsz, C | 1 |
| Kuijper, EJ | 1 |
| van Soolingen, D | 1 |
| Prins, JM | 1 |
| Sudre, P | 1 |
| Rieder, H | 1 |
| Bassetti, S | 1 |
| Hirschel, BJ | 1 |
| Malvy, D | 1 |
| Rana, F | 1 |
| Hawken, MP | 2 |
| Meme, HK | 1 |
| Chakaya, JM | 1 |
| Githui, WA | 1 |
| Odhiambo, JA | 1 |
| Porter, JD | 1 |
| McAdam, KP | 1 |
| Lucas, SJ | 1 |
| Franco Serrano, J | 1 |
| Blanquer Olivas, R | 1 |
| Flores Cid, J | 1 |
| Domínguez Martínez, A | 1 |
| Nogueira Coito, JM | 1 |
| Iñigo Zaera, C | 1 |
| MacIntyre, CR | 1 |
| Kendig, N | 1 |
| Kummer, L | 1 |
| Birago, S | 1 |
| Graham, NM | 2 |
| Miller, C | 2 |
| Brown, LS | 1 |
| John, SL | 1 |
| Klein, M | 1 |
| Vaughn, A | 1 |
| Besch, CL | 1 |
| Szabo, S | 1 |
| El-Sadr, W | 1 |
| Colmenero, JD | 1 |
| García-Ordoñez, MA | 1 |
| Sebastián, MD | 1 |
| Pérez-Ruiz, E | 1 |
| Sánchez-Lora, J | 1 |
| Sánchez-González, J | 1 |
| Bentabol, G | 1 |
| Juárez, C | 1 |
| Sahai, J | 1 |
| Gallicano, K | 1 |
| Swick, L | 1 |
| Tailor, S | 1 |
| Garber, G | 1 |
| Seguin, I | 1 |
| Oliveras, L | 1 |
| Rachlis, A | 1 |
| Hom, DL | 2 |
| Huebner, R | 4 |
| Aguado, JM | 1 |
| Pulido, F | 1 |
| Dore, GJ | 1 |
| Law, MG | 1 |
| Kaldor, JM | 1 |
| Aït Khaled, N | 1 |
| Billo, N | 1 |
| Desvarieux, M | 2 |
| Turner, MT | 1 |
| Halsey, NA | 1 |
| Coberly, JS | 1 |
| Desormeaux, J | 1 |
| Losikoff, P | 1 |
| Atkinson, J | 1 |
| Contave, M | 1 |
| Johnson, M | 1 |
| Davis, H | 1 |
| Geiter, L | 1 |
| Johnson, E | 1 |
| Boulos, R | 1 |
| Delahunty, T | 1 |
| Lee, B | 1 |
| Conte, JE | 1 |
| Jansà, JM | 1 |
| Serrano, J | 1 |
| Caylà, JA | 1 |
| Vidal, R | 1 |
| Ocaña, I | 1 |
| Español, T | 1 |
| Phillips, P | 1 |
| Patterson, P | 1 |
| Hall, M | 1 |
| Robinson, CA | 1 |
| Dunlap, NE | 1 |
| Antoun, F | 1 |
| Momas, I | 1 |
| Vieu, V | 1 |
| Poinsard, R | 1 |
| Crespy, M | 1 |
| Talarmin, F | 1 |
| Eladari, D | 1 |
| Klotz, F | 1 |
| Martínez, E | 1 |
| Collazos, J | 1 |
| Mayo, J | 1 |
| Nyole, S | 1 |
| Nsubuga, P | 2 |
| Pekovic, V | 1 |
| Wallis, RS | 1 |
| Mugyenyi, PN | 2 |
| Mwasekaga, MJ | 1 |
| Rumisha, D | 1 |
| Binkin, N | 1 |
| Maganu, E | 1 |
| Brehm, WT | 1 |
| Grange, JM | 1 |
| Pozniak, AL | 1 |
| Ormerod, LP | 1 |
| Miller, R | 1 |
| Muhindi, DW | 1 |
| Smith, PR | 1 |
| D'Cruz, D | 1 |
| Raftery, MJ | 1 |
| Dodd, SM | 1 |
| Helbert, M | 1 |
| Skinner, CJ | 1 |
| Barker, J | 1 |
| Makatini, Z | 1 |
| Millard, J | 1 |
| de Lourdes Garcia, M | 1 |
| Valdespino, JL | 1 |
| Coberly, J | 1 |
| Klukowicz, AJ | 1 |
| Barry, MA | 1 |
| Breen, RA | 1 |
| Johnson, MA | 1 |
| Wilkinson, D | 2 |
| Smieja, MJ | 1 |
| Marchetti, CA | 1 |
| Cook, DJ | 1 |
| Smaill, FM | 1 |
| Jerant, AF | 1 |
| Bannon, M | 1 |
| Rittenhouse, S | 1 |
| Cherian, T | 1 |
| Verghese, VP | 1 |
| Quigley, MA | 1 |
| Hosp, M | 2 |
| Lisse, I | 1 |
| Fuchs, D | 1 |
| Sackoff, JE | 1 |
| Torian, LV | 1 |
| Nist, A | 1 |
| James, JS | 1 |
| de March Ayuela, P | 1 |
| Piyaworawong, S | 1 |
| Yanai, H | 1 |
| Nedsuwan, S | 1 |
| Akarasewi, P | 1 |
| Sawanpanyalert, P | 1 |
| Sadaphal, P | 1 |
| Astemborski, J | 1 |
| Sheely, L | 1 |
| Bonds, M | 1 |
| Madison, A | 1 |
| Vlahov, D | 1 |
| Thomas, DL | 1 |
| Mayanja, H | 1 |
| Mutuluuza Kityo, C | 1 |
| Nakibali, JG | 1 |
| Loughlin, AM | 1 |
| Yun, H | 1 |
| Mellon, LR | 1 |
| Noel, E | 1 |
| Casado, JL | 1 |
| Antela, A | 1 |
| Quereda, C | 1 |
| Moreno, A | 1 |
| Dronda, F | 1 |
| Sretrirutchai, S | 1 |
| Silapapojakul, K | 1 |
| Palittapongarnpim, P | 1 |
| Phongdara, A | 1 |
| Vuddhakul, V | 1 |
| Zulu, I | 1 |
| Farthing, MJ | 1 |
| Mulambo, S | 1 |
| Kelly, P | 1 |
| Gicheha, C | 1 |
| Hayes, R | 1 |
| Gathua, S | 1 |
| Brindle, R | 1 |
| Kibuga, D | 1 |
| Mutie, T | 1 |
| Kamunyi, R | 1 |
| Omwega, M | 1 |
| Were, J | 1 |
| Lumb, R | 1 |
| Shaw, D | 1 |
| Ferlinz, R | 1 |
| Jordan, TJ | 1 |
| Lewit, EM | 1 |
| Montgomery, RL | 1 |
| Reichman, LB | 1 |
| Dylewski, J | 1 |
| Thibert, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Addressing Challenges in Scaling up TB and HIV Treatment Integration in Public Health Settings in South Africa[NCT02654613] | 8,000 participants (Actual) | Interventional | 2015-06-01 | Completed | |||
| Options for Delivering Isoniazid-Rifapentine (3HP) for TB Prevention: the 3HP Options Implementation Trial[NCT03934931] | 1,656 participants (Actual) | Interventional | 2020-07-13 | Active, not recruiting | |||
| Preventing Mycobacterium Tuberculosis Infection in HIV-Exposed Infants[NCT02613169] | Phase 2 | 300 participants (Actual) | Interventional | 2016-08-31 | Completed | ||
| A Randomized Double Blind Placebo Controlled Trial of Rifapentine and Isoniazid for Prevention of Tuberculosis in People With Diabetes[NCT04600167] | Phase 3 | 3,000 participants (Anticipated) | Interventional | 2022-06-17 | Recruiting | ||
| Simplified Isoniazid Preventive Therapy (SPIRIT) Strategy to Reduce TB Burden[NCT03315962] | 468 participants (Actual) | Interventional | 2017-11-15 | Active, not recruiting | |||
| Phase III Clinical Trial of Ultra-Short-Course Rifapentine/Isoniazid for the Prevention of Active Tuberculosis in HIV-Infected Individuals With Latent Tuberculosis Infection[NCT01404312] | Phase 3 | 3,000 participants (Actual) | Interventional | 2012-05-23 | Completed | ||
| Novel TB Prevention Regimens for HIV-Infected Adults[NCT00057122] | Phase 3 | 1,148 participants (Actual) | Interventional | 2002-09-30 | Completed | ||
| URBAN ARCH (3/5) Uganda Cohort TB Preventive Therapy for HIV-infected Alcohol Users in Uganda: an Evaluation of Safety Tolerability and Adherence[NCT03302299] | Phase 4 | 302 participants (Actual) | Interventional | 2017-04-07 | Completed | ||
| A Phase IV Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Safety of Immediate (Antepartum-Initiated) Versus Deferred (Postpartum-Initiated) Isoniazid Preventive Therapy Among HIV-Infected Women in High Tuberculosis (TB) Incidence Setting[NCT01494038] | Phase 4 | 956 participants (Actual) | Interventional | 2014-08-19 | Completed | ||
| TB Screening Improves Preventive Therapy Uptake Trial[NCT04557176] | 1,719 participants (Actual) | Interventional | 2020-11-16 | Active, not recruiting | |||
| Safety, Tolerability, and Drug-drug Interactions of Short-course Treatment of Latent Tuberculosis Infection With High-dose Rifapentine and Isoniazid or Standard Isoniazid Preventative Therapy Among HIV-infected Patients Taking Dolutegravir-based Antiretro[NCT03435146] | Phase 1/Phase 2 | 135 participants (Actual) | Interventional | 2018-01-18 | Completed | ||
| A Randomized Trial to Compare Effectiveness of 4 Months Rifampin (4 RIF) With 9 Months Isoniazid (9 INH) in the Prevention of Active TB in Children: The P4v9 Trial[NCT00170209] | Phase 3 | 844 participants (Actual) | Interventional | 2011-08-31 | Completed | ||
| A Randomized Clinical Trial of 4 Months of Rifampin vs. 9 Months of Isoniazid for Latent Tuberculosis Infection. Part 3 - Effectiveness[NCT00931736] | Phase 3 | 6,031 participants (Actual) | Interventional | 2009-08-31 | Completed | ||
| Drinkers' Intervention to Prevent Tuberculosis (DIPT Study)[NCT03492216] | 680 participants (Actual) | Interventional | 2018-04-16 | Completed | |||
| A Phase I/II Trial of the Pharmacokinetics, Tolerability, and Safety of Once-Weekly Rifapentine and Isoniazid in HIV-1-infected and HIV-1-uninfected Pregnant and Postpartum Women With Latent Tuberculosis Infection[NCT02651259] | Phase 1/Phase 2 | 50 participants (Actual) | Interventional | 2017-03-13 | Completed | ||
| An Open-Label, Non-Randomized Study of Pharmacokinetic Interactions Among Depot Medroxyprogesterone Acetate (DMPA), Rifampicin (RIF), and Efavirenz (EFV) in Women Co-infected With Human Immunodeficiency Virus (HIV) and Tuberculosis (TB)[NCT02412436] | Phase 2 | 62 participants (Actual) | Interventional | 2015-11-03 | Completed | ||
| A Randomised, Pragmatic, Open-Label Trial To Evaluate The Effect Of Three Months Of High Dose Rifapentine Plus Isoniazid Administered As A Single Round Or Given Annually In HIV-Positive Individuals[NCT02980016] | Phase 3 | 4,027 participants (Actual) | Interventional | 2016-11-30 | Completed | ||
| Sustainable East Africa Research in Community Health[NCT01864603] | 150,395 participants (Actual) | Interventional | 2013-04-30 | Completed | |||
| A Phase II Trial to Describe the Pharmacokinetics, Safety and Efficacy of Pharmacogenetics-guided Dosing of Isoniazid in Patients With HIV-associated TB[NCT05124678] | Phase 2 | 40 participants (Anticipated) | Interventional | 2021-12-07 | Recruiting | ||
| Evaluation of the Pharmacokinetics of Antituberculosis Drugs and Tuberculosis Treatment Outcomes in HIV-tuberculosis Co-infected Ugandan Adults[NCT01782950] | Phase 4 | 400 participants (Anticipated) | Interventional | 2013-02-28 | Recruiting | ||
| Benefits and Risks of Early Antiretroviral Therapy in HIV-infected Adults in Abidjan, Côte d'Ivoire: Randomized Controlled Trial (ANRS 12136 TEMPRANO)[NCT00495651] | Phase 3 | 2,073 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| Leveraging mHealth to Enable and Adapt Community Health Worker Strategies to Improve TB/HIV Patient Outcomes in South Africa (LEAP-TB-SA) Trial[NCT04298905] | 200 participants (Anticipated) | Interventional | 2022-03-10 | Recruiting | |||
| Impact of Once-Weekly Rifapentine and Isoniazid on the Steady State Pharmacokinetics of Dolutegravir and Darunavir Boosted With Cobicistat in Healthy Volunteers[NCT02771249] | Phase 1 | 37 participants (Actual) | Interventional | 2016-06-03 | Completed | ||
| A Randomized Controlled Clinical Trial Comparing Daily Vs. Intermittent 6 - Month Short Course Chemotherapy in Reducing Failures & Emergence of Acquired Rifampicin Resistance (ARR) in Patients With HIV and Pulmonary Tuberculosis[NCT00933790] | Phase 3 | 331 participants (Actual) | Interventional | 2009-09-14 | Completed | ||
| A Randomized, Four-arm Open Label Phase Two-b Clinical Trial to Evaluate the Pharmacokinetics, Safety/Tolerability and Efficacy of High Dose Rifampicin in TB-HIV Co-infected Patients on Efavirenz- or Dolutegravir-based Antiretroviral Therapy[NCT03982277] | Phase 2 | 130 participants (Actual) | Interventional | 2019-04-30 | Completed | ||
| Study of Neurological Aging Among People Living With HIV (SNAP)[NCT05678660] | 300 participants (Anticipated) | Observational | 2022-07-06 | Recruiting | |||
| Steady-state Pharmacokinetics of Efavirenz (Sustiva/Stocrin) 400 mg Once Daily in the Presence of Rifampicin and Isoniazid (Rifinah or the Local Generics)[NCT02832778] | Phase 1 | 35 participants (Anticipated) | Interventional | 2016-11-21 | Recruiting | ||
| One-month Latent Tuberculosis Treatment for Renal Transplant Candidates[NCT05411744] | Phase 4 | 25 participants (Anticipated) | Interventional | 2022-07-01 | Recruiting | ||
| 2R2: Higher Dose Rifampin for 2 Months vs Standard Dose Rifampin for Latent TB: a 3-arm Randomized Trial.[NCT03988933] | Phase 2 | 1,368 participants (Actual) | Interventional | 2019-09-20 | Active, not recruiting | ||
| Early Risk Assessment in TB contactS by New Diagnostic tEsts[NCT04781257] | 2,100 participants (Anticipated) | Observational | 2021-03-01 | Active, not recruiting | |||
| A Randomized, Placebo-Controlled Study of Limited vs. Continuous Isoniazid Tuberculosis Preventive Therapy in HIV-infected Persons in Botswana[NCT00164281] | Phase 4 | 2,000 participants (Actual) | Interventional | 2004-11-30 | Completed | ||
| A Randomised Open-Label Controlled Trial of a 4-Month Gatifloxacin-Containing Regimen Versus Standard Regimen for the Treatment of Adult Patients With Pulmonary Tuberculosis[NCT00216385] | Phase 3 | 2,070 participants | Interventional | 2005-01-31 | Recruiting | ||
| Impact of TB Preventive Therapy for HIV/TB Co-infected Patients With Access to Highly Active Antiretroviral Therapy in Rio de Janeiro, Brazil: A Phased Implementation Trial[NCT00107887] | Phase 4 | 17,415 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| PROvide MIner-friendly SErvices for Integrated TB/HIV Care in Lesotho Study (PROMISE Study)[NCT03537872] | 248 participants (Actual) | Interventional | 2018-03-13 | Completed | |||
| Randomized Non-inferiority Trial Comparing the Nevirapine-based Antiretroviral Therapy Versus the Standard Efavirenz-based ART for the Treatment of HIV-TB Co-infected Patients on Rifampicin-based Therapy (ANRS 12146 CARINEMO)[NCT00495326] | Phase 2/Phase 3 | 570 participants (Actual) | Interventional | 2007-12-31 | Completed | ||
| Long Term Study of 2 Isoniazid (INH) Prophylactic Regimens With Concomitant Cotrimoxazole (CTX) in HIV-infected Children - Impact on Morbidity, Mortality, Bacterial Resistance and Incidence of Tuberculosis[NCT00330304] | Phase 3 | 450 participants (Actual) | Interventional | 2003-01-31 | Completed | ||
| A Randomized-controlled Trial of Isoniazid Plus Highly Active Antiretroviral Therapy Against Placebo to Prevent Tuberculosis in HIV-infected Persons[NCT00463086] | 1,368 participants (Actual) | Interventional | 2007-11-30 | Completed | |||
| Impact of Nursing Interventions on Adherence to Treatment With Anti-tuberculosis Drugs in Children and Adolescents[NCT03230409] | 359 participants (Actual) | Interventional | 2014-01-01 | Completed | |||
| A Randomized Double Blind Placebo Controlled Trial of Adjunctive Dexamethasone for the Treatment of HIV-infected Adults With Tuberculous Meningitis[NCT03092817] | Phase 3 | 520 participants (Actual) | Interventional | 2017-05-25 | Active, not recruiting | ||
| A Randomized Double Blind Placebo Controlled Non-inferiority Trial of Adjunctive Dexamethasone for the Treatment of HIV-uninfected Adults With Tuberculous Meningitis Stratified by Leukotriene A4 Hydrolase Genotype[NCT03100786] | Phase 3 | 640 participants (Anticipated) | Interventional | 2018-02-08 | Recruiting | ||
| Plasma Drug Concentrations in the Treatment of Multidrug-resistant Tuberculosis in Relation to Minimum Inhibitory Concentrations - a Prospective Observational Study[NCT02816931] | 37 participants (Actual) | Observational | 2016-03-31 | Completed | |||
| An Open Label, Randomized Controlled Trial to Establish the Efficacy and Safety of a Study Strategy Consisting of 6 Months of Bedaquiline (BDQ), Delamanid (DLM), and Linezolid (LNZ), With Levofloxacin (LVX) and Clofazimine (CFZ) Compared to the Current So[NCT04062201] | Phase 3 | 402 participants (Actual) | Interventional | 2019-08-22 | Active, not recruiting | ||
| Pharmacometrics to Advance Novel Regimens for Drug-resistant Tuberculosis[NCT03827811] | 625 participants (Anticipated) | Observational | 2020-01-30 | Recruiting | |||
| Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in the Treatment of Tuberculosis Patient With HIV Infection in South Africa: A Phase II Trial[NCT00640887] | Phase 2 | 48 participants (Anticipated) | Interventional | 2009-02-28 | Completed | ||
| Does Providing Medical Personnel in the AMPATH Network With Patient-specific Reminders Regarding TB That Are Generated From a Patient's EMR Improve the Prevalence of IPT Initiation and Decrease the Time From Screening to Treatment?[NCT01934309] | 3,782 participants (Actual) | Interventional | 2013-09-30 | Completed | |||
| A Randomized, Double-blind, Placebo-Controlled Study of the Safety and Efficacy of Lessertia Frutescens (L.)Goldblatt and J.C. Manning (Syn. Sutherlandia Frutescens (L.)R. Br.)in HIV-infected South African Adults[NCT00549523] | Phase 1/Phase 2 | 133 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| A Multicenter Clinical Trial to Evaluate the Feasibility and Outcome of Same-day Antiretroviral Therapy With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/F/TAF) Among Patients Testing Positive by HIV Confirmatory Tests[NCT04712058] | 200 participants (Anticipated) | Interventional | 2021-01-20 | Recruiting | |||
| Same Day Community-based ART Initiation Versus Clinic-based Pre-ART Assessment and Counselling for Individuals Newly Tested HIV-positive During Community-based HIV Testing in Rural Lesotho - a Randomized Controlled Trial[NCT02692027] | Phase 3 | 276 participants (Actual) | Interventional | 2016-02-29 | Completed | ||
| Clinical Evaluation of Adjusted Doses of Darunavir/Ritonavir With Rifampicin in HIV-infected Volunteers[NCT03892161] | Phase 1 | 17 participants (Actual) | Interventional | 2018-04-12 | Terminated (stopped due to Risks to participation) | ||
| Optimal Dosing of 1st Line Antituberculosis and Antiretroviral Drugs in Children (a Pharmacokinetic Study)[NCT01637558] | Phase 4 | 200 participants (Actual) | Interventional | 2012-11-30 | Completed | ||
| Reducing Early Mortality and Early Morbidity by Empiric Tuberculosis Treatment Regimens (REMEMBER)[NCT01380080] | Phase 4 | 851 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| TBTC Study 26: Effectiveness and Tolerability of Weekly Rifapentine/Isoniazid for 3 Months Versus Daily Isoniazid for 9 Months for the Treatment of Latent Tuberculosis Infection[NCT00023452] | Phase 3 | 8,053 participants (Actual) | Interventional | 2001-06-30 | Completed | ||
| Efficacy of Risk-Targeted Video Based Directly on Observed Therapy for Latent TB[NCT03783728] | 0 participants (Actual) | Observational | 2019-06-30 | Withdrawn (stopped due to Investigator is leaving the University) | |||
| A Pilot Study to Evaluate Video Observed Treatment Among Tuberculosis Patients From Lambaréné Using an Instant Messenger Application[NCT05865626] | 30 participants (Actual) | Interventional | 2018-10-10 | Completed | |||
| Multi Center Clinical Research and Evaluation of Melting Technology for Rapid Detection of Drug Resistant Tuberculosis[NCT02776150] | 3,100 participants (Anticipated) | Observational | 2016-05-31 | Not yet recruiting | |||
| DARDAR Health Project (Disseminated Tuberculosis and HIV Infection)[NCT00052195] | Phase 2/Phase 3 | 1,975 participants (Actual) | Interventional | 2001-09-30 | Completed | ||
| DNA Sequencing of MDR TB in Eastern Siberia[NCT02508610] | 630 participants (Anticipated) | Observational | 2013-11-30 | Recruiting | |||
| Randomized Clinical Trial to Assess the Efficacy of Short Course Intermittent Regimens for the Treatment of HIV-Associated Tuberculosis[NCT00376012] | Phase 3 | 300 participants (Actual) | Interventional | 2001-02-28 | Active, not recruiting | ||
| A Nurse Case Management Intervention to Improve MDR-TB/HIV Co-Infection Outcomes[NCT02129244] | 3,600 participants (Anticipated) | Interventional | 2014-10-31 | Active, not recruiting | |||
| A Pharmacokinetics Study Comparing Lopinavir Plasma Exposure When Given as Lopinavir/Ritonavir (1:1) in the Presence of Rifampicin and Lopinavir/Ritonavir (4:1) Without Rifampicin in HIV and TB Co-infected Children in South Africa.[NCT02348177] | Phase 4 | 96 participants (Actual) | Interventional | 2013-01-31 | Completed | ||
| Transcriptional Signature of HIV And TB Co-Infection[NCT01611402] | 96 participants (Actual) | Observational | 2012-05-29 | Completed | |||
| Primary Prophylaxis for Prevention of TB in Prison's Populations[NCT03028129] | Phase 4 | 467 participants (Actual) | Interventional | 2017-09-04 | Terminated (stopped due to Interim analysis showed efficacy less than 2.5%.) | ||
| A Randomized, Double Blind, Placebo Controlled Trial to Determine the Efficacy of Isoniazid (INH) in Preventing Tuberculosis Disease and Latent Tuberculosis Infection Among Infants With Perinatal Exposure to HIV[NCT00080119] | Phase 2/Phase 3 | 1,354 participants (Actual) | Interventional | 2004-02-29 | Terminated (stopped due to Data Safety Monitoring Board (DSMB) recommended stopping study due to futility) | ||
| Evaluation of Two Different Preventive Therapy Regimens for Tuberculosis in HIV Infected Persons[NCT00351702] | Phase 3 | 650 participants (Actual) | Interventional | 2001-02-28 | Completed | ||
| Immune Activation and Drug Absorption in HIV-Infected Patients[NCT01845298] | 7 participants (Actual) | Interventional | 2014-06-30 | Completed | |||
| TBTC Study 23: Treatment of HIV-Related Tuberculosis Using a Rifabutin-Based Regimen[NCT00023361] | 215 participants | Interventional | 1999-02-28 | Completed | |||
| TBTC Study 23A: Pharmacokinetics of Intermittent Isoniazid and Rifabutin in USPHS Study 23: Treatment of HIV-Related Tuberculosis Using a Rifabutin-Based Regimen[NCT00023348] | Phase 2/Phase 3 | 150 participants | Interventional | 1999-07-31 | Completed | ||
| Pharmacokinetics and Pharmacodynamics of High Versus Standard Dose Rifampicin in Patients With Pulmonary Tuberculosis in the Kilimanjaro Region, Tanzania.[NCT00760149] | Phase 2 | 150 participants (Actual) | Interventional | 2010-07-31 | Completed | ||
| Enhanced TB Screening to Determine the Prevalence and Incidence of TB in a Cohort of HIV Clinic Patients in Lusaka, Zambia[NCT02043067] | 400 participants (Actual) | Observational | 2011-10-31 | Completed | |||
| A Single-blind Stepped Wedge Cluster Randomized Controlled Behaviour Change Trial to Determine Effectiveness of Prevention Programme of Melioidosis in Diabetics in Ubon Ratchathani, Northeast Thailand[NCT02089152] | 9,075 participants (Actual) | Interventional | 2014-04-01 | Completed | |||
| Prophylaxis Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Suspected Latent Tuberculous Infection[NCT00000959] | 600 participants | Interventional | Completed | ||||
| Prophylaxis Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Confirmed Latent Tuberculous Infection[NCT00000638] | 2,000 participants | Interventional | Completed | ||||
| Prophylaxis Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Confirmed Latent Tuberculous Infection[NCT00000636] | 2,000 participants | Interventional | Completed | ||||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The count of eligible people living with HIV (PLHIV) offered 3HP who accept to initiate treatment (by age, gender, CD4 stratum, viral load suppression) divided by the count of those randomized. (NCT03934931)
Timeframe: Within 16 weeks of treatment initiation
| Intervention | proportion of participants (Number) |
|---|---|
| Facilitated Directly Observed Therapy (DOT) | 0.998 |
| Facilitated Self-Administered Therapy (SAT) | 1.00 |
| Patient Choice Between Facilitated DOT and Facilitated SAT | 0.995 |
The count of eligible participants who accept treatment and take at least 11 of 12 once weekly doses of rifapentine (RPT)/isoniazid (INH) within 16 weeks of treatment initiation divided by the count of those randomized. (NCT03934931)
Timeframe: Within 16 weeks of treatment initiation
| Intervention | proportion of participants (Number) |
|---|---|
| Facilitated Directly Observed Therapy (DOT) | 0.946 |
| Facilitated Self-Administered Therapy (SAT) | 0.922 |
| Patient Choice Between Facilitated DOT and Facilitated SAT | 0.944 |
Count of participants who take at least 11 of 12 doses within 16 weeks of treatment initiation divided by the count those who take at least one dose of 3HP. (NCT03934931)
Timeframe: Within 16 weeks of treatment initiation
| Intervention | proportion of participants (Number) |
|---|---|
| Facilitated Directly Observed Therapy (DOT) | 0.947 |
| Facilitated Self-Administered Therapy (SAT) | 0.922 |
| Patient Choice Between Facilitated DOT and Facilitated SAT | 0.949 |
Count of participants for whom treatment is discontinued due to adverse events or intolerance divided by the count of those who initiated 3HP. (NCT03934931)
Timeframe: Within 16 weeks of treatment initiation
| Intervention | proportion of participants (Number) |
|---|---|
| Facilitated Directly Observed Therapy (DOT) | 0.0054 |
| Facilitated Self-Administered Therapy (SAT) | 0.013 |
| Patient Choice Between Facilitated DOT and Facilitated SAT | 0.0073 |
"Number of infants with a combined endpoint of MTB infection, TB disease, and death~MTB infection as measured by IGRA or tuberculin skin test at 12 months post-enrollment~TB disease including microbiologically confirmed (culture or Xpert positive), or probable TB (clinical diagnosis).~Death of infant" (NCT02613169)
Timeframe: Over 12 months after randomization
| Intervention | Participants (Count of Participants) |
|---|---|
| Isoniazid | 11 |
| No Isoniazid | 19 |
Among HEU infants enrolled at approximately 6 weeks of age, compare the risk of acquiring MTB infection during 1 year of follow-up in infants randomized to receive INH vs. no INH using an interferon-gamma release (IGRA) QuantiFERON-TB Gold Plus (QFT-Plus) assay or tuberculin skin test as part of a composite endpoint to determine MTB infection status (NCT02613169)
Timeframe: at 12 months post randomization
| Intervention | participants (Number) |
|---|---|
| Isoniazid | 10 |
| No Isoniazid | 18 |
Among HEU infants enrolled at approximately 6 weeks of age, compare the risk of acquiring MTB infection during 1 year of follow-up in infants randomized to receive INH vs. no INH using an interferon-gamma release (IGRA) QuantiFERON-TB Gold Plus (QFT-Plus) assay or tuberculin skin test as part of a composite endpoint to determine MTB infection status (NCT02613169)
Timeframe: at 12 months post randomization
| Intervention | TB infections/100 person years (Number) |
|---|---|
| Isoniazid | 7.0 |
| No Isoniazid | 13.4 |
Number of infants with grade 3 or higher treatment-related adverse events as assessed by DAIDS Table for the Grading Severity of Pediatric Adverse Experiences (NCT02613169)
Timeframe: Over 12 months after randomization
| Intervention | Participants (Count of Participants) |
|---|---|
| Isoniazid | 21 |
| No Isoniazid | 16 |
Incidence rate (events per 100 person-years) was estimated, and 95.1% confidence interval used to account for interim analysis of primary efficacy outcome. (NCT01404312)
Timeframe: From entry to occurrence of event, up to end of follow-up 3 years after last participant enrolled (median follow-up time: 3.3 years)
| Intervention | Events per 100 person-years (Number) |
|---|---|
| RPT Plus INH Regimen (Arm A) | 0.6506 |
| INH Regimen (Arm B) | 0.6736 |
Cumulative incidence function estimated nonparametrically, treating TB-related deaths as competing risks. (NCT01404312)
Timeframe: From entry to occurrence of event, up to end of follow-up 3 years after last participant enrolled (median follow-up time: 3.3 years)
| Intervention | events per 100 participants (Number) | |||
|---|---|---|---|---|
| Cumulative incidence by 1 year post-randomization | Cumulative incidence by 2 years post-randomization | Cumulative incidence by 3 years post-randomization | Cumulative incidence by 4 years post-randomization | |
| INH Regimen (Arm B) | 0.5 | 1.0 | 1.5 | 2.0 |
| RPT Plus INH Regimen (Arm A) | 0.3 | 0.4 | 0.9 | 1.6 |
Data table estimates for percentage who died by each time point were estimated using Kaplan-Meier at 1, 2, 3, and 4 years post-entry. (NCT01404312)
Timeframe: From entry to occurrence of event, up to end of follow-up 3 years after last participant enrolled (median follow-up time: 3.3 years)
| Intervention | events per 100 participants (Number) | |||
|---|---|---|---|---|
| 1 year post-entry | 2 years post-entry | 3 years post-entry | 4 years post-entry | |
| INH Regimen (Arm B) | 0.63 | 1.15 | 1.62 | 2.29 |
| RPT Plus INH Regimen (Arm A) | 0.35 | 0.49 | 1.05 | 2.00 |
"Mean and standard deviation.~Week 16 samples have not yet been analyzed because the metabolite assay is being validated, and requires submission for approval by the Clinical Pharmacology Quality Assurance Program. Analysis of week 16 samples are anticipated to be available in September 2019." (NCT01404312)
Timeframe: Measured at Weeks 0, 2, 4, and 16
| Intervention | nanograms per mL (Mean) | ||
|---|---|---|---|
| Week 0 | Week 2 | Week 4 | |
| RPT Plus INH Regimen (Arm A) | 3787 | 3870 | 4082 |
Mean and standard deviation (NCT01404312)
Timeframe: Measured at Weeks 0, 2, and 4
| Intervention | nanograms per mL (Mean) | ||
|---|---|---|---|
| Week0 | Week 2 | Week 4 | |
| RPT Plus INH Regimen (Arm A) | 7573 | 6234 | 5797 |
Among MTB-diagnosed participants who underwent drug-susceptibility testing, the number who had any resistance to a particular drug. (NCT01404312)
Timeframe: After TB diagnosis
| Intervention | Participants (Count of Participants) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rifampin72268104 | Rifampin72268105 | Isoniazid72268104 | Isoniazid72268105 | Ethambutol72268104 | Ethambutol72268105 | Pyrazinamide72268104 | Pyrazinamide72268105 | |||||||||
| Developed Resistance | Did not Develop Resistance | |||||||||||||||
| RPT Plus INH Regimen (Arm A) | 1 | |||||||||||||||
| INH Regimen (Arm B) | 1 | |||||||||||||||
| RPT Plus INH Regimen (Arm A) | 14 | |||||||||||||||
| INH Regimen (Arm B) | 11 | |||||||||||||||
| RPT Plus INH Regimen (Arm A) | 2 | |||||||||||||||
| RPT Plus INH Regimen (Arm A) | 12 | |||||||||||||||
| RPT Plus INH Regimen (Arm A) | 0 | |||||||||||||||
| RPT Plus INH Regimen (Arm A) | 7 | |||||||||||||||
| INH Regimen (Arm B) | 7 | |||||||||||||||
| INH Regimen (Arm B) | 0 | |||||||||||||||
| RPT Plus INH Regimen (Arm A) | 6 | |||||||||||||||
| INH Regimen (Arm B) | 6 | |||||||||||||||
Safety will be assessed by the occurrence of a Grade 3/4 hepatotoxicity at any time during the assigned treatment period. (NCT03302299)
Timeframe: Hepatotoxicity occurring during the six month course (180 pills) of isoniazid (INH), which may be taken over a maximum of 9 months.
| Intervention | percent (Number) |
|---|---|
| INH and Vitamin B6 | 8.3 |
Lack of tolerability will be defined as any isoniazid (INH) treatment discontinuation prior to completion of the prescribed course (6 months of INH taken over a maximum period of 9 months) due to side effects or alanine transaminase (ALT)/aspartate transaminase (AST) elevations. (NCT03302299)
Timeframe: Six month course (180 pills) of isoniazid (INH), which may be taken over a maximum of 9 months.
| Intervention | Participants (Count of Participants) |
|---|---|
| INH and Vitamin B6 | 32 |
Alanine transaminase (ALT) or aspartate transaminase (AST) elevations (>2x the upper limit of normal) at study screening (NCT03302299)
Timeframe: Study screening visit
| Intervention | Participants (Count of Participants) |
|---|---|
| Study Screening | 80 |
Latent tuberculosis assessed at screening via tuberculin skin testing (TST). A TST induration >=5mm was considered positive for latent tuberculosis. (NCT03302299)
Timeframe: Study screening visit
| Intervention | Participants (Count of Participants) |
|---|---|
| Study Screening | 308 |
INH concentration in hair (pmol/mg) will be measured at 3- and 6- months during INH therapy. (NCT03302299)
Timeframe: Measured at 3- and 6- months after INH initiation
| Intervention | pmol/mg (Median) | |
|---|---|---|
| at 3 months | at 6 months | |
| INH and Vitamin B6 | 36.0 | 37.8 |
Suboptimal INH adherence was defined as <90% of days with at least 1 electronic medication management (EMM) pill cap opening in the previous 90 days, at 3- and 6-months. (NCT03302299)
Timeframe: Adherence will be measured over the 6 months on INH or until INH discontinuation (whichever is shorter)
| Intervention | percentage of participants (Number) | |
|---|---|---|
| at 3 months | at 6 months | |
| INH and Vitamin B6 | 31.3 | 43.9 |
"Participants were asked In the past 30 days, how many days in total have you not taken your pill? and were presented with a visual analog scale (VAS) to indicate the percentage of INH taken in the past 30 days. We converted the VAS percentage into number of days out of 30 to match the first question. Our final self-report measure was the minimum number of the 2 self-reported measurements." (NCT03302299)
Timeframe: Self-reported INH medication adherence via VAS will be measured 3- and 6- months after starting INH
| Intervention | days (Median) | |
|---|---|---|
| at 3 months | at 6 months | |
| INH and Vitamin B6 | 30 | 30 |
The Self Rating Single Item (SRSI) adherence scale asks participants to rate their ability to take their medications as prescribed over the past 30 days. Participants reporting INH use in the prior 30 days at the 3- or 6-month interview are included here, and reported their INH adherence in the prior 30 days as excellent, very good, good, fair, poor, or very poor. (NCT03302299)
Timeframe: Self-reported INH medication adherence via SRSI will be measured 3- and 6- months after starting INH
| Intervention | Participants (Count of Participants) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| At 3 months72558043 | At 6 months72558043 | |||||||||||
| Excellent | Very good | Good | Fair | Poor | Very poor | |||||||
| INH and Vitamin B6 | 160 | |||||||||||
| INH and Vitamin B6 | 79 | |||||||||||
| INH and Vitamin B6 | 38 | |||||||||||
| INH and Vitamin B6 | 2 | |||||||||||
| INH and Vitamin B6 | 124 | |||||||||||
| INH and Vitamin B6 | 90 | |||||||||||
| INH and Vitamin B6 | 41 | |||||||||||
| INH and Vitamin B6 | 4 | |||||||||||
| INH and Vitamin B6 | 0 | |||||||||||
| INH and Vitamin B6 | 1 | |||||||||||
Incidence rate calculated by Mantel-Haenszel, weighted by gestational age strata (NCT01494038)
Timeframe: Measured from study entry through end of pregnancy
| Intervention | events per 100 person-years (Number) |
|---|---|
| Arm A (Immediate INH Treatment) | 15.93 |
| Arm B (Deferred INH Treatment) | 13.79 |
Incidence rate calculated by Mantel-Haenszel, weighted by gestational age strata. (NCT01494038)
Timeframe: Measured from study entry through 12 weeks after birth
| Intervention | events per 100 person-years (Number) |
|---|---|
| Arm A (Immediate INH Treatment) | 16.98 |
| Arm B (Deferred INH Treatment) | 10.09 |
Incidence rate, calculated by Mantel-Haenszel (MH), weighted by gestational age strata 1) gestational age at entry less than 24 weeks or 2) gestational age at entry greater than or equal to 24 weeks. AE's include laboratory results, signs/symptoms, or diagnoses; graded as per Division of AIDS (DAIDS) or by protocol-defined hepatotoxicity measures. Related to treatment indicates possibly, probably, or definitely related to INH or Placebo for INH as judged by Independent Endpoint Review Committee. Discontinuation refers to permanent discontinuation of study treatment. (NCT01494038)
Timeframe: Measured from study entry through Week 48 after birth
| Intervention | events per 100 person-years (Number) |
|---|---|
| Arm A (Immediate INH Treatment) | 15.03 |
| Arm B (Deferred INH Treatment) | 14.93 |
Incidence rate calculated by Mantel-Haenszel, weighted by gestational age strata. (NCT01494038)
Timeframe: Measured from study entry through Week 48 after birth
| Intervention | events per 100 person-years (Number) |
|---|---|
| Arm A (Immediate INH Treatment) | 2.99 |
| Arm B (Deferred INH Treatment) | 4.68 |
Incidence rate calculated by Mantel-Haenszel, weighted by gestational age strata. (NCT01494038)
Timeframe: Measured from study entry through Week 48 after birth
| Intervention | events per 100 person-years (Number) |
|---|---|
| Arm A (Immediate INH Treatment) | 1.00 |
| Arm B (Deferred INH Treatment) | 1.38 |
Incidence rate calculated by Mantel-Haenszel, weighted by gestational age strata. (NCT01494038)
Timeframe: Measured from study entry through Week 48 after birth
| Intervention | events per 100 person-years (Number) |
|---|---|
| Arm A (Immediate INH Treatment) | 3.42 |
| Arm B (Deferred INH Treatment) | 4.72 |
Incidence rate was calculated by Mantel-Haenszel, weighted by gestational age strata. (NCT01494038)
Timeframe: Measured from study entry through Week 48 after birth
| Intervention | events per 100 person-years (Number) |
|---|---|
| Arm A (Immediate INH Treatment) | 2.99 |
| Arm B (Deferred INH Treatment) | 4.42 |
Incidence rate calculated by Mantel-Haenszel, weighted by gestational age strata. (NCT01494038)
Timeframe: Measured from study entry through Week 48 postpartum
| Intervention | events per 100 person-years (Number) |
|---|---|
| Arm A (Immediate INH Treatment) | 0.40 |
| Arm B (Deferred INH Treatment) | 0.78 |
Incidence rates calculated by Mantel-Haenszel, weighted by gestational age strata. Probable or confirmed TB infection, as judged by Secondary Endpoint Review Committee (NCT01494038)
Timeframe: Measured from study entry to Week 48 after birth
| Intervention | events per 100 person-years (Number) |
|---|---|
| Arm A (Immediate INH Treatment) | 0.60 |
| Arm B (Deferred INH Treatment) | 0.59 |
Incidence rates calculated by Mantel-Haenszel, weighted by gestational age strata. Probable or confirmed TB, or congenital TB as defined using the Cantwell criteria (see reference), judged by the Secondary Endpoint Review Committee. Includes an infant death due to unknown cause. (NCT01494038)
Timeframe: Measured from study entry through Week 48 after birth
| Intervention | events per 100 person-years (Number) |
|---|---|
| Arm A (Immediate INH Treatment) | 0.54 |
| Arm B (Deferred INH Treatment) | 0.52 |
Incidence rates calculated by Mantel-Haenszel, weighted by gestational age strata. (NCT01494038)
Timeframe: Measured from study entry through end of pregnancy
| Intervention | events per 100 person-years (Number) |
|---|---|
| Arm A (Immediate INH Treatment) | 56.36 |
| Arm B (Deferred INH Treatment) | 50.88 |
Incidence rates calculated by Mantel-Haenszel, weighted by gestational age strata. (NCT01494038)
Timeframe: Measured from study entry through delivery
| Intervention | events per 100 person-years (Number) |
|---|---|
| Arm A (Immediate INH Treatment) | 1.77 |
| Arm B (Deferred INH Treatment) | 2.59 |
Incidence rates calculated by Mantel-Haenszel, weighted by gestational age strata. Hepatotoxicity definition as defined by DAIDS AE grading criteria 1.0. (NCT01494038)
Timeframe: Measured from study entry through delivery
| Intervention | events per 100 person-years (Number) |
|---|---|
| Arm A (Immediate INH Treatment) | 1.77 |
| Arm B (Deferred INH Treatment) | 2.59 |
Incidence rate calculated by Mantel-Haenszel, weighted by gestational age strata. Protocol-specific definition of hepatotoxicity: Any one of the following: 1) Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than 5 times the upper limit of normal (ULN), where ULN is specified by the clinic physician; 2) Total bilirubin > 3 X ULN; 3) ALT greater than 3 X ULN and total bilirubin greater than 2 X ULN; or 4) ALT > 3 X ULN and persistent symptomatic clinical hepatitis (NCT01494038)
Timeframe: Measured from study entry through delivery
| Intervention | events per 100 person-years (Number) |
|---|---|
| Arm A (Immediate INH Treatment) | 1.77 |
| Arm B (Deferred INH Treatment) | 2.59 |
Incidence rate calculated by Mantel-Haenszel, weighted by gestational age strata. (NCT01494038)
Timeframe: Measured from study entry through delivery
| Intervention | events per 100 person-years (Number) |
|---|---|
| Arm A (Immediate INH Treatment) | 1.77 |
| Arm B (Deferred INH Treatment) | 2.59 |
Incidence rates calculated by Mantel-Haenszel, weighted by gestational age strata. (NCT01494038)
Timeframe: Measured from study entry through 12 weeks postpartum
| Intervention | events per 100 person-years (Number) |
|---|---|
| Arm A (Immediate INH Treatment) | 8.37 |
| Arm B (Deferred INH Treatment) | 4.98 |
Incidence rate calculated by Mantel-Haenszel, weighted by gestational age strata (NCT01494038)
Timeframe: Measured from study entry through 12 weeks postpartum
| Intervention | events per 100 person-years (Number) |
|---|---|
| Arm A (Immediate INH Treatment) | 7.91 |
| Arm B (Deferred INH Treatment) | 4.52 |
Incidence rates calculated by Mantel-Haenszel, weighted by gestational age strata. (NCT01494038)
Timeframe: Measured from study entry through 12 weeks postpartum
| Intervention | events per 100 person-years (Number) |
|---|---|
| Arm A (Immediate INH Treatment) | 56.48 |
| Arm B (Deferred INH Treatment) | 40.59 |
Incidence rates calculated by Mantel-Haenszel, weighted by gestational age strata. (NCT01494038)
Timeframe: Measured from study start through 12 weeks postpartum
| Intervention | events per 100 person-years (Number) |
|---|---|
| Arm A (Immediate INH Treatment) | 8.37 |
| Arm B (Deferred INH Treatment) | 4.98 |
Incidence rates calculated by Mantel-Haenszel, weighted by gestational age strata (NCT01494038)
Timeframe: Measured from study start through 12 weeks postpartum
| Intervention | events per 100 person-years (Number) |
|---|---|
| Arm A (Immediate INH Treatment) | 7.91 |
| Arm B (Deferred INH Treatment) | 4.52 |
Hospitalization due to reasons other than birth (NCT01494038)
Timeframe: Measured from study entry through Week 48 after birth
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm A (Immediate INH Treatment) | 73 |
| Arm B (Deferred INH Treatment) | 75 |
Laboratory, sign/symptom, or diagnoses graded as 3 or higher by DAIDS criteria. (NCT01494038)
Timeframe: Measured from study entry through Week 48 after birth
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm A (Immediate INH Treatment) | 193 |
| Arm B (Deferred INH Treatment) | 196 |
As before, but AE is judged to be possibly, probably, or definitely related to INH or Placebo for INH, by clinic medical staff (NCT01494038)
Timeframe: Measured from study entry through Week 48 after birth
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm A (Immediate INH Treatment) | 5 |
| Arm B (Deferred INH Treatment) | 6 |
Fetal deaths include both stillbirths and spontaneous abortions; in case of a multiple birth, mothers who had at least one fetal death (NCT01494038)
Timeframe: Measured from study entry through end of pregnancy
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm A (Immediate INH Treatment) | 17 |
| Arm B (Deferred INH Treatment) | 9 |
Premature birth is defined as gestational age of < 37 weeks at delivery. (NCT01494038)
Timeframe: Measured at delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm A (Immediate INH Treatment) | 48 |
| Arm B (Deferred INH Treatment) | 40 |
Resistance to INH from isolates of Mycobacterium tuberculosis, as a percentage of mothers who develop culture-confirmed TB (NCT01494038)
Timeframe: Measured from study entry through Week 48 postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm A (Immediate INH Treatment) | 1 |
| Arm B (Deferred INH Treatment) | 0 |
Pharmacokinetic parameter was estimated from population PK modeling fitted to the intensive PK data. AUC0-24h was predicted using population pharmacokinetic model using the NONMEM software program. A 2-compartment model with first-order absorption with transit compartment and first-order elimination with well-stirred liver model to capture hepatic clearance and first-pass extraction with 1 parameter (hepatic intrinsic clearance) was used, (NCT01494038)
Timeframe: Measured at antepartum (third trimester and >= 2 weeks after starting study drug) and week 16 postpartum (+/-) 4 weeks) while on active INH; blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, and 12 hours post-dosing.
| Intervention | hour*mg/L (Mean) | |
|---|---|---|
| Third trimester of pregnancy | Week 16 postpartum | |
| Fast Metabolizers | 38.5 | 46.9 |
| Intermediate Metabolizers | 62.5 | 76.2 |
| Slow Metabolizers | 153.02 | 186 |
Pharmacokinetic parameter was estimated from population PK modeling fitted to the intensive PK data. AUC0-24h was predicted using population pharmacokinetic model using the NONMEM software program. A 2-compartment model with first-order absorption with transit compartment and first-order elimination with well-stirred liver model to capture hepatic clearance and first-pass extraction with 1 parameter (hepatic intrinsic clearance) was used, (NCT01494038)
Timeframe: Measured at antepartum (third trimester and >= 2 weeks after starting study drug) and week 16 postpartum (+/-) 4 weeks) while on active INH; blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, and 12 hours post-dosing.
| Intervention | hour*mg/L (Mean) | |
|---|---|---|
| Third trimester of pregnancy | Week 16 postpartum | |
| Fast Metabolizers | 3.63 | 4.25 |
| Intermediate Metabolizers | 6.55 | 7.67 |
| Slow Metabolizers | 21.6 | 25.3 |
"PK parameters were determined from plasma concentration-time profiles using a nonlinear mixed effects model (version 7.4; ICON PLC, Dublin, Ireland).~• Estimated a single absorption rate constant (ka) for the whole population" (NCT02651259)
Timeframe: Data used in the population PK analysis included the intensive PK visit (pre-dose (t0) and 0.5, 1, 2. 4, 5, 8, 12, 24, 48, 72 hours post-dose) and sparse PK visit (1, 4, 24, 48 hours post-dose).
| Intervention | hr-1 (Mean) |
|---|---|
| All Cohorts | 1.74 |
"PK parameters were determined from plasma concentration-time profiles using a nonlinear mixed effects model (version 7.4; ICON PLC, Dublin, Ireland).~Developed a 1 compartment PK model with transit compartments for oral absorption~Estimated the transit compartment rate constant (ktr), which is synonymous with the absorption constant (ka), for the whole population Note that the mean stated below is actually the value that is obtained from a population analysis and represents a population estimate" (NCT02651259)
Timeframe: Data used in the population PK analysis included the intensive PK visit (pre-dose (t0) and 0.5, 1, 2. 4, 5, 8, 12, 24, 48, 72 hours post-dose) and sparse PK visit (1, 4, 24, 48 hours post-dose).
| Intervention | hr-1 (Mean) |
|---|---|
| All Cohorts | 1.43 |
"PK parameters from postpartum women were determined from plasma concentration-time profiles using a nonlinear mixed effects model (version 7.4; ICON PLC, Dublin, Ireland).~Developed a 1 compartment PK model with transit compartments for oral absorption~Calculated an average CL for all post-partum individuals" (NCT02651259)
Timeframe: Data used in the population PK analysis for postpartum women included the intensive PK visit (pre-dose (t0) and 0.5, 1, 2. 4, 5, 8, 12, 24, 48, 72 hours post-dose) and sparse PK visit (1, 4, 24, 48 hours post-dose).
| Intervention | L/hr (Mean) |
|---|---|
| All Cohorts | 1.64 |
"PK parameters were determined from plasma concentration-time profiles using a nonlinear mixed effects model (version 7.4; ICON PLC, Dublin, Ireland).~Developed a 1 compartment PK model with transit compartments for oral absorption~Calculated an average CL for all women in the 2nd trimester (cohort I) and all women in the 3rd trimester (cohort II)" (NCT02651259)
Timeframe: Data used in the population PK analysis included the intensive PK visit (pre-dose (t0) and 0.5, 1, 2. 4, 5, 8, 12, 24, 48, 72 hours post-dose) and sparse PK visit (1, 4, 24, 48 hours post-dose).
| Intervention | L/hr (Mean) |
|---|---|
| Cohort 1 (Pregnant Women Enrolled in the Second Trimester) | 1.4 |
| Cohort 2 (Pregnant Women Enrolled in the Third Trimester) | 1.50 |
"PK parameters were determined from plasma concentration-time profiles using a nonlinear mixed effects model (version 7.4; ICON PLC, Dublin, Ireland).~Developed a 1 compartment PK model with transit compartments for oral absorption and a separate compartment for metabolite formation~Estimated a single des-RPT CLmet/F for the whole population Note: that the mean stated below is actually the value that is obtained from a population analysis and represents a population estimate with the relative standard error" (NCT02651259)
Timeframe: Data used in the population PK analysis included the intensive PK visit (pre-dose (t0) and 0.5, 1, 2. 4, 5, 8, 12, 24, 48, 72 hours post-dose) and sparse PK visit (1, 4, 24, 48 hours post-dose).
| Intervention | L/hr (Mean) |
|---|---|
| All Cohorts | 2.82 |
Cord blood concentrations were summarized using using R (version 3.5.1). (NCT02651259)
Timeframe: at delivery (within 3 days of life for infants).
| Intervention | mcg/mL (Mean) |
|---|---|
| All Cohorts | 3.24 |
Cord blood concentrations were summarized using using R (version 3.5.1). (NCT02651259)
Timeframe: at delivery - (within 3 days of life for infants)
| Intervention | mcg/mL (Mean) |
|---|---|
| All Cohorts | 2.97 |
At entry and follow-up, all lab results, sign and symptoms, and diagnoses were recorded. Also, during follow-up grade 2 events related to pregnancy complications, hepatotoxicity, hemorrhage, or peripheral neuropathy, and all grade 3 or events that resulted in discontinuation of study drug regimen, and that met criteria for EAE reporting would further be evaluated and recorded. The DAIDS Table for Grading Adult and Pediatric Adverse Events (V 2.0) and Expedited AE Manual (V 2.0) were used. (NCT02651259)
Timeframe: Measured from entry through participants' last study visit at 24 weeks after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Cohort 1 (Pregnant Women Enrolled in the Second Trimester) | 0 |
| Cohort 2 (Pregnant Women Enrolled in the Third Trimester) | 0 |
Based on site-specified confirmatory TB test. If women and infants were diagnosed with active TB during study they would be referred to local care for TB management and treatment. (NCT02651259)
Timeframe: Measured from birth through participants' last study visit at 24 weeks after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Cohort 1(Infants Born to Women Enrolled in Second Trimester) | 0 |
| Cohort 2 (Infants Born to Women Enrolled in Third Trimester) | 0 |
Based on site-specified confirmatory TB test. If women and infants were diagnosed with active TB during study they would be referred to local care for TB management and treatment. (NCT02651259)
Timeframe: Measured from study entry through participants' last study visit at 24 weeks after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Cohort 1 (Pregnant Women Enrolled in the Second Trimester) | 0 |
| Cohort 2 (Pregnant Women Enrolled in the Third Trimester) | 0 |
At entry and follow-up, all lab results, sign and symptoms, and diagnoses will be recorded. Also, during follow-up grade 2 events related to pregnancy complications, hepatotoxicity, hemorrhage, or peripheral neuropathy, and all grade 3 or events that result in discontinuation of study drug regimen, and that meet criteria for EAE reporting will be further evaluated and recorded. The DAIDS Table for Grading Adult and Pediatric Adverse Events (V 2.0) and Expedited AE Manual (V 2.0) were used. (NCT02651259)
Timeframe: Measured from study entry through participants' last study visit at 24 weeks after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Cohort 1 (Pregnant Women Enrolled in the Second Trimester) | 0 |
| Cohort 2 (Pregnant Women Enrolled in the Third Trimester) | 0 |
At entry and follow-up, all lab results, sign and symptoms, and diagnoses were recorded. Also, during follow-up grade 2 events related to pregnancy complications, hepatotoxicity, hemorrhage, or peripheral neuropathy, and all grade 3 or events that resulted in discontinuation of study drug regimen, and that met criteria for EAE reporting would further be evaluated and recorded. The DAIDS Table for Grading Adult and Pediatric Adverse Events (V 2.0) and Expedited AE Manual (V 2.0) were used. (NCT02651259)
Timeframe: Measured from study entry through participants' last study treatment dispensation (approximately for 12 weeks)
| Intervention | percent of participants (Number) |
|---|---|
| Cohort 1 (Pregnant Women Enrolled in the Second Trimester) | 0 |
| Cohort 2 (Pregnant Women Enrolled in the Third Trimester) | 0 |
At entry and follow-up, all lab results, sign and symptoms, and diagnoses were recorded. Also, during follow-up grade 2 events related to pregnancy complications, hepatotoxicity, hemorrhage, or peripheral neuropathy, and all grade 3 or events that resulted in discontinuation of study drug regimen, and that met criteria for EAE reporting would further be evaluated and recorded. The DAIDS Table for Grading Adult and Pediatric Adverse Events (V 2.0) and Expedited AE Manual (V 2.0) were used. (NCT02651259)
Timeframe: Measured from study entry through participants' last study visit at 24 weeks after delivery
| Intervention | percent of participants (Number) |
|---|---|
| Cohort 1 (Pregnant Women Enrolled in the Second Trimester) | 20 |
| Cohort 2 (Pregnant Women Enrolled in the Third Trimester) | 16 |
At entry and follow-up, all lab results, sign and symptoms, and diagnoses were recorded. Also, during follow-up grade 2 events related to pregnancy complications, hepatotoxicity, hemorrhage, or peripheral neuropathy, and all grade 3 or events that resulted in discontinuation of study drug regimen, and that met criteria for EAE reporting would further be evaluated and recorded. The DAIDS Table for Grading Adult and Pediatric Adverse Events (V 2.0) and Expedited AE Manual (V 2.0) were used. (NCT02651259)
Timeframe: Measured from study entry through participants' last study visit at 24 weeks after delivery
| Intervention | percent of participants (Number) |
|---|---|
| Cohort 1 (Pregnant Women Enrolled in the Second Trimester) | 8 |
| Cohort 2 (Pregnant Women Enrolled in the Third Trimester) | 12 |
At entry and follow-up, all lab results, sign and symptoms, and diagnoses were recorded. Also, during follow-up grade 2 events related to pregnancy complications, hepatotoxicity, hemorrhage, or peripheral neuropathy, and all grade 3 or events that resulted in discontinuation of study drug regimen, and that met criteria for EAE reporting would further be evaluated and recorded. The DAIDS Table for Grading Adult and Pediatric Adverse Events (V 2.0) and Expedited AE Manual (V 2.0) and were used. (NCT02651259)
Timeframe: Measured from study entry through participants' last study visit at 24 weeks after delivery
| Intervention | percent of participants (Number) |
|---|---|
| Cohort 1 (Pregnant Women Enrolled in the Second Trimester) | 4 |
| Cohort 2 (Pregnant Women Enrolled in the Third Trimester) | 0 |
At entry and follow-up, all lab results, sign and symptoms, and diagnoses were recorded. Also, during follow-up grade 2 events related to pregnancy complications, hepatotoxicity, hemorrhage, or peripheral neuropathy, and all grade 3 or events that resulted in discontinuation of study drug regimen, and that met criteria for EAE reporting would further be evaluated and recorded. The DAIDS Table for Grading Adult and Pediatric Adverse Events (V 2.0) and Expedited AE Manual (V 2.0) were used. (NCT02651259)
Timeframe: Measured from birth through infants' last study visit at 24 weeks after birth
| Intervention | percent of participants (Number) |
|---|---|
| Cohort 1 (Infants Born to Women Enrolled in Second Trimester) | 0 |
| Cohort 2 (Infants Born to Women Enrolled in Third Trimester) | 0 |
Plasma blood concentrations were summarized using using R (version 3.5.1). (NCT02651259)
Timeframe: at delivery - (within 3 days of life for infants).
| Intervention | mcg/mL (Mean) |
|---|---|
| All Cohorts | 5.31 |
Plasma concentrations were summarized using using R (version 3.5.1). (NCT02651259)
Timeframe: at delivery - (within 3 days of life for infants).
| Intervention | mcg/mL (Mean) |
|---|---|
| All Cohorts | 2.47 |
"PK parameters were determined from plasma concentration-time profiles using a nonlinear mixed effects model (version 7.4; ICON PLC, Dublin, Ireland).~• Estimated a single INH Vc/F for the whole population" (NCT02651259)
Timeframe: Data used in the population PK analysis included the intensive PK visit (pre-dose (t0) and 0.5, 1, 2. 4, 5, 8, 12, 24, 48, 72 hours post-dose) and sparse PK visit (1, 4, 24, 48 hours post-dose).
| Intervention | L (Mean) |
|---|---|
| All Cohorts | 107 |
"PK parameters were determined from plasma concentration-time profiles using a nonlinear mixed effects model (version 7.4; ICON PLC, Dublin, Ireland).~Developed a 1 compartment PK model with transit compartments for oral absorption~Estimated a single RPT Vc/F for for the whole population Note: that the mean stated below is actually the value that is obtained from a population analysis and represents a population estimate with the relative standard error" (NCT02651259)
Timeframe: Data used in the population PK analysis included the intensive PK visit (pre-dose (t0) and 0.5, 1, 2. 4, 5, 8, 12, 24, 48, 72 hours post-dose) and sparse PK visit (1, 4, 24, 48 hours post-dose).
| Intervention | L (Mean) |
|---|---|
| All Cohorts | 30.1 |
"PK parameters were determined from plasma concentration-time profiles using a nonlinear mixed effects model (version 7.4; ICON PLC, Dublin, Ireland).~Developed a 1 compartment PK model with transit compartments for oral absorption~Obtained AUC by model-based integration" (NCT02651259)
Timeframe: Data used in the population PK analysis included the intensive PK visit (pre-dose (t0) and 0.5, 1, 2. 4, 5, 8, 12, 24, 48, 72 hours post-dose) and sparse PK visit (1, 4, 24, 48 hours post-dose).
| Intervention | hour*mg/L (Mean) | |
|---|---|---|
| AUC (0-24) for RPT | AUC (0-24) for des-RPT | |
| Cohort 1 (Pregnant Women Enrolled in the Second Trimester) | 424.7 | 158.7 |
| Cohort 2 (Pregnant Women Enrolled in the Third Trimester) | 406.8 | 153.7 |
"PK parameters were determined from plasma concentration-time profiles using a nonlinear mixed effects model (version 7.4; ICON PLC, Dublin, Ireland).~Developed a 1 compartment PK model with 2 mixtures to characterize subpopulations based on acetylation status~Estimated a separate INH CL/F based on acetylation status (fast, slow)" (NCT02651259)
Timeframe: Data used in the population PK analysis included the intensive PK visit (pre-dose (t0) and 0.5, 1, 2. 4, 5, 8, 12, 24, 48, 72 hours post-dose) and sparse PK visit (1, 4, 24, 48 hours post-dose).
| Intervention | L/hr (Mean) | |
|---|---|---|
| CL/F (slow acetylators) | CL/F (fast acetylators) | |
| All Cohorts | 8.98 | 32.7 |
"PK parameters were determined from plasma concentration-time profiles using a nonlinear mixed effects model (version 7.4; ICON PLC, Dublin, Ireland).~Developed a 1 compartment PK model with transit compartments for oral absorption~Obtained Cmax by model-based estimation" (NCT02651259)
Timeframe: Data used in the population PK analysis included the intensive PK visit (pre-dose (t0) and 0.5, 1, 2. 4, 5, 8, 12, 24, 48, 72 hours post-dose) and sparse PK visit (1, 4, 24, 48 hours post-dose).
| Intervention | mg/L (Mean) | |
|---|---|---|
| Cmax for RPT | Cmax for des-RPT | |
| Cohort 1 (Pregnant Women Enrolled in the Second Trimester) | 30.2 | 8.76 |
| Cohort 2 (Pregnant Women Enrolled in the Third Trimester) | 28.6 | 8.50 |
"PK parameters were determined from plasma concentration-time profiles using a nonlinear mixed effects model (version 7.4; ICON PLC, Dublin, Ireland).~Developed a 1 compartment PK model with transit compartments for oral absorption~Obtained Cmin by model-based estimation" (NCT02651259)
Timeframe: Data used in the population PK analysis included the intensive PK visit (pre-dose (t0) and 0.5, 1, 2. 4, 5, 8, 12, 24, 48, 72 hours post-dose) and sparse PK visit (1, 4, 24, 48 hours post-dose).
| Intervention | mg/L (Mean) | |
|---|---|---|
| Cmin for RPT | Cmin for des-RPT | |
| Cohort 1 (Pregnant Women Enrolled in the Second Trimester) | 1.45 | 1.06 |
| Cohort 2 (Pregnant Women Enrolled in the Third Trimester) | 1.58 | 1.20 |
The cumulative percentage of participants having a DMPA concentration less than 0.1 ng/mL at week 12 was calculated using a Kaplan-Meier estimator with an associated standard error. The confidence interval was calculated using a log-log transformation. Suppression of ovulation generally occurs as long as the DMPA level is => 0.1 ng/mL. (NCT02412436)
Timeframe: Weeks 0, 2, 4, 6, 8, 10, and 12
| Intervention | cumulative percentage of participants (Number) |
|---|---|
| Arm A: Depot Medroxyprogesterone Acetate | 11.9 |
Describe the DMPA plasma area under the curve (AUC) between 0 and 12 weeks, where AUC(0-12wks) was calculated using non-compartmental methods.The Week 0 time point was drawn prior to DMPA injection. (NCT02412436)
Timeframe: Weeks 0, 2, 4, 6, 8, 10, and 12
| Intervention | ng*week/mL (Median) |
|---|---|
| Arm A: Depot Medroxyprogesterone Acetate | 7.63 |
Describe the apparent DMPA clearance (CL/F) between 0 and 12 weeks. The Week 0 time point was drawn prior to DMPA injection. (NCT02412436)
Timeframe: Weeks 0, 2, 4, 6, 8, 10, and 12
| Intervention | L/week (Median) |
|---|---|
| Arm A: Depot Medroxyprogesterone Acetate | 19681 |
Describe the DMPA maximum observed concentration (Cmax) between 0 and 12 weeks. The Week 0 time point was drawn prior to DMPA injection. (NCT02412436)
Timeframe: Weeks 0, 2, 4, 6, 8, 10, and 12
| Intervention | ng/mL (Median) |
|---|---|
| Arm A: Depot Medroxyprogesterone Acetate | 1.04 |
Describe the DMPA minimum observed concentration (Cmin) between 0 and 12 weeks. The Week 0 time point was drawn prior to DMPA injection. (NCT02412436)
Timeframe: Weeks 0, 2, 4, 6, 8, 10, and 12
| Intervention | ng/mL (Median) |
|---|---|
| Arm A: Depot Medroxyprogesterone Acetate | 0.33 |
Describe the terminal elimination half-life of DMPA (t½) between 0 and 12 weeks, where t½ was calculated using nonlinear mixed-effects (NLME) modelling. The Week 0 time point was drawn prior to DMPA injection. (NCT02412436)
Timeframe: Weeks 0, 2, 4, 6, 8, 10, and 12
| Intervention | hours (Median) |
|---|---|
| Arm A: Depot Medroxyprogesterone Acetate | 55 |
The percent of participants who experienced a grade 3 (severe) or higher sign/symptom or laboratory abnormality were calculated with an exact Clopper-Pearson 95% confidence interval. Events were graded (1=mild, 2=moderate, 3=severe, 4=life-threatening, 5=death) according to the DAIDS AE Grading Table (V1.0). (NCT02412436)
Timeframe: Weeks 2, 4, 6, 8, 10, and 12
| Intervention | percentage of participants (Number) |
|---|---|
| Arm A: Depot Medroxyprogesterone Acetate | 12.9 |
The percent of participants with plasma DMPA concentrations below 0.1 ng/mL was calculated with an exact Clopper-Pearson 95% confidence interval. Suppression of ovulation generally occurs as long as the DMPA level is => 0.1 ng/mL. (NCT02412436)
Timeframe: Week 12
| Intervention | percentage of participants (Number) |
|---|---|
| Arm A: Depot Medroxyprogesterone Acetate | 11.9 |
The percent of participants with plasma progesterone levels above 1 ng/mL was calculated with an exact Clopper-Pearson 95% confidence interval. Ovulation generally occurs when the progesterone level is > 5 ng/mL. If there were participants with plasma progesterone levels > 1 ng/mL, then the percent of participants with plasma progesterone levels > 5 ng/mL would have been calculated by study week. (NCT02412436)
Timeframe: Week 12
| Intervention | percentage of participants (Number) |
|---|---|
| Arm A: Depot Medroxyprogesterone Acetate | 0.0 |
Describe the time at which DMPA levels drop below the threshold of 0.1 ng/mL, based on participant-specific estimated elimination slopes from nonlinear mixed-effects (NLME) models. The Week 0 time point was drawn prior to DMPA injection. (NCT02412436)
Timeframe: Weeks 0, 2, 4, 6, 8, 10, and 12
| Intervention | days (Median) |
|---|---|
| Arm A: Depot Medroxyprogesterone Acetate | 74.2 |
The percents of participants with plasma DMPA concentrations below 0.1 ng/mL at weeks 2, 4, 6, 8, and 10 were calculated with exact Clopper-Pearson 95% confidence intervals. Suppression of ovulation generally occurs as long as the DMPA level is => 0.1 ng/mL. (NCT02412436)
Timeframe: Weeks 2, 4, 6, 8, and 10
| Intervention | percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Week 2 DMPA < 0.1 ng/mL | Week 4 DMPA < 0.1 ng/mL | Week 6 DMPA < 0.1 ng/mL | Week 8 DMPA < 0.1 ng/mL | Week 10 DMPA < 0.1 ng/mL | |
| Arm A: Depot Medroxyprogesterone Acetate | 0.0 | 0.0 | 0.0 | 0.0 | 2.4 |
Number of patients with adherence to PrEP treatment (self reported adherence at >=1 visit) (NCT01864603)
Timeframe: 3 years follow up
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention | 3282 |
HIV+ adults with on- and off-farm employment (NCT01864603)
Timeframe: 3 years follow up
| Intervention | cumulative events per 100 persons (Mean) |
|---|---|
| Intervention | 85.5 |
| Control | 82.4 |
"Cumulative 3 year HIV incidence in men and women ages ≥15 years after the start of Phase I intervention.~Mean was calculated as the average across clusters of the cluster-level cumulative incidence." (NCT01864603)
Timeframe: 3 years follow up
| Intervention | cumulative events per 100 persons (Mean) |
|---|---|
| Intervention | 0.77 |
| Control | 0.81 |
Proportion of baseline HIV+ ART-naive persons who initiate ART Mean was calculated as the average across clusters of the cluster-level cumulative incidence. (NCT01864603)
Timeframe: 3 years follow up
| Intervention | cumulative events per 100 persons (Mean) |
|---|---|
| Intervention | 83 |
| Control | 50 |
HIV incidence rate in men and women ages ≥15 years after the start of Phase II intervention (started after 3 years of Phase I). (NCT01864603)
Timeframe: 3 years follow up
| Intervention | Incident HIV per 100 person-year (Number) |
|---|---|
| Intervention | 0.35 |
| Control | 0.92 |
HIV incidence rates during the first and third year of follow up; Results from the Control arm are not provided because annual HIV incidence was not measured in the control arm (annual HIV testing was only conducted in the intervention arm). (NCT01864603)
Timeframe: 3 years follow up
| Intervention | per 100 person-years (Number) |
|---|---|
| Intervention Year 1 | 0.43 |
| Intervention Year 3 | 0.31 |
"Probability of an infant born to an HIV+ mother remaining alive and HIV uninfected.~Mean was calculated as the average across clusters of the cluster-level cumulative incidence." (NCT01864603)
Timeframe: 3 years follow up
| Intervention | cumulative events per 100 persons (Mean) |
|---|---|
| Intervention | 96.7 |
| Control | 93.6 |
"hypertension control (greater than or equal to 140 mg Hg systolic or 90 mg Hg diastolic after 3 repeated readings) at year 3 among adults aged >= 30 years with hypertension.~Mean was calculated as the average across clusters of the cluster-level cumulative incidence." (NCT01864603)
Timeframe: 3 years follow up
| Intervention | cumulative events per 100 persons (Mean) |
|---|---|
| Intervention | 47 |
| Control | 37 |
Cumulative incidence of TB or death due to illness among HIV+ population. Mean was calculated as the average across clusters of the cluster-level cumulative incidence. (NCT01864603)
Timeframe: 3 years follow up
| Intervention | cumulative events per 100 persons (Mean) |
|---|---|
| Intervention | 3.7 |
| Control | 4.6 |
Proportion of Persons Attending an HIV Clinic Visit by 30 Days After HIV Test Mean was calculated as the average across clusters of the cluster-level cumulative incidence. (NCT01864603)
Timeframe: 30 days after HIV test
| Intervention | cumulative events per 100 persons (Mean) |
|---|---|
| Intervention | 41 |
| Control | 24 |
Mortality risk among HIV+ population. Mean was calculated as the average across clusters of the cluster-level cumulative incidence. (NCT01864603)
Timeframe: 3 years follow up
| Intervention | cumulative events per 100 persons (Mean) |
|---|---|
| Intervention | 3.0 |
| Control | 3.9 |
Percent of HIV+ adults with HIV RNA <=500 c/mL. Mean was calculated as the average across clusters of the cluster-level cumulative incidence. (NCT01864603)
Timeframe: 3 years follow up
| Intervention | cumulative events per 100 persons (Mean) |
|---|---|
| Intervention | 79 |
| Control | 68 |
Percentage of participants with chronic kidney disease (CKD) (NCT01864603)
Timeframe: 3 years follow up
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention | 361 |
| Control | 248 |
HIV NNRTI drug-resistance mutations found at baseline (NCT01864603)
Timeframe: Baseline
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention | 8 |
| Control | 11 |
Percent of time spent actively engaged in HIV care among HIV+ adults with baseline viremia (NCT01864603)
Timeframe: 3 years follow up
| Intervention | percentage of days (Mean) |
|---|---|
| Intervention | 81 |
| Control | 73 |
Cost of ART streamlined care delivery amount HIV+ persons (NCT01864603)
Timeframe: Follow up year 3
| Intervention | USD per person year (Mean) |
|---|---|
| Intervention | 291 |
| Control | 221 |
Plasma HIV RNA <400 cps/ml Mean was calculated as the average across clusters of the cluster-level cumulative incidence. (NCT01864603)
Timeframe: 3 years follow up
| Intervention | cumulative events per 100 persons (Mean) |
|---|---|
| Intervention | 67 |
| Control | 47 |
The Kaplan-Meier estimate of cumulative probability of death by week 24 (NCT01380080)
Timeframe: From study entry to week 24
| Intervention | Cumulative probability per 100 persons (Number) |
|---|---|
| Arm A: Empiric | 4.8 |
| Arm B: IPT | 5.2 |
The Kaplan-Meier estimate of the cumulative probability of death or AIDS progression by week 24. AIDS progression was defined as new WHO stage 3 or 4 conditions occurred after study entry. (NCT01380080)
Timeframe: From study entry to week 24
| Intervention | Cumulative probability per 100 persons (Number) |
|---|---|
| Arm A: Empiric | 17.1 |
| Arm B: IPT | 12.5 |
The Kaplan-Meier estimate of the cumulative probability of death or AIDS progression by week 48. AIDS progression was defined as new WHO stage 3 or 4 conditions occurred after study entry. (NCT01380080)
Timeframe: From study entry to week 48
| Intervention | Cumulative probability per 100 persons (Number) |
|---|---|
| Arm A: Empiric | 19.3 |
| Arm B: IPT | 15.3 |
"The Kaplan-Meier estimate of the cumulative probability of death or unknown vital status by week 24.~The vital status was considered unknown at week 24 if a participant prematurely discontinued from the study before week 24 and no vital status was obtained at week 48." (NCT01380080)
Timeframe: From study entry to week 24
| Intervention | Cumulative probability per 100 persons (Number) |
|---|---|
| Arm A: Empiric | 5.2 |
| Arm B: IPT | 5.2 |
The Kaplan-Meier estimate of the cumulative probability of first AIDS progression which was defined as the identification of a new World Health Organization (WHO) stage 3 or 4 condition (NCT01380080)
Timeframe: From study entry to week 96
| Intervention | Cumulative probability per 100 persons (Number) |
|---|---|
| Arm A: Empiric | 16.6 |
| Arm B: IPT | 11.3 |
Proportion of participants with premature discontinuation of antiretroviral therapy (ART) by Week 48 (NCT01380080)
Timeframe: From study entry to week 48
| Intervention | Proportion of participants (Number) |
|---|---|
| Arm A: Empiric | 0.19 |
| Arm B: IPT | 0.21 |
Proportion of participants with premature discontinuation of any component of TB treatment by Week 48 (NCT01380080)
Timeframe: From study entry to week 48
| Intervention | Proportion of participants (Number) |
|---|---|
| Arm A: Empiric | 0.13 |
| Arm B: IPT | 0.05 |
Proportion of participants with at least one new Grade 3 or 4 laboratory or sign or symptom that is at least a one-grade increase from baseline by Week 48. Grade 3=Severe, Grade 4=Life-Threatening according to DAIDS AE Grading Table (see references). (NCT01380080)
Timeframe: From study entry to week 48
| Intervention | Proportion of participants (Number) |
|---|---|
| Arm A: Empiric | 0.32 |
| Arm B: IPT | 0.30 |
"Proportion of participants with at least one new Grade 3 or 4 that is at least a one-grade increase from baseline for the following targeted laboratory values by Week 48~The targeted laboratory events include hemoglobin, serum creatinine, ALT and AST" (NCT01380080)
Timeframe: From study entry to week 48. The lab events were collected at study entry, weeks 2, 4, 8, 12, 16, 20, 24, and 48.
| Intervention | Proportion of participants (Number) |
|---|---|
| Arm A: Empiric | 0.11 |
| Arm B: IPT | 0.13 |
Proportion of participants with IRIS (using current ACTG definition Appendix 60, see References) by Week 48. IRIS in participants with TB and other opportunistic infections may occur shortly after the initiation of potent combination ART, particularly in participants with advanced HIV disease. (NCT01380080)
Timeframe: From study entry to week 48
| Intervention | Proportion of participants (Number) |
|---|---|
| Arm A: Empiric | 0.04 |
| Arm B: IPT | 0.05 |
Proportion of participants with reportable hospitalization reported by Week 48 (NCT01380080)
Timeframe: From study entry to week 48
| Intervention | Proportion of participants (Number) |
|---|---|
| Arm A: Empiric | 0.10 |
| Arm B: IPT | 0.12 |
Proportion of participants with TB diagnosis per current ACTG Diagnosis Appendix 60 by week 96 (NCT01380080)
Timeframe: From study entry to week 96
| Intervention | Proportion of participants (Number) |
|---|---|
| Arm A: Empiric | 0.08 |
| Arm B: IPT | 0.05 |
Median time to TB treatment initiation since study entry (NCT01380080)
Timeframe: From study entry to week 96
| Intervention | Days (Median) |
|---|---|
| Arm A: Empiric | 0 |
| Arm B: IPT | 0 |
The absolute levels of CD4+ T-cell counts (cells/mm^3) (NCT01380080)
Timeframe: At weeks 0, 4, 24, and 48
| Intervention | cells/ mm^3 (Median) | |||
|---|---|---|---|---|
| Week 0 | Week 4 | Week 24 | Week 48 | |
| Arm A: Empiric | 18 | 74 | 121 | 176 |
| Arm B: IPT | 19 | 76 | 121 | 172 |
Change was calculated as the CD4+ T-cell count at the later weeks (4, 24 and 48) minus the baseline (week 0) CD4+ T-cell count. (NCT01380080)
Timeframe: Weeks 0, 4, 24 and 48
| Intervention | cells/ mm^3 (Median) | ||
|---|---|---|---|
| Week 4 | Week 24 | Week 48 | |
| Arm A: Empiric | 49 | 96 | 158 |
| Arm B: IPT | 54 | 102 | 146 |
Proportion of participants with HIV-1 RNA level <400 copies/mL. (NCT01380080)
Timeframe: At weeks 0, 4, 24, and 48
| Intervention | Proportion of participants (Number) | |||
|---|---|---|---|---|
| Week 0 | Week 4 | Week 24 | Week 48 | |
| Arm A: Empiric | 0 | 0.46 | 0.84 | 0.87 |
| Arm B: IPT | 0.01 | 0.49 | 0.85 | 0.89 |
Cumulative TB disease rate was defined as number of participants (regardless of age) with culture-confirmed TB disease (defined as positive culture for MTB]) or probable (clinical) TB disease (defined as objective evidence of clinical TB disease [cough, fever, night sweats, weight loss, or hemoptysis] based on history or physical exam plus radiograph, CT scan, other diagnostic tests PLUS response to antituberculosis therapy AND objective improvement of radiograph or other diagnostic tests; OR evidence of granuloma with organism positive for AFB, or caseating granulomata at autopsy or biopsy) between enrollment and the 990th Day of the Trial (33 months after enrollment, or end of the trial) per 100 participants w/33 months of follow-up and was calculated using survival analysis methods (Kaplan-Meier approach). (NCT00023452)
Timeframe: Baseline up to 33 Months
| Intervention | TB cases per 100 participants w/followup (Number) |
|---|---|
| 9INH | 0.49 |
| 3RPT/INH | 0.24 |
Cumulative TB disease rate was defined as number of participants ≥18 years old with culture-confirmed TB disease (defined as positive culture for MTB) and <18 years old with probable (clinical) TB disease (defined as objective evidence of clinical TB disease [cough, fever, night sweats, weight loss, or hemoptysis] based on history or physical exam plus radiograph, CT scan, other diagnostic tests PLUS response to antituberculosis therapy AND objective improvement of radiograph or other diagnostic tests; OR evidence of granuloma with organism positive for AFB], or caseating granulomata at autopsy or biopsy) between enrollment and 33 months after enrollment (for those who completed therapy within 33 months) per 100 participants w/33 months of follow-up and was calculated using survival analysis methods (Kaplan-Meier approach). (NCT00023452)
Timeframe: Baseline up to Month 33
| Intervention | TB cases per 100 participants w/followup (Number) |
|---|---|
| 9INH | 0.11 |
| 3RPT/INH | 0.05 |
Cumulative TB disease rate was defined as number of participants ≥18 years old with culture-confirmed TB disease (defined as positive culture for MTB) and those <18 years old with probable (clinical) TB disease (defined as objective evidence of clinical TB disease [cough, fever, night sweats, weight loss, or hemoptysis] based on history or physical exam plus radiograph, CT scan, other diagnostic tests PLUS response to antituberculosis therapy AND objective improvement of radiograph or other diagnostic tests; OR evidence of granuloma with organism positive for AFB], or caseating granulomata at autopsy or biopsy) between enrollment and 24 months after completion of study therapy per 100 participants with up to 33 months of follow-up and was calculated using survival analysis methods (Kaplan-Meier approach). (NCT00023452)
Timeframe: Baseline up to Month 27 (3RPT/INH) or Month 33 (9INH)
| Intervention | TB cases per 100 participants w/followup (Number) |
|---|---|
| 9INH | 0.37 |
| 3RPT/INH | 0.16 |
Cumulative TB disease rate defined as number of participants ≥18 years old with culture-confirmed TB disease (defined as positive culture for Mycobacterium tuberculosis [MTB]) and those <18 years old with probable (clinical) TB disease (defined as objective evidence of clinical TB disease [cough, fever, night sweats, weight loss, or hemoptysis] based on history or physical exam plus radiograph, computed tomography [CT] scan, other diagnostic tests PLUS response to antituberculosis therapy AND objective improvement of radiograph or other diagnostic tests; OR evidence of granuloma with organism positive for acid-fast bacilli [AFB], or caseating granulomata at autopsy or biopsy) between enrollment and the 990th Day of the Trial (33 months after enrollment, or end of the trial) per 100 participants with (w/)33 months of follow-up calculated using survival analysis methods (Kaplan-Meier approach). (NCT00023452)
Timeframe: Baseline up to Month 33
| Intervention | TB cases per 100 participants w/followup (Number) |
|---|---|
| 9INH | 0.43 |
| 3RPT/INH | 0.19 |
Completion in the 3RPT/INH arm was defined as: received 12 doses of RPT/INH within 16 weeks (12 weeks optimal). However, participants were considered to have completed therapy if at least 11 doses of RPT/INH had been received (~90%) during the 16-week time period. Completion in the 9INH arm was defined as: received 270 doses of INH within 52 weeks (39 weeks optimal). However, participants were considered to have completed therapy if at least 240 doses of INH were received (~90%) during the 52-week period. (NCT00023452)
Timeframe: Baseline up to Month 3 (3RPT/INH) or Month 9 (9INH)
| Intervention | percentage of participants (Number) |
|---|---|
| 9INH | 69.0 |
| 3RPT/INH | 82.1 |
(NCT00023452)
Timeframe: Baseline up to Month 35
| Intervention | percentage of participants (Number) |
|---|---|
| 9INH | 1.0 |
| 3RPT/INH | 0.8 |
Discontinuation of study drug due to an adverse drug reaction associated with either 3RPT/INH or 9INH was defined as discontinuing treatment and/or study due to a treatment-related adverse event (AE) (considered either possibly, probably, or definitely related to the study drug by the investigator). (NCT00023452)
Timeframe: Baseline up to 60 days after the last dose of study drug (Month 5 [3RPT/INH] or Month 11 [9INH])
| Intervention | percentage of participants (Number) |
|---|---|
| 9INH | 3.8 |
| 3RPT/INH | 4.9 |
Drug discontinuations for any reason associated with 3RPT/INH or 9INH included all reasons for discontinuation from study treatment, regardless of relationship to treatment. (NCT00023452)
Timeframe: Baseline up to Month 3 (3RPT/INH) or Month 9 (9INH)
| Intervention | percentage of participants (Number) |
|---|---|
| 9INH | 31.0 |
| 3RPT/INH | 17.9 |
Drug-susceptibility testing (DST) was performed on isolates of MTB obtained from participants who developed signs and symptoms of active TB disease (including sputum specimens or specimens from appropriate body site for extrapulmonary TB disease). DST was performed at site's local laboratory and sent to Sponsor for confirmatory susceptibility testing. DST included all drugs currently used to treat TB disease, including pyrazinamide (PZA) and fluoroquinolones. Susceptibility was tested for other drugs at the Sponsor laboratory at the following concentrations: INH, 0.02, 1.0, and 5.0 micrograms per milliliter (µg/mL) and rifampin (RIF), 1.0 µg/mL. Isolates resistant to RIF were assumed to be resistant to RPT. (NCT00023452)
Timeframe: Baseline up to Month 33
| Intervention | percentage of participants (Number) | |
|---|---|---|
| INH monoresistance | RIF and PZA resistant | |
| 3RPT/INH | 0 | 14 |
| 9INH | 15 | 0 |
Drug toxicities (or AEs) were graded using Common Toxicity Criteria (CTC version 2.0, Publish Date April 30, 1999, Cancer Therapy Evaluation Program). Grade 3 and 4 drug toxicities associated with 3RPT/INH or 9INH were defined as treatment-related Grade 3 or 4 AEs (considered either possibly, probably, or definitely related to the study drug by the investigator). (NCT00023452)
Timeframe: Baseline up to 60 days after the last dose of study drug (Month 5 [3RPT/INH] or Month 11 [9INH])
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Grade 3 | Grade 4 | |
| 3RPT/INH | 2.7 | 0.4 |
| 9INH | 2.2 | 0.4 |
Number of participants who had a Quantiferon TB Gold Plus (QIAGEN®) score greater than or equal to 0.35 international units per milliliter, at the time of the premature exclusion visit, on all participants in the group. (NCT03028129)
Timeframe: up to 6 months
| Intervention | participants (Number) |
|---|---|
| Treatment | 49 |
| Control | 77 |
Deaths from any cause were included. Results report percent of participants dying by week 96 calculated using the Kaplan-Meier method. (NCT00080119)
Timeframe: Through to week 96
| Intervention | Percent of participants (Number) |
|---|---|
| HIVneg/INH | 0.8 |
| HIVneg/PL | 0.8 |
| HIVpos/INH | 11.6 |
| HIVpos/PL | 7.2 |
Criteria for diagnosis with TB disease were: Definite-isolation of M.tb or positive stain on CSF; Probable-positive AFB stain on fluids/tissues other than CSF and sufficient clinical criteria/radiographic evidence suggestive of TB; Possible-abnormal chest radiograph suggestive of PTB and either a +ve TST or minimum score on algorithm to diagnose clinical TB. All records were reviewed by an Endpoint Review Group to verify that participants had met the criteria for TB disease. Results report percent of participants reaching TB disease/death by week 96 calculated using the Kaplan-Meier method. (NCT00080119)
Timeframe: Through to week 96
| Intervention | Percent of participants (Number) |
|---|---|
| HIVneg/INH | 7.8 |
| HIVneg/PL | 8.5 |
| HIVpos/INH | 20.3 |
| HIVpos/PL | 23.7 |
Criteria for diagnosis with TB disease were: Definite-isolation of M.tb or positive stain on CSF; Probable-positive AFB stain on fluids/tissues other than CSF and sufficient clinical criteria/radiographic evidence suggestive of TB; Possible-abnormal chest radiograph suggestive of PTB and either a +ve TST or minimum score on algorithm to diagnose clinical TB. All records were reviewed by an Endpoint Review Group to verify that participants had met the criteria for TB disease. Results report percent of participants reaching TB disease/death by week 96 calculated using the Kaplan-Meier method. (NCT00080119)
Timeframe: Through to week 96
| Intervention | Percent of participants (Number) |
|---|---|
| HIVneg/INH | 8.3 |
| HIVneg/PL | 9.1 |
Criteria for diagnosis with TB infection were outlined in the protocol. TB infection included TB disease (see primary outcome measure 1 for definition) and latent TB infection. Latent TB infection was diagnosed by a positive TST based on a PPD performed at week 96. Participant records were reviewed by an Endpoint Review Group to verify that participants had met the criteria for TB infection. Results report percent of participants reaching TB infection by week 96 calculated using the Kaplan-Meier method. (NCT00080119)
Timeframe: Through to week 96
| Intervention | Percent of participants (Number) |
|---|---|
| HIVneg/INH | 10.4 |
| HIVneg/PL | 12.1 |
| HIVpos/INH | 22.4 |
| HIVpos/PL | 27.9 |
Criteria for diagnosis with TB infection were outlined in the protocol. TB infection included TB disease (see primary outcome measure 1 for definition) and latent TB infection. Latent TB infection was diagnosed by a positive TST based on a PPD performed at week 96. Participant records were reviewed by an Endpoint Review Group to verify that participants had met the criteria for TB infection. Results report percent of participants reaching TB infection or death by week 96 calculated using the Kaplan-Meier method. (NCT00080119)
Timeframe: Through to week 96
| Intervention | Percent of participants (Number) |
|---|---|
| HIVpos/INH | 29.4 |
| HIVpos/PL | 32.8 |
Criteria for diagnosis with TB infection were outlined in the protocol. TB infection included TB disease (see primary outcome measure 1 for definition) and latent TB infection. Latent TB infection was diagnosed by a positive tuberculin skin test (TST) based on a purified protein derivative (PPD) performed at week 96. Participant records were reviewed by an Endpoint Review Group to verify that participants had met the criteria for TB infection. Results report percent of participants reaching TB infection or death by week 96 calculated using the Kaplan-Meier method. (NCT00080119)
Timeframe: Through to week 96
| Intervention | Percent of participants (Number) |
|---|---|
| HIVneg/INH | 10.9 |
| HIVneg/PL | 12.6 |
HIV disease progression was defined as any advancement in Centers for Disease Control (CDC) disease category from entry or death. If a participant was CDC disease category C at entry progression was defined as death. Results report percent of participants with HIV progression or death by week 96 calculated using the Kaplan-Meier method. (NCT00080119)
Timeframe: Through to week 96
| Intervention | Percent of participants (Number) |
|---|---|
| HIVpos/INH | 30.6 |
| HIVpos/PL | 22.5 |
Criteria for diagnosis with TB disease: Definite-isolation of Mycobacterium TB (M.tb) or +ve stain on cerebrospinal fluid (CSF); Probable- +ve acid fast bacilli (AFB) stain on fluids/tissues other than CSF and sufficient clinical criteria/radiographic evidence suggestive of TB; Possible-abnormal chest radiograph suggestive of pulmonary TB (PTB) and either a +ve tuberculin skin test (TST) or minimum score on algorithm for clinical TB. Records reviewed by Endpoint Review Group. Results report percent of participants reaching TB disease/death by week 96 calculated using the Kaplan-Meier method. (NCT00080119)
Timeframe: Through to week 96
| Intervention | Percent of participants (Number) |
|---|---|
| HIVpos/INH | 27.4 |
| HIVpos/PL | 28.9 |
Signs, symptoms and laboratory values were graded according to the Division of AIDS Adverse Event Grading System. Any event of grade 3 or higher not present at entry that occurred after randomization was classified as a new event. Results report percent of participants with a new event by week 96 calculated using the Kaplan-Meier method. (NCT00080119)
Timeframe: Through to week 96
| Intervention | Percent of participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| New >=grade 3 sign/symptom | New >= grade 3 peripheral neuropathy | New >=grade 3 lab abnormality | New >=grade 3 hemoglobin | New >=grade 3 ANC | New >=grade 3 platelets | New >=grade 3 SGOT | New >=grade 3 SGPT | |
| HIVneg/INH | 5.0 | 1.1 | 4.9 | 0.0 | 1.7 | 0.3 | 1.0 | 2.8 |
| HIVneg/PL | 4.2 | 0.3 | 4.6 | 0.0 | 0.3 | 0.0 | 2.8 | 4.4 |
| HIVpos/INH | 16.8 | 2.4 | 11.3 | 1.8 | 1.6 | 1.7 | 0.4 | 5.9 |
| HIVpos/PL | 11.7 | 0.8 | 10.1 | 1.2 | 3.5 | 0.9 | 2.5 | 4.0 |
81 reviews available for isoniazid and HIV Coinfection
| Article | Year |
|---|---|
Tuberculosis preventive therapy for people living with HIV: A systematic review and network meta-analysis.
Topics: Adolescent; Adult; Aged; Anti-Retroviral Agents; Antitubercular Agents; Child; Child, Preschool; Coi | 2021 |
[Primary isoniazid preventive therapy : A strategy still relevant in the era of test and treat ; literature review].
Topics: Anti-Retroviral Agents; Antitubercular Agents; HIV Infections; Humans; Isoniazid; Randomized Control | 2022 |
Efficacy, safety, and tolerability of isoniazid preventive therapy for tuberculosis in people living with HIV.
Topics: Antitubercular Agents; HIV Infections; Humans; Isoniazid; Longitudinal Studies; Tuberculosis | 2023 |
Efficacy, safety, and tolerability of isoniazid preventive therapy for tuberculosis in people living with HIV.
Topics: Antitubercular Agents; HIV Infections; Humans; Isoniazid; Longitudinal Studies; Tuberculosis | 2023 |
Efficacy, safety, and tolerability of isoniazid preventive therapy for tuberculosis in people living with HIV.
Topics: Antitubercular Agents; HIV Infections; Humans; Isoniazid; Longitudinal Studies; Tuberculosis | 2023 |
Efficacy, safety, and tolerability of isoniazid preventive therapy for tuberculosis in people living with HIV.
Topics: Antitubercular Agents; HIV Infections; Humans; Isoniazid; Longitudinal Studies; Tuberculosis | 2023 |
Efficacy, safety, and tolerability of isoniazid preventive therapy for tuberculosis in people living with HIV.
Topics: Antitubercular Agents; HIV Infections; Humans; Isoniazid; Longitudinal Studies; Tuberculosis | 2023 |
Efficacy, safety, and tolerability of isoniazid preventive therapy for tuberculosis in people living with HIV.
Topics: Antitubercular Agents; HIV Infections; Humans; Isoniazid; Longitudinal Studies; Tuberculosis | 2023 |
Efficacy, safety, and tolerability of isoniazid preventive therapy for tuberculosis in people living with HIV.
Topics: Antitubercular Agents; HIV Infections; Humans; Isoniazid; Longitudinal Studies; Tuberculosis | 2023 |
Efficacy, safety, and tolerability of isoniazid preventive therapy for tuberculosis in people living with HIV.
Topics: Antitubercular Agents; HIV Infections; Humans; Isoniazid; Longitudinal Studies; Tuberculosis | 2023 |
Efficacy, safety, and tolerability of isoniazid preventive therapy for tuberculosis in people living with HIV.
Topics: Antitubercular Agents; HIV Infections; Humans; Isoniazid; Longitudinal Studies; Tuberculosis | 2023 |
Cost-effectiveness of 3-months isoniazid and rifapentine compared to 9-months isoniazid for latent tuberculosis infection: a systematic review.
Topics: Canada; Cost-Benefit Analysis; HIV Infections; Humans; Isoniazid; Latent Tuberculosis | 2022 |
Cost-effectiveness of 3-months isoniazid and rifapentine compared to 9-months isoniazid for latent tuberculosis infection: a systematic review.
Topics: Canada; Cost-Benefit Analysis; HIV Infections; Humans; Isoniazid; Latent Tuberculosis | 2022 |
Cost-effectiveness of 3-months isoniazid and rifapentine compared to 9-months isoniazid for latent tuberculosis infection: a systematic review.
Topics: Canada; Cost-Benefit Analysis; HIV Infections; Humans; Isoniazid; Latent Tuberculosis | 2022 |
Cost-effectiveness of 3-months isoniazid and rifapentine compared to 9-months isoniazid for latent tuberculosis infection: a systematic review.
Topics: Canada; Cost-Benefit Analysis; HIV Infections; Humans; Isoniazid; Latent Tuberculosis | 2022 |
Effectiveness and Pharmacokinetic Exposures of First-Line Drugs Used to Treat Drug-Susceptible Tuberculosis in Children: A Systematic Review and Meta-Analysis.
Topics: Adolescent; Adult; Antitubercular Agents; Child; Ethambutol; HIV; HIV Infections; Humans; Isoniazid; | 2023 |
Isoniazid Preventive Therapy for Prevention of Tuberculosis among People Living with HIV in Ethiopia: A Systematic Review of Implementation and Impacts.
Topics: Antitubercular Agents; Child; Ethiopia; Female; HIV Infections; Humans; Isoniazid; Tuberculosis | 2022 |
Barriers and Facilitators of Isoniazid Preventive Therapy Implementation among People Living with HIV in Nigeria: A Scoping Review of the Literature.
Topics: Antitubercular Agents; HIV Infections; Humans; Isoniazid; Nigeria; Tuberculosis | 2023 |
Integrating 3HP-based tuberculosis preventive treatment into Zimbabwe's Fast Track HIV treatment model: experiences from a pilot study.
Topics: Adult; Antitubercular Agents; Female; HIV Infections; Humans; Isoniazid; Male; Pilot Projects; Tuber | 2023 |
The incidence rate of tuberculosis and its associated factors among HIV-positive persons in Sub-Saharan Africa: a systematic review and meta-analysis.
Topics: Adult; Africa South of the Sahara; Child; HIV Infections; Humans; Incidence; Isoniazid; Male; Trimet | 2023 |
Treatment for latent tuberculosis infection in low- and middle-income countries: progress and challenges with implementation and scale-up.
Topics: Adolescent; Adult; Antitubercular Agents; Child; Developing Countries; Drug Therapy, Combination; HI | 2020 |
Are We There Yet? Short-Course Regimens in TB and HIV: From Prevention to Treatment of Latent to XDR TB.
Topics: Anti-HIV Agents; Antitubercular Agents; Drug Interactions; Extensively Drug-Resistant Tuberculosis; | 2020 |
Isoniazid preventive therapy plus antiretroviral therapy for the prevention of tuberculosis: a systematic review and meta-analysis of individual participant data.
Topics: Adult; Anti-Retroviral Agents; Antibiotic Prophylaxis; Antitubercular Agents; CD4 Lymphocyte Count; | 2021 |
Pellagra a review exploring causes and mechanisms, including isoniazid-induced pellagra.
Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; HIV Infections; Humans; Isoniazid; Pel | 2021 |
Isoniazid for preventing tuberculosis in HIV-infected children.
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antitubercular Agents; Child; HIV Infections | 2017 |
Isoniazid for the Prevention of Tuberculosis in HIV-Infected Children: A Systematic Review and Meta-Analysis.
Topics: Antitubercular Agents; Child; HIV; HIV Infections; Humans; Isoniazid; Randomized Controlled Trials a | 2018 |
Pharmacokinetics of efavirenz in patients on antituberculosis treatment in high human immunodeficiency virus and tuberculosis burden countries: A systematic review.
Topics: Africa; Anti-HIV Agents; Antitubercular Agents; Asia; Body Weight; Central Nervous System Diseases; | 2018 |
How can integrated care and research assist in achieving the SDG targets for diabetes, tuberculosis and HIV/AIDS?
Topics: Anti-Retroviral Agents; Antitubercular Agents; Biomedical Research; Delivery of Health Care, Integra | 2018 |
A systematic review of clinical outcomes on the WHO Category II retreatment regimen for tuberculosis.
Topics: Antitubercular Agents; HIV Infections; Humans; Isoniazid; Microbial Sensitivity Tests; Recurrence; R | 2018 |
Pharmacokinetics of First-Line Anti-Tubercular Drugs.
Topics: Age Factors; Antitubercular Agents; Child; Drug Overdose; Ethambutol; Food; Genotype; HIV Infections | 2019 |
The protective effect of isoniazid preventive therapy on tuberculosis incidence among HIV positive patients receiving ART in Ethiopian settings: a meta-analysis.
Topics: Antiretroviral Therapy, Highly Active; Antitubercular Agents; Cohort Studies; Ethiopia; Health Resou | 2019 |
Severe disseminated tuberculosis in HIV-negative refugees.
Topics: Adolescent; Adult; Antibiotics, Antitubercular; Ethambutol; Fluorine Radioisotopes; HIV Infections; | 2019 |
Tuberculosis.
Topics: Antitubercular Agents; BCG Vaccine; HIV Infections; Humans; Isoniazid; Mycobacterium tuberculosis; T | 2013 |
Treatment of latent tuberculosis infection.
Topics: Antitubercular Agents; Disease Progression; Drug Resistance, Bacterial; Drug Therapy, Combination; H | 2013 |
Human immunodeficiency virus-associated tuberculosis: update on prevention and treatment.
Topics: AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Drug Interacti | 2013 |
Drug-resistant tuberculous meningitis.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Bacterial Proteins; Catalase; Child; Coinfection; DNA | 2013 |
Isoniazid preventive therapy in HIV-infected and -uninfected children (0 - 14 years).
Topics: Adolescent; Antitubercular Agents; Child; Child, Preschool; HIV Infections; Humans; Infant; Infant, | 2013 |
Factors associated with adherence to treatment with isoniazid for the prevention of tuberculosis amongst people living with HIV/AIDS: a systematic review of qualitative data.
Topics: Acquired Immunodeficiency Syndrome; Antitubercular Agents; Coinfection; Developing Countries; HIV In | 2014 |
Efficacy of isoniazid prophylactic therapy in prevention of tuberculosis in children: a meta-analysis.
Topics: Adolescent; Antitubercular Agents; Child; Child, Preschool; HIV Infections; Humans; Infant; Isoniazi | 2014 |
Tuberculosis and HIV co-infection in children.
Topics: Child; Coinfection; HIV Infections; Humans; Immune Reconstitution Inflammatory Syndrome; Incidence; | 2014 |
Understanding pharmacokinetics to improve tuberculosis treatment outcome.
Topics: Antitubercular Agents; Diabetes Mellitus; Drug Monitoring; Ethambutol; HIV Infections; Humans; Isoni | 2014 |
Treatment guidelines for latent tuberculosis infection.
Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; HIV Infections; Humans; Immunosuppress | 2014 |
Interventions to improve delivery of isoniazid preventive therapy: an overview of systematic reviews.
Topics: Antitubercular Agents; Health Personnel; HIV Infections; Humans; Isoniazid; Medication Adherence; Tu | 2014 |
Review of policy and status of implementation of collaborative HIV-TB activities in 23 high-burden countries.
Topics: Antitubercular Agents; CD4 Lymphocyte Count; Guidelines as Topic; HIV Infections; Humans; Internatio | 2014 |
TB screening among people living with HIV/AIDS in resource-limited settings.
Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Health Resources | 2015 |
Use of isoniazid preventive therapy for tuberculosis prophylaxis among people living with HIV/AIDS: a review of the literature.
Topics: Adult; Antitubercular Agents; CD4 Lymphocyte Count; Developing Countries; Health Resources; HIV Infe | 2015 |
Multidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis.
Topics: Antitubercular Agents; Child; Coinfection; Community Health Services; Drug Administration Schedule; | 2015 |
The diagnosis, management and prevention of HIV-associated tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antitubercular Agents; Disease Progre | 2014 |
Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries.
Topics: Antirheumatic Agents; Antitubercular Agents; Coinfection; Comorbidity; Disease Management; Drug User | 2015 |
Benefits of combined preventive therapy with co-trimoxazole and isoniazid in adults living with HIV: time to consider a fixed-dose, single tablet coformulation.
Topics: Adult; Africa South of the Sahara; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antituber | 2015 |
Isoniazid Prophylactic Therapy for the Prevention of Tuberculosis in HIV Infected Adults: A Systematic Review and Meta-Analysis of Randomized Trials.
Topics: Antitubercular Agents; HIV; HIV Infections; Humans; Isoniazid; Randomized Controlled Trials as Topic | 2015 |
Continuous isoniazid for the treatment of latent tuberculosis infection in people living with HIV.
Topics: Antitubercular Agents; Botswana; HIV Infections; Humans; India; Isoniazid; Latent Tuberculosis; Sout | 2016 |
Updates on the risk factors for latent tuberculosis reactivation and their managements.
Topics: Antitubercular Agents; Disease Management; Female; HIV Infections; Humans; Isoniazid; Latent Tubercu | 2016 |
Unmasked tuberculosis and tuberculosis immune reconstitution inflammatory disease: a disease spectrum after initiation of antiretroviral therapy.
Topics: Adult; Animals; Anti-Retroviral Agents; Antigens, Bacterial; Antitubercular Agents; CD4 Lymphocyte C | 2009 |
Impact of tuberculosis preventive therapy on tuberculosis and mortality in HIV-infected children.
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antitubercular Agents; Child; HIV Infections | 2009 |
Tuberculosis (HIV-negative people).
Topics: Antitubercular Agents; HIV Infections; Humans; Isoniazid; Latent Tuberculosis; Low-Level Light Thera | 2009 |
[Use of rifampicin plus pyrazinamide for antituberculosis prophylaxis does not increase the risk of severe hepatotoxicity in HIV patients: meta-analysis of randomized controlled clinical trials].
Topics: Anti-HIV Agents; Antibiotic Prophylaxis; Antitubercular Agents; Chemical and Drug Induced Liver Inju | 2010 |
Treatment of latent tuberculosis infection in HIV infected persons.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; HIV Infections; Humans; Isoniaz | 2010 |
Treatment of latent tuberculosis infection in HIV infected persons.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; HIV Infections; Humans; Isoniaz | 2010 |
Treatment of latent tuberculosis infection in HIV infected persons.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; HIV Infections; Humans; Isoniaz | 2010 |
Treatment of latent tuberculosis infection in HIV infected persons.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; HIV Infections; Humans; Isoniaz | 2010 |
Tuberculous orchiepididymitis during 1978-2003 period: review of 34 cases and role of 16S rRNA amplification.
Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Combined Modality Therapy; Comorbidity; Epidi | 2010 |
The HIV-associated tuberculosis epidemic--when will we act?
Topics: Africa South of the Sahara; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Anti-Retro | 2010 |
Review of multidrug-resistant and extensively drug-resistant TB: global perspectives with a focus on sub-Saharan Africa.
Topics: Africa South of the Sahara; Antitubercular Agents; Asia; Europe, Eastern; Extensively Drug-Resistant | 2010 |
Treatment of latent infection with Mycobacterium tuberculosis: update 2010.
Topics: Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Communicable Disease Control; Drug | 2011 |
Tuberculosis (HIV-negative people).
Topics: Antitubercular Agents; HIV Infections; Humans; Isoniazid; Low-Level Light Therapy; Tuberculosis; Tub | 2011 |
HIV: primary and secondary prophylaxis for opportunistic infections.
Topics: AIDS-Related Opportunistic Infections; Fluconazole; HIV Infections; Humans; Isoniazid; Opportunistic | 2010 |
Polyneuropathy, anti-tuberculosis treatment and the role of pyridoxine in the HIV/AIDS era: a systematic review.
Topics: Antitubercular Agents; HIV Infections; Humans; Isoniazid; Polyneuropathies; Practice Guidelines as T | 2011 |
Epidemiology of tuberculosis and HIV: recent advances in understanding and responses.
Topics: AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antigens, Bacterial; Antitubercular A | 2011 |
Intensive case finding and isoniazid preventative therapy in HIV infected individuals in Africa: economic model and value of information analysis.
Topics: Adult; Africa; Antitubercular Agents; Chemoprevention; Cost-Benefit Analysis; Data Interpretation, S | 2012 |
Isoniazid preventive therapy in correctional facilities: a systematic review.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Female; HIV Infections; Humans; | 2012 |
New vaccines for the prevention of tuberculosis in human immunodeficiency virus infection.
Topics: AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; CD4 Lymphocyte | 2012 |
Scale-up of isoniazid preventive therapy in PEPFAR-assisted clinical sites in South Africa.
Topics: Antitubercular Agents; Communicable Disease Control; Epidemics; Guideline Adherence; HIV Infections; | 2012 |
Tuberculosis and HIV in people who inject drugs: evidence for action for tuberculosis, HIV, prison and harm reduction services.
Topics: Antitubercular Agents; Chemoprevention; Comorbidity; Harm Reduction; Hepatitis B; Hepatitis C; HIV I | 2012 |
Systematic review of TST responses in people living with HIV in under-resourced settings: implications for isoniazid preventive therapy.
Topics: Antibiotic Prophylaxis; Antitubercular Agents; CD4 Lymphocyte Count; Developing Countries; HIV Infec | 2012 |
Research on implementation of interventions in tuberculosis control in low- and middle-income countries: a systematic review.
Topics: Algorithms; Antitubercular Agents; Coinfection; Cost-Benefit Analysis; Delivery of Health Care; Deve | 2012 |
Prevention of HIV-associated respiratory illness in children in developing countries: potential benefits.
Topics: Antitubercular Agents; Chemoprevention; Child; Child Welfare; Developing Countries; HIV Infections; | 2003 |
Treatment of latent tuberculosis infection in HIV infected persons.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; HIV Infections; Humans; Isoniaz | 2004 |
Drugs for tuberculosis.
Topics: Antibiotics, Antitubercular; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Drug Resi | 2004 |
Rifampicin plus pyrazinamide versus isoniazid for treating latent tuberculosis infection: a meta-analysis.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Comorbidity; Drug Therapy, Combination; HIV Infe | 2006 |
Positive PPD and chemoprophylaxis for tuberculosis infection.
Topics: Adult; Antitubercular Agents; BCG Vaccine; HIV Infections; Humans; Isoniazid; Middle Aged; Tuberculi | 1995 |
Preventive therapy for tuberculosis.
Topics: AIDS-Related Opportunistic Infections; HIV Infections; HIV-1; Humans; Isoniazid; Risk Factors; Treat | 1993 |
Fatal isoniazid-induced hepatitis. Its risk during chemoprophylaxis.
Topics: Adult; Age Factors; Aged; Cause of Death; Chemical and Drug Induced Liver Injury; Drug Combinations; | 1993 |
Multidrug-resistant tuberculosis and its control.
Topics: AIDS-Related Opportunistic Infections; Antibiotics, Antitubercular; Drug Resistance, Microbial; Drug | 1993 |
Tuberculosis symposium: emerging problems and promise.
Topics: Drug Resistance, Microbial; HIV Infections; Humans; Isoniazid; Mycobacterium tuberculosis; New York | 1993 |
[The epidemiology of tuberculosis and of the resistance to antitubercular agents].
Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; Developed Countries; Developing Countr | 1997 |
The tuberculosis pandemic--which way now?
Topics: Adult; Animals; Antibiotics, Antitubercular; Antitubercular Agents; Cattle; Child; Disease Outbreaks | 1999 |
Tuberculosis preventive therapy in HIV-infected persons: feasibility issues in developing countries.
Topics: Antitubercular Agents; Cost-Benefit Analysis; Developing Countries; HIV Infections; Humans; Isoniazi | 1999 |
Drugs for preventing tuberculosis in HIV infected persons.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; HIV Infections; Humans; Isoniaz | 2000 |
Isoniazid for preventing tuberculosis in non-HIV infected persons.
Topics: Antitubercular Agents; HIV Infections; Humans; Isoniazid; Tuberculosis, Pulmonary | 2000 |
Drugs for preventing tuberculosis in HIV infected persons.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; HIV Infections; Humans; Isoniaz | 2000 |
Tuberculosis with human immunodeficiency virus infection.
Topics: AIDS-Related Opportunistic Infections; BCG Vaccine; Child; HIV Infections; Humans; Isoniazid; Risk F | 2000 |
New developments in the treatment of latent tuberculosis.
Topics: Antitubercular Agents; Global Health; Guidelines as Topic; HIV Infections; Humans; Isoniazid; Mass S | 2000 |
[Drug-resistant tuberculosis in Spain. Trends and influence of the human immunodeficiency virus].
Topics: Antitubercular Agents; HIV Infections; Humans; Isoniazid; Spain; Tuberculosis, Multidrug-Resistant | 2001 |
Prevention of lung infections associated with human immunodeficiency virus infection.
Topics: Acquired Immunodeficiency Syndrome; CD4-Positive T-Lymphocytes; HIV Infections; Humans; Isoniazid; L | 1989 |
135 trials available for isoniazid and HIV Coinfection
| Article | Year |
|---|---|
A cluster-randomized controlled trial to improve the quality of integrated HIV-tuberculosis services in primary healthcareclinics in South Africa.
Topics: Ambulatory Care Facilities; HIV Infections; Humans; Isoniazid; South Africa; Tuberculosis | 2021 |
Organizational contextual factors that predict success of a quality improvement collaborative approach to enhance integrated HIV-tuberculosis services: a sub-study of the Scaling up TB/HIV Integration trial.
Topics: HIV Infections; Humans; Isoniazid; Quality Improvement; Research Design; South Africa; Tuberculosis | 2021 |
Completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV: Interim analysis of a hybrid type 3 effectiveness-implementation randomized trial.
Topics: Adult; Antitubercular Agents; Directly Observed Therapy; Drug Therapy, Combination; Female; HIV Infe | 2021 |
A CD4+ TNF+ monofunctional memory T-cell response to BCG vaccination is associated with Mycobacterium tuberculosis infection in infants exposed to HIV.
Topics: Antitubercular Agents; BCG Vaccine; CD4-Positive T-Lymphocytes; Cytokines; HIV Infections; Humans; I | 2022 |
Cumulative Mycobacterium tuberculosis Infection Incidence (Measured Primarily by Tuberculin Skin Test) Among Infants With Human Immunodeficiency Virus Exposure: Observational Follow-up of an Isoniazid Prophylaxis Trial.
Topics: Antitubercular Agents; Child, Preschool; Follow-Up Studies; HIV; HIV Infections; Humans; Incidence; | 2022 |
Rifapentine and isoniazid for prevention of tuberculosis in people with diabetes (PROTID): protocol for a randomised controlled trial.
Topics: Adult; Antitubercular Agents; Cohort Studies; Diabetes Mellitus, Type 2; HIV Infections; Humans; Iso | 2022 |
A mid-level health manager intervention to promote uptake of isoniazid preventive therapy among people with HIV in Uganda: a cluster randomised trial.
Topics: Adult; Antitubercular Agents; COVID-19; HIV Infections; Humans; Isoniazid; Pandemics; Uganda | 2022 |
Pregnancy in Women With HIV in a Tuberculosis Preventive Therapy Trial.
Topics: Antitubercular Agents; Contraceptive Agents; Drug Administration Schedule; Drug Therapy, Combination | 2022 |
Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349).
Topics: Antitubercular Agents; Drug Therapy, Combination; HIV; HIV Infections; Humans; Isoniazid; Moxifloxac | 2023 |
Isoniazid preventive therapy-related adverse events among Malawian adults on antiretroviral therapy: A cohort study.
Topics: Adult; Antitubercular Agents; Chloroquine; Cohort Studies; HIV Infections; Humans; Isoniazid; Retros | 2022 |
Prevalence of neurotoxicity symptoms among postpartum women on isoniazid preventive therapy and efavirenz-based treatment for HIV: an exploratory objective of the IMPAACT P1078 randomized trial.
Topics: Antitubercular Agents; Female; HIV Infections; Humans; Isoniazid; Postpartum Period; Pregnancy; Prev | 2023 |
Standard-dose versus double-dose dolutegravir in HIV-associated tuberculosis in South Africa (RADIANT-TB): a phase 2, non-comparative, randomised controlled trial.
Topics: Adult; Anti-Retroviral Agents; Antitubercular Agents; Female; Heterocyclic Compounds, 3-Ring; HIV In | 2023 |
Timing of maternal isoniazid preventive therapy on tuberculosis infection among infants exposed to HIV in low-income and middle-income settings: a secondary analysis of the TB APPRISE trial.
Topics: Antitubercular Agents; BCG Vaccine; Female; HIV Infections; Humans; Infant; Isoniazid; Pregnancy; Tu | 2023 |
Financial incentives for reduced alcohol use and increased isoniazid adherence during tuberculosis preventive therapy among people with HIV in Uganda: an open-label, factorial randomised controlled trial.
Topics: Adolescent; Adult; Alcoholism; Biomarkers; Ethanol; Female; HIV Infections; Humans; Isoniazid; Male; | 2023 |
Isoniazid Preventive Therapy in HIV-Infected Pregnant and Postpartum Women.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Double-Blind Method | 2019 |
Isoniazid Preventive Therapy in HIV-Infected Pregnant and Postpartum Women.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Double-Blind Method | 2019 |
Isoniazid Preventive Therapy in HIV-Infected Pregnant and Postpartum Women.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Double-Blind Method | 2019 |
Isoniazid Preventive Therapy in HIV-Infected Pregnant and Postpartum Women.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Double-Blind Method | 2019 |
CD4+ cell count stratification to guide tuberculosis preventive therapy for people living with HIV.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Brazil; CD4 Lymphocyte Count; Female; HIV Infections; | 2020 |
Infant TB Infection Prevention Study (iTIPS): a randomised trial protocol evaluating isoniazid to prevent
Topics: Antitubercular Agents; Female; HIV; HIV Infections; Humans; Incidence; Infant; Isoniazid; Kenya; Mal | 2020 |
Once-weekly rifapentine and isoniazid for tuberculosis prevention in patients with HIV taking dolutegravir-based antiretroviral therapy: a phase 1/2 trial.
Topics: Adult; Drug Administration Schedule; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; | 2020 |
Twice-Daily Doravirine Overcomes the Interaction Effect from Once-Weekly Rifapentine and Isoniazid in Healthy Volunteers.
Topics: Adolescent; Adult; Antitubercular Agents; Area Under Curve; Drug Administration Schedule; Drug Inter | 2020 |
A Randomized Controlled Trial of Isoniazid to Prevent Mycobacterium tuberculosis Infection in Kenyan Human Immunodeficiency Virus-Exposed Uninfected Infants.
Topics: Antitubercular Agents; HIV; HIV Infections; Humans; Infant; Isoniazid; Kenya; Mycobacterium tubercul | 2021 |
Effects of Pregnancy and Isoniazid Preventive Therapy on Mycobacterium tuberculosis Interferon Gamma Response Assays in Women With HIV.
Topics: Female; HIV Infections; Humans; Interferon-gamma; Interferon-gamma Release Tests; Isoniazid; Latent | 2021 |
Pharmacogenetic interactions of rifapentine plus isoniazid with efavirenz or nevirapine.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Arylamine N-Acetyltransferase; Benzoxazines; Cyclopropa | 2021 |
Inference without randomization or ignorability: A stability-controlled quasi-experiment on the prevention of tuberculosis.
Topics: Antitubercular Agents; HIV Infections; Humans; Isoniazid; Random Allocation; Tuberculosis | 2020 |
Pharmacokinetics and Drug-Drug Interactions of Isoniazid and Efavirenz in Pregnant Women Living With HIV in High TB Incidence Settings: Importance of Genotyping.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Antitubercular Agents; Arylamine N-Acetyltransferase; B | 2021 |
Individual and Composite Adverse Pregnancy Outcomes in a Randomized Trial on Isoniazid Preventative Therapy Among Women Living With Human Immunodeficiency Virus.
Topics: Adolescent; Child; Female; HIV; HIV Infections; Humans; Infant, Newborn; Isoniazid; Pregnancy; Pregn | 2021 |
Nevirapine pharmacokinetics in HIV-infected persons receiving rifapentine and isoniazid for TB prevention.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Antitubercular Agents; Female; HIV Infections; Humans; Iso | 2021 |
Evaluation of a serum-based antigen test for tuberculosis in HIV-exposed infants: a diagnostic accuracy study.
Topics: Antigens, Bacterial; Child; HIV Infections; Humans; Infant; Isoniazid; Mycobacterium tuberculosis; S | 2021 |
The Drinkers' Intervention to Prevent Tuberculosis (DIPT) trial among heavy drinkers living with HIV in Uganda: study protocol of a 2×2 factorial trial.
Topics: Adult; Antitubercular Agents; HIV Infections; Humans; Isoniazid; Motivation; Randomized Controlled T | 2021 |
Pharmacokinetics and Safety of 3 Months of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention in Pregnant Women.
Topics: Adult; Antitubercular Agents; Child; Drug Therapy, Combination; Female; HIV Infections; Humans; Ison | 2022 |
Pharmacogenetics of interaction between depot medroxyprogesterone acetate and efavirenz, rifampicin, and isoniazid during treatment of HIV and tuberculosis.
Topics: Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Drug Interactions; Female; HIV Infections; Hum | 2022 |
Annual Tuberculosis Preventive Therapy for Persons With HIV Infection : A Randomized Trial.
Topics: Adolescent; Adult; Anti-HIV Agents; Antitubercular Agents; Drug Administration Schedule; Drug Therap | 2021 |
Enhanced Prophylaxis plus Antiretroviral Therapy for Advanced HIV Infection in Africa.
Topics: Adolescent; Adult; Africa South of the Sahara; Aged; AIDS-Related Opportunistic Infections; Anti-Inf | 2017 |
Adherence, tolerability, and outcome after 36 months of isoniazid-preventive therapy in 2 rural clinics of Swaziland: A prospective observational feasibility study.
Topics: Adult; Antitubercular Agents; Cohort Studies; Drug Administration Schedule; Eswatini; Feasibility St | 2017 |
Effect of isoniazid preventive therapy on risk of death in west African, HIV-infected adults with high CD4 cell counts: long-term follow-up of the Temprano ANRS 12136 trial.
Topics: Adult; Africa, Western; Anti-Retroviral Agents; Antitubercular Agents; CD4 Lymphocyte Count; Drug Th | 2017 |
Screening for active tuberculosis before isoniazid preventive therapy among HIV-infected West African adults.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antitubercular Agents; CD4 Lymphocyte | 2017 |
Hepatotoxicity During Isoniazid Preventive Therapy and Antiretroviral Therapy in People Living With HIV With Severe Immunosuppression: A Secondary Analysis of a Multi-Country Open-Label Randomized Controlled Clinical Trial.
Topics: Adult; Alanine Transaminase; Anti-Retroviral Agents; Antitubercular Agents; Aspartate Aminotransfera | 2018 |
Cytokine-Mediated Systemic Adverse Drug Reactions in a Drug-Drug Interaction Study of Dolutegravir With Once-Weekly Isoniazid and Rifapentine.
Topics: Adolescent; Adult; Aged; Antibiotics, Antitubercular; Cytokines; Drug Administration Schedule; Drug | 2018 |
High Incidence of Tuberculosis Infection in HIV-exposed Children Exiting an Isoniazid Preventive Therapy Trial.
Topics: Antitubercular Agents; Child, Preschool; Clinical Trials as Topic; Double-Blind Method; Female; HIV | 2018 |
Completion of isoniazid preventive therapy among human immunodeficiency virus positive adults in urban Malawi.
Topics: Adolescent; Adult; Anti-Retroviral Agents; Antitubercular Agents; CD4 Lymphocyte Count; Female; HIV | 2018 |
Daily vs Intermittent Antituberculosis Therapy for Pulmonary Tuberculosis in Patients With HIV: A Randomized Clinical Trial.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; CD4 Lymphocyte Count; Directly Observed Therapy; Drug | 2018 |
Delayed Sputum Culture Conversion in Tuberculosis-Human Immunodeficiency Virus-Coinfected Patients With Low Isoniazid and Rifampicin Concentrations.
Topics: Adult; Antitubercular Agents; Coinfection; Drug Therapy, Combination; Female; HIV Infections; Humans | 2018 |
Delayed Sputum Culture Conversion in Tuberculosis-Human Immunodeficiency Virus-Coinfected Patients With Low Isoniazid and Rifampicin Concentrations.
Topics: Adult; Antitubercular Agents; Coinfection; Drug Therapy, Combination; Female; HIV Infections; Humans | 2018 |
Delayed Sputum Culture Conversion in Tuberculosis-Human Immunodeficiency Virus-Coinfected Patients With Low Isoniazid and Rifampicin Concentrations.
Topics: Adult; Antitubercular Agents; Coinfection; Drug Therapy, Combination; Female; HIV Infections; Humans | 2018 |
Delayed Sputum Culture Conversion in Tuberculosis-Human Immunodeficiency Virus-Coinfected Patients With Low Isoniazid and Rifampicin Concentrations.
Topics: Adult; Antitubercular Agents; Coinfection; Drug Therapy, Combination; Female; HIV Infections; Humans | 2018 |
Delayed Sputum Culture Conversion in Tuberculosis-Human Immunodeficiency Virus-Coinfected Patients With Low Isoniazid and Rifampicin Concentrations.
Topics: Adult; Antitubercular Agents; Coinfection; Drug Therapy, Combination; Female; HIV Infections; Humans | 2018 |
Delayed Sputum Culture Conversion in Tuberculosis-Human Immunodeficiency Virus-Coinfected Patients With Low Isoniazid and Rifampicin Concentrations.
Topics: Adult; Antitubercular Agents; Coinfection; Drug Therapy, Combination; Female; HIV Infections; Humans | 2018 |
Delayed Sputum Culture Conversion in Tuberculosis-Human Immunodeficiency Virus-Coinfected Patients With Low Isoniazid and Rifampicin Concentrations.
Topics: Adult; Antitubercular Agents; Coinfection; Drug Therapy, Combination; Female; HIV Infections; Humans | 2018 |
Delayed Sputum Culture Conversion in Tuberculosis-Human Immunodeficiency Virus-Coinfected Patients With Low Isoniazid and Rifampicin Concentrations.
Topics: Adult; Antitubercular Agents; Coinfection; Drug Therapy, Combination; Female; HIV Infections; Humans | 2018 |
Delayed Sputum Culture Conversion in Tuberculosis-Human Immunodeficiency Virus-Coinfected Patients With Low Isoniazid and Rifampicin Concentrations.
Topics: Adult; Antitubercular Agents; Coinfection; Drug Therapy, Combination; Female; HIV Infections; Humans | 2018 |
Predictors of isoniazid preventive therapy completion among adults newly diagnosed with HIV in rural Malawi.
Topics: Adolescent; Adult; Antitubercular Agents; Female; HIV Infections; Humans; Isoniazid; Kaplan-Meier Es | 2018 |
Effect of efavirenz-based antiretroviral therapy and high-dose rifampicin on the pharmacokinetics of isoniazid and acetyl-isoniazid.
Topics: Adolescent; Adult; Africa, Western; Aged; Aged, 80 and over; Alkynes; Anti-Retroviral Agents; Antire | 2019 |
Cost-effectiveness of universal isoniazid preventive therapy among HIV-infected pregnant women in South Africa.
Topics: Adolescent; Adult; Antitubercular Agents; Cost-Benefit Analysis; Female; HIV Infections; Humans; Int | 2018 |
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2019 |
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2019 |
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2019 |
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2019 |
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2019 |
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2019 |
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2019 |
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2019 |
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2019 |
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2019 |
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2019 |
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2019 |
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2019 |
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2019 |
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2019 |
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2019 |
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2019 |
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2019 |
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2019 |
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2019 |
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2019 |
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2019 |
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2019 |
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2019 |
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2019 |
The pharmacokinetics of nevirapine when given with isoniazid in South African HIV-infected individuals.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Area Under Curve; Biotransformation; Cytochrome P-450 | 2013 |
Pregnancy outcomes in HIV-infected women receiving long-term isoniazid prophylaxis for tuberculosis and antiretroviral therapy.
Topics: Adult; AIDS-Related Opportunistic Infections; Analysis of Variance; Antibiotic Prophylaxis; Antitube | 2013 |
Evaluation of initial and steady-state gatifloxacin pharmacokinetics and dose in pulmonary tuberculosis patients by using monte carlo simulations.
Topics: Adult; Antitubercular Agents; Area Under Curve; Coinfection; Drug Administration Schedule; Drug Dosa | 2013 |
Impact of tuberculosis treatment on CD4 cell count, HIV RNA, and p24 antigen in patients with HIV and tuberculosis.
Topics: Adult; Antitubercular Agents; Biomarkers; CD4 Lymphocyte Count; Coinfection; Dietary Supplements; Dr | 2013 |
Effect of improved tuberculosis screening and isoniazid preventive therapy on incidence of tuberculosis and death in patients with HIV in clinics in Rio de Janeiro, Brazil: a stepped wedge, cluster-randomised trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Retroviral Agents; Antitubercular Agents; Brazil; F | 2013 |
Effect of improved tuberculosis screening and isoniazid preventive therapy on incidence of tuberculosis and death in patients with HIV in clinics in Rio de Janeiro, Brazil: a stepped wedge, cluster-randomised trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Retroviral Agents; Antitubercular Agents; Brazil; F | 2013 |
Effect of improved tuberculosis screening and isoniazid preventive therapy on incidence of tuberculosis and death in patients with HIV in clinics in Rio de Janeiro, Brazil: a stepped wedge, cluster-randomised trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Retroviral Agents; Antitubercular Agents; Brazil; F | 2013 |
Effect of improved tuberculosis screening and isoniazid preventive therapy on incidence of tuberculosis and death in patients with HIV in clinics in Rio de Janeiro, Brazil: a stepped wedge, cluster-randomised trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Retroviral Agents; Antitubercular Agents; Brazil; F | 2013 |
Effect of improved tuberculosis screening and isoniazid preventive therapy on incidence of tuberculosis and death in patients with HIV in clinics in Rio de Janeiro, Brazil: a stepped wedge, cluster-randomised trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Retroviral Agents; Antitubercular Agents; Brazil; F | 2013 |
Effect of improved tuberculosis screening and isoniazid preventive therapy on incidence of tuberculosis and death in patients with HIV in clinics in Rio de Janeiro, Brazil: a stepped wedge, cluster-randomised trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Retroviral Agents; Antitubercular Agents; Brazil; F | 2013 |
Effect of improved tuberculosis screening and isoniazid preventive therapy on incidence of tuberculosis and death in patients with HIV in clinics in Rio de Janeiro, Brazil: a stepped wedge, cluster-randomised trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Retroviral Agents; Antitubercular Agents; Brazil; F | 2013 |
Effect of improved tuberculosis screening and isoniazid preventive therapy on incidence of tuberculosis and death in patients with HIV in clinics in Rio de Janeiro, Brazil: a stepped wedge, cluster-randomised trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Retroviral Agents; Antitubercular Agents; Brazil; F | 2013 |
Effect of improved tuberculosis screening and isoniazid preventive therapy on incidence of tuberculosis and death in patients with HIV in clinics in Rio de Janeiro, Brazil: a stepped wedge, cluster-randomised trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Retroviral Agents; Antitubercular Agents; Brazil; F | 2013 |
Effect of improved tuberculosis screening and isoniazid preventive therapy on incidence of tuberculosis and death in patients with HIV in clinics in Rio de Janeiro, Brazil: a stepped wedge, cluster-randomised trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Retroviral Agents; Antitubercular Agents; Brazil; F | 2013 |
Effect of improved tuberculosis screening and isoniazid preventive therapy on incidence of tuberculosis and death in patients with HIV in clinics in Rio de Janeiro, Brazil: a stepped wedge, cluster-randomised trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Retroviral Agents; Antitubercular Agents; Brazil; F | 2013 |
Effect of improved tuberculosis screening and isoniazid preventive therapy on incidence of tuberculosis and death in patients with HIV in clinics in Rio de Janeiro, Brazil: a stepped wedge, cluster-randomised trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Retroviral Agents; Antitubercular Agents; Brazil; F | 2013 |
Effect of improved tuberculosis screening and isoniazid preventive therapy on incidence of tuberculosis and death in patients with HIV in clinics in Rio de Janeiro, Brazil: a stepped wedge, cluster-randomised trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Retroviral Agents; Antitubercular Agents; Brazil; F | 2013 |
Effect of improved tuberculosis screening and isoniazid preventive therapy on incidence of tuberculosis and death in patients with HIV in clinics in Rio de Janeiro, Brazil: a stepped wedge, cluster-randomised trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Retroviral Agents; Antitubercular Agents; Brazil; F | 2013 |
Effect of improved tuberculosis screening and isoniazid preventive therapy on incidence of tuberculosis and death in patients with HIV in clinics in Rio de Janeiro, Brazil: a stepped wedge, cluster-randomised trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Retroviral Agents; Antitubercular Agents; Brazil; F | 2013 |
Effect of improved tuberculosis screening and isoniazid preventive therapy on incidence of tuberculosis and death in patients with HIV in clinics in Rio de Janeiro, Brazil: a stepped wedge, cluster-randomised trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Retroviral Agents; Antitubercular Agents; Brazil; F | 2013 |
Dependence of efavirenz- and rifampicin-isoniazid-based antituberculosis treatment drug-drug interaction on CYP2B6 and NAT2 genetic polymorphisms: ANRS 12154 study in Cambodia.
Topics: Alkynes; Anti-HIV Agents; Antitubercular Agents; Aryl Hydrocarbon Hydroxylases; Arylamine N-Acetyltr | 2014 |
Strategy to better select HIV-infected individuals for latent TB treatment in BCG-vaccinated population.
Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Female; Follow-Up Studies; HIV Infections; Hu | 2013 |
Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatment.
Topics: Adult; Alkynes; Antitubercular Agents; Benzoxazines; Coinfection; Cyclopropanes; Female; Half-Life; | 2014 |
Isoniazid preventive therapy in HIV-infected children on antiretroviral therapy: a pilot study.
Topics: Age Factors; Anti-HIV Agents; Antitubercular Agents; Child Mortality; Child, Preschool; Coinfection; | 2014 |
Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Double- | 2014 |
Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Double- | 2014 |
Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Double- | 2014 |
Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Double- | 2014 |
Impact of isoniazid preventive therapy for HIV-infected adults in Rio de Janeiro, Brazil: an epidemiological model.
Topics: Adolescent; Adult; Anti-HIV Agents; Antitubercular Agents; Brazil; HIV Infections; Humans; Isoniazid | 2014 |
Isoniazid/acetylisoniazid urine concentrations: markers of adherence to isoniazid preventive therapy in children.
Topics: Age Factors; Antitubercular Agents; Biomarkers; Biotransformation; Child; Chromatography, High Press | 2014 |
Isoniazid/acetylisoniazid urine concentrations: markers of adherence to isoniazid preventive therapy in children.
Topics: Age Factors; Antitubercular Agents; Biomarkers; Biotransformation; Child; Chromatography, High Press | 2014 |
Isoniazid/acetylisoniazid urine concentrations: markers of adherence to isoniazid preventive therapy in children.
Topics: Age Factors; Antitubercular Agents; Biomarkers; Biotransformation; Child; Chromatography, High Press | 2014 |
Isoniazid/acetylisoniazid urine concentrations: markers of adherence to isoniazid preventive therapy in children.
Topics: Age Factors; Antitubercular Agents; Biomarkers; Biotransformation; Child; Chromatography, High Press | 2014 |
Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis.
Topics: Adolescent; Adult; Antitubercular Agents; Area Under Curve; Disinfection; Drug Antagonism; Drug Syne | 2015 |
Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis.
Topics: Adolescent; Adult; Antitubercular Agents; Area Under Curve; Disinfection; Drug Antagonism; Drug Syne | 2015 |
Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis.
Topics: Adolescent; Adult; Antitubercular Agents; Area Under Curve; Disinfection; Drug Antagonism; Drug Syne | 2015 |
Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis.
Topics: Adolescent; Adult; Antitubercular Agents; Area Under Curve; Disinfection; Drug Antagonism; Drug Syne | 2015 |
Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis.
Topics: Adolescent; Adult; Antitubercular Agents; Area Under Curve; Disinfection; Drug Antagonism; Drug Syne | 2015 |
Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis.
Topics: Adolescent; Adult; Antitubercular Agents; Area Under Curve; Disinfection; Drug Antagonism; Drug Syne | 2015 |
Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis.
Topics: Adolescent; Adult; Antitubercular Agents; Area Under Curve; Disinfection; Drug Antagonism; Drug Syne | 2015 |
Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis.
Topics: Adolescent; Adult; Antitubercular Agents; Area Under Curve; Disinfection; Drug Antagonism; Drug Syne | 2015 |
Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis.
Topics: Adolescent; Adult; Antitubercular Agents; Area Under Curve; Disinfection; Drug Antagonism; Drug Syne | 2015 |
Quantiferon-TB Gold: performance for ruling out active tuberculosis in HIV-infected adults with high CD4 count in Côte d'Ivoire, West Africa.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cote d'Ivoire; Enzyme-Linked Immunosorbent Assay; Fema | 2014 |
Isoniazid-associated hepatitis in adults infected with HIV receiving 36 months of isoniazid prophylaxis in Botswana.
Topics: Adult; Antitubercular Agents; Botswana; Chemical and Drug Induced Liver Injury; Double-Blind Method; | 2015 |
Isoniazid-associated hepatitis in adults infected with HIV receiving 36 months of isoniazid prophylaxis in Botswana.
Topics: Adult; Antitubercular Agents; Botswana; Chemical and Drug Induced Liver Injury; Double-Blind Method; | 2015 |
Isoniazid-associated hepatitis in adults infected with HIV receiving 36 months of isoniazid prophylaxis in Botswana.
Topics: Adult; Antitubercular Agents; Botswana; Chemical and Drug Induced Liver Injury; Double-Blind Method; | 2015 |
Isoniazid-associated hepatitis in adults infected with HIV receiving 36 months of isoniazid prophylaxis in Botswana.
Topics: Adult; Antitubercular Agents; Botswana; Chemical and Drug Induced Liver Injury; Double-Blind Method; | 2015 |
Randomized pharmacokinetic evaluation of different rifabutin doses in African HIV- infected tuberculosis patients on lopinavir/ritonavir-based antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; Antibiotics, Antitubercular; Black People; Coinfection; Cross-Over Studies; | 2014 |
Pharmacokinetics of first-line antituberculosis drugs in HIV-infected children with tuberculosis treated with intermittent regimens in India.
Topics: Adolescent; Antitubercular Agents; Child; Child, Preschool; Female; HIV Infections; Humans; India; I | 2015 |
Cost-effectiveness of tuberculosis screening and isoniazid treatment in the TB/HIV in Rio (THRio) Study.
Topics: Allied Health Personnel; Antitubercular Agents; Bacteriological Techniques; Brazil; Coinfection; Cos | 2014 |
Prevalence, incidence and predictors of peripheral neuropathy in African adults with HIV infection within the DART trial.
Topics: Adolescent; Adult; Aged; Anti-Retroviral Agents; Antitubercular Agents; Didanosine; Female; HIV Infe | 2014 |
Tuberculosis incidence after 36 months' isoniazid prophylaxis in HIV-infected adults in Botswana: a posttrial observational analysis.
Topics: Adult; Antitubercular Agents; Botswana; Double-Blind Method; Female; HIV Infections; Humans; Inciden | 2015 |
Tuberculosis control in South African gold mines: mathematical modeling of a trial of community-wide isoniazid preventive therapy.
Topics: Adult; Antitubercular Agents; Gold; HIV Infections; Humans; Isoniazid; Middle Aged; Mining; Models, | 2015 |
Do clinical decision-support reminders for medical providers improve isoniazid preventative therapy prescription rates among HIV-positive adults? Study protocol for a randomized controlled trial.
Topics: Antitubercular Agents; Clinical Protocols; Coinfection; Decision Support Techniques; Drug Prescripti | 2015 |
Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention.
Topics: Administration, Oral; Adult; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Cyclopro | 2015 |
Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention.
Topics: Administration, Oral; Adult; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Cyclopro | 2015 |
Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention.
Topics: Administration, Oral; Adult; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Cyclopro | 2015 |
Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention.
Topics: Administration, Oral; Adult; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Cyclopro | 2015 |
Consumption of Sutherlandia frutescens by HIV-Seropositive South African Adults: An Adaptive Double-Blind Randomized Placebo Controlled Trial.
Topics: Administration, Oral; Adult; Antitubercular Agents; CD4 Lymphocyte Count; Drug Administration Schedu | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
Pharmacokinetics of Antituberculosis Drugs in HIV-Positive and HIV-Negative Adults in Malawi.
Topics: Adolescent; Adult; Antitubercular Agents; Ethambutol; Female; HIV Infections; Humans; Isoniazid; Mal | 2015 |
Implementation and Operational Research: Cost-Effectiveness of Antiretroviral Therapy and Isoniazid Prophylaxis to Reduce Tuberculosis and Death in People Living With HIV in Botswana.
Topics: Anti-HIV Agents; Botswana; Cost-Benefit Analysis; HIV Infections; Humans; Isoniazid; Tuberculosis | 2015 |
Peripheral neuropathy in HIV patients in sub-Saharan Africa failing first-line therapy and the response to second-line ART in the EARNEST trial.
Topics: Adult; Africa South of the Sahara; Alcohol Abstinence; Anti-HIV Agents; Antiretroviral Therapy, High | 2016 |
The pharmacokinetics of lopinavir/ritonavir when given with isoniazid in South African HIV-infected individuals.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Area Under Curve; Biological Availability; Disease Pr | 2015 |
Effect of SLCO1B1 Polymorphisms on Rifabutin Pharmacokinetics in African HIV-Infected Patients with Tuberculosis.
Topics: Adult; Antitubercular Agents; Area Under Curve; CD4 Lymphocyte Count; Coinfection; Ethambutol; Femal | 2016 |
Pharmacokinetics of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol in Infants Dosed According to Revised WHO-Recommended Treatment Guidelines.
Topics: Anti-Bacterial Agents; Area Under Curve; Coinfection; Drug Dosage Calculations; Ethambutol; Female; | 2016 |
High prevalence of being Overweight and Obese HIV-infected persons, before and after 24 months on early ART in the ANRS 12136 Temprano Trial.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Body Mass Index; Cote d'Ivoire; Female; HIV Infection | 2016 |
Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label randomised controlled trial.
Topics: Adult; AIDS-Related Opportunistic Infections; Ambulatory Care Facilities; Anti-HIV Agents; Antituber | 2016 |
Household HIV Testing Uptake among Contacts of TB Patients in South Africa.
Topics: Adolescent; Adult; CD4-Positive T-Lymphocytes; Cluster Analysis; Contact Tracing; Family Characteris | 2016 |
Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons.
Topics: Adolescent; Adult; Americas; Antitubercular Agents; Asia; Child; Drug-Related Side Effects and Adver | 2016 |
Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons.
Topics: Adolescent; Adult; Americas; Antitubercular Agents; Asia; Child; Drug-Related Side Effects and Adver | 2016 |
Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons.
Topics: Adolescent; Adult; Americas; Antitubercular Agents; Asia; Child; Drug-Related Side Effects and Adver | 2016 |
Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons.
Topics: Adolescent; Adult; Americas; Antitubercular Agents; Asia; Child; Drug-Related Side Effects and Adver | 2016 |
Source case identification in HIV-exposed infants and tuberculosis diagnosis in an isoniazid prevention study.
Topics: Age Factors; Antitubercular Agents; Coinfection; Early Diagnosis; Female; HIV Infections; Humans; In | 2016 |
Use of antiretrovirals in HIV-infected children in a tuberculosis prevention trial: IMPAACT P1041.
Topics: Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Child; Child, Preschool; Double-Blind | 2017 |
Completion of isoniazid preventive therapy among HIV-infected patients in Tanzania.
Topics: Adult; Antitubercular Agents; Counseling; Female; HIV; HIV Infections; Humans; Isoniazid; Male; Medi | 2008 |
Completion of isoniazid preventive therapy among HIV-infected patients in Tanzania.
Topics: Adult; Antitubercular Agents; Counseling; Female; HIV; HIV Infections; Humans; Isoniazid; Male; Medi | 2008 |
Completion of isoniazid preventive therapy among HIV-infected patients in Tanzania.
Topics: Adult; Antitubercular Agents; Counseling; Female; HIV; HIV Infections; Humans; Isoniazid; Male; Medi | 2008 |
Completion of isoniazid preventive therapy among HIV-infected patients in Tanzania.
Topics: Adult; Antitubercular Agents; Counseling; Female; HIV; HIV Infections; Humans; Isoniazid; Male; Medi | 2008 |
Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiretroviral Therapy, Highly Active | 2009 |
Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiretroviral Therapy, Highly Active | 2009 |
Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiretroviral Therapy, Highly Active | 2009 |
Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiretroviral Therapy, Highly Active | 2009 |
Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiretroviral Therapy, Highly Active | 2009 |
Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiretroviral Therapy, Highly Active | 2009 |
Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiretroviral Therapy, Highly Active | 2009 |
Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiretroviral Therapy, Highly Active | 2009 |
Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiretroviral Therapy, Highly Active | 2009 |
Adherence to isoniazid prophylaxis among HIV-infected children: a randomized controlled trial comparing two dosing schedules.
Topics: Antitubercular Agents; Child; Child, Preschool; Female; HIV Infections; Humans; Infant; Infant, Newb | 2009 |
Isoniazid tuberculosis preventive therapy in HIV-infected adults accessing antiretroviral therapy: a Botswana Experience, 2004-2006.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antitubercular Agen | 2010 |
Isoniazid tuberculosis preventive therapy in HIV-infected adults accessing antiretroviral therapy: a Botswana Experience, 2004-2006.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antitubercular Agen | 2010 |
Isoniazid tuberculosis preventive therapy in HIV-infected adults accessing antiretroviral therapy: a Botswana Experience, 2004-2006.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antitubercular Agen | 2010 |
Isoniazid tuberculosis preventive therapy in HIV-infected adults accessing antiretroviral therapy: a Botswana Experience, 2004-2006.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antitubercular Agen | 2010 |
Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: a randomized clinical trial.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2010 |
Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: a randomized clinical trial.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2010 |
Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: a randomized clinical trial.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2010 |
Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: a randomized clinical trial.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2010 |
Tuberculosis treatment in HIV infected Ugandans with CD4 counts>350 cells/mm reduces immune activation with no effect on HIV load or CD4 count.
Topics: Adult; Antitubercular Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymph | 2010 |
Initial response to protease-inhibitor-based antiretroviral therapy among children less than 2 years of age in South Africa: effect of cotreatment for tuberculosis.
Topics: Antiretroviral Therapy, Highly Active; Antitubercular Agents; Child, Preschool; Drug Therapy, Combin | 2010 |
Isoniazid-associated hepatitis and antiretroviral drugs during tuberculosis prophylaxis in hiv-infected adults in Botswana.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Alcohol Drinking; Anti-Retroviral Agents; Antitubercu | 2010 |
Isoniazid-associated hepatitis and antiretroviral drugs during tuberculosis prophylaxis in hiv-infected adults in Botswana.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Alcohol Drinking; Anti-Retroviral Agents; Antitubercu | 2010 |
Isoniazid-associated hepatitis and antiretroviral drugs during tuberculosis prophylaxis in hiv-infected adults in Botswana.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Alcohol Drinking; Anti-Retroviral Agents; Antitubercu | 2010 |
Isoniazid-associated hepatitis and antiretroviral drugs during tuberculosis prophylaxis in hiv-infected adults in Botswana.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Alcohol Drinking; Anti-Retroviral Agents; Antitubercu | 2010 |
Immunogenicity of a protective whole cell mycobacterial vaccine in HIV-infected adults: a phase III study in Tanzania.
Topics: Adult; Antibodies, Bacterial; Antibody Formation; Antigens, Bacterial; Antitubercular Agents; BCG Va | 2010 |
Adverse events with isoniazid preventive therapy: experience from a large trial.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Female; HIV Infections; Humans; | 2010 |
The implementation of isoniazid preventive therapy in HIV clinics: the experience from the TB/HIV in Rio (THRio) study.
Topics: Antitubercular Agents; Brazil; Delivery of Health Care, Integrated; Female; HIV Infections; HIV-1; H | 2010 |
The implementation of isoniazid preventive therapy in HIV clinics: the experience from the TB/HIV in Rio (THRio) study.
Topics: Antitubercular Agents; Brazil; Delivery of Health Care, Integrated; Female; HIV Infections; HIV-1; H | 2010 |
The implementation of isoniazid preventive therapy in HIV clinics: the experience from the TB/HIV in Rio (THRio) study.
Topics: Antitubercular Agents; Brazil; Delivery of Health Care, Integrated; Female; HIV Infections; HIV-1; H | 2010 |
The implementation of isoniazid preventive therapy in HIV clinics: the experience from the TB/HIV in Rio (THRio) study.
Topics: Antitubercular Agents; Brazil; Delivery of Health Care, Integrated; Female; HIV Infections; HIV-1; H | 2010 |
Thibela TB: design and methods of a cluster randomised trial of the effect of community-wide isoniazid preventive therapy on tuberculosis amongst gold miners in South Africa.
Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; Female; Gold; HIV Infections; Humans; | 2011 |
The impact of isoniazid preventive therapy and antiretroviral therapy on tuberculosis in children infected with HIV in a high tuberculosis incidence setting.
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antitubercular Agents; Child; Child, Prescho | 2011 |
6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial.
Topics: Adult; Antitubercular Agents; Botswana; Double-Blind Method; Drug Administration Schedule; Drug Resi | 2011 |
6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial.
Topics: Adult; Antitubercular Agents; Botswana; Double-Blind Method; Drug Administration Schedule; Drug Resi | 2011 |
6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial.
Topics: Adult; Antitubercular Agents; Botswana; Double-Blind Method; Drug Administration Schedule; Drug Resi | 2011 |
6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial.
Topics: Adult; Antitubercular Agents; Botswana; Double-Blind Method; Drug Administration Schedule; Drug Resi | 2011 |
6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial.
Topics: Adult; Antitubercular Agents; Botswana; Double-Blind Method; Drug Administration Schedule; Drug Resi | 2011 |
6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial.
Topics: Adult; Antitubercular Agents; Botswana; Double-Blind Method; Drug Administration Schedule; Drug Resi | 2011 |
6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial.
Topics: Adult; Antitubercular Agents; Botswana; Double-Blind Method; Drug Administration Schedule; Drug Resi | 2011 |
6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial.
Topics: Adult; Antitubercular Agents; Botswana; Double-Blind Method; Drug Administration Schedule; Drug Resi | 2011 |
6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial.
Topics: Adult; Antitubercular Agents; Botswana; Double-Blind Method; Drug Administration Schedule; Drug Resi | 2011 |
The pharmacogenetics of NAT2 enzyme maturation in perinatally HIV exposed infants receiving isoniazid.
Topics: Administration, Oral; Age Factors; Antitubercular Agents; Arylamine N-Acetyltransferase; Child, Pres | 2012 |
New regimens to prevent tuberculosis in adults with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Cause o | 2011 |
New regimens to prevent tuberculosis in adults with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Cause o | 2011 |
New regimens to prevent tuberculosis in adults with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Cause o | 2011 |
New regimens to prevent tuberculosis in adults with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Cause o | 2011 |
New regimens to prevent tuberculosis in adults with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Cause o | 2011 |
New regimens to prevent tuberculosis in adults with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Cause o | 2011 |
New regimens to prevent tuberculosis in adults with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Cause o | 2011 |
New regimens to prevent tuberculosis in adults with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Cause o | 2011 |
New regimens to prevent tuberculosis in adults with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Cause o | 2011 |
New regimens to prevent tuberculosis in adults with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Cause o | 2011 |
New regimens to prevent tuberculosis in adults with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Cause o | 2011 |
New regimens to prevent tuberculosis in adults with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Cause o | 2011 |
New regimens to prevent tuberculosis in adults with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Cause o | 2011 |
New regimens to prevent tuberculosis in adults with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Cause o | 2011 |
New regimens to prevent tuberculosis in adults with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Cause o | 2011 |
New regimens to prevent tuberculosis in adults with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Cause o | 2011 |
New regimens to prevent tuberculosis in adults with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Cause o | 2011 |
New regimens to prevent tuberculosis in adults with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Cause o | 2011 |
New regimens to prevent tuberculosis in adults with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Cause o | 2011 |
New regimens to prevent tuberculosis in adults with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Cause o | 2011 |
New regimens to prevent tuberculosis in adults with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Cause o | 2011 |
New regimens to prevent tuberculosis in adults with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Cause o | 2011 |
New regimens to prevent tuberculosis in adults with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Cause o | 2011 |
New regimens to prevent tuberculosis in adults with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Cause o | 2011 |
New regimens to prevent tuberculosis in adults with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Cause o | 2011 |
New regimens to prevent tuberculosis in adults with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Cause o | 2011 |
New regimens to prevent tuberculosis in adults with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Cause o | 2011 |
New regimens to prevent tuberculosis in adults with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Cause o | 2011 |
New regimens to prevent tuberculosis in adults with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Cause o | 2011 |
New regimens to prevent tuberculosis in adults with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Cause o | 2011 |
New regimens to prevent tuberculosis in adults with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Cause o | 2011 |
New regimens to prevent tuberculosis in adults with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Cause o | 2011 |
New regimens to prevent tuberculosis in adults with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Cause o | 2011 |
New regimens to prevent tuberculosis in adults with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Cause o | 2011 |
New regimens to prevent tuberculosis in adults with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Cause o | 2011 |
New regimens to prevent tuberculosis in adults with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Cause o | 2011 |
Primary isoniazid prophylaxis against tuberculosis in HIV-exposed children.
Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; Double-Blind Method; Drug Resistance, | 2011 |
Primary isoniazid prophylaxis against tuberculosis in HIV-exposed children.
Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; Double-Blind Method; Drug Resistance, | 2011 |
Primary isoniazid prophylaxis against tuberculosis in HIV-exposed children.
Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; Double-Blind Method; Drug Resistance, | 2011 |
Primary isoniazid prophylaxis against tuberculosis in HIV-exposed children.
Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; Double-Blind Method; Drug Resistance, | 2011 |
Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations.
Topics: Antitubercular Agents; Area Under Curve; Child, Preschool; Coinfection; Female; HIV Infections; Huma | 2011 |
Completion of isoniazid preventive therapy and survival in HIV-infected, TST-positive adults in Tanzania.
Topics: Adult; Aged; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antitubercular Agents; CD4 Lymp | 2011 |
Isoniazid preventive therapy and 4-year incidence of pulmonary tuberculosis among HIV-infected Thai patients.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Female; Follow-Up Studies; HIV Infections; Humans; In | 2012 |
High prevalence of drug resistance amongst HIV-exposed and -infected children in a tuberculosis prevention trial.
Topics: Adolescent; Antitubercular Agents; Child; Child, Preschool; Dose-Response Relationship, Drug; Double | 2012 |
Influence of antituberculosis drug resistance and Mycobacterium tuberculosis lineage on outcome in HIV-associated tuberculous meningitis.
Topics: Adult; Antitubercular Agents; Female; Genotype; HIV Infections; Humans; Isoniazid; Male; Mycobacteri | 2012 |
Influence of antituberculosis drug resistance and Mycobacterium tuberculosis lineage on outcome in HIV-associated tuberculous meningitis.
Topics: Adult; Antitubercular Agents; Female; Genotype; HIV Infections; Humans; Isoniazid; Male; Mycobacteri | 2012 |
Influence of antituberculosis drug resistance and Mycobacterium tuberculosis lineage on outcome in HIV-associated tuberculous meningitis.
Topics: Adult; Antitubercular Agents; Female; Genotype; HIV Infections; Humans; Isoniazid; Male; Mycobacteri | 2012 |
Influence of antituberculosis drug resistance and Mycobacterium tuberculosis lineage on outcome in HIV-associated tuberculous meningitis.
Topics: Adult; Antitubercular Agents; Female; Genotype; HIV Infections; Humans; Isoniazid; Male; Mycobacteri | 2012 |
Isoniazid pharmacokinetics, pharmacodynamics, and dosing in South African infants.
Topics: Antitubercular Agents; Area Under Curve; Child, Preschool; Double-Blind Method; Female; HIV Infectio | 2012 |
Efavirenz, tenofovir and emtricitabine combined with first-line tuberculosis treatment in tuberculosis-HIV-coinfected Tanzanian patients: a pharmacokinetic and safety study.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Cyclopropanes; Deoxyc | 2013 |
Safety of long-term isoniazid preventive therapy in children with HIV: a comparison of two dosing schedules.
Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; Chemical and Drug Induced Liver Injury | 2013 |
Loss to follow-up among infants in a study of isoniazid prophylaxis (P1041) in South Africa.
Topics: Antitubercular Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Humans; Infan | 2013 |
Efficacy of a six-month versus a 36-month regimen for prevention of tuberculosis in HIV-infected persons in India: a randomized clinical trial.
Topics: Adult; Antitubercular Agents; Drug Administration Schedule; Ethambutol; Female; HIV Infections; Huma | 2012 |
The short-term effects of anti-tuberculosis therapy on plasma pyridoxine levels in patients with pulmonary tuberculosis.
Topics: Adult; Antitubercular Agents; Ethambutol; Female; Follow-Up Studies; HIV Infections; Humans; Isoniaz | 2004 |
Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease.
Topics: Acetylation; Adult; Antibiotics, Antitubercular; Antitubercular Agents; Biological Availability; Eth | 2004 |
Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease.
Topics: Acetylation; Adult; Antibiotics, Antitubercular; Antitubercular Agents; Biological Availability; Eth | 2004 |
Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease.
Topics: Acetylation; Adult; Antibiotics, Antitubercular; Antitubercular Agents; Biological Availability; Eth | 2004 |
Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease.
Topics: Acetylation; Adult; Antibiotics, Antitubercular; Antitubercular Agents; Biological Availability; Eth | 2004 |
Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease.
Topics: Acetylation; Adult; Antibiotics, Antitubercular; Antitubercular Agents; Biological Availability; Eth | 2004 |
Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease.
Topics: Acetylation; Adult; Antibiotics, Antitubercular; Antitubercular Agents; Biological Availability; Eth | 2004 |
Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease.
Topics: Acetylation; Adult; Antibiotics, Antitubercular; Antitubercular Agents; Biological Availability; Eth | 2004 |
Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease.
Topics: Acetylation; Adult; Antibiotics, Antitubercular; Antitubercular Agents; Biological Availability; Eth | 2004 |
Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease.
Topics: Acetylation; Adult; Antibiotics, Antitubercular; Antitubercular Agents; Biological Availability; Eth | 2004 |
INH preventive therapy among adult HIV-infected patients in Thailand.
Topics: Adult; Antitubercular Agents; CD4 Lymphocyte Count; Dose-Response Relationship, Drug; Female; Follow | 2005 |
Evaluation of modified short course chemotherapy in active pulmonary tuberculosis patients with human immunodeficiency virus infection in University College Hospital, Ibadan, Nigeria--a preliminary report.
Topics: Acne Vulgaris; Adolescent; Adult; Age Distribution; Aged; Antitubercular Agents; Drug Therapy, Combi | 2004 |
Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis.
Topics: Adult; Antitubercular Agents; Area Under Curve; CD4 Lymphocyte Count; Directly Observed Therapy; Dru | 2005 |
Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis.
Topics: Adult; Antitubercular Agents; Area Under Curve; CD4 Lymphocyte Count; Directly Observed Therapy; Dru | 2005 |
Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis.
Topics: Adult; Antitubercular Agents; Area Under Curve; CD4 Lymphocyte Count; Directly Observed Therapy; Dru | 2005 |
Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis.
Topics: Adult; Antitubercular Agents; Area Under Curve; CD4 Lymphocyte Count; Directly Observed Therapy; Dru | 2005 |
Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis.
Topics: Adult; Antitubercular Agents; Area Under Curve; CD4 Lymphocyte Count; Directly Observed Therapy; Dru | 2005 |
Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis.
Topics: Adult; Antitubercular Agents; Area Under Curve; CD4 Lymphocyte Count; Directly Observed Therapy; Dru | 2005 |
Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis.
Topics: Adult; Antitubercular Agents; Area Under Curve; CD4 Lymphocyte Count; Directly Observed Therapy; Dru | 2005 |
Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis.
Topics: Adult; Antitubercular Agents; Area Under Curve; CD4 Lymphocyte Count; Directly Observed Therapy; Dru | 2005 |
Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis.
Topics: Adult; Antitubercular Agents; Area Under Curve; CD4 Lymphocyte Count; Directly Observed Therapy; Dru | 2005 |
Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial.
Topics: Africa South of the Sahara; Anti-Retroviral Agents; Antitubercular Agents; Child; Child, Preschool; | 2007 |
Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial.
Topics: Africa South of the Sahara; Anti-Retroviral Agents; Antitubercular Agents; Child; Child, Preschool; | 2007 |
Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial.
Topics: Africa South of the Sahara; Anti-Retroviral Agents; Antitubercular Agents; Child; Child, Preschool; | 2007 |
Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial.
Topics: Africa South of the Sahara; Anti-Retroviral Agents; Antitubercular Agents; Child; Child, Preschool; | 2007 |
Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial.
Topics: Africa South of the Sahara; Anti-Retroviral Agents; Antitubercular Agents; Child; Child, Preschool; | 2007 |
Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial.
Topics: Africa South of the Sahara; Anti-Retroviral Agents; Antitubercular Agents; Child; Child, Preschool; | 2007 |
Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial.
Topics: Africa South of the Sahara; Anti-Retroviral Agents; Antitubercular Agents; Child; Child, Preschool; | 2007 |
Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial.
Topics: Africa South of the Sahara; Anti-Retroviral Agents; Antitubercular Agents; Child; Child, Preschool; | 2007 |
Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial.
Topics: Africa South of the Sahara; Anti-Retroviral Agents; Antitubercular Agents; Child; Child, Preschool; | 2007 |
Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial.
Topics: Africa South of the Sahara; Anti-Retroviral Agents; Antitubercular Agents; Child; Child, Preschool; | 2007 |
Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial.
Topics: Africa South of the Sahara; Anti-Retroviral Agents; Antitubercular Agents; Child; Child, Preschool; | 2007 |
Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial.
Topics: Africa South of the Sahara; Anti-Retroviral Agents; Antitubercular Agents; Child; Child, Preschool; | 2007 |
Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial.
Topics: Africa South of the Sahara; Anti-Retroviral Agents; Antitubercular Agents; Child; Child, Preschool; | 2007 |
Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial.
Topics: Africa South of the Sahara; Anti-Retroviral Agents; Antitubercular Agents; Child; Child, Preschool; | 2007 |
Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial.
Topics: Africa South of the Sahara; Anti-Retroviral Agents; Antitubercular Agents; Child; Child, Preschool; | 2007 |
Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial.
Topics: Africa South of the Sahara; Anti-Retroviral Agents; Antitubercular Agents; Child; Child, Preschool; | 2007 |
Statistical design of THRio: a phased implementation clinic-randomized study of a tuberculosis preventive therapy intervention.
Topics: Antitubercular Agents; Brazil; HIV Infections; Humans; Isoniazid; Models, Statistical; Patient Care | 2007 |
[Randomized clinical trial investigating three chemoprophylaxis regimens for latent tuberculosis infection in HIV-infected patients].
Topics: Adult; Antitubercular Agents; Drug Therapy, Combination; Female; HIV Infections; Humans; Isoniazid; | 2007 |
Clinical evaluation of the nelfinavir-rifabutin interaction in patients with tuberculosis and human immunodeficiency virus infection.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Area Under Curve; Cohort Studies; Drug Interacti | 2007 |
HIV risk reduction in a nurse case-managed TB and HIV intervention among homeless adults.
Topics: Adult; Antitubercular Agents; Case Management; Directly Observed Therapy; Female; Health Knowledge, | 2007 |
Randomised controlled trial of isoniazid preventive therapy in South African adults with advanced HIV disease.
Topics: Adult; Antitubercular Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Humans | 2007 |
Nutritional status of persons with HIV infection, persons with HIV infection and tuberculosis, and HIV-negative individuals from southern India.
Topics: Adult; AIDS-Related Opportunistic Infections; Anemia; Antitubercular Agents; Body Composition; Drug | 2008 |
Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Drug Therapy, Comb | 1993 |
Effect of isoniazid prophylaxis on incidence of active tuberculosis among Thai HIV-infected individuals.
Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; Female; HIV Infections; Humans; Incide | 1996 |
[Multicenter transversal study of tuberculosis and drug resistance in Madrid (October 1993-April 1994)].
Topics: Adolescent; Adult; Antibiotics, Antitubercular; Antitubercular Agents; Drug Resistance, Multiple; Et | 1996 |
A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Double-Blind Method; Female; HI | 1997 |
[Compliance, efficacy and tolerability of the therapeutic regimen recommended by National Consensus on Tuberculosis].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antitubercular Agents; Child; Chi | 1997 |
A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Therapy, Combination; Fema | 1997 |
A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Therapy, Combination; Fema | 1997 |
A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Therapy, Combination; Fema | 1997 |
A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Therapy, Combination; Fema | 1997 |
Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Administration Schedule; F | 1998 |
Instability of tuberculin and Candida skin test reactivity in HIV-infected Ugandans. The Uganda-Case Western Reserve University Research Collaboration.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Antigens, Fungal; Antitubercular Agents; C | 1998 |
Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health O
Topics: Adolescent; Adult; Aged; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Administ | 2000 |
Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health O
Topics: Adolescent; Adult; Aged; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Administ | 2000 |
Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health O
Topics: Adolescent; Adult; Aged; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Administ | 2000 |
Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health O
Topics: Adolescent; Adult; Aged; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Administ | 2000 |
Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health O
Topics: Adolescent; Adult; Aged; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Administ | 2000 |
Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health O
Topics: Adolescent; Adult; Aged; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Administ | 2000 |
Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health O
Topics: Adolescent; Adult; Aged; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Administ | 2000 |
Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health O
Topics: Adolescent; Adult; Aged; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Administ | 2000 |
Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health O
Topics: Adolescent; Adult; Aged; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Administ | 2000 |
Effect of post-treatment isoniazid on prevention of recurrent tuberculosis in HIV-1-infected individuals: a randomised trial.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Female; H | 2000 |
Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Cohort St | 2001 |
Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Therapy, Combi | 2001 |
No effect of isoniazid prophylaxis for purified protein derivative-negative HIV-infected adults living in a country with endemic tuberculosis: results of a randomized trial.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Endemic Diseases; H | 2001 |
Risk factors for development of tuberculosis after isoniazid chemoprophylaxis in human immunodeficiency virus-infected patients.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Chemoprevention; Female; Follow | 2002 |
474 other studies available for isoniazid and HIV Coinfection
| Article | Year |
|---|---|
Novel isatinyl thiosemicarbazones derivatives as potential molecule to combat HIV-TB co-infection.
Topics: Anti-Bacterial Agents; Anti-HIV Agents; Cell Line; HIV; HIV Infections; HIV Reverse Transcriptase; I | 2011 |
Tuberculosis preventive treatment in people living with HIV-Is the glass half empty or half full?
Topics: Antibiotic Prophylaxis; Antitubercular Agents; HIV Infections; Humans; Isoniazid; Tuberculosis | 2021 |
Low prevalence of isoniazid preventive therapy uptake among HIV-infected patients attending tertiary health facility in Lagos, Southwest Nigeria.
Topics: Adult; Aged; AIDS-Related Opportunistic Infections; Antitubercular Agents; Cross-Sectional Studies; | 2021 |
Tuberculosis screening coverage and isoniazid preventive therapy among people living with HIV at Gambella Hospital, southwest Ethiopia: a retrospective study design.
Topics: Adolescent; Adult; Antitubercular Agents; Ethiopia; HIV Infections; Hospitals; Humans; Isoniazid; Ma | 2021 |
Diagnostic performance of the Abbott RealTime MTB assay for tuberculosis diagnosis in people living with HIV.
Topics: Adult; DNA, Bacterial; Drug Resistance, Bacterial; Female; HIV Infections; Humans; Isoniazid; Male; | 2021 |
A Quality Improvement Intervention to Inform Scale-Up of Integrated HIV-TB Services: Lessons Learned From KwaZulu-Natal, South Africa.
Topics: HIV Infections; Humans; Isoniazid; Quality Improvement; South Africa; Tuberculosis | 2021 |
Adherence of HIV clinics to guidelines for the delivery of TB screening among people living with HIV/AIDS in Ghana.
Topics: Antitubercular Agents; Cross-Sectional Studies; Ghana; HIV Infections; Humans; Isoniazid; Tuberculos | 2021 |
Effect of mobile-phone messaging on patient and health-worker knowledge and adherence to the isoniazid preventive therapy guideline in HIV clinics in Southeast, Nigeria.
Topics: Antitubercular Agents; Cell Phone; Guideline Adherence; HIV Infections; Humans; Isoniazid; Nigeria; | 2021 |
No implication of HIV coinfection on the plasma exposure to rifampicin, pyrazinamide, and ethambutol in tuberculosis patients.
Topics: Adult; Antitubercular Agents; Ethambutol; HIV Infections; Humans; Isoniazid; Pyrazinamide; Rifampin; | 2022 |
High Burden of Adverse Drug Reactions to Isoniazid Preventive Therapy in People Living With HIV at 3 Tertiary Hospitals in Uganda: Associated Factors.
Topics: Antitubercular Agents; Child; Cross-Sectional Studies; Drug-Related Side Effects and Adverse Reactio | 2022 |
The impact of blood transcriptomic biomarker targeted tuberculosis preventive therapy in people living with HIV: a mathematical modelling study.
Topics: Antitubercular Agents; Biomarkers; HIV Infections; Humans; Isoniazid; Mass Screening; Transcriptome; | 2021 |
Short-course daily isoniazid and rifapentine for latent tuberculosis infection in people living with HIV who received coformulated bictegravir/emtricitabine/tenofovir alafenamide.
Topics: Adenine; Alanine; Amides; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infect | 2021 |
Pharmacogenetics of the Late-Onset Efavirenz Neurotoxicity Syndrome (LENS).
Topics: Adult; Alkynes; Anti-HIV Agents; Arylamine N-Acetyltransferase; Benzoxazines; Cyclopropanes; Cytochr | 2022 |
Adherence to Isoniazid Preventive Therapy among children living with tuberculosis patients in Delhi, India: An exploratory prospective study.
Topics: Antitubercular Agents; Child; HIV Infections; Humans; India; Isoniazid; Prospective Studies; Tubercu | 2022 |
Influence of NAT2 Genotype and Maturation on Isoniazid Exposure in Low-Birth-Weight and Preterm Infants With or Without Human Immunodeficiency Virus (HIV) Exposure.
Topics: Antitubercular Agents; Arylamine N-Acetyltransferase; Child, Preschool; Genotype; HIV; HIV Infection | 2022 |
Tuberculosis treatment intermittency in the continuation phase and mortality in HIV-positive persons receiving antiretroviral therapy.
Topics: Adult; Antitubercular Agents; Brazil; Cohort Studies; HIV Infections; Humans; Isoniazid; Tuberculosi | 2022 |
Barriers and facilitators for isoniazid preventive therapy (IPT) administration in children under 5 years of age in the Dominican Republic.
Topics: Antitubercular Agents; Child; Child, Preschool; Dominican Republic; HIV Infections; Humans; Isoniazi | 2022 |
Isoniazid-associated pellagra during mass scale-up of tuberculosis preventive therapy: a case-control study.
Topics: Antitubercular Agents; Case-Control Studies; Exanthema; Female; HIV Infections; Humans; Isoniazid; M | 2022 |
Tuberculosis and isoniazid prophylaxis among adult HIV positive patients on ART in Northwest Ethiopia.
Topics: Adult; Antitubercular Agents; Ethiopia; HIV Infections; HIV Seropositivity; Humans; Incidence; Isoni | 2022 |
Incidence of tuberculosis among PLHIV on antiretroviral therapy who initiated isoniazid preventive therapy: A multi-center retrospective cohort study.
Topics: Antitubercular Agents; Cohort Studies; HIV Infections; Humans; Incidence; Isoniazid; Multicenter Stu | 2022 |
Diagnostic Accuracy of Therapeutic Drug Monitoring During Tuberculosis Treatment.
Topics: Antitubercular Agents; Drug Monitoring; Ethambutol; HIV Infections; Humans; Isoniazid; Pyrazinamide; | 2022 |
High mortality among patients hospitalized for drug-resistant tuberculosis with acquired second-line drug resistance and high HIV prevalence.
Topics: Adult; Antitubercular Agents; Drug Resistance; Female; Fluoroquinolones; HIV Infections; Humans; Iso | 2022 |
Isoniazid preventive therapy and tuberculosis transcriptional signatures in people with HIV.
Topics: Adult; Antitubercular Agents; Cross-Sectional Studies; HIV Infections; Humans; Isoniazid; Tuberculos | 2022 |
IFN-γ ELISpot in Severe Cutaneous Adverse Reactions to First-Line Antituberculosis Drugs in an HIV Endemic Setting.
Topics: Antitubercular Agents; Ethambutol; HIV Infections; Humans; Interferon-gamma; Isoniazid; Pyrazinamide | 2022 |
The impact of HIV and tuberculosis interventions on South African adult tuberculosis trends, 1990-2019: a mathematical modeling analysis.
Topics: Adult; Bayes Theorem; HIV Infections; Humans; Incidence; Isoniazid; South Africa; Tuberculosis | 2022 |
Promoting tuberculosis preventive therapy in HIV.
Topics: Antitubercular Agents; HIV Infections; Humans; Isoniazid; Tuberculosis | 2022 |
Drop-offs in the isoniazid preventive therapy cascade among children living with HIV in western Kenya, 2015-2019.
Topics: Antitubercular Agents; Child; HIV Infections; Humans; Isoniazid; Kenya; Tuberculosis | 2022 |
Prevalence and associated factors of tuberculosis among isoniazid users and non-users of HIV patients in Dessie, Ethiopia.
Topics: Adult; Antitubercular Agents; Cross-Sectional Studies; Ethiopia; HIV Infections; Humans; Incidence; | 2022 |
Population Pharmacokinetic Modeling and Simulation of Rifapentine Supports Concomitant Antiretroviral Therapy with Efavirenz and Non-Weight Based Dosing.
Topics: Alkynes; Anti-Retroviral Agents; Antitubercular Agents; Benzoxazines; Cyclopropanes; HIV Infections; | 2022 |
An evaluation of the isoniazid preventive therapy program performance for under-fives in Kwekwe City, January 2019 - December 2020: a descriptive cross-sectional study.
Topics: Antitubercular Agents; Child; Contact Tracing; Cross-Sectional Studies; HIV Infections; Humans; Ison | 2022 |
Unhealthy Alcohol Use Is Associated With Suboptimal Adherence to Isoniazid Preventive Therapy in Persons With HIV in Southwestern Uganda.
Topics: Alcohol Drinking; Alcoholism; Antitubercular Agents; Female; HIV Infections; Humans; Isoniazid; Male | 2022 |
Effectiveness and safety of available preventive tuberculosis treatment regimens for children and adolescents: protocol for a systematic review and network meta-analysis.
Topics: Adolescent; Child; HIV Infections; Humans; Isoniazid; Latent Tuberculosis; Network Meta-Analysis; Sy | 2022 |
Effects of Enzyme Induction and Polymorphism on the Pharmacokinetics of Isoniazid and Rifampin in Tuberculosis/HIV Patients.
Topics: Antitubercular Agents; Chromatography, Liquid; Cytochrome P-450 CYP2C19; Enzyme Induction; HIV Infec | 2022 |
Knowledge and Attitudes of Indonesian General Practitioners Towards the Isoniazid Preventive Therapy Program in Indonesia.
Topics: Antitubercular Agents; Attitude; General Practitioners; HIV Infections; Humans; Indonesia; Isoniazid | 2022 |
Isoniazid prophylaxis: highly effective but underutilised to prevent tuberculosis in people living with HIV.
Topics: Antitubercular Agents; HIV Infections; Humans; Isoniazid; Tuberculosis | 2022 |
Re-evaluating the health impact and cost-effectiveness of tuberculosis preventive treatment for modern HIV cohorts on antiretroviral therapy: a modelling analysis using data from Tanzania.
Topics: Antitubercular Agents; CD4 Lymphocyte Count; Cost-Benefit Analysis; HIV Infections; Humans; Isoniazi | 2022 |
Health workers' knowledge and practice of Isoniazid preventive treatment guidelines in health facilities in Ebonyi State, Nigeria.
Topics: Cross-Sectional Studies; Health Facilities; HIV Infections; Humans; Isoniazid; Nigeria | 2022 |
Health workers' knowledge and practice of Isoniazid preventive treatment guidelines in health facilities in Ebonyi State, Nigeria.
Topics: Cross-Sectional Studies; Health Facilities; HIV Infections; Humans; Isoniazid; Nigeria | 2022 |
Health workers' knowledge and practice of Isoniazid preventive treatment guidelines in health facilities in Ebonyi State, Nigeria.
Topics: Cross-Sectional Studies; Health Facilities; HIV Infections; Humans; Isoniazid; Nigeria | 2022 |
Health workers' knowledge and practice of Isoniazid preventive treatment guidelines in health facilities in Ebonyi State, Nigeria.
Topics: Cross-Sectional Studies; Health Facilities; HIV Infections; Humans; Isoniazid; Nigeria | 2022 |
Health workers' knowledge and practice of Isoniazid preventive treatment guidelines in health facilities in Ebonyi State, Nigeria.
Topics: Cross-Sectional Studies; Health Facilities; HIV Infections; Humans; Isoniazid; Nigeria | 2022 |
Health workers' knowledge and practice of Isoniazid preventive treatment guidelines in health facilities in Ebonyi State, Nigeria.
Topics: Cross-Sectional Studies; Health Facilities; HIV Infections; Humans; Isoniazid; Nigeria | 2022 |
Health workers' knowledge and practice of Isoniazid preventive treatment guidelines in health facilities in Ebonyi State, Nigeria.
Topics: Cross-Sectional Studies; Health Facilities; HIV Infections; Humans; Isoniazid; Nigeria | 2022 |
Health workers' knowledge and practice of Isoniazid preventive treatment guidelines in health facilities in Ebonyi State, Nigeria.
Topics: Cross-Sectional Studies; Health Facilities; HIV Infections; Humans; Isoniazid; Nigeria | 2022 |
Health workers' knowledge and practice of Isoniazid preventive treatment guidelines in health facilities in Ebonyi State, Nigeria.
Topics: Cross-Sectional Studies; Health Facilities; HIV Infections; Humans; Isoniazid; Nigeria | 2022 |
Assessment of contextual factors shaping delivery and uptake of isoniazid preventive therapy among people living with HIV in Dar es salaam, Tanzania.
Topics: Antitubercular Agents; HIV Infections; Humans; Isoniazid; Tanzania; Tuberculosis | 2022 |
Assessment of contextual factors shaping delivery and uptake of isoniazid preventive therapy among people living with HIV in Dar es salaam, Tanzania.
Topics: Antitubercular Agents; HIV Infections; Humans; Isoniazid; Tanzania; Tuberculosis | 2022 |
Assessment of contextual factors shaping delivery and uptake of isoniazid preventive therapy among people living with HIV in Dar es salaam, Tanzania.
Topics: Antitubercular Agents; HIV Infections; Humans; Isoniazid; Tanzania; Tuberculosis | 2022 |
Assessment of contextual factors shaping delivery and uptake of isoniazid preventive therapy among people living with HIV in Dar es salaam, Tanzania.
Topics: Antitubercular Agents; HIV Infections; Humans; Isoniazid; Tanzania; Tuberculosis | 2022 |
Assessment of contextual factors shaping delivery and uptake of isoniazid preventive therapy among people living with HIV in Dar es salaam, Tanzania.
Topics: Antitubercular Agents; HIV Infections; Humans; Isoniazid; Tanzania; Tuberculosis | 2022 |
Assessment of contextual factors shaping delivery and uptake of isoniazid preventive therapy among people living with HIV in Dar es salaam, Tanzania.
Topics: Antitubercular Agents; HIV Infections; Humans; Isoniazid; Tanzania; Tuberculosis | 2022 |
Assessment of contextual factors shaping delivery and uptake of isoniazid preventive therapy among people living with HIV in Dar es salaam, Tanzania.
Topics: Antitubercular Agents; HIV Infections; Humans; Isoniazid; Tanzania; Tuberculosis | 2022 |
Assessment of contextual factors shaping delivery and uptake of isoniazid preventive therapy among people living with HIV in Dar es salaam, Tanzania.
Topics: Antitubercular Agents; HIV Infections; Humans; Isoniazid; Tanzania; Tuberculosis | 2022 |
Assessment of contextual factors shaping delivery and uptake of isoniazid preventive therapy among people living with HIV in Dar es salaam, Tanzania.
Topics: Antitubercular Agents; HIV Infections; Humans; Isoniazid; Tanzania; Tuberculosis | 2022 |
High Isoniazid Exposures When Administered with Rifapentine Once Weekly for Latent Tuberculosis in Individuals with Human Immunodeficiency Virus.
Topics: Adult; Antitubercular Agents; Arylamine N-Acetyltransferase; Body Weight; Drug Therapy, Combination; | 2023 |
Initiation and adherence to isoniazid preventive therapy in children under 5 years of age in Manhiça, Southern Mozambique.
Topics: Adult; Antitubercular Agents; Child; Child, Preschool; Health Facilities; HIV Infections; Humans; Is | 2022 |
Viral suppression among adults with HIV receiving routine dolutegravir-based antiretroviral therapy and 3 months weekly isoniazid-rifapentine.
Topics: Adult; Antitubercular Agents; Drug Therapy, Combination; Female; HIV Infections; Humans; Isoniazid; | 2023 |
Progress on diagnosis and treatment of latent tuberculosis infection.
Topics: Antitubercular Agents; HIV Infections; Humans; Isoniazid; Latent Tuberculosis; Rifampin | 2022 |
Healthcare workers' knowledge and practice of the South African national tuberculosis management guidelines.
Topics: Child; Cross-Sectional Studies; Female; HIV Infections; Humans; Isoniazid; Male; South Africa; Tuber | 2023 |
Safety and tolerability of isoniazid preventive therapy for tuberculosis for persons with HIV with and without alcohol use.
Topics: Alcohol Drinking; Antitubercular Agents; HIV Infections; Humans; Isoniazid; Prospective Studies; Tub | 2023 |
Pharmacogenetic interactions of efavirenz or rifampin and isoniazid with levonorgestrel emergency contraception during treatment of HIV or tuberculosis.
Topics: Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Contraception, Postcoital; Cytochrome P-450 CY | 2023 |
Clinicopathological profile of peritoneal tuberculosis and a new scoring model for predicting mortality: an international ID-IRI study.
Topics: Adult; Antitubercular Agents; Female; HIV Infections; Humans; Isoniazid; Liver Cirrhosis; Male; Midd | 2023 |
Isoniazid preventive therapy completion and factors associated with non-completion among patients on antiretroviral therapy at Kisenyi Health Centre IV, Kampala, Uganda.
Topics: Female; Health Facilities; HIV Infections; Humans; Isoniazid; Male; Retrospective Studies; Uganda | 2023 |
Alternative dolutegravir dosing strategies with concurrent rifapentine utilized for latent tuberculosis treatment.
Topics: Anti-HIV Agents; Drug Therapy, Combination; HIV Infections; Humans; Isoniazid; Latent Tuberculosis; | 2023 |
Prevalence and predictors of tuberculosis among HIV patients who completed isoniazid preventive therapy (IPT) at Reach out Mbuya community health initiative.
Topics: Adult; Antitubercular Agents; Cross-Sectional Studies; HIV; HIV Infections; HIV Seropositivity; Huma | 2023 |
Pharmacokinetics, Safety, and Tolerability of Once-Daily Darunavir With Cobicistat and Weekly Isoniazid/Rifapentine.
Topics: Cobicistat; Cross-Over Studies; Darunavir; Drug Combinations; HIV Infections; Humans; Isoniazid | 2023 |
Evaluating pediatric tuberculosis dosing guidelines: A model-based individual data pooled analysis.
Topics: Adolescent; Adult; Antitubercular Agents; Child; Child, Preschool; Female; HIV; HIV Infections; Huma | 2023 |
The effect of antenatal isoniazid preventive therapy on birth outcomes in Western Kenya.
Topics: Female; HIV Infections; Humans; Infant, Newborn; Isoniazid; Kenya; Perinatal Death; Pregnancy; Prema | 2023 |
Effect of HIV infection on plasma exposure to first-line TB drugs and target attainment in children.
Topics: Antitubercular Agents; Child; Child, Preschool; Coinfection; HIV Infections; Humans; Isoniazid; Pyra | 2023 |
Drug rash vs. immune reconstitution inflammatory syndrome (IRIS)-a diagnostic dilemma.
Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Diagnosis, Differential; Exanthe | 2019 |
Brief Report: High Programmatic Isoniazid Preventive Therapy (IPT) Use in Pregnancy Among HIV-Infected Women.
Topics: Adult; Antitubercular Agents; Female; HIV Infections; Humans; Isoniazid; Kenya; Postpartum Period; P | 2019 |
Gynecomastia in HIV-positive adult men receiving efavirenz-based antiretroviral therapy at Newlands clinic, Harare, Zimbabwe.
Topics: Adult; Alkynes; Amlodipine; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cohort Studies; Cyc | 2019 |
Factors associated with isoniazid resistant tuberculosis among human immunodeficiency virus positive patients in Swaziland: a case-control study.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Case-Control Studies; Eswatini; | 2019 |
Incidence and determinants of mortality among adult HIV infected patients on second-line antiretroviral treatment in Amhara region, Ethiopia: a retrospective follow up study.
Topics: Adolescent; Adult; Anti-HIV Agents; Bedridden Persons; Educational Status; Ethiopia; Female; Follow- | 2019 |
High mortality during tuberculosis retreatment at a Ghanaian tertiary center: a retrospective cohort study.
Topics: Adult; Antitubercular Agents; Cohort Studies; Drug Resistance, Multiple, Bacterial; Female; Ghana; H | 2019 |
Determinants of alcohol use among people living with HIV initiating isoniazid preventive therapy in Ethiopia.
Topics: Adult; Alcohol Drinking; Alcoholism; Antitubercular Agents; Catha; Cross-Sectional Studies; Ethiopia | 2019 |
Promoting Tuberculosis Preventive Therapy for People Living with HIV in South Africa: Interventions Hindered by Complicated Clinical Guidelines and Imbalanced Patient-Provider Dynamics.
Topics: Antitubercular Agents; Female; Health Promotion; HIV Infections; Humans; Isoniazid; Male; South Afri | 2020 |
Body mass index variation over time and associated factors among HIV-positive adults on second-line ART in north-west Ethiopia: a retrospective follow-up study.
Topics: Adult; Anti-HIV Agents; Anti-Infective Agents; Antiretroviral Therapy, Highly Active; Body Mass Inde | 2019 |
Comparative analysis of the effectiveness of tuberculosis prophylaxis in patients with HIV/AIDS treated with isoniazid.
Topics: Antibiotic Prophylaxis; Antitubercular Agents; Female; HIV Infections; Humans; Isoniazid; Male; Pros | 2019 |
Adherence to tuberculosis preventive therapy measured by urine metabolite testing among people with HIV.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Brazil; Cross-Sectional Studies; Female; HIV Infectio | 2020 |
Isoniazid preventive therapy: Uptake, incidence of tuberculosis and survival among people living with HIV in Bulawayo, Zimbabwe.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Female; HIV Infections; Humans; | 2019 |
Isoniazid Preventive Therapy and Pregnancy Outcomes in Women Living With Human Immunodeficiency Virus in the Tshepiso Cohort.
Topics: Antitubercular Agents; Female; HIV; HIV Infections; Humans; Infant; Infant, Newborn; Isoniazid; Preg | 2020 |
Implementation of isoniazid preventive therapy in people living with HIV in Zambia: challenges and lessons.
Topics: Anti-Retroviral Agents; Antitubercular Agents; Female; HIV Infections; Humans; Incidence; Isoniazid; | 2019 |
Inequality in uptake of isoniazid prevention therapy and Mantoux test among pregnant women with HIV in the Eastern Cape, South Africa.
Topics: Adolescent; Adult; Female; Healthcare Disparities; HIV Infections; Humans; Infectious Disease Transm | 2019 |
Safety and Effectiveness of Isoniazid Preventive Therapy in Pregnant Women Living with Human Immunodeficiency Virus on Antiretroviral Therapy: An Observational Study Using Linked Population Data.
Topics: Antitubercular Agents; Female; HIV; HIV Infections; Humans; Isoniazid; Pregnancy; Pregnant Women; So | 2020 |
Early antituberculosis drug exposure in hospitalized patients with human immunodeficiency virus-associated tuberculosis.
Topics: Adult; Antitubercular Agents; Female; HIV; HIV Infections; Humans; Isoniazid; Male; Pyrazinamide; Tu | 2020 |
To start or to complete? - Challenges in implementing tuberculosis preventive therapy among people living with HIV: a mixed-methods study from Karnataka, India.
Topics: Adolescent; Adult; Aged; AIDS-Related Opportunistic Infections; Antitubercular Agents; Cohort Studie | 2020 |
Outcome of Isoniaiz Preventive Therapy in HIV Positive Patient.
Topics: Antitubercular Agents; HIV Infections; Humans; Isoniazid | 2020 |
Incidence of Tuberculosis after Routine IPT (Isoniazid Preventive Therapy) in HIV Infected Patients at a Tertiary Center.
Topics: Antitubercular Agents; HIV Infections; Humans; Incidence; Isoniazid; Tuberculosis | 2020 |
Model-Based Assessment of Variability in Isoniazid Pharmacokinetics and Metabolism in Patients Co-Infected With Tuberculosis and HIV: Implications for a Novel Dosing Strategy.
Topics: Adult; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Biological Availability; CD4 L | 2020 |
Access and adherence to isoniazid preventive therapy and occurrence of active TB in a cohort of people living with HIV: a retrospective cohort study in Sao Paulo, Brazil.
Topics: Adult; Antitubercular Agents; Brazil; Cohort Studies; Female; HIV Infections; Humans; Isoniazid; Lat | 2020 |
Effectiveness of Isoniazid Preventive Therapy to Reduce Tuberculosis Incidence in the Context of Antiretroviral Therapy.
Topics: Adolescent; Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Female; HIV Infections; Humans; Inc | 2020 |
Improving coverage and completion rate of isoniazid preventive therapy among eligible HIV patients using quality improvement approaches: a case study of State Hospital, Ijebu Ode, Ogun State, Nigeria.
Topics: Adolescent; Adult; Antitubercular Agents; Child; Delivery of Health Care; HIV Infections; Humans; Is | 2019 |
HIV, Pregnancy, and Isoniazid Preventive Therapy.
Topics: Antitubercular Agents; Female; HIV Infections; Humans; Isoniazid; Postpartum Period; Pregnancy; Tube | 2020 |
HIV, Pregnancy, and Isoniazid Preventive Therapy. Reply.
Topics: Antitubercular Agents; Female; HIV Infections; Humans; Isoniazid; Pregnancy; Tuberculosis | 2020 |
New guidelines for latent tuberculosis.
Topics: Adult; Antibiotics, Antitubercular; Child; Clinical Trials as Topic; Drug Therapy, Combination; Guid | 2020 |
Prevention of tuberculosis in HIV infection with novel drugs.
Topics: Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Isoniazid; Oxazines; Piperazines; Pyridones; | 2020 |
Trend analysis of tuberculosis case notifications with scale-up of antiretroviral therapy and roll-out of isoniazid preventive therapy in Zimbabwe, 2000-2018.
Topics: Antitubercular Agents; HIV Infections; Humans; Isoniazid; Tuberculosis; Zimbabwe | 2020 |
Determinants of isoniazid preventive therapy completion among people living with HIV attending care and treatment clinics from 2013 to 2017 in Dar es Salaam Region, Tanzania. A cross-sectional analytical study.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Antibiotic Prophylaxis; Antitubercular Age | 2020 |
Trials of Tuberculosis-Preventive Therapy in People with HIV Infection.
Topics: Antibiotic Prophylaxis; Antitubercular Agents; HIV Infections; Humans; Isoniazid; Latent Tuberculosi | 2020 |
Reply to Swindells
Topics: Antitubercular Agents; HIV Infections; Humans; Isoniazid; Latent Tuberculosis | 2020 |
Priorities among HIV-positive individuals for tuberculosis preventive therapies.
Topics: Adult; Antitubercular Agents; Health Personnel; HIV Infections; Humans; Isoniazid; Tuberculosis | 2020 |
A prospective cohort study of outcomes for isoniazid prevention therapy: a nested study from a national QI collaborative in Uganda.
Topics: Adolescent; Adult; Antitubercular Agents; Child; Female; HIV Infections; Humans; Incidence; Intersec | 2020 |
The social implications of participant choice on adherence to Isonaizid Preventive Therapy (IPT): A follow-up study to high completion rates in Eswatini.
Topics: Adult; Ambulatory Care Facilities; Antitubercular Agents; Choice Behavior; Community Health Workers; | 2020 |
Primary breast tuberculosis in an HIV-infected patient.
Topics: Adult; Antitubercular Agents; Biopsy; Breast; Ethambutol; Female; HIV Infections; Humans; Isoniazid; | 2020 |
Performance of the Roche cobas MTB Assay for the Molecular Diagnosis of Pulmonary Tuberculosis in a High HIV Burden Setting.
Topics: Adolescent; Adult; Aged; Biological Assay; Cohort Studies; Cost of Illness; Female; HIV Infections; | 2020 |
Safety and Efficacy of Rifampin or Isoniazid Among People With Mycobacterium tuberculosis Infection and Living With Human Immunodeficiency Virus or Other Health Conditions: Post Hoc Analysis of 2 Randomized Trials.
Topics: Adult; Antitubercular Agents; Drug Administration Schedule; HIV; HIV Infections; Humans; Isoniazid; | 2021 |
Safety and Efficacy of Rifampin or Isoniazid Among People With Mycobacterium tuberculosis Infection and Living With Human Immunodeficiency Virus or Other Health Conditions: Post Hoc Analysis of 2 Randomized Trials.
Topics: Adult; Antitubercular Agents; Drug Administration Schedule; HIV; HIV Infections; Humans; Isoniazid; | 2021 |
Safety and Efficacy of Rifampin or Isoniazid Among People With Mycobacterium tuberculosis Infection and Living With Human Immunodeficiency Virus or Other Health Conditions: Post Hoc Analysis of 2 Randomized Trials.
Topics: Adult; Antitubercular Agents; Drug Administration Schedule; HIV; HIV Infections; Humans; Isoniazid; | 2021 |
Safety and Efficacy of Rifampin or Isoniazid Among People With Mycobacterium tuberculosis Infection and Living With Human Immunodeficiency Virus or Other Health Conditions: Post Hoc Analysis of 2 Randomized Trials.
Topics: Adult; Antitubercular Agents; Drug Administration Schedule; HIV; HIV Infections; Humans; Isoniazid; | 2021 |
Multidrug-resistant tuberculosis in Imo State, Southeast, Nigeria.
Topics: Antitubercular Agents; Cross-Sectional Studies; HIV Infections; Humans; Isoniazid; Male; Microbial S | 2020 |
Characteristics of pulmonary multidrug-resistant tuberculosis patients in Tigray Region, Ethiopia: A cross-sectional study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Cross-Sectional Studies; Ethiopia | 2020 |
Prevalence, risk factors and treatment outcomes of isoniazid resistant TB in Bulawayo city, Zimbabwe: A cohort study.
Topics: Adolescent; Adult; Female; HIV Infections; Humans; Isoniazid; Male; Middle Aged; Mycobacterium tuber | 2020 |
Knowledge and adherence to isoniazid preventive therapy among people living with HIV in multilevel health facilities in South-East, Nigeria: baseline findings from a quasi-experimental study.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Female; Health Knowledge, Attitudes, Practice; HIV In | 2020 |
Successful implementation of isoniazid preventive therapy at a pediatric HIV clinic in Tanzania.
Topics: Adolescent; Ambulatory Care Facilities; Anti-Retroviral Agents; Antitubercular Agents; Caregivers; C | 2020 |
Urine Biomarker Assessment of Infant Adherence to Isoniazid Prophylaxis.
Topics: Antitubercular Agents; Biomarkers; Cohort Studies; Female; HIV Infections; Humans; Infant; Isoniazid | 2021 |
Cost-effectiveness of one month of daily isoniazid and rifapentine versus three months of weekly isoniazid and rifapentine for prevention of tuberculosis among people receiving antiretroviral therapy in Uganda.
Topics: Anti-HIV Agents; Antitubercular Agents; Cost-Benefit Analysis; Drug Administration Schedule; Drug Th | 2020 |
Tuberculosis prevention in children: a prospective community-based study in South Africa.
Topics: Adult; Antitubercular Agents; Child; Child, Preschool; Cohort Studies; HIV Infections; Humans; Infan | 2021 |
Evaluation of 6-Month Versus Continuous Isoniazid Preventive Therapy for Mycobacterium tuberculosis in Adults Living With HIV/AIDS in Malawi.
Topics: Adult; Antitubercular Agents; Drug Administration Schedule; HIV Infections; Humans; Incidence; Isoni | 2020 |
Treatment outcomes and factors associated with unfavourable outcome among previously treated tuberculosis patients with isoniazid resistance in four regions of Cameroon.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Cameroon; Child; Child, Preschool | 2020 |
Evaluation of the uptake of tuberculosis preventative therapy for people living with HIV in Namibia: a multiple methods analysis.
Topics: Adult; Antitubercular Agents; Coinfection; Female; HIV Infections; Humans; Isoniazid; Male; Mass Scr | 2020 |
Outcomes of isoniazid preventive therapy among people living with HIV in Kenya: A retrospective study of routine health care data.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; AIDS-Related Opportunistic Infections; Ambulatory Care F | 2020 |
Coverage of isoniazid preventive therapy among people living with HIV; A retrospective cohort study in Tanzania (2012-2016).
Topics: Adolescent; Adult; Antitubercular Agents; Child; Child, Preschool; Cohort Studies; Female; HIV Infec | 2021 |
Predictors of suboptimal adherence to isoniazid preventive therapy among adolescents and children living with HIV.
Topics: Adolescent; Adolescent Behavior; Adult; Age Factors; Caregivers; Child; Child Behavior; Eswatini; Fe | 2020 |
Implementation of TB preventive therapy in Uganda: effect of an intervention on completion rates.
Topics: Antitubercular Agents; HIV Infections; Humans; Isoniazid; Tuberculosis; Uganda | 2021 |
Integrated TB and HIV care for Mozambican children: temporal trends, site-level determinants of performance, and recommendations for improved TB preventive treatment.
Topics: Antitubercular Agents; Child; HIV Infections; Humans; Incidence; Isoniazid; Mozambique; Retrospectiv | 2021 |
Patient choice improves self-efficacy and intention to complete tuberculosis preventive therapy in a routine HIV program setting in Uganda.
Topics: Adult; Decision Making; Directly Observed Therapy; Female; HIV Infections; Humans; Isoniazid; Latent | 2021 |
Closing the loop in child TB contact management: completion of TB preventive therapy outcomes in western Kenya.
Topics: Antitubercular Agents; Child; HIV Infections; Humans; Isoniazid; Kenya; Retrospective Studies; Tuber | 2021 |
Drug-resistant TB prevalence study in 5 health institutions in Haiti.
Topics: Adult; Antitubercular Agents; Coinfection; Cross-Sectional Studies; Drug Resistance, Multiple, Bacte | 2021 |
Early-phase scale-up of isoniazid preventive therapy for people living with HIV in two districts in Malawi (2017).
Topics: Adolescent; Adult; Ambulatory Care Facilities; Antitubercular Agents; Child; Child, Preschool; Femal | 2021 |
Implementation of isoniazid preventive therapy in southern Lima, Peru: an analysis of health center characteristics.
Topics: Adolescent; Adult; Antitubercular Agents; Child; Child, Preschool; Female; HIV Infections; Humans; I | 2021 |
Can isoniazid preventive therapy be scaled up rapidly? Lessons learned in Kenya, 2014-2018.
Topics: Antitubercular Agents; HIV Infections; Humans; Isoniazid; Kenya; Tuberculosis | 2021 |
Isoniazid preventive therapy use among adult people living with HIV in Zimbabwe.
Topics: Adult; Antitubercular Agents; Cross-Sectional Studies; HIV Infections; Humans; Isoniazid; Tuberculos | 2021 |
Facility and patient barriers in the implementation of isoniazid preventive therapy for people living with HIV attending Care and Treatment Centers, Songea Municipality, Tanzania.
Topics: Adult; Aged; Antitubercular Agents; Cross-Sectional Studies; Female; HIV Infections; Humans; Isoniaz | 2021 |
Topics: Cross-Sectional Studies; DNA; Ethiopia; HeLa Cells; HIV Infections; Humans; Hydrogen Peroxide; Isoni | 2021 |
Effectiveness of isoniazid preventive therapy on incidence of tuberculosis among HIV-infected adults in programme setting.
Topics: Adult; Antitubercular Agents; HIV Infections; Humans; Incidence; India; Isoniazid; Pilot Projects; P | 2020 |
A Semimechanistic Pharmacokinetic Model for Depot Medroxyprogesterone Acetate and Drug-Drug Interactions With Antiretroviral and Antituberculosis Treatment.
Topics: Alkynes; Anti-Retroviral Agents; Antitubercular Agents; Benzoxazines; Contraceptive Agents, Hormonal | 2021 |
A Clinical Prediction Model for Unsuccessful Pulmonary Tuberculosis Treatment Outcomes.
Topics: Antitubercular Agents; HIV Infections; Humans; Isoniazid; Models, Statistical; Prognosis; Treatment | 2022 |
Impact of Isoniazid Preventive Therapy on Tuberculosis incidence among people living with HIV: A secondary data analysis using Inverse Probability Weighting of individuals attending HIV care and treatment clinics in Tanzania.
Topics: Adolescent; Adult; Child; Child, Preschool; Data Analysis; Female; Follow-Up Studies; HIV Infections | 2021 |
Unusual Recurrence of Antituberculosis Drug-Induced Hepatotoxicity in Children: A Case Series.
Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Child; HIV Infections; Humans; Isonia | 2021 |
Vikela Ekhaya: A Novel, Community-based, Tuberculosis Contact Management Program in a High Burden Setting.
Topics: Adult; Child; Contact Tracing; HIV Infections; Humans; Isoniazid; Levonorgestrel; Rifampin; Tubercul | 2022 |
Brief Report: Yield of Repeat Tuberculin Skin Testing for People Living With HIV in Brazil.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Brazil; CD4 Lymphocyte Count; F | 2021 |
A peculiarly characterised case of isoniazid-induced pellagra- 2 Ds and a C: a case report.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Constipation; Dementia; Dermatitis; Female; HIV Infec | 2021 |
Tuberculosis Preventive Therapy for People With HIV Infection in High Tuberculosis Burden Settings: How Much Is Enough?
Topics: Antibiotic Prophylaxis; HIV Infections; Humans; Isoniazid; Tuberculosis | 2021 |
QuantiFERON-TB Gold In-Tube Test for Tuberculosis Prevention in HIV-Infected Patients.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Diagnostic Tests, Routine; Disease Transmission, Inf | 2017 |
Tuberculosis resistance-conferring mutations with fitness cost among HIV-positive individuals in Uganda.
Topics: Adolescent; Adult; Antitubercular Agents; Drug Resistance, Multiple, Bacterial; Female; Genome, Bact | 2017 |
Implementing isoniazid preventive therapy in a tuberculosis treatment-experienced cohort on ART.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Cohort Studies; Female; HIV Infections; Humans; Incid | 2017 |
Prevention of TB using rifampicin plus isoniazid reduces nevirapine concentrations in HIV-exposed infants.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Breast Feeding; Case-Control Studies; Drug Therapy, C | 2017 |
Isoniazid-monoresistant tuberculosis is associated with poor treatment outcomes in Durban, South Africa.
Topics: Adult; Antitubercular Agents; Drug Resistance, Bacterial; Female; HIV Infections; Humans; Isoniazid; | 2017 |
[Characterization of clinical isolates of Mycobacterium tuberculosis from HIV positive individuals in Colombia, 2012].
Topics: Antitubercular Agents; Colombia; HIV Infections; Humans; Isoniazid; Rifampin; Streptomycin; Tubercul | 2017 |
Poncet's disease in human immunodeficiency virus: a case report.
Topics: Adult; Antibiotics, Antitubercular; Antiretroviral Therapy, Highly Active; Arthritis, Reactive; Etha | 2017 |
Pharmacokinetics of Pyrazinamide and Optimal Dosing Regimens for Drug-Sensitive and -Resistant Tuberculosis.
Topics: Adolescent; Adult; Antitubercular Agents; Coinfection; Drug Combinations; Ethambutol; HIV Infections | 2017 |
Cost-Effectiveness of isoniazid preventive therapy among HIV-infected patients clinicaly screened for latent tuberculosis infection in Dar es Salaam, Tanzania: A prospective Cohort study.
Topics: Antitubercular Agents; Cost-Benefit Analysis; HIV Infections; Humans; Isoniazid; Latent Tuberculosis | 2017 |
Distribution scheme of antituberculosis drug resistance among HIV patients in a referral centre over 10 years.
Topics: Adult; Antitubercular Agents; Coinfection; Cross-Sectional Studies; Drug Resistance, Multiple, Bacte | 2017 |
Prospective cohort study of the feasibility and yield of household child tuberculosis contact screening in Uganda.
Topics: Algorithms; Antitubercular Agents; Child, Preschool; Cohort Studies; Contact Tracing; Cough; Feasibi | 2017 |
Evaluation of the Isoniazid Preventive Therapy Care Cascade Among HIV-Positive Female Sex Workers in Mombasa, Kenya.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Directive | 2017 |
Isoniazid Preventive Therapy Completion in the Era of Differentiated HIV Care.
Topics: Adult; AIDS-Related Opportunistic Infections; Ambulatory Care Facilities; Antitubercular Agents; Com | 2017 |
High completion rates of isoniazid preventive therapy among persons living with HIV in Swaziland.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Child; Child, Preschool; Cohort Studies; Eswatini; F | 2017 |
Cohort profile of a study on outcomes related to tuberculosis and antiretroviral drug concentrations in Uganda: design, methods and patient characteristics of the SOUTH study.
Topics: Adult; Anti-Retroviral Agents; Antitubercular Agents; Biomedical Research; CD4 Lymphocyte Count; Coh | 2017 |
Low Frequency of Acquired Isoniazid and Rifampicin Resistance in Rifampicin-Susceptible Pulmonary Tuberculosis in a Setting of High HIV-1 Infection and Tuberculosis Coprevalence.
Topics: Adult; Anti-Retroviral Agents; Antitubercular Agents; Drug Resistance, Multiple, Bacterial; Female; | 2017 |
Treatment outcomes of rifampin-sparing treatment in patients with pulmonary tuberculosis with rifampin-mono-resistance or rifampin adverse events: A retrospective cohort analysis.
Topics: Adult; Age Distribution; Aged; Alcohol Drinking; Aminosalicylic Acid; Antitubercular Agents; Cohort | 2017 |
Implementing an isoniazid preventive therapy program for people living with HIV in Thailand.
Topics: Adolescent; Adult; Antitubercular Agents; Female; HIV Infections; Humans; Isoniazid; Male; Thailand; | 2017 |
Programmatic Evaluation of an Algorithm for Intensified Tuberculosis Case Finding and Isoniazid Preventive Therapy for People Living With HIV in Thailand and Vietnam.
Topics: Adolescent; Adult; Algorithms; Antitubercular Agents; Communicable Disease Control; Female; HIV Infe | 2017 |
Pharmacokinetics and Drug-Drug Interactions of Lopinavir-Ritonavir Administered with First- and Second-Line Antituberculosis Drugs in HIV-Infected Children Treated for Multidrug-Resistant Tuberculosis.
Topics: Anti-HIV Agents; Antitubercular Agents; Child; Drug Administration Schedule; Drug Combinations; Drug | 2018 |
A retrospective study on tuberculosis treatment outcomes at Jinka General Hospital, southern Ethiopia.
Topics: Adolescent; Adult; Antitubercular Agents; Coinfection; Drug Combinations; Ethambutol; Ethiopia; Fema | 2017 |
Isoniazid Preventive Therapy for People With HIV Who Are Heavy Alcohol Drinkers in High TB-/HIV-Burden Countries: A Risk-Benefit Analysis.
Topics: Adult; Alcoholism; Anti-Retroviral Agents; Antitubercular Agents; Brazil; Chemoprevention; Female; H | 2018 |
Suboptimal Antituberculosis Drug Concentrations and Outcomes in Small and HIV-Coinfected Children in India: Recommendations for Dose Modifications.
Topics: Adolescent; Age Factors; Antitubercular Agents; Body Weight; Child; Child, Preschool; Coinfection; D | 2018 |
Treatment outcomes and tolerability of the revised WHO anti-tuberculosis drug dosages for children.
Topics: Antitubercular Agents; Child, Preschool; Cohort Studies; Female; HIV Infections; Humans; Infant; Inf | 2018 |
Comment on: Effects of isoniazid resistance on TB treatment outcomes under programmatic conditions in a high-TB and -HIV setting: a prospective multicentre study.
Topics: Antitubercular Agents; HIV Infections; Humans; Isoniazid; Prospective Studies; Treatment Outcome | 2018 |
Completion of the tuberculosis care cascade in a community-based HIV linkage-to-care study in South Africa and Uganda.
Topics: Adolescent; Adult; Community Health Services; Female; HIV Infections; Humans; Isoniazid; Male; South | 2018 |
Incidence and determinants of tuberculosis infection among adult patients with HIV attending HIV care in north-east Ethiopia: a retrospective cohort study.
Topics: Adolescent; Adult; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Body Mass Index; Di | 2018 |
Tuberculosis treatment outcome and predictors in northern Ethiopian prisons: a five-year retrospective analysis.
Topics: Adolescent; Adult; Aftercare; Anti-Retroviral Agents; Antitubercular Agents; Coinfection; Directly O | 2018 |
Tuberculosis control interventions targeted to previously treated people in a high-incidence setting: a modelling study.
Topics: Adolescent; Adult; Antitubercular Agents; Bayes Theorem; Child; Child, Preschool; Epidemics; HIV Inf | 2018 |
Household point of care CD4 testing and isoniazid preventive therapy initiation in a household TB contact tracing programme in two districts of South Africa.
Topics: Adolescent; Adult; Antitubercular Agents; CD4 Antigens; CD4 Lymphocyte Count; Cluster Analysis; Cont | 2018 |
Individualizing Tuberculosis (TB) Treatment: Are TB Programs in High Burden Settings Ready for Prime Time Therapeutic Drug Monitoring?
Topics: Antitubercular Agents; Coinfection; Drug Monitoring; HIV; HIV Infections; Humans; Isoniazid; Rifampi | 2018 |
Priorities for Decreasing Morbidity and Mortality in Children With Advanced HIV Disease.
Topics: Adolescent; Africa South of the Sahara; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Anti | 2018 |
High rates of exposure to tuberculosis patients among HIV-infected health care workers in Botswana.
Topics: Adult; Antitubercular Agents; Botswana; Cross Infection; Cross-Sectional Studies; Female; Health Per | 2018 |
The effect of partner HIV status on motivation to take antiretroviral and isoniazid preventive therapies: a conjoint analysis.
Topics: Adult; Ambulatory Care Facilities; Anti-HIV Agents; Antitubercular Agents; Counseling; Female; HIV I | 2018 |
Cost-effectiveness of Preventive Therapy for Tuberculosis With Isoniazid and Rifapentine Versus Isoniazid Alone in High-Burden Settings.
Topics: Anti-HIV Agents; Antitubercular Agents; Cost-Benefit Analysis; Drug Therapy, Combination; HIV Infect | 2018 |
A proposed management algorithm for late-onset efavirenz neurotoxicity.
Topics: Adult; Algorithms; Alkynes; Antitubercular Agents; Benzoxazines; Brain Diseases; Cerebellar Ataxia; | 2018 |
Effects of isoniazid resistance on TB treatment outcomes under programmatic conditions in a high-TB and -HIV setting: a prospective multicentre study-authors' response.
Topics: Antitubercular Agents; HIV Infections; Humans; Isoniazid; Prospective Studies; Treatment Outcome | 2018 |
Drug-resistance patterns of Mycobacterium tuberculosis strains and associated risk factors among multi drug-resistant tuberculosis suspected patients from Ethiopia.
Topics: Antitubercular Agents; Ethambutol; Ethiopia; Female; HIV Infections; Humans; Isoniazid; Male; Mycoba | 2018 |
New and Noteworthy in Tuberculosis Diagnostics and Treatment.
Topics: Adult; Antitubercular Agents; Female; HIV Infections; Humans; Isoniazid; Latent Tuberculosis; Male; | 2018 |
Magnitude of opportunistic diseases and their predictors among adult people living with HIV enrolled in care: national level cross sectional study, Ethiopia.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; CD4 Lymphocyte Count; Cross-Se | 2018 |
Serious hepatotoxicity following use of isoniazid preventive therapy in HIV patients in Eritrea.
Topics: Adult; Aged; AIDS-Related Opportunistic Infections; Antiretroviral Therapy, Highly Active; Antituber | 2018 |
Pharmacokinetics of Efavirenz 400 mg Once Daily Coadministered With Isoniazid and Rifampicin in Human Immunodeficiency Virus-Infected Individuals.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Cyclopropanes; Fem | 2019 |
Burden, spectrum and outcomes of children with tuberculosis diagnosed at a district-level hospital in South Africa.
Topics: Adolescent; Antitubercular Agents; Child; Child, Preschool; Coinfection; Comorbidity; Cost of Illnes | 2018 |
Modeling the implementation of population-level isoniazid preventive therapy for tuberculosis control in a high HIV-prevalence setting.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Chemoprevention; Child; Female; H | 2018 |
Improved Treatment Outcomes With Bedaquiline When Substituted for Second-line Injectable Agents in Multidrug-resistant Tuberculosis: A Retrospective Cohort Study.
Topics: Adult; Antitubercular Agents; Coinfection; Diarylquinolines; Drug Resistance, Multiple, Bacterial; E | 2019 |
Therapeutic Drug Monitoring: The Need for Practical Guidance.
Topics: Coinfection; Drug Monitoring; HIV; HIV Infections; Humans; Isoniazid; Rifampin; Sputum; Tuberculosis | 2019 |
Projected population-wide impact of antiretroviral therapy-linked isoniazid preventive therapy in a high-burden setting.
Topics: Adult; Anti-Retroviral Agents; Antitubercular Agents; Chemoprevention; Disease Transmission, Infecti | 2019 |
Evaluation of the intensified tuberculosis case finding guidelines for children living with HIV.
Topics: Ambulatory Care; Anti-Retroviral Agents; Antitubercular Agents; Child; Child, Preschool; Female; Fol | 2018 |
Rapid drug susceptibility testing and treatment outcomes for multidrug-resistant tuberculosis in Peru.
Topics: Adolescent; Adult; Antitubercular Agents; Coinfection; Female; HIV Infections; Humans; Isoniazid; Lo | 2018 |
Revised Antituberculosis Drug Doses and Hepatotoxicity in HIV Negative Children.
Topics: Adolescent; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; | 2019 |
Factors affecting the acceptability of isoniazid preventive therapy among healthcare providers in selected HIV clinics in Nairobi County, Kenya: a qualitative study.
Topics: Ambulatory Care Facilities; Antitubercular Agents; Attitude of Health Personnel; Evaluation Studies | 2018 |
Potentially High Number of Ineffective Drugs with the Standard Shorter Course Regimen for Multidrug-Resistant Tuberculosis Treatment in Haiti.
Topics: Adult; Antitubercular Agents; Coinfection; Drug Resistance, Multiple, Bacterial; Ethambutol; Ethiona | 2019 |
Effect of isoniazid preventive therapy on tuberculosis incidence and associated risk factors among HIV infected adults in Tanzania: a retrospective cohort study.
Topics: Adult; Antitubercular Agents; Chemoprevention; Coinfection; Female; HIV Infections; HIV-1; Humans; I | 2019 |
Breakthrough tuberculosis disease among people with HIV - Should we be worried? A retrospective longitudinal study.
Topics: Adolescent; Adult; Antiretroviral Therapy, Highly Active; Antitubercular Agents; CD4 Lymphocyte Coun | 2019 |
Incidence and predictors of LTFU among adults with TB/HIV co-infection in two governmental hospitals, Mekelle, Ethiopia, 2009-2016: survival model approach.
Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Coinfection; Ethiopia; Female; HIV; HIV Infec | 2019 |
The Influence of Pharmacogenetic Variants in HIV/Tuberculosis Coinfected Patients in Uganda in the SOUTH Study.
Topics: Adult; Antitubercular Agents; Arylamine N-Acetyltransferase; Correlation of Data; Female; HIV Infect | 2019 |
Challenges and opportunities to prevent tuberculosis in people living with HIV in low-income countries.
Topics: Anti-HIV Agents; Antitubercular Agents; CD4 Lymphocyte Count; Developing Countries; HIV Infections; | 2019 |
Isoniazid preventive therapy for children in sub-Saharan Africa.
Topics: Africa South of the Sahara; Antitubercular Agents; Chemoprevention; Child; Disease Progression; HIV | 2019 |
IPT in people living with HIV in Myanmar: a five-fold decrease in incidence of TB disease and all-cause mortality.
Topics: Adolescent; Adult; Antitubercular Agents; Cohort Studies; Female; HIV Infections; Humans; Incidence; | 2019 |
High prevalence and incidence of tuberculosis in people living with the HIV in Mandalay, Myanmar, 2011-2017.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; CD4 Lymphocyte Count; Cohort Studies; Female; Follow- | 2019 |
Topics: Adult; Antitubercular Agents; Attitude of Health Personnel; Cross-Sectional Studies; Ethiopia; Femal | 2019 |
Risk factors for multidrug-resistant tuberculosis in northwest Ethiopia: A case-control study.
Topics: Adult; Antitubercular Agents; Case-Control Studies; Demography; Ethiopia; Female; HIV Infections; Ho | 2019 |
Drug resistance and pathogenic spectrum of patients coinfected with nontuberculous mycobacteria and human-immunodeficiency virus in Chengdu, China.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Aged, 80 and over; Antitubercular Agents; China; Cl | 2019 |
High prevalence of multi drug resistant tuberculosis in people living with HIV in Western India.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Child; Cross-Sectio | 2019 |
Initiation and completion rates of isoniazid preventive therapy among people living with HIV in Far-Western Region of Nepal: a retrospective cohort study.
Topics: Adolescent; Adult; Age Distribution; Aged; Antitubercular Agents; Child; Child, Preschool; Female; H | 2019 |
Predictors of isoniazid preventive therapy completion among HIV-infected patients receiving differentiated and non-differentiated HIV care in rural Uganda.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Cross-Sectional Studies; Female; HIV Infections; Huma | 2020 |
Tuberculosis decline in populations affected by HIV: a retrospective study of 12 countries in the WHO African Region.
Topics: Africa; Anti-Retroviral Agents; Antitubercular Agents; HIV Infections; Humans; Isoniazid; Mycobacter | 2019 |
Rifampin-resistant Tuberculosis in the United States, 1998-2014.
Topics: Antitubercular Agents; HIV Infections; Humans; Isoniazid; Microbial Sensitivity Tests; Mycobacterium | 2020 |
Incidence and predictors of tuberculosis among HIV-positive children at Adama Referral Hospital and Medical College, Oromia, Ethiopia: a retrospective follow-up study.
Topics: Anti-Retroviral Agents; Antitubercular Agents; Child; Child, Preschool; Coinfection; Ethiopia; Femal | 2019 |
A new tool for monitoring isoniazid preventive therapy.
Topics: Antitubercular Agents; Communicable Disease Control; Epidemics; HIV Infections; Humans; Isoniazid; N | 2013 |
Current integration of tuberculosis (TB) and HIV services in South Africa, 2011.
Topics: Anti-HIV Agents; Antitubercular Agents; Community Health Services; Cross-Sectional Studies; HIV Infe | 2013 |
High prevalence of tuberculosis and insufficient case detection in two communities in the Western Cape, South Africa.
Topics: Adolescent; Adult; Antitubercular Agents; Comorbidity; Directly Observed Therapy; Female; Health Sur | 2013 |
Isoniazid preventive treatment: predictors of adverse events and treatment completion.
Topics: Adolescent; Adult; Age Factors; Antitubercular Agents; Databases, Factual; Feasibility Studies; Fema | 2013 |
Drug resistance among new smear-positive pulmonary tuberculosis cases in Thailand.
Topics: Adult; Antitubercular Agents; Cohort Studies; Female; HIV Infections; Humans; Isoniazid; Male; Micro | 2013 |
Barriers to and motivations for the implementation of a treatment programme for latent tuberculosis infection using isoniazid for people living with HIV, in upper northern Thailand.
Topics: Adult; Antitubercular Agents; Cross-Sectional Studies; Female; Health Knowledge, Attitudes, Practice | 2013 |
Multidrug- and isoniazid-resistant tuberculosis in three high HIV burden African regions.
Topics: Adolescent; Adult; Africa South of the Sahara; Antitubercular Agents; Cross-Sectional Studies; Drug | 2013 |
Rifampin monoresistant tuberculosis and HIV comorbidity in California, 1993-2008: a retrospective cohort study.
Topics: Adult; Aged; Antitubercular Agents; California; Cohort Studies; Comorbidity; Drug Resistance, Bacter | 2013 |
Isoniazid prevention of HIV-associated tuberculosis.
Topics: Antitubercular Agents; Female; HIV Infections; Humans; Isoniazid; Male; Tuberculosis | 2013 |
Preventive therapy for child contacts of multidrug-resistant tuberculosis: a prospective cohort study.
Topics: Antitubercular Agents; Child, Preschool; Ethambutol; Female; HIV Infections; Humans; Infant; Infant, | 2013 |
Improving tuberculosis screening and isoniazid preventive therapy in an HIV clinic in Addis Ababa, Ethiopia.
Topics: Adult; Ambulatory Care Facilities; Antitubercular Agents; Checklist; Coinfection; Ethiopia; Female; | 2013 |
Effect of mycobacterial drug resistance patterns on patients' survival: a cohort study in Thailand.
Topics: Adolescent; Adult; Aged; Anti-Retroviral Agents; Antitubercular Agents; Child; Child, Preschool; Dia | 2013 |
Point-of-care C-reactive protein testing to facilitate implementation of isoniazid preventive therapy for people living with HIV.
Topics: Adult; Antitubercular Agents; C-Reactive Protein; Clinical Laboratory Techniques; Cohort Studies; Fe | 2014 |
A patient with HIV and tuberculosis with diminished clopidogrel response.
Topics: Antitubercular Agents; Clopidogrel; Drug Interactions; Drug Resistance; HIV Infections; HIV Protease | 2014 |
Tuberculosis case finding and isoniazid preventive therapy among people living with HIV at public health facilities of Addis Ababa, Ethiopia: a cross-sectional facility based study.
Topics: Adult; Antitubercular Agents; Cross-Sectional Studies; Ethiopia; Female; Health Facilities; HIV Infe | 2014 |
Tuberculosis screening and isoniazid preventive therapy implementation: a Brazilian experience.
Topics: Antitubercular Agents; Female; HIV Infections; Humans; Isoniazid; Male; Tuberculosis | 2014 |
The HIV basic care package: where is it available and who receives it? Findings from a mixed methods evaluation in Kenya and Uganda.
Topics: Adolescent; Adult; Anti-Infective Agents; Communicable Disease Control; Condoms; Cross-Sectional Stu | 2014 |
Detection of drug resistant Mycobacterium tuberculosis among patients with and without HIV infection in a rural setting.
Topics: Antitubercular Agents; Case-Control Studies; Coinfection; Drug Resistance, Bacterial; Drug Resistanc | 2013 |
Isoniazid preventive therapy use among patients on antiretroviral therapy: a missed opportunity.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; CD4 Lymphocyte Count; Chi-Square Distribution; Coinfe | 2014 |
Determinants of tuberculosis treatment completion among newborns in a high-burden setting.
Topics: Adult; Age Factors; Antitubercular Agents; Caregivers; Chi-Square Distribution; Coinfection; Female; | 2014 |
6-year follow-up of 522 HIV-positive individuals screened for Mycobacterium tuberculosis infection in Denmark.
Topics: Cohort Studies; Communicable Disease Control; Denmark; Diagnostic Tests, Routine; Female; Follow-Up | 2014 |
Preventive treatment for tuberculosis in people with HIV.
Topics: AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Female; HIV In | 2014 |
A home tracing program for contacts of people with tuberculosis or HIV and patients lost to care.
Topics: Ambulatory Care Facilities; Antitubercular Agents; Bacteriological Techniques; Contact Tracing; HIV | 2014 |
Perceived barriers to the implementation of Isoniazid preventive therapy for people living with HIV in resource constrained settings: a qualitative study.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Chemoprevention; Communication | 2014 |
Lichenoid drug reaction to isoniazid presenting as exfoliative dermatitis in a patient with acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antitubercular Agents; Dermatitis, Exfoliative; Drug Erup | 2015 |
The association between the ratio of monocytes:lymphocytes at age 3 months and risk of tuberculosis (TB) in the first two years of life.
Topics: Antitubercular Agents; Child, Preschool; Female; HIV Infections; Humans; Infant; Isoniazid; Lymphocy | 2014 |
The association between the ratio of monocytes:lymphocytes at age 3 months and risk of tuberculosis (TB) in the first two years of life.
Topics: Antitubercular Agents; Child, Preschool; Female; HIV Infections; Humans; Infant; Isoniazid; Lymphocy | 2014 |
The association between the ratio of monocytes:lymphocytes at age 3 months and risk of tuberculosis (TB) in the first two years of life.
Topics: Antitubercular Agents; Child, Preschool; Female; HIV Infections; Humans; Infant; Isoniazid; Lymphocy | 2014 |
The association between the ratio of monocytes:lymphocytes at age 3 months and risk of tuberculosis (TB) in the first two years of life.
Topics: Antitubercular Agents; Child, Preschool; Female; HIV Infections; Humans; Infant; Isoniazid; Lymphocy | 2014 |
Beneficial effect of isoniazid preventive therapy and antiretroviral therapy on the incidence of tuberculosis in people living with HIV in Ethiopia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Retroviral Agents; Antitubercular Agents; Child; Ch | 2014 |
Preventing tuberculosis among HIV-infected pregnant women in Lesotho: the case for rolling out active case finding and isoniazid preventive therapy.
Topics: Adult; Antitubercular Agents; Female; HIV Infections; Humans; Isoniazid; Lesotho; Logistic Models; P | 2014 |
Contact dermatitis-like cutaneous leishmaniasis in a Libyan HIV patient.
Topics: Adult; Antiprotozoal Agents; Drug Therapy, Combination; Fatty Acid Synthesis Inhibitors; HIV Infecti | 2014 |
Molecular detection and characterization of resistant genes in Mycobacterium tuberculosis complex from DNA isolated from tuberculosis patients in the Eastern Cape province South Africa.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Child; Child, Preschool; DNA, Bacterial; Female; HIV | 2014 |
Implementation of isoniazid preventive therapy for HIV-infected adults: overstatement of district reports.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Female; HIV Infections; Humans; | 2014 |
Cost-effectiveness of the Three I's for HIV/TB and ART to prevent TB among people living with HIV.
Topics: Algorithms; Antitubercular Agents; CD4 Lymphocyte Count; Cost-Benefit Analysis; Drug Resistance, Bac | 2014 |
Isoniazid prevented active tuberculosis in patients with HIV treated with antiretroviral therapy.
Topics: AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Female; HIV In | 2014 |
Effects of dosage, comorbidities, and food on isoniazid pharmacokinetics in Peruvian tuberculosis patients.
Topics: Adolescent; Adult; Anti-HIV Agents; Antitubercular Agents; Area Under Curve; Comorbidity; Diabetes M | 2014 |
[Epidemiology of bacillary pulmonary tuberculosis according to HIV status of patients followed in the department of infectious diseases Conakry (Guinea)].
Topics: Adult; Antitubercular Agents; CD4 Lymphocyte Count; Comorbidity; Female; Guinea; HIV Infections; Hos | 2014 |
Differences in clinical features of two immigrant populations with tuberculosis.
Topics: Adult; Antitubercular Agents; Asia; Comorbidity; Crowding; Drug Resistance, Bacterial; Drug Therapy, | 2015 |
Recurrence due to relapse or reinfection with Mycobacterium tuberculosis: a whole-genome sequencing approach in a large, population-based cohort with a high HIV infection prevalence and active follow-up.
Topics: Adult; Antitubercular Agents; Cohort Studies; Female; Follow-Up Studies; Genetic Variation; Genome-W | 2015 |
Investigating gender disparities in the profile and treatment outcomes of tuberculosis in Ebonyi state, Nigeria.
Topics: Adult; Antitubercular Agents; Cohort Studies; Coinfection; Ethambutol; Female; Health Status Dispari | 2015 |
Long-term protection from isoniazid preventive therapy for tuberculosis in HIV-infected patients in a medium-burden tuberculosis setting: the TB/HIV in Rio (THRio) study.
Topics: Adult; Antitubercular Agents; Brazil; Female; Follow-Up Studies; HIV Infections; Humans; Incidence; | 2015 |
Isoniazid preventive therapy in medium-incidence settings: the price is right.
Topics: Antitubercular Agents; Coinfection; Drug Costs; HIV Infections; Humans; Isoniazid; Latent Tuberculos | 2014 |
Effective anti-tuberculosis therapy correlates with plasma small RNA.
Topics: Adult; Antitubercular Agents; Biomarkers; Coinfection; Ethambutol; Female; Gene Expression Profiling | 2015 |
Tuberculosis prevention in South Africa.
Topics: Anti-HIV Agents; Antitubercular Agents; HIV Infections; Humans; Incidence; Isoniazid; Models, Theore | 2015 |
The effect of isoniazid preventive therapy on incidence of tuberculosis among HIV-infected clients under pre-ART care, Jimma, Ethiopia: a retrospective cohort study.
Topics: Adolescent; Adult; Age Factors; Antitubercular Agents; Cohort Studies; Disease-Free Survival; Ethiop | 2015 |
High mortality associated with retreatment of tuberculosis in a clinic in Kampala, Uganda: a retrospective study.
Topics: Adult; Antitubercular Agents; Coinfection; Ethambutol; Female; Follow-Up Studies; HIV Infections; Hu | 2015 |
Whole Genome Sequencing Investigation of a Tuberculosis Outbreak in Port-au-Prince, Haiti Caused by a Strain with a "Low-Level" rpoB Mutation L511P - Insights into a Mechanism of Resistance Escalation.
Topics: Adolescent; Adult; Antitubercular Agents; Bacterial Proteins; Coinfection; Disease Outbreaks; DNA-Di | 2015 |
Comparison of Three Commercial Molecular Assays for Detection of Rifampin and Isoniazid Resistance among Mycobacterium tuberculosis Isolates in a High-HIV-Prevalence Setting.
Topics: Antitubercular Agents; Drug Resistance, Bacterial; Genotyping Techniques; HIV Infections; Humans; Is | 2015 |
Overcoming Impediments to Global Implementation of Early Antiretroviral Therapy.
Topics: AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Female; HIV In | 2015 |
Effect of isoniazid preventive therapy on tuberculosis or death in persons with HIV: a retrospective cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Cohort Studies; Ethiopia; Female; | 2015 |
Acceptability and adherence to Isoniazid preventive therapy in HIV-infected patients clinically screened for latent tuberculosis in Dar es Salaam, Tanzania.
Topics: Adolescent; Adult; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Female; HIV Infecti | 2015 |
Interpreting hazard ratios.
Topics: Antitubercular Agents; Data Interpretation, Statistical; HIV Infections; Humans; Isoniazid; Randomiz | 2015 |
A Description of Mortality Associated with IPT plus ART Compared to ART Alone among HIV-Infected Individuals in Addis Ababa, Ethiopia: A Cohort Study.
Topics: Adolescent; Adult; Aged; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Cohort Studie | 2015 |
High completion of isoniazid preventive therapy among HIV-infected children and adults in Kinshasa, Democratic Republic of Congo.
Topics: Adult; Anti-Retroviral Agents; Antitubercular Agents; Child; Child, Preschool; Democratic Republic o | 2015 |
Implementation of isoniazid preventive therapy in an HIV clinic in Cambodia: high rates of discontinuation when combined with antiretroviral therapy.
Topics: Adult; Ambulatory Care Facilities; Anti-HIV Agents; Antitubercular Agents; Cambodia; Drug Interactio | 2015 |
Isoniazid exposure and pyridoxine levels in human immunodeficiency virus associated distal sensory neuropathy.
Topics: Adult; Antiretroviral Therapy, Highly Active; Arylamine N-Acetyltransferase; Coinfection; Female; HI | 2015 |
Determinants of the Sympatric Host-Pathogen Relationship in Tuberculosis.
Topics: Adolescent; Adult; Age Factors; Aged; Antitubercular Agents; Child; Child, Preschool; DNA, Intergeni | 2015 |
Model-Based Evaluation of Higher Doses of Rifampin Using a Semimechanistic Model Incorporating Autoinduction and Saturation of Hepatic Extraction.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Area Under Curve; Biological Availability; Biotransfo | 2016 |
Model-Based Evaluation of Higher Doses of Rifampin Using a Semimechanistic Model Incorporating Autoinduction and Saturation of Hepatic Extraction.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Area Under Curve; Biological Availability; Biotransfo | 2016 |
Model-Based Evaluation of Higher Doses of Rifampin Using a Semimechanistic Model Incorporating Autoinduction and Saturation of Hepatic Extraction.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Area Under Curve; Biological Availability; Biotransfo | 2016 |
Model-Based Evaluation of Higher Doses of Rifampin Using a Semimechanistic Model Incorporating Autoinduction and Saturation of Hepatic Extraction.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Area Under Curve; Biological Availability; Biotransfo | 2016 |
Prevalence of drug resistant TB among outpatients at an HIV/TB clinic in Lilongwe, Malawi.
Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Coinfection; Female; HIV Infections; Humans; | 2015 |
Cost-effectiveness of isoniazid preventive therapy for HIV-infected pregnant women in India.
Topics: Adolescent; Adult; Antitubercular Agents; Cost-Benefit Analysis; Female; HIV Infections; Humans; Ind | 2016 |
Cure of tuberculosis despite serum concentrations of antituberculosis drugs below published reference ranges.
Topics: Adult; Aged; Antitubercular Agents; Drug Monitoring; Female; HIV Infections; Humans; Isoniazid; Line | 2015 |
Implementation and Operational Research: Implementation of the WHO 2011 Recommendations for Isoniazid Preventive Therapy (IPT) in Children Living With HIV/AIDS: A Ugandan Experience.
Topics: Adolescent; AIDS-Related Opportunistic Infections; Antitubercular Agents; Child; Child, Preschool; F | 2016 |
Low Serum Concentrations of Rifampicin and Pyrazinamide Associated with Poor Treatment Outcomes in Children with Tuberculosis Related to HIV Status.
Topics: Antitubercular Agents; Child; Child, Preschool; Chromatography, High Pressure Liquid; Female; Follow | 2016 |
Factors associated with treatment for latent tuberculosis in persons living with HIV/AIDS.
Topics: Adult; Antitubercular Agents; Female; HIV Infections; Humans; Isoniazid; Latent Tuberculosis; Male; | 2015 |
Implementation and Operational Research: Feasibility of Using Tuberculin Skin Test Screening for Initiation of 36-Month Isoniazid Preventive Therapy in HIV-Infected Patients in Resource-Constrained Settings.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Cohort Studies; Eswatini; Female; HIV Infections; Hum | 2016 |
Post-treatment effect of isoniazid preventive therapy on tuberculosis incidence in HIV-infected individuals on antiretroviral therapy.
Topics: Anti-Retroviral Agents; Antitubercular Agents; Chemoprevention; HIV Infections; Humans; Incidence; I | 2016 |
Tuberculosis and immigration in an area of southwest Madrid.
Topics: Adult; Africa South of the Sahara; Antitubercular Agents; Emigrants and Immigrants; Female; HIV Infe | 2016 |
Implementation of Tuberculosis Intensive Case Finding, Isoniazid Preventive Therapy, and Infection Control ("Three I's") and HIV-Tuberculosis Service Integration in Lower Income Countries.
Topics: Africa; AIDS-Related Opportunistic Infections; Antitubercular Agents; Asia; Caribbean Region; HIV In | 2016 |
Determinants for tuberculosis in HIV-infected adults in Northwest Ethiopia: a multicentre case-control study.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Case-Control Studies; CD4 Lymph | 2016 |
Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in HIV-infected Indian children.
Topics: Adolescent; Age Factors; Antitubercular Agents; Child; Child, Preschool; Chromatography, Liquid; Coi | 2016 |
A Qualitative Evaluation of the Acceptability of an Interactive Voice Response System to Enhance Adherence to Isoniazid Preventive Therapy Among People Living with HIV in Ethiopia.
Topics: Adult; Cell Phone; Ethiopia; Female; HIV Infections; Humans; Isoniazid; Medication Adherence; Middle | 2017 |
Isoniazid therapy for Mycobacterium tuberculosis infection in HIV clinics, Los Angeles, California.
Topics: Adult; Ambulatory Care Facilities; Antitubercular Agents; Coinfection; Cross-Sectional Studies; Fema | 2016 |
Tuberculosis Treatment Outcome and Drug Resistance in Lambaréné, Gabon: A Prospective Cohort Study.
Topics: Adolescent; Adult; Antitubercular Agents; Child; Child, Preschool; Coinfection; Drug Resistance, Mul | 2016 |
HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Area Under Cur | 2016 |
Implications of the 2015 World Health Organization isoniazid preventive therapy recommendations on tuberculosis prevention efforts in Namibia.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Health Care Rationi | 2016 |
Surveillance provides insight into epidemiology and spectrum of culture-confirmed mycobacterial disease in children.
Topics: Anti-Retroviral Agents; Antitubercular Agents; Child; Child, Preschool; Coinfection; Epidemiological | 2016 |
Barriers in the implementation of isoniazid preventive therapy for people living with HIV in Northern Ethiopia: a mixed quantitative and qualitative study.
Topics: Adult; Antitubercular Agents; Attitude of Health Personnel; Delivery of Health Care; Drug Resistance | 2016 |
Rapid urine-based screening for tuberculosis to reduce AIDS-related mortality in hospitalized patients in Africa (the STAMP trial): study protocol for a randomised controlled trial.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; HIV Infections; Ho | 2016 |
Feasibility of achieving the 2025 WHO global tuberculosis targets in South Africa, China, and India: a combined analysis of 11 mathematical models.
Topics: Achievement; Antitubercular Agents; Cause of Death; China; Delivery of Health Care; Forecasting; Goa | 2016 |
Cost-effectiveness analysis of microscopic observation drug susceptibility test versus Xpert MTB/Rif test for diagnosis of pulmonary tuberculosis in HIV patients in Uganda.
Topics: AIDS-Related Opportunistic Infections; Algorithms; Bacteriological Techniques; Cost-Benefit Analysis | 2016 |
Predictors of adherence to isoniazid preventive therapy in people living with HIV in Ethiopia.
Topics: Adult; Anti-Retroviral Agents; Antitubercular Agents; Ethiopia; Female; Follow-Up Studies; HIV Infec | 2016 |
Outcome of culture-confirmed isoniazid-resistant rifampicin-susceptible tuberculosis in children.
Topics: Antitubercular Agents; Child; Child, Preschool; Drug Resistance, Multiple, Bacterial; Female; Follow | 2016 |
Benefits of continuous isoniazid preventive therapy may outweigh resistance risks in a declining tuberculosis/HIV coepidemic.
Topics: Antitubercular Agents; Botswana; Chemoprevention; Drug Resistance, Bacterial; HIV Infections; Humans | 2016 |
Isoniazid clearance is impaired among human immunodeficiency virus/tuberculosis patients with high levels of immune activation.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Arylamine N-Acetyltransferase; Female; Genotype; HIV | 2017 |
Health system challenges: An obstacle to the success of isoniazid preventive therapy.
Topics: Antitubercular Agents; Coinfection; Delivery of Health Care; Disease Management; Female; HIV Infecti | 2016 |
Characterization of 2-hydroxy-1-naphthaldehyde isonicotinoyl hydrazone as a novel inhibitor of methionine aminopeptidases from Mycobacterium tuberculosis.
Topics: Aminopeptidases; Anti-HIV Agents; Antitubercular Agents; Bacterial Proteins; Coinfection; Dose-Respo | 2016 |
Effects of isoniazid resistance on TB treatment outcomes under programmatic conditions in a high-TB and -HIV setting: a prospective multicentre study.
Topics: Adolescent; Adult; Antitubercular Agents; Drug Resistance, Bacterial; Female; HIV Infections; Humans | 2017 |
Effectiveness of isoniazid preventative therapy in reducing incidence of active tuberculosis among people living with HIV/AIDS in public health facilities of Addis Ababa, Ethiopia: a historical cohort study.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Antiretroviral Therapy, Highly Active; Antitubercul | 2017 |
High prevalence and low cure rate of tuberculosis among patients with HIV in Xinjiang, China.
Topics: Adult; Chemoprevention; China; Coinfection; Cross-Sectional Studies; Female; HIV Infections; HIV-1; | 2017 |
One-year mortality of HIV-positive patients treated for rifampicin- and isoniazid-susceptible tuberculosis in Eastern Europe, Western Europe, and Latin America.
Topics: Adult; Antitubercular Agents; Europe; Europe, Eastern; Female; HIV Infections; Humans; Isoniazid; La | 2017 |
Anti-TB drug concentrations and drug-associated toxicities among TB/HIV-coinfected patients.
Topics: Adult; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Coinfection; Female; HIV Infec | 2017 |
Anti-TB drug concentrations and drug-associated toxicities among TB/HIV-coinfected patients.
Topics: Adult; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Coinfection; Female; HIV Infec | 2017 |
Anti-TB drug concentrations and drug-associated toxicities among TB/HIV-coinfected patients.
Topics: Adult; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Coinfection; Female; HIV Infec | 2017 |
Anti-TB drug concentrations and drug-associated toxicities among TB/HIV-coinfected patients.
Topics: Adult; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Coinfection; Female; HIV Infec | 2017 |
"It's about my life": facilitators of and barriers to isoniazid preventive therapy completion among people living with HIV in rural South Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Ambulatory Care Facilities; Antitubercular Agents; Cou | 2017 |
Tuberculosis along the continuum of HIV care in a cohort of adolescents living with HIV in Ethiopia.
Topics: Adolescent; Antiretroviral Therapy, Highly Active; Antitubercular Agents; CD4 Lymphocyte Count; Chil | 2017 |
Concentration-Dependent Antagonism and Culture Conversion in Pulmonary Tuberculosis.
Topics: Adult; Antitubercular Agents; Coinfection; Drug Interactions; Drug Therapy, Combination; Female; HIV | 2017 |
Integrating tuberculosis screening in Kenyan Prevention of Mother-To-Child Transmission programs.
Topics: Adult; Antitubercular Agents; Female; HIV Infections; Humans; Infant; Infectious Disease Transmissio | 2017 |
HIV care in Yangon, Myanmar; successes, challenges and implications for policy.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antitubercular Agents; CD4 Lymphocyte Count; CD4-Posit | 2017 |
Opportunities and challenges for HIV care in overlapping HIV and TB epidemics.
Topics: AIDS-Related Opportunistic Infections; Antiretroviral Therapy, Highly Active; Antitubercular Agents; | 2008 |
Update on the treatment of tuberculosis.
Topics: Antitubercular Agents; Comorbidity; Directly Observed Therapy; Disease Progression; Drug Therapy, Co | 2008 |
Mycobacterium tuberculosis and nontuberculous mycobacterial isolates among patients with recent HIV infection in Mozambique.
Topics: Adult; Antitubercular Agents; CD4 Lymphocyte Count; Ethambutol; Female; HIV Infections; Humans; Ison | 2008 |
Few HIV patients tested for tuberculosis.
Topics: Antitubercular Agents; Delivery of Health Care, Integrated; HIV Infections; Humans; Internationality | 2008 |
Tuberculous meningitis in HIV-infected and non-infected patients: comparison of cerebrospinal fluid findings.
Topics: Adult; Antitubercular Agents; Cerebrospinal Fluid; Cerebrospinal Fluid Proteins; Drug Resistance, Mu | 2009 |
Anti-tuberculosis drug resistance and HIV co-infection in Phnom Penh, Cambodia.
Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; Cambodia; HIV Infections; HIV Seroposi | 2009 |
The spectrum of liver diseases in HIV infected individuals at an HIV treatment clinic in Kampala, Uganda.
Topics: Anti-HIV Agents; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Comorbidity; Female; | 2008 |
Therapeutic drug monitoring of antimycobacterial drugs in patients with both tuberculosis and advanced human immunodeficiency virus infection.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Retroviral Agents; Cohort Studies; Drug Monitoring; Drug Th | 2009 |
Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Botswana; CD4 Lymphocyte Count; E | 2009 |
Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Botswana; CD4 Lymphocyte Count; E | 2009 |
Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Botswana; CD4 Lymphocyte Count; E | 2009 |
Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Botswana; CD4 Lymphocyte Count; E | 2009 |
Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Botswana; CD4 Lymphocyte Count; E | 2009 |
Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Botswana; CD4 Lymphocyte Count; E | 2009 |
Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Botswana; CD4 Lymphocyte Count; E | 2009 |
Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Botswana; CD4 Lymphocyte Count; E | 2009 |
Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Botswana; CD4 Lymphocyte Count; E | 2009 |
The cost of intensified case finding and isoniazid preventive therapy for HIV-infected patients in Battambang, Cambodia.
Topics: Antitubercular Agents; Cambodia; Costs and Cost Analysis; HIV Infections; Humans; Isoniazid; Patient | 2009 |
Limited utility of name-based tuberculosis contact investigations among persons using illicit drugs: results of an outbreak investigation.
Topics: Adult; Aged; Cluster Analysis; Cocaine-Related Disorders; Comorbidity; Contact Tracing; Crack Cocain | 2009 |
Isoniazid-resistant disseminated Mycobacterium tuberculosis in a Jamaican infant with HIV/AIDS.
Topics: Antitubercular Agents; HIV Infections; Humans; Infant; Isoniazid; Jamaica; Male; Mycobacterium tuber | 2008 |
Low rates of hepatotoxicity in HIV-infected children on anti-retroviral therapy with and without isoniazid prophylaxis.
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antitubercular Agents; Child, Preschool; Fem | 2010 |
Erring on the side of action: time for HIV programmes to implement isoniazid preventive therapy.
Topics: Anti-Retroviral Agents; Antitubercular Agents; Comorbidity; HIV Infections; Humans; Isoniazid; Publi | 2009 |
Isoniazid preventive therapy for people living with HIV: public health challenges and implementation issues.
Topics: Antitubercular Agents; Comorbidity; Drug Resistance, Microbial; Global Health; HIV Infections; Human | 2009 |
Mortality benefit of isoniazid preventive therapy in HIV-positive persons: a simulation study.
Topics: Antitubercular Agents; Comorbidity; HIV Infections; Humans; Isoniazid; Meta-Analysis as Topic; Tuber | 2009 |
Commentary: Reducing HIV-associated tuberculosis in children.
Topics: Anti-Retroviral Agents; Antibiotic Prophylaxis; Antitubercular Agents; Child; HIV Infections; Humans | 2009 |
Active tuberculosis and Mycobacterium tuberculosis latent infection in patients with HIV/AIDS.
Topics: Adult; Aged; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Antitubercular Agents; B | 2009 |
Tuberculosis in asymptomatic HIV-infected adults with abnormal chest radiographs screened for tuberculosis prevention.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Botswana; CD4 Lymphocyte Count; | 2010 |
Association of chest radiographic abnormalities with tuberculosis disease in asymptomatic HIV-infected adults.
Topics: Adolescent; Adult; Aged; AIDS-Related Opportunistic Infections; Antitubercular Agents; Botswana; Fem | 2010 |
Pyridoxal-5-phosphate plasma concentrations in children receiving tuberculosis chemotherapy including isoniazid.
Topics: Adolescent; AIDS-Related Opportunistic Infections; Antitubercular Agents; Child; Child, Preschool; F | 2010 |
Expanding the role of the microscopic observation drug susceptibility assay in tuberculosis and HIV management.
Topics: Antitubercular Agents; Bacterial Typing Techniques; HIV Infections; Humans; Isoniazid; Microbial Sen | 2010 |
Microscopic observation drug susceptibility assay for tuberculosis screening before isoniazid preventive therapy in HIV-infected persons.
Topics: Adult; Antitubercular Agents; Bacterial Typing Techniques; Chi-Square Distribution; Drug Resistance, | 2010 |
Tuberculosis outcomes and drug susceptibility in individuals exposed to isoniazid preventive therapy in a high HIV prevalence setting.
Topics: Adult; Antitubercular Agents; CD4 Lymphocyte Count; Drug Resistance, Viral; Female; HIV Infections; | 2010 |
Predicting outcomes and drug resistance with standardised treatment of active tuberculosis.
Topics: Cohort Studies; Communicable Disease Control; Drug Resistance, Bacterial; Global Health; HIV Infecti | 2010 |
Implementation of co-trimoxazole prophylaxis and isoniazid preventive therapy for people living with HIV.
Topics: Anti-Infective Agents; Antitubercular Agents; Cross-Sectional Studies; HIV Infections; HIV Long-Term | 2010 |
The deadly synergy of HIV and tuberculosis.
Topics: Anti-Retroviral Agents; Antitubercular Agents; Global Health; Health Policy; HIV Infections; Humans; | 2010 |
Antiretrovirals and isoniazid preventive therapy in the prevention of HIV-associated tuberculosis in settings with limited health-care resources.
Topics: Anti-Retroviral Agents; CD4 Lymphocyte Count; Disease Progression; HIV Infections; Humans; Isoniazid | 2010 |
[Epidemiology of the resistance of Mycobacterium tuberculosis to antituberculosis drugs at the main hospital in Dakar, Senegal. A 4-year retrospective study (2000-2003)].
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Therapy, Combination; Etha | 2010 |
Isoniazid preventive therapy for HIV-infected people: evidence to support implementation.
Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; Evidence-Based Medicine; HIV Infection | 2010 |
Why have trials of isoniazid preventive therapy among people with HIV infection not demonstrated an effect on mortality?: did close examination of the trees obscure our view of the wood?
Topics: Antiretroviral Therapy, Highly Active; Antitubercular Agents; CD4 Lymphocyte Count; HIV Infections; | 2010 |
Symptom and chest radiographic screening for infectious tuberculosis prior to starting isoniazid preventive therapy: yield and proportion missed at screening.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Female; HIV Infections; Humans; | 2010 |
'Team up against TB': promoting involvement in Thibela TB, a trial of community-wide tuberculosis preventive therapy.
Topics: Adult; Female; Health Education; Health Promotion; HIV Infections; HIV-1; Humans; Isoniazid; Male; P | 2010 |
Barriers to implementation of isoniazid preventive therapy in HIV clinics: a qualitative study.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Delivery of Health Care; Female | 2010 |
Implementation of isoniazid preventive therapy for people living with HIV worldwide: barriers and solutions.
Topics: Antitubercular Agents; Delivery of Health Care, Integrated; Female; HIV Infections; Humans; Isoniazi | 2010 |
Association of isoniazid preventive therapy with lower early mortality in individuals on antiretroviral therapy in a workplace programme.
Topics: Antiretroviral Therapy, Highly Active; Antitubercular Agents; CD4 Lymphocyte Count; Female; HIV Infe | 2010 |
Epidemic levels of drug resistant tuberculosis (MDR and XDR-TB) in a high HIV prevalence setting in Khayelitsha, South Africa.
Topics: Adolescent; Adult; Antibiotics, Antitubercular; Comorbidity; Cross-Sectional Studies; Epidemics; Eth | 2010 |
Acceptability of treatment of latent tuberculosis infection in newly HIV-infected young women in Uganda.
Topics: Adolescent; Adult; Antitubercular Agents; Cohort Studies; Female; HIV Infections; Humans; Isoniazid; | 2010 |
[Sputum smear conversion during intensive TB treatment phase according to HIV status, in hospitalised patients in Togo].
Topics: Adult; Antitubercular Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; Ethambutol; Female; F | 2011 |
Comparison of isoniazid monoresistant tuberculosis with drug-susceptible tuberculosis and multidrug-resistant tuberculosis.
Topics: Adult; Aged; Antitubercular Agents; Drug Resistance, Bacterial; Drug Therapy; Emigrants and Immigran | 2011 |
Mycobacterium tuberculosis spoligotypes and drug susceptibility pattern of isolates from tuberculosis patients in South-Western Uganda.
Topics: Adult; Antitubercular Agents; Female; Genetic Variation; Genotype; HIV Infections; Humans; Isoniazid | 2011 |
Isoniazid preventive therapy in HIV infection.
Topics: Antitubercular Agents; HIV Infections; Isoniazid; Tuberculosis | 2011 |
Modelling the performance of isoniazid preventive therapy for reducing tuberculosis in HIV endemic settings: the effects of network structure.
Topics: Africa South of the Sahara; Antitubercular Agents; Computer Simulation; Contact Tracing; Endemic Dis | 2011 |
Interferon release does not add discriminatory value to smear-negative HIV-tuberculosis algorithms.
Topics: Adult; Algorithms; Area Under Curve; Female; HIV Infections; Humans; Infectious Disease Medicine; In | 2012 |
Changes in the epidemiology of tuberculosis: the influence of international migration flows.
Topics: Adult; Africa; Age Distribution; Aged; Aged, 80 and over; Antitubercular Agents; Comorbidity; Diabet | 2011 |
Tuberculosis in HIV programmes in lower-income countries: practices and risk factors.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antitubercular Agents; Co | 2011 |
The impact and cost-effectiveness of strategies to detect drug-resistant tuberculosis.
Topics: Antitubercular Agents; Cost-Benefit Analysis; Decision Support Techniques; HIV Infections; Humans; I | 2012 |
Quantifying the burden and trends of isoniazid resistant tuberculosis, 1994-2009.
Topics: Adult; Antitubercular Agents; Comorbidity; Directly Observed Therapy; HIV; HIV Infections; Humans; I | 2011 |
Tuberculosis management--time for paradigm shift?
Topics: Antitubercular Agents; Comorbidity; HIV Infections; Humans; Isoniazid; Practice Guidelines as Topic; | 2011 |
Duration of isoniazid preventive therapy in HIV-infected patients.
Topics: Antitubercular Agents; Female; HIV Infections; Humans; Isoniazid; Male; Tuberculosis | 2011 |
Duration of isoniazid preventive therapy in HIV-infected patients.
Topics: Antitubercular Agents; Female; HIV Infections; Humans; Isoniazid; Male; Tuberculosis | 2011 |
Isoniazid prophylaxis against tuberculosis in children.
Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; Female; HIV Infections; HIV-1; Humans; | 2011 |
Systemic exposure to rifampicin in patients with tuberculosis and advanced HIV disease during highly active antiretroviral therapy in Burkina Faso.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Burkina Faso; | 2012 |
When tuberculosis comes back: who develops recurrent tuberculosis in california?
Topics: Adult; Antitubercular Agents; California; Drug Therapy, Combination; Female; HIV; HIV Infections; Hu | 2011 |
Resistance patterns of Mycobacterium tuberculosis isolates from pulmonary tuberculosis patients in Nairobi.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Resistance, Bacterial; Fem | 2012 |
Reduced antituberculosis drug concentrations in HIV-infected patients who are men or have low weight: implications for international dosing guidelines.
Topics: Adolescent; Adult; Age Factors; Aged; Antitubercular Agents; Birth Weight; Drug Resistance, Multiple | 2012 |
Reduced antituberculosis drug concentrations in HIV-infected patients who are men or have low weight: implications for international dosing guidelines.
Topics: Adolescent; Adult; Age Factors; Aged; Antitubercular Agents; Birth Weight; Drug Resistance, Multiple | 2012 |
Reduced antituberculosis drug concentrations in HIV-infected patients who are men or have low weight: implications for international dosing guidelines.
Topics: Adolescent; Adult; Age Factors; Aged; Antitubercular Agents; Birth Weight; Drug Resistance, Multiple | 2012 |
Reduced antituberculosis drug concentrations in HIV-infected patients who are men or have low weight: implications for international dosing guidelines.
Topics: Adolescent; Adult; Age Factors; Aged; Antitubercular Agents; Birth Weight; Drug Resistance, Multiple | 2012 |
Prevalence of peripheral neuropathy in antiretroviral therapy naïve HIV-positive patients and the impact on treatment outcomes--a retrospective study from a large urban cohort in Johannesburg, South Africa.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Coinfection; Female; HIV Infections; HIV-1; Humans; I | 2012 |
The cost-effectiveness of tuberculosis preventive therapy for HIV-infected individuals in southern India: a trial-based analysis.
Topics: Adult; Clinical Trials as Topic; Cohort Studies; Cost-Benefit Analysis; Ethambutol; Female; HIV Infe | 2012 |
Should tuberculin skin testing be a prerequisite to prolonged IPT for HIV-infected adults?
Topics: Adult; Antitubercular Agents; HIV Infections; Humans; Infection Control; Isoniazid; Mass Screening; | 2012 |
Relatively low primary drug resistant tuberculosis in southwestern Ethiopia.
Topics: Adolescent; Adult; Antitubercular Agents; Coinfection; Cross-Sectional Studies; Drug Resistance, Mul | 2012 |
The evolving epidemic of drug-resistant tuberculosis among children in Cape Town, South Africa.
Topics: Adolescent; AIDS-Related Opportunistic Infections; Antitubercular Agents; Child; Child, Preschool; C | 2012 |
Survey of isoniazid preventive therapy in South Africa, 2011.
Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; Cross-Sectional Studies; HIV Infection | 2012 |
Trends in drug-resistant tuberculosis in a gold-mining workforce in South Africa, 2002-2008.
Topics: Adult; Antitubercular Agents; Gold; HIV Infections; Humans; Isoniazid; Middle Aged; Mining; Mycobact | 2012 |
Undiagnosed tuberculosis among HIV clinic attendees: association with antiretroviral therapy and implications for intensified case finding, isoniazid preventive therapy, and infection control.
Topics: Adult; Antiretroviral Therapy, Highly Active; Bacteriological Techniques; Biopsy, Fine-Needle; Chemo | 2012 |
Community-based multi-disease prevention campaigns for controlling human immunodeficiency virus-associated tuberculosis.
Topics: Africa South of the Sahara; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antitubercular A | 2012 |
Completion of isoniazid preventive therapy and survival in HIV-infected TST-positive adults in Tanzania.
Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; Coinfection; Female; HIV Infections; H | 2012 |
Isoniazid preventive therapy in human immunodeficiency virus infection.
Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; Coinfection; Female; HIV Infections; H | 2012 |
Hurry up and wait? Accelerating access to the Three I's for HIV-TB.
Topics: Antitubercular Agents; HIV Infections; Humans; Infection Control; Isoniazid; Tuberculin Test; Tuberc | 2012 |
Short-course untargeted isoniazid preventive therapy in South Africa: time to rethink policy?
Topics: Antitubercular Agents; Communicable Disease Control; Epidemics; HIV Infections; Humans; Isoniazid; N | 2012 |
Drug-resistant tuberculosis among HIV-infected patients starting antiretroviral therapy in Durban, South Africa.
Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Cohort Studies; Cross-Sectional Studies; Drug R | 2012 |
Recurrent tuberculosis risk among HIV-infected adults in Tanzania with prior active tuberculosis.
Topics: Adult; Antitubercular Agents; BCG Vaccine; Female; HIV Infections; Humans; Isoniazid; Male; Proporti | 2013 |
Nosocomial transmission of extensively drug-resistant tuberculosis in a rural hospital in South Africa.
Topics: Adult; Antitubercular Agents; Cluster Analysis; Cross Infection; Drug Therapy, Combination; Ethambut | 2013 |
Prolonged isoniazid prevention in HIV-positive children: hepatotoxicity is not a major problem.
Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; Chemical and Drug Induced Liver Injury | 2013 |
Tuberculosis treatment survival of HIV positive TB patients on directly observed treatment short-course in Southern Ethiopia: a retrospective cohort study.
Topics: Adult; Anti-Retroviral Agents; Antitubercular Agents; Coinfection; Drug Administration Schedule; Fem | 2012 |
Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients.
Topics: Adenine; Adolescent; Adult; Alkynes; Anti-HIV Agents; Antitubercular Agents; Aryl Hydrocarbon Hydrox | 2013 |
A recent HIV diagnosis is associated with non-completion of Isoniazid Preventive Therapy in an HIV-infected cohort in Cape Town.
Topics: Adult; Cohort Studies; Female; HIV Infections; Humans; Isoniazid; Male; Patient Compliance; South Af | 2012 |
Anti-tuberculosis treatment outcomes in HIV-infected adults exposed to isoniazid preventive therapy in Botswana.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Botswana; Drug Therapy, Combination; Female; HIV Infe | 2013 |
Antitubercular therapy decreases nitric oxide production in HIV/TB coinfected patients.
Topics: Adult; Antibiotics, Antitubercular; Antitubercular Agents; Biomarkers; CD4 Lymphocyte Count; CD4-Pos | 2002 |
Prevalence of purified protein derivative positivity in human immunodeficiency virus infected individuals in Hong Kong.
Topics: Adult; Aged; BCG Vaccine; Female; HIV Infections; Humans; Isoniazid; Male; Middle Aged; Prevalence; | 2002 |
Isoniazid resistance, mycobacterial genotype and outcome in Vietnamese adults with tuberculous meningitis.
Topics: Adolescent; Adult; Antitubercular Agents; Drug Resistance, Bacterial; Female; Genotype; HIV Infectio | 2002 |
Chronic plasma cell pneumonia in a patient with long-standing HIV infection.
Topics: Adrenal Cortex Hormones; Adult; AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Antire | 2002 |
Isoniazid prophylaxis for tuberculosis prevention among HIV infected police officers in Dar es Salaam.
Topics: Adult; Antitubercular Agents; Cohort Studies; Female; Follow-Up Studies; HIV Infections; Humans; Iso | 2000 |
Preventing recurrent tuberculosis in high HIV-prevalent areas in sub-Saharan Africa: what are the options for tuberculosis control programmes?
Topics: Africa South of the Sahara; Antiretroviral Therapy, Highly Active; Health Policy; HIV Infections; Hu | 2003 |
Efficacy of secondary isoniazid preventive therapy among HIV-infected Southern Africans: time to change policy?
Topics: Adult; Age Distribution; Antitubercular Agents; Black People; CD4 Lymphocyte Count; Cohort Studies; | 2003 |
Passive versus active tuberculosis case finding and isoniazid preventive therapy among household contacts in a rural district of Malawi.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Child, Preschool; Comorbidity; Contact Tracing; Cros | 2003 |
Is there a role for chest radiography in identification of asymptomatic tuberculosis in HIV-infected people?
Topics: Adult; Antitubercular Agents; Comorbidity; Evaluation Studies as Topic; Health Care Costs; HIV Infec | 2003 |
Value of chest radiography in a tuberculosis prevention programme for HIV-infected people, Botswana.
Topics: Adolescent; Adult; Ambulatory Care; Antitubercular Agents; Botswana; Comorbidity; Evaluation Studies | 2003 |
Effectiveness of isoniazid treatment for latent tuberculosis infection among human immunodeficiency virus (HIV)-infected and HIV-uninfected injection drug users in methadone programs.
Topics: Adult; Aged; AIDS-Related Opportunistic Infections; Antitubercular Agents; Female; HIV; HIV Infectio | 2003 |
Malabsorption of rifampin and isoniazid in HIV-infected patients with and without tuberculosis.
Topics: Adolescent; Adult; Antibiotics, Antitubercular; HIV Infections; Humans; Intestinal Absorption; Isoni | 2004 |
Multidrug-resistant Mycobacterium tuberculosis in HIV-infected persons, Peru.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Drug Resistance, Multiple, Bacter | 2003 |
Resistant Mycobacterium bovis Bacillus Calmette-Guérin disease: implications for management of Bacillus Calmette-Guérin Disease in human immunodeficiency virus-infected children.
Topics: Animals; Antitubercular Agents; BCG Vaccine; Cattle; DNA-Directed RNA Polymerases; Drug Resistance, | 2004 |
Hepatotoxicity of rifampin and pyrazinamide in the treatment of latent tuberculosis infection in HIV-infected persons: is it different than in HIV-uninfected persons?
Topics: Adolescent; Adult; Aspartate Aminotransferases; Bilirubin; Chemical and Drug Induced Liver Injury; D | 2004 |
Efficacy and safety of Efavirenz in HIV patients on Rifampin for tuberculosis.
Topics: Adult; Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Antiretroviral Therapy, Highly Active; | 2004 |
Drug-resistant tuberculosis in HIV-infected persons: Italy 1999-2000.
Topics: Adult; Aged; Antibiotics, Antitubercular; Antitubercular Agents; Drug Resistance, Bacterial; Drug Re | 2004 |
[Medicine and television: a diagnosis history].
Topics: Adult; Antitubercular Agents; Cholestasis, Intrahepatic; Diagnostic Errors; Hepatitis B; Hepatitis C | 2005 |
Serum concentrations of antimycobacterial drugs in patients with pulmonary tuberculosis in Botswana.
Topics: Adult; Antitubercular Agents; Botswana; Comorbidity; Ethambutol; Female; HIV Infections; Humans; Iso | 2005 |
Immune reconstitution syndrome due to bacillus Calmette-Guérin after initiation of antiretroviral therapy in children with HIV infection.
Topics: Anti-HIV Agents; Antitubercular Agents; BCG Vaccine; Child; Female; HIV Infections; Humans; Infant; | 2005 |
Developing an evidence-based, preventive care package for persons with HIV in Africa.
Topics: Africa; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Antitubercular Agents; Bedding | 2005 |
Effectiveness and cost effectiveness of early and late prevention of HIV/AIDS progression with antiretrovirals or antibiotics in Southern African adults.
Topics: Africa, Southern; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Anti-Retroviral Agen | 2006 |
Physician adherence to isoniazid preventive therapy guidelines for HIV-infected patients in Thailand.
Topics: Antitubercular Agents; Guideline Adherence; HIV Infections; Humans; Isoniazid; Practice Guidelines a | 2005 |
Treatment outcomes by drug resistance and HIV status among tuberculosis patients in Ho Chi Minh City, Vietnam.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Resistance, Ba | 2006 |
[Stevens-Johnson syndrome and toxic epidermal necrolysis after intake of rifampicin-isoniazid: report of 8 cases in HIV-infected patients in Togo].
Topics: Adult; Antibiotics, Antitubercular; Antitubercular Agents; Drug Therapy, Combination; Female; HIV In | 2005 |
Beneficial and perverse effects of isoniazid preventive therapy for latent tuberculosis infection in HIV-tuberculosis coinfected populations.
Topics: Africa South of the Sahara; AIDS-Related Opportunistic Infections; Antitubercular Agents; Comorbidit | 2006 |
Screening for tuberculosis prior to isoniazid preventive therapy among HIV-infected gold miners in South Africa.
Topics: Adult; Antitubercular Agents; Cross-Sectional Studies; Gold; HIV Infections; Humans; Isoniazid; Male | 2006 |
Adherence with isoniazid for prevention of tuberculosis among HIV-infected adults in South Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Administration Schedule; H | 2006 |
Cost-effectiveness of including tuberculin skin testing in an IPT program for HIV-infected persons in Uganda.
Topics: Antitubercular Agents; Cost-Benefit Analysis; HIV Infections; Humans; Isoniazid; Program Evaluation; | 2006 |
[Isoniazid induced neuropathy: consider prevention].
Topics: Acetylation; Achilles Tendon; Adult; Antiretroviral Therapy, Highly Active; Antitubercular Agents; E | 2006 |
Preventing latent tuberculosis among HIV-infected patients: efficacious and effective, yet inefficient?
Topics: AIDS-Related Opportunistic Infections; Antibiotic Prophylaxis; Antitubercular Agents; Cohort Studies | 2007 |
Tuberculosis in resource poor countries.
Topics: Anti-Retroviral Agents; Antitubercular Agents; Developing Countries; Health Services Accessibility; | 2007 |
Sputum conversion among patients with pulmonary tuberculosis: are there implications for removal of respiratory isolation?
Topics: Adult; Aged; Antitubercular Agents; Colony Count, Microbial; Drug Resistance, Multiple, Bacterial; F | 2007 |
The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil.
Topics: Adult; Anti-Retroviral Agents; Antitubercular Agents; Brazil; CD4 Lymphocyte Count; Female; Follow-U | 2007 |
The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil.
Topics: Adult; Anti-Retroviral Agents; Antitubercular Agents; Brazil; CD4 Lymphocyte Count; Female; Follow-U | 2007 |
The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil.
Topics: Adult; Anti-Retroviral Agents; Antitubercular Agents; Brazil; CD4 Lymphocyte Count; Female; Follow-U | 2007 |
The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil.
Topics: Adult; Anti-Retroviral Agents; Antitubercular Agents; Brazil; CD4 Lymphocyte Count; Female; Follow-U | 2007 |
Urine levels of rifampicin & isoniazid in asymptomatic HIV-positive individuals.
Topics: Adult; Antitubercular Agents; CD4-Positive T-Lymphocytes; Drug Administration Schedule; Drug Resista | 2007 |
Sexual risk behaviour and HAART: a comparative study of HIV-infected persons on HAART and on preventive therapy in Kenya.
Topics: Adult; Antiretroviral Therapy, Highly Active; Condoms; Cross-Sectional Studies; Female; HIV Infectio | 2008 |
High incidence of antimicrobial resistant organisms including extended spectrum beta-lactamase producing Enterobacteriaceae and methicillin-resistant Staphylococcus aureus in nasopharyngeal and blood isolates of HIV-infected children from Cape Town, South
Topics: Anti-Infective Agents; Bacteremia; beta-Lactam Resistance; beta-Lactamases; Carrier State; Child; Ch | 2008 |
Modeling the joint epidemics of TB and HIV in a South African township.
Topics: Antiretroviral Therapy, Highly Active; Antitubercular Agents; Comorbidity; Condoms; Disease Notifica | 2008 |
Increasing drug resistant tuberculosis in the UK.
Topics: Antitubercular Agents; HIV Infections; Humans; Isoniazid; Tuberculosis, Multidrug-Resistant; United | 2008 |
Outcomes in HIV-infected patients who develop tuberculosis after starting antiretroviral treatment in Malawi.
Topics: Anti-Retroviral Agents; Antitubercular Agents; Child; Comorbidity; HIV Infections; Humans; Isoniazid | 2008 |
Drug resistance of Mycobacterium tuberculosis strains isolated from HIV-infected Italian patients: preliminary report from a multicentric study. The Italian Tuberculosis Drug Resistance Study Group.
Topics: Antitubercular Agents; Drug Resistance, Microbial; Ethambutol; HIV Infections; Humans; Isoniazid; It | 1995 |
Tuberculosis in human immunodeficiency virus-exposed or -infected United States children.
Topics: Adult; Child; Child, Preschool; Drug Resistance, Multiple; HIV Infections; Humans; Infant; Isoniazid | 1994 |
[Treatment and prevention of main infections associated with HIV].
Topics: Adrenal Cortex Hormones; Amphotericin B; Controlled Clinical Trials as Topic; Cryptococcosis; Flucon | 1994 |
Tuberculosis and HIV infection.
Topics: Africa; AIDS-Related Opportunistic Infections; Drug Resistance, Microbial; HIV Infections; Humans; I | 1994 |
[Two pulmonary tuberculosis cases with HIV infection].
Topics: Adult; Female; HIV Infections; Humans; Isoniazid; Male; Pyrazinamide; Rifampin; Streptomycin; Tuberc | 1994 |
[Human immunodeficiency virus infection and tuberculosis: who should receive chemoprophylaxis?].
Topics: Global Health; HIV Infections; Humans; Isoniazid; Tuberculosis | 1994 |
[Decision regarding chemoprophylaxis with isoniazid in patients using parenteral drugs and infected with HIV].
Topics: Decision Support Techniques; Decision Trees; HIV Infections; Humans; Isoniazid; Substance Abuse, Int | 1994 |
From the Food and Drug Administration.
Topics: Antitubercular Agents; Blood Donors; Drug Approval; Drug Combinations; Electromagnetic Phenomena; Eq | 1994 |
Human immunodeficiency virus type-1 infection in Zambian children with tuberculosis: changing seroprevalence and evaluation of a thioacetazone-free regimen.
Topics: Adolescent; Child; Child, Preschool; Drug Hypersensitivity; Drug Therapy, Combination; Female; HIV I | 1994 |
Tuberculosis preventive therapy in HIV-infected individuals. A joint statement of the International Union Against Tuberculosis and Lung Disease (IUATLD) and the Global Programme on AIDS and the Tuberculosis Programme of the World Health Organization (WHO)
Topics: Contraindications; Hepatitis, Chronic; HIV Infections; Humans; Isoniazid; Tuberculin Test; Tuberculo | 1994 |
Risk for developing tuberculosis among anergic patients infected with HIV.
Topics: Adult; CD4-Positive T-Lymphocytes; Female; HIV Infections; Humans; Hypersensitivity, Delayed; Immune | 1993 |
Tuberculosis preventive therapy in HIV-infected individuals.
Topics: AIDS-Related Opportunistic Infections; HIV Infections; Humans; Isoniazid; Mass Screening; Tuberculos | 1994 |
Tuberculosis preventive therapy in HIV-infected individuals. A Joint Statement of the WHO Tuberculosis Programme and the Global Programme on AIDS, and the International Union Against Tuberculosis and Lung Disease (IUATLD).
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Child, Preschool; | 1993 |
Low prevalence of positive tuberculin tests in homo-/bisexual white men from Seattle: implications for anergy testing.
Topics: Adult; Bisexuality; Comorbidity; False Negative Reactions; HIV Infections; Homosexuality; Humans; Im | 1993 |
The emergence of drug-resistant tuberculosis in New York City.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Antitubercular Agents; Centers for Disease Co | 1993 |
[Indications for chemoprophylaxis of tuberculosis. Arguments for].
Topics: Adolescent; Adult; Age Factors; Aged; AIDS-Related Opportunistic Infections; Child; Child, Preschool | 1993 |
Rifampin-resistant, isoniazid-susceptible TB in HIV patients.
Topics: Antitubercular Agents; Drug Resistance, Microbial; Genes, Bacterial; HIV Infections; Humans; Isoniaz | 1995 |
Active tuberculosis in HIV-infected injecting drug users from a low-rate tuberculosis area.
Topics: Antitubercular Agents; Connecticut; Female; Follow-Up Studies; HIV Infections; Humans; Incidence; Is | 1996 |
We reap what we sow.
Topics: Antitubercular Agents; Cross Infection; HIV Infections; HIV Seronegativity; Humans; Isoniazid; Los A | 1996 |
Relationship of isoniazid resistance to human immunodeficiency virus infection in patients with tuberculosis.
Topics: Antitubercular Agents; Confidence Intervals; Drug Resistance, Microbial; Ethnicity; Female; HIV Infe | 1996 |
[Multidrug-resistant tuberculosis. Remarks and reflections on a controversial subject of current utmost importance].
Topics: Antitubercular Agents; Drug Resistance, Multiple; HIV Infections; HIV Seronegativity; HIV Seropositi | 1996 |
A multi-institutional outbreak of highly drug-resistant tuberculosis: epidemiology and clinical outcomes.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Blotting, Southern; Cause of Death; Child; Child, Pr | 1996 |
Human immunodeficiency virus infection in children with tuberculosis in Santo Domingo, Dominican Republic: prevalence, clinical findings, and response to antituberculosis treatment.
Topics: AIDS Serodiagnosis; Antibiotics, Antitubercular; Antitubercular Agents; Child, Preschool; Dominican | 1996 |
The management of mycobacterial infections in HIV seropositive individuals. Jefferiss Wing Therapeutics and Protocols Group.
Topics: Adrenal Cortex Hormones; Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Antibiotics, Antitu | 1996 |
Disseminated infection due to multidrug-resistant Mycobacterium bovis in a patient who was seropositive for human immunodeficiency virus.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; DNA Fingerprinting; DNA, Bacterial; Drug Resista | 1996 |
[HIV infection, tuberculosis and tuberculin test in Switzerland. The Swiss HIV Cohort Study].
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Cohort St | 1996 |
Autopsy findings in HIV-1-infected adults in Kenya.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Autopsy; Female; HIV Infections | 1997 |
[Can we improve the prevention of tuberculosis? Analysis of the application of chemoprophylaxis].
Topics: Adult; Antitubercular Agents; Female; HIV Infections; Humans; Isoniazid; Male; Tuberculosis, Pulmona | 1996 |
Impact of tuberculosis control measures and crowding on the incidence of tuberculous infection in Maryland prisons.
Topics: Adult; Cohort Studies; Crowding; HIV Infections; Humans; Incidence; Isoniazid; Longitudinal Studies; | 1997 |
Reduced plasma concentrations of antituberculosis drugs in patients with HIV infection.
Topics: Adult; Aged; Antitubercular Agents; Case-Control Studies; Diarrhea; Ethambutol; Female; HIV Infectio | 1997 |
Anergy skin testing and tuberculosis [corrected] preventive therapy for HIV-infected persons: revised recommendations. Centers for Disease Control and Prevention.
Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; Clonal Anergy; HIV Infections; Humans; | 1997 |
Isoniazid prophylaxis for high-risk patients with anergy and HIV infection.
Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; HIV Infections; Humans; Isoniazid; Tub | 1997 |
Isoniazid prophylaxis for high-risk patients with anergy and HIV infection.
Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; HIV Infections; Humans; Isoniazid; Res | 1997 |
Questions about a placebo-controlled trial of preventive therapy for tuberculosis in HIV-infected Ugandans.
Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; Ethics, Medical; Haiti; HIV Infections | 1998 |
Questions about a placebo-controlled trial of preventive therapy for tuberculosis in HIV-infected Ugandans.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Child; Control Groups; Ethics C | 1998 |
Sensitive liquid chromatographic technique to measure isoniazid in alveolar cells, bronchoalveolar lavage and plasma in HIV-infected patients.
Topics: Administration, Oral; Bronchoalveolar Lavage Fluid; Chromatography, High Pressure Liquid; Chromatogr | 1998 |
Influence of the human immunodeficiency virus in the incidence of tuberculosis in a cohort of intravenous drug users: effectiveness of anti-tuberculosis chemoprophylaxis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Cohort Studies; Female; HIV Inf | 1998 |
Low serum antimycobacterial drug levels in non-HIV-infected tuberculosis patients.
Topics: Adult; Aged; Antibiotics, Antitubercular; Antitubercular Agents; Drug Monitoring; Drug Therapy, Comb | 1998 |
[Epidemiologic followup of cases of tuberculosis in the medical-social centers of Paris for the year 1994].
Topics: Adolescent; Adult; Africa; Antibiotics, Antitubercular; Antitubercular Agents; BCG Vaccine; Female; | 1998 |
[Fulminant hepatitis in the course of antitubercular treatment (apropos of 2 cases)].
Topics: Adult; Anti-Bacterial Agents; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Th | 1995 |
Shock and cerebral infarct after rifampin re-exposure in a patient infected with human immunodeficiency virus.
Topics: Adult; Anaphylaxis; Antibiotics, Antitubercular; Antitubercular Agents; Cerebral Infarction; Drug Hy | 1998 |
Low levels of drug resistance amidst rapidly increasing tuberculosis and human immunodeficiency virus co-epidemics in Botswana.
Topics: Adolescent; Adult; Antitubercular Agents; Botswana; Child; Comorbidity; Disease Outbreaks; Female; H | 1999 |
Tuberculosis vaccination versus isoniazid preventive therapy: a decision analysis to determine the preferred strategy of tuberculosis prevention in HIV-infected adults in the developing world.
Topics: Adult; Antitubercular Agents; BCG Vaccine; Decision Support Techniques; Developing Countries; HIV In | 1999 |
Reply: Treatment of tuberculosis in HIV-infected patients.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Drug Therapy, Combination; HIV Infections; Human | 1999 |
Drug-induced lupus nephritis in HIV infection.
Topics: Adult; Antibiotics, Antitubercular; Drug Therapy, Combination; Female; HIV Infections; Humans; Isoni | 1999 |
Preventive therapy against tuberculosis in people living with HIV.
Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; Counseling; Feasibility Studies; Globa | 1999 |
Reply to Davis and colleagues: Twice weekly, directly observed treatment for HIV-infected and uninfected tuberculosis patients: cohort study in rural South Africa.
Topics: Antitubercular Agents; Drug Administration Schedule; Drug Resistance, Microbial; Drug Resistance, Mu | 1999 |
Increased incidence of peripheral neuropathy with co-administration of stavudine and isoniazid in HIV-infected individuals.
Topics: Adult; Aged; Anti-HIV Agents; Antitubercular Agents; Drug Therapy, Combination; HIV Infections; Huma | 2000 |
Identification and management of tuberculosis.
Topics: Adult; Algorithms; Antitubercular Agents; Child; HIV Infections; Humans; Isoniazid; Patient Complian | 2000 |
Missed opportunities for prevention of tuberculosis among persons with HIV infection--selected locations, United States, 1996-1997.
Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; HIV Infections; Humans; Isoniazid; Mas | 2000 |
Second episode of tuberculosis in an HIV-infected child: relapse or reinfection?
Topics: AIDS-Related Opportunistic Infections; Amoxicillin-Potassium Clavulanate Combination; Antibiotics, A | 2000 |
From the Centers for Disease Control and Prevention. Missed opportunities for prevention of tuberculosis among persons with HIV infection--selected locations, United States, 1996-1997.
Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; HIV Infections; Humans; Isoniazid; Mas | 2000 |
TB prevention in HIV clinics in New York City.
Topics: Adult; Antitubercular Agents; Disease Progression; Female; HIV Infections; Humans; Incidence; Isonia | 2001 |
Isoniazid TB prophylaxis effective in drug users with HIV.
Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; HIV Infections; Humans; Isoniazid; Sub | 1996 |
Tuberculosis in farmworkers.
Topics: Antitubercular Agents; HIV Infections; Humans; Isoniazid; Medical History Taking; Risk Factors; Tube | 1996 |
Medical advances with international impact.
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antibiotics, Antitubercular; Antitubercular | 1998 |
New TB therapy works for HIV-positive patients.
Topics: Antitubercular Agents; Clinical Trials as Topic; Disease Progression; HIV Infections; Humans; Isonia | 1998 |
Tuberculosis preventative therapy as part of a care package for people living with HIV in a district of Thailand.
Topics: Adult; Antitubercular Agents; Cohort Studies; Comprehensive Health Care; Female; HIV Infections; Hum | 2001 |
Isoniazid preventive therapy, hepatitis C virus infection, and hepatotoxicity among injection drug users infected with Mycobacterium tuberculosis.
Topics: Adult; Antibiotic Prophylaxis; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Female | 2001 |
Acquired rifamycin resistance in persons with advanced HIV disease being treated for active tuberculosis with intermittent rifamycin-based regimens.
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antibiotics, Antitubercular; Antiretroviral | 2002 |
Tuberculosis in Thai prisons: magnitude, transmission and drug susceptibility.
Topics: Adult; Aged; Antibiotics, Antitubercular; Antitubercular Agents; Cross-Sectional Studies; DNA Finger | 2002 |
Tuberculosis preventative treatment also prevented diarrhoea in HIV-infected patients in Zambia.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Diarrhea; Drug Therapy, Combination; Follow-Up S | 2002 |
Cross-sectional survey of HIV infection among patients with tuberculosis in Nairobi, Kenya.
Topics: Adolescent; Adult; Cross-Sectional Studies; Drug Combinations; Drug Therapy, Combination; Female; HI | 1992 |
Mycobacterium bovis (BCG) vaccination. Progressive disease in a patient asymptomatically infected with the human immunodeficiency virus.
Topics: Adult; BCG Vaccine; Ethambutol; HIV Infections; Humans; Isoniazid; Male; Mycobacterium bovis; Rifamp | 1992 |
Nosocomial transmission of multidrug-resistant tuberculosis among HIV-infected persons--Florida and New York, 1988-1991.
Topics: Acquired Immunodeficiency Syndrome; Cross Infection; Drug Resistance, Microbial; Ethambutol; Florida | 1991 |
From the Centers for Disease Control. Nosocomial transmission of multidrug-resistant tuberculosis among HIV-infected persons--Florida and New York, 1988-1991.
Topics: Acquired Immunodeficiency Syndrome; Cross Infection; Disease Outbreaks; Drug Resistance, Microbial; | 1991 |
[Hiv infection and tuberculosis. Recommendations of the German Central Committee for the Control of Tuberculosis].
Topics: Antitubercular Agents; Drug Therapy, Combination; HIV Infections; Humans; Isoniazid; Records; Tuberc | 1991 |
Isoniazid as preventive therapy in HIV-infected intravenous drug abusers. A decision analysis.
Topics: Adult; Chemical and Drug Induced Liver Injury; Decision Trees; HIV Infections; HIV Seropositivity; H | 1991 |
Failure of tuberculosis chemotherapy in a human immunodeficiency virus-infected patient.
Topics: Adult; HIV Infections; Humans; Isoniazid; Male; Rifampin; Tuberculosis | 1990 |